



(51) International Patent Classification:

A61K 47/68 (2017.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2021/026718

(22) International Filing Date:

09 April 2021 (09.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/008,551 10 April 2020 (10.04.2020) US
63/016,219 27 April 2020 (27.04.2020) US

(71) Applicant: SEAGEN INC. [US/US]; 21823 30th Drive SE, Bothell, Washington 98021 (US).

(72) Inventors: NEUMANN, Christopher Scott; 21823 30th Drive SE, Bothell, Washington 98021 (US). HUNTER, Joshua; 21823 30th Drive SE, Bothell, Washington 98021 (US).

(74) Agent: BATES, Caleb A. et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: CHARGE VARIANT LINKERS

(57) Abstract: The present disclosure provides, *inter alia*, ADCs with charge variant chemical linkers useful in treating various diseases such as cancer and autoimmune disorders.



CHARGE VARIANT LINKERS


BACKGROUND

Antibody-drug conjugates (ADCs) combine the tumor targeting specificity of monoclonal antibodies with the potent cell-killing activity of cytotoxic warheads. There has been a surge of interest in designing new ADC formats due in part to the recent clinical success of ADCs, which includes the approvals of brentuximab vedotin (ADCETRIS[®]) in relapsed Hodgkin lymphoma and anaplastic large-cell lymphoma, and ado-trastuzumab mertansine (KADCYLA[®]) in HER2-positive metastatic breast cancer.

The absolute quantity of delivered drug is limited, in part, by the level of antigen expression, the internalization rate of the ADC, and the number of molecules of drug conjugated to the antibody (the drug-antibody ratio or “DAR”). These restrictions contribute to the observation that highly potent cytotoxic molecules are typically used for the construction of active ADCs, because payloads of more modest potency tend to show more limited activity. One route to increasing the amount of drug delivered to cells is to increase the DAR of the conjugate; however, this approach often leads to a reduced half-life and reduced *in vivo* efficacy. The fast clearance of many such higher-loaded ADCs is often attributed to poor biophysical properties, but specific identification of these properties is lacking. Recent developments in higher loaded conjugates, such as those with hydrophobic drugs leading to ADC aggregation, have depended on hydrophilic polymer-based systems having heterogenous structure and drug loading to avoid aggregation and related issues.

SUMMARY

Some embodiments provide an antibody-drug conjugate (ADC) compound of Formula (I):




wherein:

Ab is an antibody;


each S* is a sulfur atom from a cysteine residue of the antibody, an ϵ -nitrogen atom from a lysine residue of the antibody, or a triazole moiety, and

each L^1 is a first linker optionally substituted with a PEG Unit ranging from PEG2 to PEG72;


wherein S^*-L^1 is selected from the group consisting of formulae A-K:




A




B




C




D




E




F




G




H



I



J



K

wherein:

each L^A is a C_{1-10} alkylene optionally substituted with 1-3 independently selected R^a , or a 2-24 membered heteroalkylene optionally substituted with 1-3 independently selected R^b ;

each Ring B is an 8-12 membered heterocyclyl optionally substituted with 1-3 independently selected R^c , and further optionally fused to 1-2 rings each independently selected from the group consisting of C_{6-10} aryl and 5-6 membered heteroaryl;

each R^a , R^b , and R^c is independently selected from the group consisting of: C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, halogen, $-OH$, $=O$, $-NR^dR^e$, $-C(O)NR^dR^e$, $-C(O)(C_{1-6} \text{ alkyl})$, $-(C_{1-6} \text{ alkylene})-NR^dR^e$, and $-C(O)O(C_{1-6} \text{ alkyl})$;

each R^d and R^e are independently hydrogen or C_{1-3} alkyl; or R^d and R^e together with the nitrogen atom to which both are attached form a 5-6 membered heterocyclyl;

L^2 is an optional second linker optionally substituted with a PEG Unit selected from PEG2 to PEG20;

each M is a multiplexer;

subscript x is 0, 1, 2, 3, or 4;

subscript y is 2^x ;

each D is a Drug Unit;

wherein L^1 and each $(M)_x-(D)_y$ when L^2 is absent, or each $(M)_x-(L^2-D)_y$ when L^2 is present, have a net zero charge at physiological pH;

subscript p is an integer ranging from 2 to 10; and

the ratio of D to Ab is 8:1 to 64:1.

Some embodiments provide a composition comprising an ADC as describe herein, or a pharmaceutically acceptable salt thereof.

Some embodiments provide a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount an ADC as describe herein, or a pharmaceutically acceptable salt thereof, or a composition comprising an ADC as describe herein, or a pharmaceutically acceptable salt thereof, as described herein.

Some embodiments provide a method of treating an autoimmune disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount an ADC as describe herein, or a pharmaceutically acceptable salt thereof, or a composition comprising an ADC as describe herein, or a pharmaceutically acceptable salt thereof, as described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 provides the HIC chromatogram (at 280 nm) of hAC10ec and its conjugates with MC1 or MC3 (DAR = 10, 20, or 38.5).

FIG. 2 schematically depicts sequential reactions of MC2 and *N*-ethyl maleimide onto cysteine residues of an antibody. An antibody (cAC10) having a L0=23152 was reacted with MC2

to form an antibody-duplexer compound (expected mass: 23,476; observed mass: 23,475). The disulfide bond of the MC2 duplexer of the antibody-duplexer compound was then reduced with TCEP, followed by reaction of the reduced antibody-duplexer compound with *N*-ethylmaleimide (NEM) (2 equivalents) to form an antibody-duplexer-NEM compound (expected mass 23,723; observed mass 23,725).

FIG. 3 provides the size exclusion chromatogram of auristatin ADCs (DAR = 16). **FIG. 3A** provides the size exclusion chromatogram of the ADC cAC10-MC2(8)-MC4(16) (retention time: about 6.6 minutes). **FIG. 3B** provides the size exclusion chromatogram of the ADC cAC10-MC2(8)-MC5(16) (retention time: about 6.6 minutes).

FIG. 4A provides the PLRP chromatogram of reduced cAC10 antibody that has undergone sequential reactions with MC2 and MC4 (retention time of light chain: about 1.29 minutes; retention time of heavy chain: about 1.97 minutes). **FIG. 4B** provides the mass spectrum of antibody (cAC10) light chain from the intact antibody that has undergone reaction with one unit of MC2 (expected: 25,737; observed 25,737). **FIG. 4C** provides the mass spectrum of antibody (cAC10) light chain from the intact antibody attached to MC2(1)-MC4(2) (expected: 28,072; observed 28,072). **FIG. 4D** provides the mass spectrum of antibody (cAC10) heavy chain from the intact antibody attached to MC2(3)-MC4(6) (expected: 63,364; observed: 63,364).

FIG. 5A provides the PLRP chromatogram of reduced cAC10 antibody that has undergone sequential reactions with MC2 and MC5 (retention time of light chain: about 0.33 minutes; retention time of heavy chain: about 1.0 minutes). **FIG. 5B** provides the mass spectrum of the antibody (cAC10) light chain to MC2(1)-MC5(2) (expected: 26,244; observed: 26,244). **FIG. 5C** provides the mass spectrum data of the antibody (cAC10) heavy chain attached to MC2(3)-MC5(6) (expected: 57,880; observed: 57,879).

FIG. 6 schematically depicts an exemplary method for the preparation of ADCs comprising one or more multiplexer moieties. In that method an individual antibody is reduced and reacted with MC2. In a monoclonal antibody with engineered two cysteine residues (ECmAb), having 10 total Cys residues (eight native and two engineered), the thiol group of each cysteine is reacted with a MC2 unit. Each MC2 unit (after disulfide reduction) is then reacted with two additional MC2 units. Conjugation of L²-D moieties to the terminal MC2 units upon reduction of their disulfide bonds forms ADCs with DAR = 40. Those ADCs have the general formula of Ab-MC2(10)-MC2(20)-(L²-D)(40).

FIG. 7 provides the HIC chromatogram of hAC10 conjugates with MC1 or MC3 having different DARs (DAR = 0, 10, 20, and 38.5).

FIG. 8 provides the *in vitro* cytotoxicity of cAc10ec-MC1 ADCs having different DARs (DAR = 10, 20, and 38.5) to Hodgkin's Lymphoma cell line L540cy.

5 **FIG. 9** provides the rat pharmacokinetic data of DAR16 conjugates of a non-binding IgG1 antibody with conjugation to a NAMPT inhibitor, with each conjugate having different charges in the L²-D moieties. ADCs with L²-D = MC9 (neutral) or MC8 (zwitterionic) are compared with those having L²-D = MC7 (negatively charged) and MC10 (positively charged).

10 **FIG. 10** provides the efficacy of cAC10 or non-binding IgG1 conjugates with an NAMPT inhibitor, which have the general formula of cAC10-MC6(8)-(L²-D)(16) or IgG1-MC6(8)-(L²-D)(16), respectively, in an *in vivo* xenograft model with L540cy cells, wherein L²-D is MC7, MC8, MC9, or MC10.

15 **FIG. 11** provides the efficacy of Ab3(ec)-MC6(10)-MC9(20) and Ab3(ec)-MC7(10) ADCs on KG1-22 cells in an *in vivo* xenograft model using both antibody- and drug-normalized dosing (mean tumor data).

DETAILED DESCRIPTION

It is expected that ADCs with linkers having a net charge would have superior biophysical properties due to their greater hydrophilicity. In contrast, it has been unexpectedly
20 found that having a net charge on the linker in a higher-loaded ADC can have a profound negative effect on its biophysical properties. For example, ADCs with drug-linkers having a net zero charge outperform comparator ADCs in which the linkers have a net positive charge or a net negative charge.

Accordingly, provided herein are ADCs of Formula (I) having charge-variant linkers and
25 a range of drug-antibody ratios (DARs), including ADCs with high DARs (e.g., DAR > 8). Traditional high DAR ADCs exhibit reduced potency and/or require heterogenous polymer-based systems to avoid aggregation (and concomitant loss of potency). In some embodiments, the ADCs described herein exhibit more favorable biophysical properties as compared to that typically observed with traditional high-load ADCs. In some embodiments, the ADCs described herein
30 have more favorable biophysical properties as compared to high DAR ADCs with a linker having a net charge. In some embodiments, the ADCs described herein have improved *in vivo* efficacy

as compared to high DAR ADCs with a linker having a net charge. The *in vivo* efficacy of ADCs largely depends on their pharmacokinetics and the potency of its payload. ADCs of Formula (I) have charge-variant linkers such that the drug-linker moieties of the ADC are zwitterionic or neutral (i.e., have a net zero charge) at physiological pH. In some embodiments, ADCs of Formula (I) exhibit extended half-lives relative to traditional high-load ADCs or comparator ADC with drug-linker moieties that have a net positive or negative charge. This approach can enable tuning of an ADC's half-life, and the use of less potent compounds (e.g., less cytotoxic compounds) as the Drug Unit of the ADC, which typically requires a higher DAR compared to those with conjugation to more cytotoxic compounds, in order to exhibit the required efficacy for treating cancer.

Definitions

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Methods and materials are described herein for use in the present application; other, suitable methods and materials known in the art in some aspects of this disclosure are also used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entireties. In case of conflict, the present specification, including definitions, will control. When trade names are used herein, the trade name includes the product formulation, the generic drug, and the active pharmaceutical ingredient(s) of the trade name product, unless otherwise indicated by context.

The terms "a," "an," or "the" as used herein not only include aspects with one member, but also include aspects with more than one member. For instance, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a linker" includes reference to one or more such linkers, and reference to "the cell" includes reference to a plurality of such cells.

The term "about" when referring to a number or a numerical range means that the number or numerical range referred to is an approximation, for example, within experimental variability and/or statistical experimental error, and thus the number or numerical range may vary up to $\pm 10\%$ of the stated number or numerical range. In reference to an ADC composition comprising a

distribution of ADCs as described herein, the average number of conjugated Drug Units to an antibody in the composition can be an integer or a non-integer, particularly when the antibody is to be partially loaded. Thus, the term “about” recited prior to an average drug loading value is intended to capture the expected variations in drug loading within an ADC composition.

5 The term "inhibit" or "inhibition of" means to reduce by a measurable amount, or to prevent entirely (e.g., 100% inhibition).

 The term “therapeutically effective amount” refers to an amount of an ADC, or a salt thereof (as described herein), that is effective to treat a disease or disorder in a mammal. In the case of cancer, the therapeutically effective amount of the ADC provides one or more of the
10 following biological effects: reduction of the number of cancer cells; reduction of tumor size; inhibition of cancer cell infiltration into peripheral organs; inhibition of tumor metastasis; inhibition, to some extent, of tumor growth; and/or relief, to some extent, of one or more of the symptoms associated with the cancer. For cancer therapy, efficacy, in some aspects, is measured by assessing the time to disease progression (TTP) and/or determining the response rate (RR).

15 Unless otherwise indicated or implied by context, the term “substantial” or “substantially” refers to a majority, *i.e.* >50% of a population, of a mixture, or a sample, typically more than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98%, or 99%.

 The terms “intracellularly cleaved” and “intracellular cleavage” refer to a metabolic
20 process or reaction occurring inside a cell, in which the cellular machinery acts on the ADC or a fragment thereof, to intracellularly release free drug from the ADC, or other degradant products thereof. The moieties resulting from that metabolic process or reaction are thus intracellular metabolites.

 The term “cytotoxic activity” refers to a cell-killing effect of a drug or ADC or an
25 intracellular metabolite of an ADC. Cytotoxic activity is typically expressed by an IC₅₀ value, which is the concentration (molar or mass) per unit volume at which half the cells survive exposure to a cytotoxic agent.

 The term “cytostatic activity” refers to an anti-proliferative effect other than cell killing
30 of a cytostatic agent, or an ADC having a cytostatic agent as its Drug Unit (D) or an intracellular metabolite thereof wherein the metabolite is a cytostatic agent.

The term “cytotoxic agent” as used herein refers to a substance that has cytotoxic activity, as defined herein. The term is intended to include chemotherapeutic agents, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including synthetic analogs and derivatives thereof.

5 The term “cytostatic agent” as used herein refers to a substance that has cytostatic activity as defined herein. Cytostatic agents include, for example, enzyme inhibitors.

The terms “cancer” and “cancerous” refer to or describe the physiological condition or disorder in mammals that is typically characterized by unregulated cell growth. A “tumor” comprises multiple cancerous cells.

10 An “autoimmune disorder” herein is a disease or disorder arising from and directed against a subject’s own tissues or proteins.

“Subject” as used herein refers to an individual to which an ADC, as described herein, is administered. Examples of a “subject” include, but are not limited to, a mammal such as a human, rat, mouse, guinea pig, non-human primate, pig, goat, cow, horse, dog, cat, bird and fowl.

15 Typically, a subject is a rat, mouse, dog, non-human primate, or human. In some aspects, the subject is a human.

The terms “treat” or “treatment,” unless otherwise indicated or implied by context, refer to therapeutic treatment and prophylactic measures to prevent relapse, wherein the object is to inhibit an undesired physiological change or disorder, such as, for example, the development or spread of cancer. For purposes of the present disclosure, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (*i.e.*, not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” in some aspects also means prolonging survival as compared to expected survival if not receiving treatment.

20 In the context of cancer, the term “treating” includes any or all of: inhibiting growth of tumor cells, cancer cells, or of a tumor; inhibiting replication of tumor cells or cancer cells, lessening of overall tumor burden or decreasing the number of cancerous cells, and ameliorating one or more symptoms associated with the disease.

30 In the context of an autoimmune disorder, the term “treating” includes any or all of: inhibiting replication of cells associated with an autoimmune disorder state including, but not

limited to, cells that produce an autoimmune antibody, lessening the autoimmune-antibody burden and ameliorating one or more symptoms of an autoimmune disorder.

The term “salt,” as used herein, refers to organic or inorganic salts of a compound, such as a Drug Unit (D), a linker such as those described herein, or an ADC. In some aspects, the compound contains at least one amino group, and accordingly, acid addition salts can be formed with the amino group. Exemplary salts include, but are not limited to, sulfate, trifluoroacetate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, *p*-toluenesulfonate, and pamoate (*i.e.*, 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. A salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion. The counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a salt has one or more than one charged atom in its structure. In instances where there are multiple charged atoms as part of the salt multiple counter ions are sometimes present. Hence, a salt can have one or more charged atoms and/or one or more counterions. A “pharmaceutically acceptable salt” is one that is suitable for administration to a subject as described herein and in some aspects includes salts as described by P. H. Stahl and C. G. Wermuth, editors, *Handbook of Pharmaceutical Salts: Properties, Selection and Use*, Weinheim/Zürich:Wiley-VCH/VHCA, 2002, the list for which is specifically incorporated by reference herein.

The term “alkyl” refers to a straight chain or branched, saturated hydrocarbon having the indicated number of carbon atoms (e.g., “C₁-C₄ alkyl,” “C₁-C₆ alkyl,” “C₁-C₈ alkyl,” or “C₁-C₁₀” alkyl have from 1 to 4, to 6, 1 to 8, or 1 to 10 carbon atoms, respectively) and is derived by the removal of one hydrogen atom from the parent alkane. Representative straight chain “C₁-C₈ alkyl” groups include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl and n-octyl; while branched C₁-C₈ alkyls include, but are not limited to, isopropyl, *sec*-butyl, isobutyl, *tert*-butyl, isopentyl, and 2-methylbutyl.

The term “alkylene” refers to a bivalent saturated branched or straight chain hydrocarbon of the stated number of carbon atoms (e.g., a C₁-C₆ alkylene has from 1 to 6 carbon atoms) and having two monovalent centers derived by the removal of two hydrogen atoms from the same or

two different carbon atoms of the parent alkane. Alkylene groups can be substituted with 1-6 fluoro groups, for example, on the carbon backbone (as $-\text{CHF}-$ or $-\text{CF}_2-$) or on terminal carbons of straight chain or branched alkyls (such as $-\text{CHF}_2$ or $-\text{CF}_3$). Alkylene groups include but are not limited to: methylene ($-\text{CH}_2-$), ethylene ($-\text{CH}_2\text{CH}_2-$), n-propylene ($-\text{CH}_2\text{CH}_2\text{CH}_2-$), n-propylene ($-\text{CH}_2\text{CH}_2\text{CH}_2-$), n-butylene ($-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$), difluoromethylene ($-\text{CF}_2-$), tetrafluoroethylene ($-\text{CF}_2\text{CF}_2-$), and the like.

The term "heteroalkyl" refers to a stable straight or branched chain hydrocarbon that is fully or partially saturated having the stated number of total atoms and at least one (e.g., 1 to 15) heteroatom selected from the group consisting of O, N, Si and S. The carbon and heteroatoms of the heteroalkyl group can be oxidized (e.g., to form ketones, N-oxides, sulfones, and the like) and the nitrogen atoms can be quaternized. The heteroatom(s) can be placed at any interior position of the heteroalkyl group and/or at any terminus of the heteroalkyl group, including termini of branched heteroalkyl groups), and/or at the position at which the heteroalkyl group is attached to the remainder of the molecule. Heteroalkyl groups can be substituted with 1-6 fluoro groups, for example, on the carbon backbone (as $-\text{CHF}-$ or $-\text{CF}_2-$) or on terminal carbons of straight chain or branched heteroalkyls (such as $-\text{CHF}_2$ or $-\text{CF}_3$). Examples of heteroalkyl groups include, but are not limited to, $-\text{CH}_2\text{-CH}_2\text{-O-CH}_3$, $-\text{CH}_2\text{-CH}_2\text{-NH-CH}_3$, $-\text{CH}_2\text{-CH}_2\text{-N(CH}_3)_2$, $-\text{C(=O)-NH-CH}_2\text{-CH}_2\text{-NH-CH}_3$, $-\text{C(=O)-N(CH}_3)\text{-CH}_2\text{-CH}_2\text{-N(CH}_3)_2$, $-\text{C(=O)-NH-CH}_2\text{-CH}_2\text{-NH-C(=O)-CH}_2\text{-CH}_3$, $-\text{C(=O)-N(CH}_3)\text{-CH}_2\text{-CH}_2\text{-N(CH}_3)\text{-C(=O)-CH}_2\text{-CH}_3$, $-\text{O-CH}_2\text{-CH}_2\text{-CH}_2\text{-NH(CH}_3)$, $-\text{O-CH}_2\text{-CH}_2\text{-CH}_2\text{-N(CH}_3)_2$, $-\text{O-CH}_2\text{-CH}_2\text{-CH}_2\text{-NH-C(=O)-CH}_2\text{-CH}_3$, $-\text{O-CH}_2\text{-CH}_2\text{-CH}_2\text{-N(CH}_3)\text{-C(=O)-CH}_2\text{-CH}_3$, $-\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-NH(CH}_3)$, $-\text{O-CH}_2\text{-CH}_2\text{-CH}_2\text{-N(CH}_3)_2$, $-\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-NH-C(=O)-CH}_2\text{-CH}_3$, $-\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N(CH}_3)\text{-C(=O)-CH}_2\text{-CH}_3$, $-\text{CH}_2\text{-S-CH}_2\text{-CH}_3$, $-\text{CH}_2\text{-CH}_2\text{-S(O)-CH}_3$, $-\text{NH-CH}_2\text{-CH}_2\text{-NH-C(=O)-CH}_2\text{-CH}_3$, $-\text{CH}_2\text{-CH}_2\text{-S(O)}_2\text{-CH}_3$, $-\text{CH}_2\text{-CH}_2\text{-O-CF}_3$, and $-\text{Si(CH}_3)_3$. Up to two heteroatoms may be consecutive, such as, for example, $-\text{CH}_2\text{-NH-OCH}_3$ and $-\text{CH}_2\text{-O-Si(CH}_3)_3$. A terminal polyethylene glycol (PEG) moiety is a type of heteroalkyl group.

The term "heteroalkylene" refers to a bivalent unsubstituted straight or branched group derived from heteroalkyl (as defined herein). Examples of heteroalkylene groups include, but are not limited to, $-\text{CH}_2\text{-CH}_2\text{-O-CH}_2-$, $-\text{CH}_2\text{-CH}_2\text{-O-CF}_2-$, $-\text{CH}_2\text{-CH}_2\text{-NH-CH}_2-$, $-\text{C(=O)-NH-CH}_2\text{-CH}_2\text{-NH-CH}_2-$, $-\text{C(=O)-N(CH}_3)\text{-CH}_2\text{-CH}_2\text{-N(CH}_3)\text{-CH}_2-$, $-\text{C(=O)-NH-CH}_2\text{-CH}_2\text{-NH-C(=O)-CH}_2\text{-CH}_2-$, $-\text{C(=O)-N(CH}_3)\text{-CH}_2\text{-CH}_2\text{-N(CH}_3)\text{-C(=O)-CH}_2\text{-CH}_2-$, $-\text{O-CH}_2\text{-CH}_2\text{-CH}_2\text{-NH-CH}_2-$,

-O-CH₂-CH₂-CH₂-N(CH₃)-CH₂-, -O-CH₂-CH₂-CH₂-NH-C(=O)-CH₂-CH₂-, -O-CH₂-CH₂-CH₂-N(CH₃)-C(=O)-CH₂-CH₂-, -CH₂-CH₂-CH₂-NH-CH₂-, -CH₂-CH₂-CH₂-N(CH₃)-CH₂-, -CH₂-CH₂-CH₂-NH-C(=O)-CH₂-CH₂-, -CH₂-CH₂-CH₂-N(CH₃)-C(=O)-CH₂-CH₂-, -CH₂-CH₂-NH-C(=O)-, -CH₂-CH₂-N(CH₃)-CH₂-, -CH₂-CH₂-N⁺(CH₃)₂-, -NH-CH₂-CH₂(NH₂)-CH₂-, and -NH-CH₂-CH₂(NHCH₃)-CH₂-. A bivalent polyethylene glycol (PEG) moiety is a type of heteroalkylene group.

The term “alkoxy” refers to an alkyl group, as defined herein, which is attached to a molecule via an oxygen atom. For example, alkoxy groups include, but are not limited to methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy and n-hexoxy.

The term “haloalkyl” refers to a straight chain or branched, saturated hydrocarbon having the indicated number of carbon atoms (*e.g.*, “C₁-C₄ alkyl,” “C₁-C₆ alkyl,” “C₁-C₈ alkyl,” or “C₁-C₁₀” alkyl have from 1 to 4, to 6, 1 to 8, or 1 to 10 carbon atoms, respectively) wherein at least one hydrogen atom of the alkyl group is replaced by a halogen (*e.g.*, fluoro, chloro, bromo, or iodo). When the number of carbon atoms is not indicated, the haloalkyl group has from 1 to 6 carbon atoms. Representative C₁₋₆ haloalkyl groups include, but are not limited to, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, and 1-chloroisopropyl.

The term “haloalkoxy” refers to a haloalkyl group, as defined herein, which is attached to a molecule via an oxygen atom. For example, haloalkoxy groups include, but are not limited to difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, and 1,1,1-trifluoro-2-methylpropoxy.

The term “aryl” refers to a monovalent carbocyclic aromatic hydrocarbon group of 6-10 carbon atoms derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, biphenyl, and the like.

The term “heterocyclyl” refers to a saturated or partially unsaturated ring or a multiple condensed ring system, including bridged, fused, and spiro ring systems. Heterocycles can be described by the total number of atoms in the ring system, for example a 3-10 membered heterocycle has 3 to 10 total ring atoms. The term includes single saturated or partially unsaturated rings (*e.g.*, 3, 4, 5, 6 or 7-membered rings) from about 1 to 6 carbon atoms and from about 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. The ring may be substituted with one or more (*e.g.*, 1, 2, or 3) oxo groups and the sulfur and nitrogen atoms may also be present in their oxidized forms. Such rings include but are not limited to azetidiny,

tetrahydrofuranyl, and piperidinyl. The term “heterocycle” also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a single heterocycle ring (as defined above) can be condensed with one or more heterocycles (e.g., decahydronaphthyridinyl), carbocycles (e.g., decahydroquinolyl), or aryls. The rings of a multiple condensed ring system can be connected to each other via fused, spiro, or bridged bonds when allowed by valency requirements. It is to be understood that the point of attachment of a multiple condensed ring system (as defined above for a heterocycle) can be at any position of the multiple condensed ring system including a heterocycle, aryl and carbocycle portion of the ring. It is also to be understood that the point of attachment for a heterocycle or heterocycle multiple condensed ring system can be at any suitable atom of the heterocycle or heterocycle multiple condensed ring system including carbon atoms and heteroatoms (e.g., a nitrogen). Exemplary heterocycles include, but are not limited to aziridinyl, azetidiny, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1,2,3,4-tetrahydroquinolyl, benzoxazinyl, dihydrooxazolyl, chromanyl, 1,2-dihydropyridinyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl, and 1,4-benzodioxanyl.

The term “heteroaryl” refers to an aromatic hydrocarbon ring system with at least one heteroatom within a single ring or within a fused ring system, selected from the group consisting of O, N and S. The ring or ring system has $4n + 2$ electrons in a conjugated π system where all atoms contributing to the conjugated π system are in the same plane. In some embodiments, heteroaryl groups have 5-10 total ring atoms and 1, 2, or 3 heteroatoms (referred to as a “5-10 membered heteroaryl”). Heteroaryl groups include, but are not limited to, imidazole, triazole, thiophene, furan, pyrrole, benzimidazole, pyrazole, pyrazine, pyridine, pyrimidine, and indole.

As used herein, the term “free drug” refers to a biologically active species that is not covalently attached to an antibody. Accordingly, free drug refers to a compound as it exists immediately upon cleavage from the ADC. The release mechanism can be via a cleavable linker in the ADC, or via intracellular conversion or metabolism of the ADC. In some aspects, the free drug will be protonated and/or may exist as a charged moiety. The free drug is a pharmacologically active species which is capable of exerting the desired biological effect. In some embodiments, the pharmacologically active species is the parent drug alone. In some embodiments, the pharmacologically active species is the parent drug bonded to a component or vestige of the ADC

(e.g., a component of the linker, succinimide, hydrolyzed succinimide, and/or antibody that has not undergone subsequent intracellular metabolism).

Exemplary free drug compounds have cytotoxic, cytostatic, immunosuppressive, immunostimulatory, or immunomodulatory drug. In some embodiments, D is a tubulin disrupting agent, DNA minor groove binder, DNA damaging agent or DNA replication inhibitor.

As used herein, the term “Drug Unit” refers to the free drug that is conjugated to an antibody in an ADC, as described herein.

As used herein, the term “hydrophilic drug” refers to a Drug Unit or free drug, as defined herein, having a logP value of 1.0 or less. Exemplary hydrophilic drugs include, but are not limited to antifolates, nucleosides and NAMPT inhibitors.

As used herein, “net zero charge” refers to a compound, or specific part of a compound, that has no net charge at physiological pH. For example, in the compounds of Formula (I) described herein, the L^2 and/or $L^1-[(M)_x-(D)_y]$ parts of Formula (I) can have a net zero charge. Compounds, or parts of a compound, having a net zero charge includes those with two or more charged species, wherein the sum of the two or more charges is zero (such as a zwitterionic compound).

“Physiological pH,” as used herein, refers to a pH of about 7.3 to about 7.5, or a pH of 7.3 to 7.5.

Antibody-Drug Conjugates (ADCs) and Intermediates Thereof

First generation ADCs contained highly toxic payloads traditionally used for cancer chemotherapy, such as doxorubicin, microtubule inhibitors, and DNA-damaging agents. *See* Diamantis and Banerji, Br. J. Cancer, Vol. 114, pp. 362–367 (2016). Those early ADCs were highly toxic and generally had poor physiochemical properties, with only an estimated 1-2% of the payload reaching the targeted cells. *See* Beck, et al., Nat. Rev. Drug Discov., Vol. 16, pp. 315–337 (2017). Second generation ADCs, such as ado-trastuzumab emtansine (Kadcyla®) also provide cytotoxic payloads and include improved linkers facilitating release of the payload at or near the target cells. Despite these improvements, complex issues still remain in the design of ADCs.


The linker between the antibody and the payload controls the release, and thus the delivery, of the drug to the target. *See* Gerber, et al., Nat. Prod. Rep., Vol. 30, pp. 625–639 (2013). Premature drug release can cause severe off-target toxicities by killing healthy cells. Indeed, the

linker must be stable enough to survive until binding of the antibody to the target, but labile enough for drug release (whether through direct enzymatic action, or a combination of enzymatic cleavage and hydrolysis). However, linkers may also effect the solubility, aggregation, and clearance of ADCs, thus influencing their distribution. *See* Jain, et al., Pharm. Res., Vol. 32, pp. 3526–3540 (2015). These issues contribute to the high interpatient variability and distribution patterns observed with many ADCs, impeding administration of the correct dose. *See* Krop, et al., Breast Cancer Res., Vol. 18, p. 34 (2016).

Moreover, a higher DAR generally leads to greater *in vitro* potency, but typically at the cost of poorer pharmacokinetic properties *in vivo*. *See* Hamblett, et al., Clin. Cancer Res., Vol. 10, pp. 7063–7070 (2004); *see also*, Sun, et al., Bioconj. Chem., Vol. 28, pp. 1371–1381 (2017). Indeed, when otherwise identical ADCs were prepared with DARs of 2, 4, and 8, the clearance of the ADCs increased at the DAR increased. *See, e.g.*, Hamblett, et al. (2004), *supra*.

The present application is based, in part, on the surprising finding that modulation of the charge of the linker between the antibody and the drug can have a dramatic impact on the pharmacokinetic properties of the ADC. In particular, linkers that are uncharged, or have a net zero charge (e.g., zwitterionic linkers) provide access to ADCs with a range of DARs. In some embodiments, the ADCs provided herein exhibit *in vitro* potency as well as improved pharmacokinetic properties.

Some embodiments provide an antibody drug conjugate (ADC) compound of Formula (I):




wherein Ab is an antibody;


each S* is a sulfur atom from a cysteine residue of the antibody, an ϵ -nitrogen atom from a lysine residue of the antibody, or a triazole moiety, and

each L¹ is a first linker optionally substituted with a PEG Unit ranging from PEG2 to PEG72,


wherein S*-L¹ is selected from the group consisting of formulae A-K:




A




B



C



D



wherein:

each L^A is a C_{1-10} alkylene optionally substituted with 1-3 independently selected R^a , or a 2-24 membered heteroalkylene optionally substituted with 1-3 independently selected R^b ;

each Ring B is an 8-12 membered heterocyclyl optionally substituted with 1-3 independently selected R^c , and further optionally fused to 1-2 rings each independently selected from the group consisting of C_{6-10} aryl and 5-6 membered heteroaryl;

each R^a , R^b , and R^c is independently selected from the group consisting of: C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, halogen, $-OH$, $=O$, $-NR^dR^e$, $-(C_{1-6} \text{ alkylene})-NR^dR^e$, $-C(O)NR^dR^e$, $-C(O)(C_{1-6} \text{ alkyl})$, and $-C(O)O(C_{1-6} \text{ alkyl})$;

each R^d and R^e are independently hydrogen or C_{1-3} alkyl; or R^d and R^e together with the nitrogen atom to which both are attached form a 5-6 membered heterocyclyl;

L^2 is an optional second linker optionally substituted with a PEG Unit ranging from PEG2 to PEG72;

each M is a multiplexer;

subscript x is 0, 1, 2, 3, or 4;

subscript y is 2^x ;

each D is a Drug Unit;

5 wherein each L^2 -D has a net zero charge at physiological pH; or wherein L^1 and each $(M)_x$ - $(D)_y$, when L^2 is absent or each $(M)_x$ - $(L^2$ -D) $_y$, when L^2 is present has a net zero charge at physiological pH;

subscript p is an integer ranging from 2 to 10; and


wherein the ratio of D to Ab is 8:1 to 64:1

10 In some embodiments, each S^* is a sulfur atom from a cysteine residue of the antibody. In some embodiments, the cysteine residue is a native cysteine residue, an engineered cysteine residue, or a combination thereof. In some embodiments, each cysteine residue is from a reduced interchain disulfide bond. In some embodiments, each cysteine residue is an engineered cysteine residue. In some embodiments, each cysteine residue is a native cysteine residue. In some
15 embodiments, one or more S^* is a sulfur atom from an engineered cysteine residue; and any remaining S^* is a sulfur atom from a native cysteine residue. In some embodiments, 1, 2, 3, or 4 S^* is a sulfur atom from an engineered cysteine residue; and any remaining S^* is a sulfur atom from a native cysteine residue.


In some embodiments, each S^* is an ϵ -nitrogen atom from a lysine residue of the antibody. In some embodiments, the lysine residue is a native lysine residue, an engineered lysine residue,
20 or a combination thereof. In some embodiments, each lysine residue is an engineered lysine residue. In some embodiments, each lysine residue is a native lysine residue. In some embodiments, one or more S^* is an ϵ -nitrogen atom from an engineered lysine residue; and any remaining S^* is an ϵ -nitrogen atom from a native lysine residue. In some embodiments, 1, 2, 3, or 4 S^* is an ϵ -nitrogen atom from an engineered lysine residue; and any remaining S^* is an ϵ -nitrogen
25 atom from a native lysine residue.


In some embodiments, each S^* is a triazole moiety. In some embodiments, when S^* is a triazole moiety, that triazole moiety is formed through an azide-alkyne polar cycloaddition reaction (“click chemistry”) between an azide group and an alkyne group, as described herein. Methods to
30 incorporate the azide or the alkyne precursors for cycloaddition that results in S^* being a triazole moiety is by modifying one or more amino acid residues of the antibody.


In some embodiments, L^1 terminates in a component having a sufficiently strained alkyne functional group that is reactive towards a modified antibody bearing a suitable azide functional group. A dipolar cycloaddition between these two functional groups results in a triazole. In some embodiments, Diels-Alder type chemistry (4+2 cycloaddition, inverse electron demand) is used for the covalent attachment of an L^1 having a terminal 1,2,4,5-tetrazine to a modified antibody bearing a suitable trans cyclooctene functional group. For illustration, general depictions of the Click and Diels-Alder (4+2 cycloaddition) reactions are shown in a) and b) respectively. One of skill in the art will appreciate that a variety of modifications are possible, including, but not limited to, varying the substitution patterns of the reactive components, switching the portion (Ab or L^1) to which each reactive component is attached.



In some embodiments, S^*-L^1 has formula A: (A). In some


embodiments, S^*-L^1 has formula B:  (B). In some embodiments, S^*-L^1 has

formula C:  (C).




In some embodiments, S^*-L^1 has formula D:

(D). In some




embodiments, S^*-L^1 has formula E:

(E). In some embodiments, S^*-L^1 has formula




F:

(F). In some embodiments, S^*-L^1 has formula G:




(G). In some embodiments, S^*-L^1 has formula H:




5


(H). In some embodiments, S^*-L^1 has formula I:



(I). In some embodiments, S^*-L^1 has formula J:




(J). In some embodiments, S^*-L^1 has formula K:



(K).

In some embodiments, when each S^* is an ϵ -nitrogen atom from a lysine residue of the antibody, S^*-L^1 is selected from the group consisting of formulae E1-K1:

10



5

10 In some embodiments, L^1 is unsubstituted. In some embodiments, L^1 is substituted with a PEG Unit ranging from PEG2 to PEG72, for example, PEG2, PEG4, PEG6, PEG8, PEG10, PEG12, PEG16, PEG20, PEG 24, PEG36, or PEG72.


15 In some embodiments, L^A is C_{1-10} alkylene optionally substituted with 1-3 independently selected R^a . In some embodiments, L^A is C_{1-8} alkylene optionally substituted with 1-3 independently selected R^a . In some embodiments, L^A is C_{1-6} alkylene optionally substituted with 1-3 independently selected R^a . In some embodiments, L^A is C_{1-4} alkylene optionally substituted with 1-3 independently selected R^a .

20 In some embodiments, L^A is unsubstituted. In some embodiments, L^A is substituted with one R^a . In some embodiments, L^A is substituted with two R^a . In some embodiments, L^A is substituted with three R^a .

 In some embodiments, L^A , together with its 0, 1, 2, or 3 R^a , is uncharged at physiological pH. In some embodiments, L^A , together with its 0, 1, 2, or 3 R^a , is charged neutral at physiological


pH. In some embodiments, L^A is substituted with 2 R^a , wherein one R^a is positively charged and the other R^a is negatively charged.

In some embodiments, each R^a is selected from the group consisting of: C_{1-6} alkoxy, halogen, -OH, $-(C_{1-6} \text{ alkylene})-NR^dR^e$, $-C(O)NR^dR^e$ and $-C(O)(C_{1-6} \text{ alkyl})$. In some embodiments, one of R^a is NR^dR^e , and the remaining R^a is not NR^dR^e . In some embodiments, one of R^a is $-(C_{1-6} \text{ alkylene})-NR^dR^e$, and the remaining R^a is not $-(C_{1-6} \text{ alkylene})-NR^dR^e$. In some embodiments, one of R^a is NR^dR^e , and the remaining R^a is selected from the group consisting of: C_{1-6} alkoxy, halogen, -OH, $-C(O)NR^dR^e$ and $-C(O)(C_{1-6} \text{ alkyl})$. In some embodiments, one of R^a is $-(C_{1-6} \text{ alkylene})-NR^dR^e$, and the remaining R^a is selected from the group consisting of: C_{1-6} alkoxy, halogen, -OH, $-C(O)NR^dR^e$ and $-C(O)(C_{1-6} \text{ alkyl})$.

In some embodiments, L^A is ; wherein L^{A1} is a bond or a

C_{1-5} alkylene optionally substituted with R^a ; subscript $n1$ is 1-4; and subscript $n2$ is 0-4. In some embodiments, subscript $n1$ is 1. In some embodiments, subscript $n1$ is 2. In some embodiments, subscript $n1$ is 3. In some embodiments, subscript $n1$ is 4. In some embodiments, subscript $n2$ is 0. In some embodiments, subscript $n2$ is 1. In some embodiments, subscript $n2$ is 2. In some embodiments, subscript $n2$ is 3. In some embodiments, subscript $n2$ is 4.

In some embodiments, L^{A1} is a bond. In some embodiments, L^{A1} is a C_{1-5} alkylene. In some embodiments, L^{A1} is unsubstituted. In some embodiments, L^{A1} is substituted with one R^a .

In some embodiments, L^A is ; wherein subscript $n1$ is 1 or 2; and subscript $n2$ is 0, 1, or 2. In some embodiments, subscript $n1$ is 1. In some embodiments, subscript $n1$ is 2. In some embodiments, subscript $n2$ is 0. In some embodiments, subscript $n2$ is 1. In some embodiments, subscript $n2$ is 2. In some embodiments, subscript $n1$ is 1 and subscript $n2$ is 0. In some embodiments, subscript $n1$ is 1 and subscript $n2$ is 1. In some embodiments, subscript $n1$ is 1 and subscript $n2$ is 2. In some embodiments, subscript $n1$ is 2 and subscript $n2$ is 0. In some embodiments, subscript $n1$ is 2, and subscript $n2$ is 1. In some embodiments, subscript $n1$ is 2 and subscript $n2$ is 2.

In some embodiments, L^A is an unsubstituted C_{1-10} alkylene, such as methylene, ethylene, propylene, n-butylene, sec-butylene, pentylene, or hexylene.

In some embodiments, L^A is a 2-24 membered heteroalkylene optionally substituted with 1-3 independently selected R^b , and optionally further substituted with a PEG Unit ranging from PEG2 to PEG24. In some embodiments, L^A is 2-12 membered heteroalkylene optionally substituted with 1-3 independently selected R^b , and optionally further substituted with a PEG Unit ranging from PEG2 to PEG24. In some embodiments, L^A is a 2-24 membered heteroalkylene having no charged heteroatoms at physiological pH optionally substituted with 1-3 independently selected R^b , and optionally further substituted with a PEG Unit ranging from PEG2 to PEG24. In some embodiments, L^A is unsubstituted. In some embodiments, R^b is not $-NR^dR^e$ in formula A and formula D. In some embodiments, only one of R^b is $-NR^dR^e$ in formula B and formula C.



In some embodiments, when L^A is substituted by a PEG Unit, the heteroalkylene of L^A is the site of substitution by the PEG Unit.



In some embodiments, L^A is substituted with 1-3 independently selected R^b , as described herein. In some embodiments, L^A is substituted with one R^b , as described herein. In some embodiments, L^A is substituted with two independently selected R^b , as described herein. In some embodiments, L^A is substituted with three independently selected R^b , as described herein.

In some embodiments, L^A is substituted with 1 R^b that is a PEG Unit ranging from PEG2 to PEG24.


In some embodiments, L^A is substituted with 1-3 independently selected R^b as described herein, one of which is a PEG Unit ranging from PEG8 to PEG24.

In some embodiments, each R^b is selected from the group consisting of: C_{1-6} alkoxy, halogen, $-OH$, $-(C_{1-6} \text{ alkylene})-NR^dR^e$, $-C(O)NR^dR^e$ and $-C(O)(C_{1-6} \text{ alkyl})$. In some embodiments, one of R^b is NR^dR^e , and the remaining R^b is not $-NR^dR^e$. In some embodiments, one of R^b is $-(C_{1-6} \text{ alkylene})-NR^dR^e$, and the remaining R^b is not $-(C_{1-6} \text{ alkylene})-NR^dR^e$. In some embodiments, one of R^b is NR^dR^e , and the remaining R^b is selected from the group consisting of: C_{1-6} alkoxy, halogen, $-OH$, $-C(O)NR^dR^e$ and $-C(O)(C_{1-6} \text{ alkyl})$. In some embodiments, one of R^b is $-(C_{1-6} \text{ alkylene})-NR^dR^e$, and the remaining R^b is selected from the group consisting of: C_{1-6} alkoxy, halogen, $-OH$, $-C(O)NR^dR^e$ and $-C(O)(C_{1-6} \text{ alkyl})$.

In some embodiments, L^A is  or ; wherein L^{A2} is a 2-19 membered heteroalkylene optionally substituted with 1 R^b ; subscript $n1$ is 1-4; subscript $n2$ is 0-3; and L^{A2} is further optionally substituted with a PEG Unit ranging from PEG2 to PEG24. In some embodiments, R^d is hydrogen. In some embodiments, R^d is C_{1-3} alkyl. In some embodiments, R^d is methyl.

In some embodiments, L^A is . In some embodiments, L^A is . In some embodiments, L^{A2} is a 2-12 membered heteroalkylene optionally substituted with R^a and further optionally substituted with a PEG Unit ranging from PEG2 to PEG24. In some embodiments, subscript $n1$ is 1. In some embodiments, subscript $n1$ is 2. In some embodiments, subscript $n1$ is 3. In some embodiments, subscript $n1$ is 4. In some embodiments, subscript $n2$ is 0. In some embodiments, subscript $n2$ is 1. In some embodiments, subscript $n2$ is 2. In some embodiments, subscript $n2$ is 3.

In some embodiments, L^{A2} is unsubstituted. In some embodiments, L^{A2} is substituted with 1 R^a , as described herein. In some embodiments, L^{A2} is substituted with a PEG Unit ranging from PEG8 to PEG24. In some embodiments, L^{A2} is substituted with 1 R^a , as described herein with a PEG Unit ranging from PEG8 to PEG24. In some embodiments, L^A is a C_1 - C_{10} alkylene substituted with $-(CH_2)NH_2$ or $-(CH_2CH_2)NH_2$. In some embodiments, L^A is a C_1 - C_6 alkylene substituted with $-(CH_2)NH_2$ or $-(CH_2CH_2)NH_2$. In some embodiments, L^A is a C_1 - C_{10} alkylene substituted with oxo ($C=O$); and with one of $-(CH_2)NH_2$ and $-(CH_2CH_2)NH_2$. In some embodiments, L^A is a C_1 - C_6 alkylene substituted with oxo ($C=O$); and with one of $-(CH_2)NH_2$ and $-(CH_2CH_2)NH_2$. In some embodiments, L^A is a 2-24 membered heteroalkylene substituted with $-(CH_2)NH_2$ or $-(CH_2CH_2)NH_2$. In some embodiments, L^A is a 4-12 membered heteroalkylene substituted with $-(CH_2)NH_2$ or $-(CH_2CH_2)NH_2$.

In some embodiments, L^A is , wherein subscript $n3$ is 1-5. In some embodiments, subscript $n3$ is 1. In some embodiments, subscript $n3$ is 2. In some

embodiments, subscript n3 is 3. In some embodiments, subscript n3 is 4. In some embodiments, subscript n3 is 5.

In some embodiments, each R^a is independently selected from the group consisting of: C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, halogen, -OH, =O, -C(O)NR^dR^e, -C(O)(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-NR^dR^e, and -C(O)O(C₁₋₆ alkyl). In some embodiments, one of R^a is -NR^dR^e and the other R^a are independently selected from the group consisting of: C₁₋₆ alkyl, C₁₋₆ alkoxy, halogen, -OH, =O, -C(O)(C₁₋₆ alkyl), and -C(O)O(C₁₋₆ alkyl).

In some embodiments, one of R^a is C₁₋₆ haloalkyl. In some embodiments, one of R^a is C₁₋₆ alkoxy. In some embodiments, one of R^a is C₁₋₆ haloalkoxy. In some embodiments, one of R^a is halogen. In some embodiments, one of R^a is -OH. In some embodiments, one of R^a is =O. In some embodiments, one of R^a is C(O)NR^dR^e. In some embodiments, one of R^a is -C(O)(C₁₋₆ alkyl). In some embodiments, one of R^a is -C(O)O(C₁₋₆ alkyl). In some embodiments, one R^a is -NR^dR^e. In some embodiments, one R^a is -(C₁₋₆ alkylene)-NR^dR^e.

In some embodiments, each R^b is independently selected from the group consisting of: C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, halogen, -OH, =O, -C(O)NR^dR^e, -C(O)(C₁₋₆ alkyl), -(C₁₋₆ alkylene)-NR^dR^e, and -C(O)O(C₁₋₆ alkyl). In some embodiments, one R^b is NR^dR^e and the other R^b are independently selected from the group consisting of: C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, halogen, -OH, =O, -C(O)NR^dR^e, -C(O)(C₁₋₆ alkyl), and -C(O)O(C₁₋₆ alkyl). In some embodiments, one of R^b is C₁₋₆ haloalkyl. In some embodiments, one of R^b is C₁₋₆ alkoxy. In some embodiments, one of R^b is C₁₋₆ haloalkoxy. In some embodiments, one of R^b is halogen. In some embodiments, one of R^b is -OH. In some embodiments, one of R^b is =O. In some embodiments, one of R^b is C(O)NR^dR^e. In some embodiments, one of R^b is -C(O)(C₁₋₆ alkyl). In some embodiments, one of R^b is -C(O)O(C₁₋₆ alkyl). In some embodiments, one R^b is -NR^dR^e. In some embodiments, one R^b is -(C₁₋₆ alkylene)-NR^dR^e.

In some embodiments of formulae A and D, the 2-24 membered heteroalkylene is optionally substituted with 1-2 independently selected R^b that are uncharged at physiological pH. In some embodiments of formulae A and D, the 2-24 membered heteroalkylene is optionally substituted with 2 R^b ; wherein one R^b is positively charged and the other R^b is negatively charged.

In some embodiments, R^d and R^e are independently selected from hydrogen and C₁-C₃ alkyl. In some embodiments, R^d and R^e are the same. In some embodiments, R^d and R^e are different. In some embodiments, one of R^d and R^e is hydrogen and the other of R^d and R^e is C₁-C₃

alkyl. In some embodiments, R^d and R^e are both hydrogen. In some embodiments, R^d and R^e are independently C₁-C₃ alkyl. In some embodiments, R^d and R^e are both methyl. In some embodiments, R^d and R^e together with the nitrogen atom to which both are attached form a 5-6 membered heterocyclyl.

5 In some embodiments, the heteroalkylene group of any of formulae A-K is uncharged at physiological pH.

In some embodiments, Ring B is an unfused 8-12 membered heterocyclyl. In some embodiments, Ring B is an unfused 8-10 membered heterocyclyl. In some embodiments, Ring B is an unfused 8 membered heterocyclyl ring. In some embodiments, Ring B contains one carbon-carbon double bond and one nitrogen atom in the ring. In some embodiments, Ring B is (Z)-1,2,3,4,7,8-hexahydroazocine.

In some embodiments, Ring B is an 8-12 membered heterocyclyl fused to a C₆₋₁₀ aryl or 5-6 membered heteroaryl ring. In some embodiments, Ring B is an 8-12 membered heterocyclyl fused to two C₆₋₁₀ aryl rings or two 5-6 membered heteroaryl rings. In some embodiments, Ring B is an 8-10 membered heterocyclyl fused to a C₆₋₁₀ aryl or 5-6 membered heteroaryl ring. In some embodiments, Ring B is an 8-10 membered heterocyclyl fused to two C₆₋₁₀ aryl rings or two 5-6 membered heteroaryl ring rings. In some embodiments, Ring B is fused to one or two C₆₋₁₀ aryl rings. In some embodiments, Ring B is fused to one or two 5-6 membered heteroaryl rings. In some embodiments, Ring B is an 8-12 membered heterocyclyl fused to one or two phenyl rings. In some embodiments, Ring B is an 8-10 membered heterocyclyl fused to one or two phenyl rings. In some embodiments, Ring B is an 8 membered heterocyclyl fused to one or two phenyl rings. In some embodiments, Ring B has one nitrogen atom in the ring. In some embodiments, Ring B has no charged ring heteroatoms at physiological pH.


In some embodiments, Ring B is unsubstituted. In some embodiments, Ring B is substituted with 1-3 independently selected R^c. In some embodiments, Ring B is substituted with one R^c. In some embodiments, Ring B is substituted with two independently selected R^c. In some embodiments, Ring B is substituted with three independently selected R^c.

In some embodiments, Ring B is uncharged at physiological pH.

In some embodiments, each R^c is independently selected from the group consisting of: C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, halogen, -OH, =O, -C(O)NR^dR^e, -C(O)(C₁₋₆ alkyl), -C(O)O(C₁₋₆ alkyl). In some embodiments, each R^c is C₁₋₆ alkyl.


In some embodiments, one or two of R^c is C_{1-6} haloalkyl. In some embodiments, 1-3 R^c are independently a C_{1-6} alkoxy. In some embodiments, one of R^c is C_{1-6} haloalkoxy. In some embodiments, each R^c is independently a halogen. In some embodiments, 1-3 R^c is $-OH$. In some embodiments, one of R^c is $=O$. In some embodiments, one of R^c is $C(O)NR^dR^e$. In some
 5 embodiments, one of R^c is $-C(O)(C_{1-6} \text{ alkyl})$. In some embodiments, one of R^c is $-C(O)O(C_{1-6} \text{ alkyl})$.

In some embodiments, each R^a , R^b and R^c are independently selected from the group consisting of: C_{1-6} alkyl, C_{1-6} haloalkoxy, C_{1-6} alkoxy, halogen, $-OH$, $-NR^dR^e$, $-(C_{1-6} \text{ alkylene})-NR^dR^e$, $-C(O)NR^dR^e$ and $-C(O)(C_{1-6} \text{ alkyl})$. In some embodiments, each R^a , R^b and R^c are
 10 independently selected from the group consisting of: C_{1-6} alkyl, C_{1-6} alkoxy, halogen, $-(C_{1-6} \text{ alkylene})-NR^dR^e$, $-OH$, and $-NR^dR^e$. In some embodiments, none of R^a , R^b and R^c are present in formulae A and D as $-(C_{1-6} \text{ alkylene})-NR^dR^e$ or $-NR^dR^e$ (e.g., so that L^1 remains uncharged at physiological pH). In some embodiments, R^a or R^b is $-NR^dR^e$ in formulae B and C (e.g., so that the carboxylic acid in deprotonated form and $-NR^dR^e$ is in protonated form at physiological pH).
 15 In some embodiments, R^a or R^b is $-(C_{1-6} \text{ alkylene})-NR^dR^e$ in formulae B and C (e.g., so that the carboxylic acid in deprotonated form and $-(C_{1-6} \text{ alkylene})-NR^dR^e$ is in protonated form at physiological pH).




In some embodiments, Ring B is:


In some embodiments, S^*-L^1 is selected from the group consisting of formulae A1, A2,
 20 A3, B1, B2, B3, C1, C2 and C3:




A1




B1




C2




A2




B2




C2



A3




B3




C3

wherein R^d is hydrogen or C_{1-3} alkyl and subscript n_1 is 1 or 2; subscript n_2 is 0, 1 or 2.




In some embodiments, S^*-L^1 is

In some embodiments, S^*-L^1 is




10

In some embodiments, S^*-L^1 is




In some




embodiments, S^*-L^1 is


In some embodiments, S^*-L^1 is




In some embodiments, S^*-L^1 is




In some


embodiments, S^*-L^1 is . In some embodiments, S^*-L^1 is




In some embodiments of S^*-L^1 , subscript n_1 is 1 or 2 or subscript n_2 is 0, 1, or 2; and S^* is a sulfur atom from a cysteine residue of the antibody. In some embodiments, subscript n_1 is 1.


5 In some embodiments, subscript n_2 is 1. In some embodiments, subscript n_2 is 2. In some embodiments, subscript n_1 is 2.

In some embodiments, S^*-L^1 is . In some


embodiments, S^*-L^1 is . In some embodiments, S^*-L^1 is




In some embodiments, S^*-L^1 is




10 In some embodiments, S^*-L^1 is




In some embodiments, S^*-L^1 is




In some embodiments, S^*-L^1 is



In some embodiments, S^*-L^1 is



In some embodiments, S^*-L^1 is







5 In some embodiments of S^*-L^1 , subscript $n1$ is 1 or 2 or subscript $n2$ is 0, 1, or 2; and S^* is an ϵ -nitrogen atom from a lysine residue of the antibody. In some embodiments, subscript $n1$ is 1. In some embodiments, subscript $n2$ is 1. In some embodiments, subscript $n2$ is 2. In some embodiments, subscript $n1$ is 2.

In some embodiments, R^d is hydrogen or C_{1-3} alkyl. In some embodiments, R^d is hydrogen.

10 In some embodiments, R^d is C_{1-3} alkyl. In some embodiments, R^d is methyl.


In some embodiments, $*S-L^1$ is :






In some embodiments, $*S-L^1$ is


. In some embodiments, $*S-L^1$ is




. In some embodiments, $*S-L^1$ is



In some embodiments, S^*-L^1 is:




or




. In


some embodiments, S^*-L^1 is:



. In some embodiments, S^*-L^1 is:




5




In some embodiments, S^*-L^1 is:

. In some




embodiments, S^*-L^1 is:


. In some embodiments, S^*-L^1 is:




In some embodiments, S^*-L^1 is:




In some embodiments, S^*-L^1 is:




In some embodiments, S^*-L^1 is:




In some embodiments, S^*-L^1 is:




In some embodiments, S^*-L^1 is:




In some embodiments, S^*-L^1 is:




In some embodiments, S^*-L^1 is:









In some embodiments, S^*-L^1 is:



is:


In some embodiments, $*S-L^1$ is selected from the group consisting of:



5


In some embodiments, $*S-L^1$ is


. In some embodiments, $*S-$




L^1 is

. In some embodiments, $*S-L^1$ is






In some embodiments, $*S-L^1$ is



embodiments, $*S-L^1$ is




. In some embodiments, $*S-L^1$ is

In some embodiments, $*S-L^1$ comprises R^P , wherein R^P is attached to the nitrogen atom through a functional group that retains that atom in uncharged form under physiological conditions, such as functional groups comprised of $-C(=O)-$, in which the carbonyl carbon atom is bonded to that nitrogen atom. In some embodiments, $*S-L^1$ comprises R^P , wherein R^P is attached to the nitrogen atom via an amide linkage.


In some embodiments, S^* is a sulfur atom from a cysteine residue of the antibody. In some embodiments, S^* is an ϵ -nitrogen atom from a lysine residue from the antibody.

In some embodiments, R^P is $-C(=O)-(C_{1-3} \text{ alkylene})-$, or is a PEG Unit ranging from PEG2 to PEG72. In some embodiments, R^P is $-C(=O)-(C_{1-3} \text{ alkylene})-$, or is a PEG Unit ranging from PEG8 to PEG24 or PEG12 to PEG36, that is covalently attached to the nitrogen atom through the carbon atom a carbonyl functional group of the PEG Unit. In some embodiments, the ethylene glycol chain of the PEG Unit is connected to the nitrogen atom through a $-C(=O)-(C_{1-3} \text{ alkylene})-$ group.

In some embodiments, $*S-L^1$ is:



In some embodiments, S^* is a triazole moiety.



In some embodiments, S^*L^1 is:


In some embodiments, subscript x is 0. In some embodiments, subscript x is 1, 2, 3, or 4.

5 In some embodiments, subscript x is 1. In some embodiments, subscript x is 2. In some embodiments, subscript x is 3. In some embodiments, subscript x is 4.

The multiplexer (M) in the ADCs described herein serves as a branching component (e.g., a trifunctional linking group). For example, when subscript $x = 1$, the initial multiplexer provides both covalent attachment to the first linker (L^1) as well as covalent attachments to two second linker (L^2) groups, when present. As another example, when subscript $x = 2$, the initial multiplexer provides a covalent attachment to L^1 as well as covalent attachments to two subsequent multiplexer (M) groups, each of which is covalently attached to two L^2 groups, when present. In some
10 embodiments, the multiplexer comprises a single functional group, such as a single tertiary amine, providing covalent attachment to L^1 as well as covalent attachment to two L^2 groups (when


present). In some embodiments, the multiplexer comprises two or three functional groups that provides covalent attachments to L^1 and two L^2 groups (when present). For example, in some embodiments, a first function group such as a thiol, a hydroxyl, an amine, or another nucleophilic group provide covalent attachment to L^1 , while a covalent attachment to either or both of the L^2 groups (when present) is provided by a second functional group such as a thiol, a hydroxy, an amine, or another nucleophilic group. In embodiments, where the multiplexer comprises two or more functional groups for covalent attachment to L^1 and each L^2 , the two or more functional groups are linked by a C_{1-8} alkylene or 2-8 membered heteroalkylene. In some embodiments, either or both L^2 are present.

In some embodiments, the multiplexer is represented by the structure:



wherein, the wavy lines to the right indicate covalent attachments to two L^2 groups, and the wavy line to the left indicates covalent attachment to L^1 . In some embodiments, the covalent attachments to the nitrogen atoms render those nitrogen atoms uncharged at physiological pH.


In some embodiments, the multiplexer is a thiol multiplexer, where the thiol multiplexer is covalently attached at a single site (shown as 'a'), is ring closed or ring opened to form two thiols (b) which serve as two sites for further attachments (as in 'c') of a linker or drug-linker moiety. Examples of thiol multiplexers include, but are not limited to, the structures shown below.




In some embodiments, the wavy line adjacent to the nitrogen atom represents the site of covalent attachment to the ADCs through a functional group that is uncharged at physiological pH. In some embodiments, the functional group comprises $-C(=O)-$, wherein the carbon atom is bonded to the nitrogen atom adjacent to the wavy line (i.e., at the “a” position noted above).

In some embodiments, the thiol multiplexer is based on a commercially available component having a five-, six-, seven- or eight-membered carbocyclic ring in which two adjacent ring vertices are replaced by sulfur-forming 1,2-dithiolanes, 1,2-dithianes, 1,2-dithiepanes and 1,2-dithiocanes. The five- and six-membered rings will generally have a functional group external to the ring that is suitable for the synthetic chemistries described herein. In some embodiments, the larger seven- and eight-membered rings have an exocyclic functional group that is suitable for the synthetic chemistries described herein, and in other embodiments another ring vertex is replaced with, for example, a nitrogen (amine) which sometimes serves as a functional group in the linking chemistries provided.


Further examples of thiol multiplexers (in disulfide form) include:






The functional groups present in the above thiol multiplexers in disulfide form are all nucleophilic groups; however, a person of skill in the art will recognize that the choice of the nucleophilic group for covalent attachment of L^1 , L^2 , or subsequent multiplexer groups can be changed without departing from the scope of the current disclosure.


Other non-limiting examples of thiol multiplexers in disulfide form include the following:





The carboxylic acid groups present in certain thiol multiplexers, as described herein, can be activated for covalent attachment of a nucleophilic group to L^1 , L^2 , or subsequent multiplexer groups; however, a person of skill in the art will recognize that the choice of nucleophilic group for that subsequent covalent attachment can be changed without departing from the scope of the current disclosure. Thus, it is apparent that the choice of nucleophilic group or electrophilic group depends on the chemical identity of the functional group providing covalent attachment to the multiplexer in L^1 and L^2 .

In some embodiments, M has the structure of formula M^a :



wherein the wavy line represents the covalent attachment of M^a to L^1 ;

each * represents the covalent attachment of M^a to $-L^2-D$;

Y^1 is selected from the group consisting of: a bond, -S-, -O-, and -NH-;

Y^2 is selected from the group consisting of: -CH- and -N-;

L^B is absent or a C_{1-6} alkylene that is optionally interrupted with a group selected from the group consisting of: -O-, -C(=O)NH-, -NHC(=O)-, -C(=O)O-, -O(C=O)-, -NH-, and -N(C_{1-3} alkyl)-;

X^1 and X^2 are each independently -S-, -O-, or -NH-; and

subscripts m1 and m2 are each independently 1-4.

In some embodiments, a bond to a nitrogen atom of M when Y¹ is -NH- or Y², X¹ or X² is -N- is through a functional group that retains that atom in uncharged form at physiological pH and includes functional groups comprised of -C(=O)-, in which the carbonyl carbon atom is bonded to that nitrogen atom. In some embodiments, a bond to a nitrogen atom of M when Y¹ is -NH- or Y², X¹ or X² is -N- is via an amide linkage.

In some embodiments, Y¹ is a bond. In some embodiments, Y¹ is -S-. In some embodiments, Y¹ is -O-. In some embodiments, Y¹ is -NH-. In some embodiments, Y² is -CH-. In some embodiments, Y² is -N-. In some embodiments, X¹ and X² are both -NH-.

In some embodiments, L^B is present or absent, Y¹ is a bond, and Y² is -CH-. In some embodiments, L^B is present or absent, Y¹ is a bond, and Y² is -N-. In some embodiments, L^B is present or absent, Y¹ is -S-, and Y² is -CH-. In some embodiments, L^B is present, Y¹ is -S-, and Y² is -N-. In some embodiments, L^B is present or absent, Y¹ is -O-, and Y² is -CH-. In some embodiments, L^B is present, Y¹ is -O-, and Y² is -N-. In some embodiments, L^B is present or absent, Y¹ is -NH-, and Y² is -CH-. In some embodiments, L^B is present, Y¹ is -NH-, and Y² is -N-.

In some embodiments, X¹ is -S-. In some embodiments, X¹ is -O-. In some embodiments, X¹ is -NH-. In some embodiments, X² is -S-. In some embodiments, X² is -O-. In some embodiments, X² is -NH-. In some embodiments, X¹ and X² are the same. In some embodiments, X¹ and X² are different.

In some embodiments, subscript m1 is 1. In some embodiments, subscript m1 is 2. In some embodiments, subscript m1 is 3. In some embodiments, subscript m1 is 4. In some embodiments, subscript m2 is 1. In some embodiments, subscript m2 is 2. In some embodiments, subscript m2 is 3. In some embodiments, subscript m2 is 4. In some embodiments, subscripts m1 and m2 are equal. In some embodiments, subscripts m1 and m2 are equal and range from 2-4. In some embodiments, subscripts m1 and m2 are each 2.

In some embodiments, Y¹ is -NH-; L^B is present; Y² is CH; and X¹ and X² are each -S-. In some embodiments, Y¹ is a bond; L^B is absent; Y² is N; and X¹ and X² are each -S-. In some embodiments, Y¹ is a bond; L^B is absent; Y² is -N-; and X¹ and X² are each -NH-.


In some embodiments, L^B is absent. In some embodiments, when L^B is present, L^B is a C₁₋₆ alkylene that is optionally interrupted with a group selected from the group consisting of: -O-, -C(=O)NH-, -NHC(=O)-, -C(=O)O-, -O(C=O)-, -NH-, and -N(C₁₋₃ alkyl)-. In some

embodiments, when L^B is present, L^B is a C_{1-6} alkylene that is optionally interrupted with $-NH-$ or $-N(C_{1-3} \text{ alkyl})-$. In some embodiments, M^a is interrupted with a functional group capable of deprotonation at physiological pH so that the net charge of M^a remains zero when so interrupted. In some embodiments, L^B is a C_{1-6} alkylene, a C_{1-4} alkylene, or a C_{1-2} alkylene. In some

5 embodiments, L^B is a C_{1-6} alkylene that is interrupted with a group selected from the group consisting of: $-O-$, $-C(=O)NH-$, $-NHC(=O)-$, $-C(=O)O-$, $-O(C=O)-$, $-NH-$, and $-N(C_{1-3} \text{ alkyl})-$. In some embodiments, L^B is a C_{1-6} alkylene that is interrupted with $-NH-$ or $-N(C_{1-3} \text{ alkyl})-$, wherein L^B is connected via a functional group capable of deprotonation at physiological pH so that the net charge of L^B is zero. In some embodiments, the C_{1-6} alkylene of L^B is interrupted with $-O-$. In

10 some embodiments, the C_{1-6} alkylene of L^B is interrupted with $-NH-$. In some embodiments, L^B is interrupted with $-N(C_{1-3} \text{ alkyl})-$. In some embodiments, the C_{1-6} alkylene of L^B is interrupted with $-C(=O)NH-$. In some embodiments, the C_{1-6} alkylene of L^B is interrupted with $-NHC(=O)-$. In some embodiments, the C_{1-6} alkylene of L^B is interrupted with $-C(=O)O-$. In some embodiments, the C_{1-6} alkylene of L^B is interrupted with $-O(C=O)-$.


15 In some embodiments, M is selected from the group consisting of:




wherein the wavy line represents the covalent attachment of M to L^1 ; and

wherein each $*$ represents the covalent attachment of M to $-(L^2-D)$.

In some embodiments, M is







In some embodiments, M is



The wavy line(s) to nitrogen atom(s) in the multiplexers disclosed herein represent site(s) of covalent attachment(s) within Formula (I) through a functional group that retains these atoms in uncharged form at physiological pH and includes functional groups comprised of -C(=O)-, in which the carbonyl carbon atom is bonded to that nitrogen atom.

In some embodiments, prior to the attachment of L^1 to Ab, and M to L^2 (or D, when L^2 is absent), L^1 -M comprises






or

In some embodiments, subscript x is 2-4; and

- 5 (M)_x is -M¹-(M²)_{x-1}, wherein M¹ and each M² are independently selected multiplexers, as described herein. In some embodiments, subscript x is 2; and (M)_x is -M¹-M². In some embodiments, subscript x is 3; and (M)_x is -M¹-(M²)₂.

In some embodiments, M¹ has the structure of formula M^{1a}:



- 10 wherein the wavy line represents covalent attachment of M^{1a} to L¹;
 each * represents covalent attachment of M^{1a} to M² or M^{2a} as defined herein;
 Y¹ is selected from the group consisting of: a bond, -S-, -O-, and -NH-;
 Y² is selected from the group consisting of: -CH- and -N-;

L^B is absent or a C_{1-6} alkylene that is optionally interrupted with a group selected from the group consisting of: -O-, -C(=O)NH-, -NHC(=O)-, -C(=O)O-, -O(C=O)-, -NH-, and -N(C_{1-3} alkyl)-;

X^1 and X^2 are each independently -S-, -O-, or -NH-; and

5 m_1 and m_2 are each independently 1-4.

In some embodiments, a bond to a nitrogen atom of M^{1a} when Y^1 , X^1 or X^2 is -NH- or Y^2 is -N-, is through a functional group that retains that atom in uncharged form under physiological conditions and includes functional groups comprised of -C(=O)-, in which the carbonyl carbon atom is bonded to that nitrogen atom. In some embodiments, a bond to a nitrogen atom of M^{1a} 10 when Y^1 , X^1 or X^2 is -NH- or Y^2 is -N-, is via an amide linkage.

In some embodiments, Y^1 is a bond. In some embodiments, Y^1 is -S-. In some embodiments, Y^1 is -O-. In some embodiments, Y^1 is -NH-. In some embodiments, Y^2 is -CH-. In some embodiments, Y^2 is -N-. X^1 and X^2 are each independently -S-, -O-, or -NH-. In some embodiments, X^1 and X^2 are both -NH-.

15 In some embodiments, L^B is present or absent, Y^1 is a bond, and Y^2 is -CH-. In some embodiments, L^B is present or absent, Y^1 is a bond, and Y^2 is -N-. In some embodiments, L^B is present or absent, Y^1 is -S-, and Y^2 is -CH-. In some embodiments, L^B is present, Y^1 is -S-, and Y^2 is -N-. In some embodiments, L^B is present or absent, Y^1 is -O-, and Y^2 is -CH-. In some 20 embodiments, L^B is present, Y^1 is -O-, and Y^2 is -N-. In some embodiments, L^B is present or absent, Y^1 is -NH-, and Y^2 is -CH-. In some embodiments, L^B is present, Y^1 is -NH-, and Y^2 is -N-.


In some embodiments, X^1 is -S-. In some embodiments, X^1 is -O-. In some embodiments, X^1 is -NH-. In some embodiments, X^2 is -S-. In some embodiments, X^2 is -O-. In some 25 embodiments, X^2 is -NH-. In some embodiments, X^1 and X^2 are the same. In some embodiments, X^1 and X^2 are different.

In some embodiments, subscript m_1 is 1. In some embodiments, subscript m_1 is 2. In some embodiments, subscript m_1 is 3. In some embodiments, subscript m_1 is 4. In some 30 embodiments, subscript m_2 is 1. In some embodiments, subscript m_2 is 2. In some embodiments, subscript m_2 is 3. In some embodiments, subscript m_2 is 4. In some embodiments, subscripts m_1 and m_2 are equal and range from 2-4. In some embodiments, subscripts m_1 and m_2 are each 2.


In some embodiments, Y^1 is $-NH-$; L^B is present; Y^2 is CH ; and X^1 and X^2 are each $-S-$. In some embodiments, Y^1 is a bond; L^B is absent; Y^2 is $-N-$; and X^1 and X^2 are each $-S-$. In some embodiments, Y^1 is a bond; L^B is absent; Y^2 is $-N-$; and X^1 and X^2 are each $-NH-$.

In some embodiments, L^B is absent. In some embodiments, when L^B is present, L^B is a C₁₋₆ alkylene that is optionally interrupted with a group selected from the group consisting of: $-O-$, $-C(=O)NH-$, $-NHC(=O)-$, $-C(=O)O-$, $-O(C=O)-$, $-NH-$, and $-N(C_{1-3} \text{ alkyl})-$. In some embodiments, M^{1a} is interrupted by a functional group capable of deprotonation at physiological pH so that the net charge of M^a remains zero when so interrupted. In some embodiments, L^B is a C₁₋₆ alkylene, a C₁₋₄ alkylene, or a C₁₋₂ alkylene. In some embodiments, L^B is a C₁₋₆ alkylene that is interrupted with a group selected from the group consisting of: $-O-$, $-C(=O)NH-$, $-NHC(=O)-$, $-C(=O)O-$, $-O(C=O)-$, $-NH-$, and $-N(C_{1-3} \text{ alkyl})-$. In some embodiments, L^B is a C₁₋₆ alkylene that is interrupted with $-NH-$ or $-N(C_{1-3} \text{ alkyl})-$, wherein L^B is connected via a functional group capable of deprotonation at physiological pH so that the net charge of L^B is zero. In some embodiments, L^B is interrupted with $-O-$. In some embodiments, L^B is interrupted with $-NH-$. In some embodiments, L^B is interrupted with $-N(C_{1-3} \text{ alkyl})-$. In some embodiments, L^B is interrupted with $-C(=O)NH-$. In some embodiments, L^B is interrupted with $-NHC(=O)-$. In some embodiments, L^B is interrupted with $-C(=O)O-$. In some embodiments, L^B is interrupted with $-O(C=O)-$.

In some embodiments, M^1 is selected from the group consisting of:




wherein the wavy line represents the covalent attachment of M^1 to L^1 ; and
 wherein each * represents the covalent attachment of M^1 to M^2 .



In some embodiments of M^1 , each site of covalent attachment from a nitrogen atom of M^1 within Formula (I) is through a functional group that retains the nitrogen atom in uncharged form at physiological pH and includes functional groups comprised of $-C(=O)-$, in which the carbonyl carbon atom is bonded to that nitrogen atom.

In some embodiments, each M^2 independently has the structure of M^{2a} :



wherein the wavy line represents covalent attachment of M^{2a} to M^1/M^{1a} or to another M^2/M^{2a} ;

each * represents the covalent attachment of M^{2a} to L^2-D or another M^2/M^{2a} ;

Y^1 is a bond, $-S-$, $-O-$, or $-NH-$;

Y^2 is $-CH-$ or $-N-$;

Y^3 is an optional group that provides covalent attachment of M^1/M^{1a} to the L^C (when present) or to Y^1 (when L^C is absent) of M^{2a} ;

L^B is absent or a C_{1-6} alkylene that is optionally interrupted with a group selected from the group consisting of: $-O-$, $-C(=O)NH-$, $-NHC(=O)-$, $-C(=O)O-$, $-O(C=O)-$, $-NH-$, and $-N(C_{1-3} \text{ alkyl})-$;

X^1 and X^2 are each independently $-S-$, $-O-$, or $-NH-$;

L^C is a C_{1-10} alkylene or a C_{2-10} heteroalkylene either of which is optionally substituted with 1-3 substituents each independently selected from $-NR^dR^e$, $-(C_{1-6} \text{ alkylene})-NR^dR^e$, $-CO_2H$ and oxo; and

subscripts $m1$ and $m2$ are each independently 1-4.

5 In some embodiments, when subscript x is 2 (i.e., there are two multiplexers, M^1/M^{1a} and M^2/M^{2a}), the wavy line represents the covalent attachment of M^2/M^{2a} to M^1/M^{1a} . In some embodiments, when subscript x is 3 (i.e., there are three multiplexers), the wavy bond either represents the covalent attachment of M^2/M^{2a} to M^1/M^{1a} or the covalent attachment of the first M^2/M^{2a} to the second M^2/M^{2a} .

10 In some embodiments of M^{2a} , Y^1 is a bond. In some embodiments of M^{2a} , Y^1 is $-S-$. In some embodiments of M^{2a} , Y^1 is $-O-$. In some embodiments of M^{2a} , Y^1 is $-NH-$. In some embodiments of M^{2a} , Y^2 is $-CH-$. In some embodiments, Y^2 is $-N-$. In some embodiments, when M^{2a} is charged at physiological pH, then M^{2a} has a net even number of excess positive or negative charges. In some embodiments, when M^{2a} is charged at physiological pH, then M^{2a} has a net odd
15 number of excess positive or negative charges.

In some embodiments, L^B is present or absent, Y^1 is a bond, and Y^2 is $-CH-$. In some embodiments, L^B is present or absent, Y^1 is a bond, and Y^2 is $-N-$. In some embodiments, L^B is present or absent, Y^1 is $-S-$, and Y^2 is $-CH-$. In some embodiments, L^B is present, Y^1 is $-S-$, and Y^2 is $-N-$. In some embodiments, L^B is present or absent, Y^1 is $-O-$, and Y^2 is $-CH-$. In some
20 embodiments, L^B is present, Y^1 is $-O-$, and Y^2 is $-N-$. In some embodiments, L^B is present or absent, Y^1 is $-NH-$, and Y^2 is $-CH-$. In some embodiments, L^B is present, Y^1 is $-NH-$, and Y^2 is $-N-$.

In some embodiments, X^1 is $-S-$. In some embodiments, X^1 is $-O-$. In some embodiments of M^{2a} , X^1 is $-NH-$. In some embodiments of M^{2a} , X^2 is $-S-$. In some embodiments of M^{2a} , X^2 is $-O-$. In some embodiments of M^{2a} , X^2 is $-NH-$. In some embodiments of M^{2a} , X^1 and X^2 are the
25 same. In some embodiments of M^{2a} , X^1 and X^2 are different.

In some embodiments, subscript $m1$ is 1. In some embodiments, subscript $m1$ is 2. In some embodiments, $m1$ is 3. In some embodiments, subscript $m1$ is 4. In some embodiments, $m2$ is 1. In some embodiments, subscript $m2$ is 2. In some embodiments, subscript $m2$ is 3. In some
embodiments, subscript $m2$ is 4.

30 In some embodiments, L^B is absent. In some embodiments, L^B is a C_{1-6} alkylene that is interrupted with a group selected from the group consisting of: $-O-$, $-C(=O)NH-$, $-NHC(=O)-$,


-C(=O)O-, -O(C=O)-, -NH-, and -N(C₁₋₃ alkyl)-. In some embodiments, L^B is a C₁₋₆ alkylene that is interrupted with -NH- or -N(C₁₋₃ alkyl)-, wherein L^B is connected via a functional group capable of deprotonation at physiological pH so that the net charge of L^B is zero. In some embodiments of M^{2a}, L^B is present as a C₁₋₆ alkylene, a C₁₋₄ alkylene, or a C₁₋₂ alkylene. In some embodiments, L^B is a C₁₋₆ alkylene that is interrupted with a group selected from the group consisting of: -O-, -C(=O)NH-, -NHC(=O)-, -C(=O)O-, -O(C=O)-, -NH-, and -N(C₁₋₃ alkyl)-. In some embodiments, L^B is a C₁₋₆ alkylene that is interrupted with -NH- or -N(C₁₋₃ alkyl)-, wherein L^B is connected via a functional group capable of deprotonation at physiological pH so that the net charge of L^B is zero. In some embodiments, the C₁₋₆ alkylene of L^B is interrupted with -O-. In some embodiments, the C₁₋₆ alkylene of L^B is interrupted with -NH-. In some embodiments, the C₁₋₆ alkylene of L^B is interrupted with -N(C₁₋₃ alkyl)-. In some embodiments, the C₁₋₆ alkylene of L^B is interrupted with -C(=O)NH-. In some embodiments, L^B is interrupted with -NHC(=O)-. In some embodiments, the C₁₋₆ alkylene of L^B is interrupted with -C(=O)O-. In some embodiments, the C₁₋₆ alkylene of L^B is interrupted with -O(C=O)-.

In some embodiments, L^C is a C₁₋₁₀ alkylene or a C₂₋₁₀ heteroalkylene, each substituted with -(C₁₋₆ alkylene)-NR^dR^e. In some embodiments, L^C is a C₁₋₁₀ alkylene or a C₂₋₁₀ heteroalkylene, each substituted with -(C₁₋₃ alkylene)-NR^dR^e. In some embodiments, R^d and R^e are both hydrogen.

In some embodiments, Y³ is present as a carbonyl group (-C(=O-)), a succinimide, or a hydrolyzed succinimide.


In some embodiments, Y³ is -C(=O)-. In some embodiments, Y³ is a succinimide. In some embodiments, Y³ is a hydrolyzed succinimide.

In some embodiments, Y³ is selected from the group consisting of:




wherein * represents covalent attachment to L^C; and the wavy line represents covalent attachment to M¹/M^{1a} or another M²/M^{2a}.

In some embodiments, Y³-L^C is selected from the group consisting of:



wherein * represents covalent attachment to Y^1 ; and the wavy line represents covalent attachment to M^1 or another M^2 .


In some embodiments, Y^3-L^C is selected from the group consisting of:



5 or , wherein the amino group is protected by an acid-labile protecting group. Exemplary acid-labile protecting groups include, but are not limited to t-butyloxycarbonyl (Boc), triphenylmethyl (trityl), and benzylidene.


In some embodiments, Y^1 is a bond; L^B is absent; Y^2 is -N-; and X^1 and X^2 are each -NH-. In some embodiments, a bond to a nitrogen atom of M^{2a} when Y^1 , X^1 or X^2 is -NH- or Y^2 is -N- is through a functional group that retains that atom in uncharged form at physiological pH and includes functional groups comprised of -C(=O)-, in which the carbonyl carbon atom is bonded to that nitrogen atom. In some embodiments, a bond to a nitrogen atom of M^{2a} when Y^1 , X^1 or X^2 is -NH- or Y^2 is -N- is via an amide linkage.

In some embodiments, M^2 is selected from the group consisting of:




wherein each * represents the covalent attachment to L^2 -D or another M^2/M^{2a} , and the wavy bond presents the covalent attachment to M^1/M^{1a} or another M^2/M^{2a} . For example, when L^2 is absent, each * represents a covalent attachment to D. When subscript x is 2 (i.e., there are two multiplexers, M^1/M^{1a} and M^2/M^{2a}), the wavy bond represents a covalent attachment to M^1/M^{1a} .

In some embodiments, M^2 is selected from the group consisting of:




and in some embodiments, M^2 is selected from the group consisting of:



wherein the nitrogen atom of the $-\text{CH}_2\text{NH}_2$ moiety is protected by an acid-labile protecting group; and

wherein each * represents covalent attachment to $\text{L}^2\text{-D}$ or another M^2/M^{2a} ; and the wavy bond presents the covalent attachment to M^1/M^{1a} or another M^2/M^{2a} . For example, when L^2 is absent, each * represents a covalent attachment to D. When subscript x is 2 (i.e., there are two multiplexers, M^1/M^{1a} and M^2/M^{2a}), the wavy bond represents a covalent attachment to M^1/M^{1a} .


In some embodiments, subscript x is 2; and $(\text{M})_x$ is:



wherein each * represents the covalent attachment to $\text{L}^2\text{-D}$; the wavy line represents the covalent attachment to L^1 ; and each succinimide ring is optionally hydrolyzed. When L^2 is absent, each * represents a covalent attachment to D.

In some embodiments, when $(\text{M})_x$ comprises $-\text{CH}_2\text{NH}_2$, the nitrogen atoms of that moiety is protonated and the succinimide ring is in hydrolyzed form at physiological pH. In some embodiments, $(\text{M})_x$ comprises $-\text{CH}_2\text{NH}_2$. In some embodiments, $(\text{M})_x$ comprises $-\text{CH}_2\text{NPG}^1\text{PG}^2$, wherein PG^1 is an acid-labile nitrogen protecting group and PG^2 is hydrogen; or PG^1 and PG^2 together form an acid-labile nitrogen protecting group. In some embodiments, one succinimide ring is hydrolyzed and the other succinimide ring is not hydrolyzed.

In some embodiments, subscript x is 3; and $(\text{M})_x$ is:



wherein each * represents covalent attachment to L^2 -D; and each succinimide ring is optionally hydrolyzed as previously described for M_x in which subscript x is 2. When L^2 is absent, each * represents covalent attachment to D.

5 In some embodiments, each M of $(M)_x$ that comprises $-\text{CH}_2\text{NH}_2$ and a succinimide ring, has its succinimide ring in hydrolyzed form. In some embodiments, none of the succinimide rings are in hydrolyzed form. For example, when M_x is present, in which each M comprises a succinimide ring and a $-\text{CH}_2\text{NH}_2$ moiety having its nitrogen atom protected by an acid-labile protecting group. In some embodiments, one succinimide ring is hydrolyzed and the other
 10 succinimide rings are not hydrolyzed. In some embodiments, two succinimide rings are hydrolyzed and the other succinimide rings are not hydrolyzed. In some embodiments, three of the succinimide ring are hydrolyzed and the other succinimide ring is not hydrolyzed.

In some embodiments, x is 0 and the multiplexer (M) is absent.

In some embodiments, L^2 has the formula $-(Q)_q-(A)_a-(W)_w-(Y)_y$, wherein:

15 Q is a succinimide or hydrolyzed succinimide;

subscript q is 0 or 1;

A is a C₂₋₂₀ alkylene optionally substituted with 1-3 R^{al}; or a 2 to 40 membered heteroalkylene optionally substituted with 1-3 R^{bl};


each R^{al} is independently selected from the group consisting of: C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, halogen, -OH, =O, -NR^{dl}R^{el}, -(C₁₋₆ alkylene)-NR^{dl}R^{el}, -C(=O)NR^{dl}R^{el}, -C(=O)(C₁₋₆ alkyl), and -C(=O)O(C₁₋₆ alkyl);

each R^{bl} is independently selected from the group consisting of: C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, halogen, -OH, -NR^{dl}R^{el}, -(C₁₋₆ alkylene)-NR^{dl}R^{el}, -C(=O)NR^{dl}R^{el}, -C(=O)(C₁₋₆ alkyl), and -C(=O)O(C₁₋₆ alkyl);

each R^{dl} and R^{el} are independently hydrogen or C₁₋₃ alkyl;

subscript a is 0 or 1;

W is a Peptide Cleavable Unit having from 1-12 amino acids, or W is a Glucuronide Unit having the structure:



wherein Su is a Sugar moiety;

-O^A- represents the oxygen atom of a glycosidic bond;

each R^g is independently H, halogen, -CN, or -NO₂;

subscript w is 0 or 1;

W¹ is selected from the group consisting of: -O-, -NH-, -N(C₁₋₆ alkyl)-, -[N(C₁₋₆ alkyl)₂]⁺- and -OC(=O)-;

the wavy line represents covalent attachment to A, Q, or L¹; and

the * represents covalent attachment to Y or D;

subscript w is 0 or 1;

subscript y is 0 or 1;

Y is a self-immolative or non-self-immolative moiety; and

wherein each of L²-D has a net zero charge at physiological pH.




A “sugar moiety” as used herein, refers to a monovalent monosaccharide group, for example, a pyranose or a furanose. A sugar moiety may comprise a hemiacetal or a carboxylic acid (from oxidation of the pendant $-\text{CH}_2\text{OH}$ group). In some embodiments, the sugar moiety is in the β -D conformation. In some embodiments, the sugar moiety is a glucose, glucuronic acid, or mannose group.


In some embodiments, L^2 has a net zero charge at physiological pH. In some embodiments, D has a net zero charge at physiological pH. In some embodiments, L^2 is uncharged at physiological pH. In some embodiments, D is uncharged at physiological pH. In some embodiments, D is charged neutral at physiological pH.

In some embodiments, $-\text{O}^{\text{A}}$ represents the oxygen atom of a glycosidic bond. In some embodiments, the glycosidic bond provides a β -glucuronidase or a α -mannosidase-cleavage site. In some embodiments, the β -glucuronidase or a α -mannosidase-cleavage site is cleavable by human lysosomal β -glucuronidase or by human lysosomal α -mannosidase.

In some embodiments, subscript q is 0. In some embodiments, subscript q is 1.

In some embodiments, Q is a succinimide. In some embodiments, Q is a hydrolyzed succinimide. It will be understood that a hydrolyzed succinimide may exist in two regioisomeric form(s). Those forms are exemplified below for Q as a succinimide, wherein the structures representing the regioisomers from that hydrolysis are formula Q' and Q''; wherein wavy line a indicates the point of covalent attachment to the antibody, and wavy line b indicates the point of covalent attachment to A.





In some embodiments, subscript a is 1. In some embodiments, subscript x ≥ 1 ; and subscript a is 1. In some embodiments, subscript a is 0.

In some embodiments, subscript q is 0 and subscript a is 0.

In some embodiments, A is a C₂₋₂₀ alkylene optionally substituted with 1-3 R^{al}. In some embodiments, A is a C₂₋₁₀ alkylene optionally substituted with 1-3 R^{al}. In some embodiments, A is a C₄₋₁₀ alkylene optionally substituted with 1-3 R^{al}. In some embodiments, A is a C₂₋₂₀ alkylene substituted with one R^{al}. In some embodiments, A is a C₂₋₁₀ alkylene substituted with one R^{al}. In some embodiments, A is a C₂₋₁₀ alkylene substituted with one R^{al}.

In some embodiments, each R^{al} is independently selected from the group consisting of: C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, halogen, -OH, =O, -NR^{dl}R^{el}, -C(=O)NR^{dl}R^{el}, -C(=O)(C₁₋₆ alkyl), and -C(=O)O(C₁₋₆ alkyl). In some embodiments, each R^{al} is C₁₋₆ alkyl. In some embodiments, each R^{al} is C₁₋₆ haloalkyl. In some embodiments, each R^{al} is C₁₋₆ alkoxy. In some embodiments, each R^{al} is C₁₋₆ haloalkoxy. In some embodiments, each R^{al} is halogen. In some embodiments, each R^{al} is -OH. In some embodiments, each R^{al} is =O. In some embodiments, each R^{al} is -NR^{dl}R^{el}. In some embodiments, each R^{al} is -(C₁₋₆ alkylene)-NR^{dl}R^{el}. In some embodiments, each R^{al} is -C(=O)NR^{dl}R^{el}. In some embodiments, each R^{al} is -C(=O)(C₁₋₆ alkyl). In some embodiments, each R^{al} is -C(=O)O(C₁₋₆ alkyl). In some embodiments, one R^{al} is -NR^{dl}R^{el}. In some embodiments, one R^{al} is -(C₁₋₆ alkylene)-NR^{dl}R^{el}. In some embodiments, one R^{al} is -(C₁₋₂ alkylene)-NR^{dl}R^{el}. In some embodiments, A is a C₂₋₂₀ alkylene substituted with 1 or 2 R^{al}, each of which is =O.

In some embodiments, R^{dl} and R^{el} are independently hydrogen or C_{1-3} alkyl. In some embodiments, one of R^{dl} and R^{el} is hydrogen, and the other of R^{dl} and R^{el} is C_{1-3} alkyl. In some embodiments, R^{dl} and R^{el} are both hydrogen or C_{1-3} alkyl. In some embodiments, R^{dl} and R^{el} are both C_{1-3} alkyl. In some embodiments, R^{dl} and R^{el} are both methyl.

5 In some embodiments, A is a C_{2-20} alkylene. In some embodiments, A is a C_{2-10} alkylene. In some embodiments, A is a C_{2-10} alkylene. In some embodiments, A is a C_{2-6} alkylene. In some embodiments, A is a C_{4-10} alkylene.


In some embodiments, A is a 2 to 40 membered heteroalkylene optionally substituted with 1-3 R^{bl} . In some embodiments, A is a 2 to 20 membered heteroalkylene optionally substituted with 1-3 R^{bl} . In some embodiments, A is a 2 to 12 membered heteroalkylene optionally substituted with 1-3 R^{bl} . In some embodiments, A is a 4 to 12 membered heteroalkylene optionally substituted with 1-3 R^{bl} . In some embodiments, A is a 4 to 8 membered heteroalkylene optionally substituted with 1-3 R^{bl} . In some embodiments, A is a 2 to 40 membered heteroalkylene substituted with one R^{bl} . In some embodiments, A is a 2 to 20 membered heteroalkylene substituted with one R^{bl} . In some embodiments, A is a 2 to 12 membered heteroalkylene substituted with one R^{bl} . In some embodiments, A is a 4 to 12 membered heteroalkylene substituted with one R^{bl} . In some embodiments, A is a 4 to 8 membered heteroalkylene substituted with one R^{bl} .

In some embodiments, each R^{bl} is independently selected from the group consisting of: C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, halogen, -OH, $-NR^{dl}R^{el}$, $-(C_{1-6} \text{ alkylene})-NR^{dl}R^{el}$, $-C(=O)NR^{dl}R^{el}$, $-C(=O)(C_{1-6} \text{ alkyl})$, and $-C(=O)O(C_{1-6} \text{ alkyl})$. In some embodiments, each R^{bl} is C_{1-6} alkyl. In some embodiments, each R^{bl} is C_{1-6} haloalkyl. In some embodiments, each R^{bl} is C_{1-6} alkoxy. In some embodiments, each R^{bl} is C_{1-6} haloalkoxy. In some embodiments, each R^{bl} is halogen. In some embodiments, each R^{bl} is -OH. In some embodiments, each R^{bl} is $-NR^{dl}R^{el}$. In some embodiments, each R^{bl} is $-(C_{1-6} \text{ alkylene})-NR^{dl}R^{el}$. In some embodiments, each R^{bl} is $C(=O)NR^{dl}R^{el}$. In some embodiments, each R^{bl} is $-C(=O)(C_{1-6} \text{ alkyl})$. In some embodiments, each R^{bl} is $-C(=O)O(C_{1-6} \text{ alkyl})$. In some embodiments, one R^{bl} is $-NR^{dl}R^{el}$. In some embodiments, one R^{bl} is $-(C_{1-6} \text{ alkylene})-NR^{dl}R^{el}$. In some embodiments, one R^{bl} is $-(C_{1-2} \text{ alkylene})-NR^{dl}R^{el}$.


30 In some embodiments, R^{dl} and R^{el} are independently hydrogen or C_{1-3} alkyl. In some embodiments, one of R^{dl} and R^{el} is hydrogen, and the other of R^{dl} and R^{el} is C_{1-3} alkyl. In some

embodiments, R^{d1} and R^{e1} are both hydrogen or C_{1-3} alkyl. In some embodiments, R^{d1} and R^{e1} are both C_{1-3} alkyl. In some embodiments, R^{d1} and R^{e1} are both methyl.


In some embodiments, Q-A is selected from the group consisting of Ai, Aii or Aiii:



Ai




Aii




Aiii

In some embodiments, Q is Q^1 . In some embodiments, Q^1 is selected from the group



consisting of:



(Aiv);

In some embodiments, Q-A has the formula of Aiv:


wherein the wavy line adjacent to Q^1 represents covalent attachment to $(M)_x$;

subscript a1 is 1-4; subscript a2 is 0-3; subscript a3 is 0 or 1;

L^D is a C_{1-6} alkylene;

A^3 is $-NH-(C_{1-10} \text{ alkylene})-C(=O)-$, or $-NH-(2-20 \text{ membered heteroalkylene})-C(=O)-$, wherein the C_{1-6} alkylene is optionally substituted with 1-3 independently selected R^a , and the 2-20 membered heteroalkylene is optionally substituted with 1-3 independently selected R^b ; and

wherein A^3 is further optionally substituted with a PEG Unit selected from PEG2 to PEG72.



In some embodiments, Q^1 has the structure of:


In some embodiments, A^3 is further optionally substituted with PEG12 to PEG32 or PEG8 to PEG24.

In some embodiments, subscript a3 is 0. In some embodiments, subscript a3 is 1.

In some embodiments, A^3 is $-NH-(C_{1-10} \text{ alkylene})-C(=O)-$.

In some embodiments, A^3 is $-NH-(CH_2CH_2)-C(=O)-$.

In some embodiments, A^3 is $-NH-(2-20 \text{ membered heteroalkylene})-C(=O)-$, wherein the 2-20 membered heteroalkylene is optionally substituted with 1-3 independently selected R^b .




In some embodiments, A^3 is of formula Av (Av), wherein R^P is comprised polyethylene glycol chain. In some embodiments, R^P is covalently attached to the nitrogen atom via the carbonyl carbon atom of a $-(C_{1-6} \text{ alkylene})C(=O)-$ group, wherein the polyethylene glycol chain and the $-(C_{1-6} \text{ alkylene})C(=O)-$ group form a PEG Unit ranging from PEG2 to PEG72 (e.g., PEG12 or PEG24).

In some embodiments, W is a single amino acid. In some embodiments, W is a single natural amino acid. In some embodiments, W is a peptide including from 2-12 amino acids, wherein each amino acid is independently a natural or unnatural amino acid. In some embodiments, each amino acid is independently a natural amino acid. In some embodiments, W is a dipeptide. In some embodiments, W is a tripeptide. In some embodiments, W is a tetrapeptide. In some embodiments, W is a pentapeptide. In some embodiments, W is a hexapeptide. In some embodiments, W is 7, 8, 9, 10, 11, or 12 amino acids. In some embodiments, each amino acid of W is independently selected from the group consisting of valine, alanine, β -alanine, glycine, lysine, leucine, phenylalanine, proline, aspartic acid, glutamate, arginine, and citrulline. In some embodiments, each amino acid of W is independently selected from the group consisting of valine, alanine, β -alanine, glycine, lysine, leucine, phenylalanine, proline, aspartic acid, serine, glutamic acid, homoserine methyl ether, aspartate methyl ester, N,N-dimethyl lysine, arginine, valine-alanine, valine-citrulline, phenylalanine-lysine, and citrulline. In some embodiments, W is an aspartic acid. In some embodiments, W is a lysine. In some embodiments, W is a glycine. In some embodiments, W is an alanine. In some embodiments, W is aspartate methyl ester. In some embodiments, W is a N,N-dimethyl lysine. In some embodiments, W is a homoserine methyl ether. In some embodiments, W is a serine. In some embodiments, W is a valine-alanine.

In some embodiments, W is from 1-12 amino acids and the bond between W and Y or W and D is enzymatically cleavable by a tumor-associated protease. In some embodiments, W is an amino acid or a dipeptide; and the bond between W and D or between W and Y is enzymatically cleavable by a tumor-associated protease. In some embodiments, the tumor-associated protease is

a lysosomal protease such as a cathepsin. In some embodiments, the tumor-associated protease is cathepsin B.

In some embodiments, W is a Glucuronide Unit, having the structure of formula Wi, Wii or Wiii:



wherein Su is a Sugar moiety;

-O^A- represents the oxygen atom of a glycosidic bond;

each R^g is independently hydrogen, halogen, -CN, or -NO₂;


W¹ is selected from the group consisting of: a bond, -O-, -C(=O)-, S(O)₀₋₂-, -NH-, -N(C₁₋₆ alkyl)-, -[N(C₁₋₆ alkyl)₂]⁺-, -OC(=O)-, -NHC(=O)-, -C(=O)O-, and -C(=O)NH-;

the wavy line represents the covalent attachment to A, Q, or L¹; and

the * represents the covalent attachment to Y or D.


In some embodiments, -O^A- represents the oxygen atom of a glycosidic bond. In some embodiments, the glycosidic bond provides a β-glucuronidase or a α-mannosidase-cleavage site. In some embodiments, the β-glucuronidase or a α-mannosidase-cleavage site is cleavable by human lysosomal β-glucuronidase or by human lysosomal α-mannosidase.

In some embodiments, O^A -Su has zero net charge at physiological pH. In some embodiments, O^A -Su is uncharged at physiological pH. In some embodiments, O^A -Su is mannose.



In some embodiments, O^A -Su is

In some embodiments, Su of O^A -Su in formula Wi, Wii or Wiii comprises a carboxylate moiety. In some embodiments, O^A -Su is glucuronic acid moiety. In some embodiments, O^A -Su




In some embodiments, each R^g is hydrogen. In some embodiments, one R^g is hydrogen, and the remaining R^g are independently halogen, -CN, or -NO₂. In some embodiments, two R^g are hydrogen, and the remaining R^g is halogen, -CN, or -NO₂.


In some embodiments, W^1 is a bond. In some embodiments, W^1 is -O-. In some embodiments, W^1 is -C(=O)-. In some embodiments, W^1 is -NH-. In some embodiments, W^1 is -N(C₁₋₆ alkyl)-. In some embodiments, W^1 is -[N(C₁₋₆ alkyl)₂]⁺-. In some embodiments, W^1 is -OC(=O)-; and O^A -Su is charged neutral. In some

embodiments, W^1 is a bond; D is conjugated to W through a nitrogen atom which forms an ammonium cation at physiological pH; and Su of O^A -Su is a sugar moiety having a carboxylate substituent.


In some embodiments, W is Wi having the structure of:





. In



or



, respectively. In some embodiments, W is Wiii having the structure



In some embodiments, subscript w is 1 and subscript a is 0.

In some embodiments, W¹ is a bond. In some embodiments, W¹ is -O(C=O)-.

- 5 In some embodiments, W is a Peptide Cleavable Unit and subscript y is 0. In some embodiments, W is a Peptide Cleavable Unit and subscript y is 1. In some embodiments, W is a Peptide Cleavable Unit and subscript y is 1. In some embodiments, W is a Peptide Cleavable Unit and subscript y is 0.


10 A non-self-immolative moiety is one which requires enzymatic cleavage, and in which part or all of the group remains bound to the Drug after cleavage from the ADC. Examples of a non-self-immolative moiety include, but are not limited to: -glycine-; and -glycine-glycine-. In some embodiments, in which Y is -glycine- or -glycine-glycine-, L₂-D undergoes enzymatic cleavage, for example, via a tumor-cell associated-protease, a cancer-cell-associated protease, or a lymphocyte-associated protease to provide a glycine-Drug Unit or glycine-glycine-Drug Unit
15 fragment as the free drug. In some embodiments, an independent hydrolysis or proteolysis reaction takes place within the target cell, further cleaving the glycine-Drug or glycine-glycine-Drug Unit to liberate the parent drug as the free drug.

20 In some embodiments, in which Y is a p-aminobenzyl alcohol (PAB) optionally substituted with one or more halogen, cyano, or nitro groups, Y undergoes enzymatic cleavage, for example, via a tumor-cell associated-protease, a cancer-cell-associated protease, or a lymphocyte-associated protease, releasing a PAB-Drug Unit fragment further undergoes 1,6-elimination of the PAB to liberate free drug. In some embodiments, enzymatic cleavage of the non-self-immolative moiety, as described herein, directly liberates free drug without any further hydrolysis or proteolysis step(s).

A self-immolative moiety is one which does not require any additional hydrolysis steps to liberate D as free drug. For example, the phenylene moiety of a p-aminobenzyl alcohol (PAB) moiety as previously described, is covalently attached to $—W_w—$ via the amino nitrogen atom of the PAB group, and is covalently attached to -D via a carbonate, carbamate or ether group. *See*,
 5 *e.g.*, Told et al., 2002, *J. Org. Chem.* 67:1866-1872.

Examples of a self-immolative moiety include, but are not limited to, a p-aminobenzyl alcohol (PAB) moiety, the phenylene of which is unsubstituted at the remaining aromatic carbon atoms or is substituted with one or more C_{1-3} alkoxy, halogen, cyano, or nitro groups. In some embodiments, when subscript w is 1 and W is a Peptide Cleavable Unit, the phenylene of a PAB
 10 moiety is optionally substituted with one C_{1-3} alkoxy group.

Other examples of self-immolative groups include, but are not limited to, aromatic compounds that are electronically similar to the PAB moiety such as 2-aminoimidazol-5-methanol derivatives (*see, e.g.*, Hay et al., 1999, *Bioorg. Med. Chem. Lett.* 9:2237), ortho or para-aminobenzylacetals, substituted and unsubstituted 4-aminobutyric acid amides (*see, e.g.*,
 15 Rodrigues et al., 1995, *Chemistry Biology* 2:223), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (*see, e.g.*, Storm et al., 1972, *J. Amer. Chem. Soc.* 94:5815), 2-aminophenylpropionic acid amides (*see, e.g.*, Amsberry et al., 1990, *J. Org. Chem.* 55:5867), elimination of amine-containing drugs that are substituted at the α -position of glycine (*see, e.g.*,

Kingsbury et al., 1984, *J. Med. Chem.* 27:1447), and group such as , where * represents
 20 covalent attachment to D and the nitrogen adjacent to $\sim\sim\sim$ forms a carbamate with W.

In some embodiments, Y is a para-aminobenzyl-oxy-carbonyl (PABC) group optionally substituted with a sugar moiety. In some embodiments, Y is -glycine- or -glycine-glycine-. In some embodiments, Y is a branched bis(hydroxymethyl)styrene (BHMS) unit, which is capable of incorporating (and releasing) multiple Drug Units.


25 In some embodiments, of L_2-D , subscript w is 1, and $-(Q)_q-(A)_a-(W)_w-(Y)_y$ comprises a releasable linker, which provides release of free drug once the ADC has been internalized into the target cell. In some embodiments, subscript w is 1, and $-(Q)_q-(A)_a-(W)_w-(Y)_y$ is a releasable linker, which provides release of free drug in the vicinity of targeted cells. Releasable linkers possess a

suitable recognition site, such as a peptide cleavage site, sugar cleavage site, or a disulfide cleavage side. In some embodiments, each releasable linker is a di-peptide. In some embodiments, each releasable linker independently comprises succinimido-caproyl (mc), succinimido-caproyl-valine-citrulline (sc-vc), succinimido-caproyl-valine-citrulline-paraaminobenzyloxycarbonyl (sc-vc-PABC), SDPr-vc (where “S” refers to succinimido), -propionyl-valine-citrulline-, Val-Cit-, -Phe-Lys-, or -Val-Ala-.



In some embodiments, each releasable linker is independently selected from Val-Cit-, -Phe-Lys-, and -Val-Ala-. In some embodiments, each releasable linker is independently selected from succinimido-caproyl (mc), succinimido-caproyl-valine-citrulline (sc-vc), succinimido-caproyl-valine-citrulline-paraaminobenzyloxycarbonyl (sc-vc-PABC), SDPr-vc (where “S” refers to succinimido), and -propionyl-valine-citrulline-.

In some embodiments, $-(Q)_q-(A)_a-(W)_w-(Y)_y-$ a non-releasable linker, wherein the Drug Unit is released after the ADC has been internalized into the target cell and degraded, liberating free drug.

In some embodiments, $-(Q)_q-(A)_a-(W)_w-(Y)_y$ is a releasable linker, wherein subscript y is



In some embodiments, subscript a is 1; subscript w is 1; and Q-A-W is



In some embodiments, R^P is a PEG Unit ranging from PEG2 to PEG72 (e.g., PEG12 or PEG24). In some embodiments, this PEG Unit comprises a -(C₁₋₆ alkylene)C(=O)-, group wherein the carbonyl carbon atom of the -(C₁₋₆ alkylene)C(=O)-, group is covalently attached to the nitrogen atom substituted by R^P.

5 In some embodiments, W is a Peptide Cleavable Unit or a Glucuronide Unit, A is not comprised of R^P substituted with a PEG Unit. In some embodiments, L² is substituted with a PEG Unit ranging from PEG2, PEG4, PEG6, PEG8, PEG10, PEG12, PEG16, PEG20, and PEG24. In some embodiments, W is a Peptide Cleavable Unit or a Glucuronide Unit, A is substituted with a PEG Unit ranging from PEG2 to PEG72, for example, PEG12 to PEG32, or PEG8 to PEG24. In
10 some embodiments, L² is substituted with a PEG Unit selected from PEG2, PEG4, PEG6, PEG8, PEG10, PEG12, PEG16, PEG20, and PEG24.

 Upon review of the present disclosure and the examples provided therein, a person of skill in the art will recognize that the operability of the ADCs and intermediates thereof described herein is not dependent on the exact structure of any one linker (L¹ or L²), and the additional
15 structural features that are not explicitly described herein are capable of being incorporated into one or more linkers (L¹ or L²) without departing from the scope of the present disclosure.

 Additionally, one of skill in the art will also appreciate that the specific attachment chemistry to an antibody, for example, can alter the synthetic steps leading to a product. In particular, when attachment to the sulfur atom of a thiol group on an antibody is to be carried out
20 by means of a thiol reactive group, that attachment to the antibody will take place prior to reducing the cyclic thiol multiplexing moieties (M) to avoid unwanted or off target reactions between thiols in the linkers (L¹ and L²) and the aforementioned thiol reactive groups.

Drug Units

25 In some embodiments, D is a Drug Unit that is conjugated to a Drug Linker compound or to an antibody-drug conjugate. In some embodiments, D is free drug (from the corresponding Drug Unit), or a pharmaceutically acceptable salt thereof), and may be useful for pharmaceutical treatment of hyperproliferative diseases and disorders. The substituent designations in this section (R¹, R², R³, and the like) refer only to the Drug Units and corresponding free drugs described in
30 the present application. These designations are not applicable to linkers (as standalone compounds

or as components of ADCs) or to linker intermediate compounds, which have distinct substituents designations as described herein.

In some embodiments, D is a cytotoxic, cytostatic, immunosuppressive, immunostimulatory, or immunomodulatory drug. In some embodiments, D is a tubulin disrupting agent, DNA minor groove binder, DNA damaging agent or DNA replication inhibitor.

Useful classes of cytotoxic, cytostatic, immunosuppressive, immunostimulatory, or immunomodulatory agents include, for example, antitubulin agents (which may also be referred to as tubulin disrupting agents), DNA minor groove binders, DNA replication inhibitors, DNA damaging agents, alkylating agents, antibiotics, antifolates, antimetabolites, chemotherapy sensitizers, Toll-like receptor (TLR) agonists, STimulator of Interferon Genes (STING) agonists, Retinoic acid-inducible gene I (RIG-I) agonists, topoisomerase inhibitors (including topoisomerase I and II inhibitors), vinca alkaloids, auristatins, camptothecins, enediynes, lexitropsins, anthracyclins, taxanes, and the like. Particularly examples of useful classes of cytotoxic agents include, for example, DNA minor groove binders (enediynes and lexitropsins), DNA alkylating agents, and tubulin inhibitors. Exemplary agents include, for example, anthracyclines, auristatins (e.g., auristatin T, auristatin E, AFP, monomethyl auristatin F (MMAF), lipophilic monomethyl auristatin F, monomethyl auristatin E (MMAE)), camptothecins, CC-1065 analogues, calicheamicin, analogues of dolastatin 10, duocarmycins, etoposides, maytansines and maytansinoids, melphalan, methotrexate, mitomycin C, taxanes (e.g., paclitaxel and docetaxel), nicotinamide phosphoribosyltransferase inhibitor (NAMPTi), tubulysin M, benzodiazepines and benzodiazepine containing drugs (e.g., pyrrolo[1,4]-benzodiazepines (PBDs), indolinobenzodiazepines, rhizoxin, paltoxin, and oxazolidinobenzodiazepines) and vinca alkaloids. Select benzodiazepine containing drugs are described in WO 2010/091150, WO 2012/112708, WO 2007/085930, and WO 2011/023883.

Particularly useful classes of cytotoxic agents include, for example, DNA minor groove binders, DNA alkylating agents, tubulin disrupting agents, anthracyclines and topoisomerase II inhibitors. Other particularly useful cytotoxic agents include, for example, auristatins (e.g., auristatin T, auristatin E, AFP, monomethyl auristatin F (MMAF), lipophilic analogs of monomethyl auristatin F, monomethyl auristatin E (MMAE)) and camptothecins (e.g., camptothecin, irinotecan and topotecan).

The cytotoxic agent can be a chemotherapeutic agent such as, for example, doxorubicin, paclitaxel, melphalan, vinca alkaloids, methotrexate, mitomycin C or etoposide. The agent can also be a CC-1065 analogue, calicheamicin, maytansine, an analog of dolastatin 10, rhizoxin, or palytoxin.

5 The cytotoxic agent can also be an auristatin. The auristatin can be an auristatin E derivative is, e.g., an ester formed between auristatin E and a keto acid. For example, auristatin E can be reacted with paraacetyl benzoic acid or benzoylvaleric acid to produce AEB and AEVB, respectively. Other typical auristatins include auristatin T, AFP, MMAF, and MMAE. The synthesis and structure of various auristatins are described in, for example, US 2005-0238649 and
10 US2006-0074008.

The cytotoxic agent can be a DNA minor groove binding agent. (*See*, e.g., U.S. Pat. No. 6,130,237.) For example, the minor groove binding agent can be a CBI compound or an enediyne (e.g., calicheamicin).

The cytotoxic or cytostatic agent can be an anti-tubulin agent. Examples of anti-tubulin
15 agents include taxanes (e.g., Taxol® (paclitaxel), Taxotere® (docetaxel)), T67 (Tularik), vinca alkyls (e.g., vincristine, vinblastine, vindesine, and vinorelbine), and auristatins (e.g., auristatin E, AFP, MMAF, MMAE, AEB, AEVB). Other suitable antitubulin agents include, for example, baccatin derivatives, taxane analogs (e.g., epothilone A and B), nocodazole, colchicine and colcimid, estramustine, cryptophysins, cemadotin, maytansinoids, combretastatins, discodermoide
20 and eleuthrobin.



The cytotoxic agent can be maytansine or a maytansinoid, another group of anti-tubulin agents (e.g., DM1, DM2, DM3, DM4). For example, the maytansinoid can be maytansine or a maytansine containing drug linker such as DM-1 or DM-4 (ImmunoGen, Inc.; see also Chari et al., 1992, Cancer Res.).

25 In some embodiments, D is a tubulin disrupting agent. In some embodiments, D is an auristatin or a tubulysin. In some embodiments, D is an auristatin. In some embodiments, D is a tubulysin.

In some embodiments, D is a TLR agonist. Exemplary TLR agonists include, but are not limited to, a TLR1 agonist, a TLR2 agonist, a TLR3 agonist, a TLR4 agonist, a TLR5 agonist, a TLR6
30 agonist, a TLR7 agonist, a TLR8 agonist, a TLR7/8 agonist, a TLR9 agonist, or a TLR10 agonist.

In some embodiments, D is a STING agonist. Exemplary STING agonists include, but are not limited to, cyclic di-nucleotides (CDNs), and non-nucleotide STING agonists.




An auristatin Drug Unit of an antibody-drug conjugate or Drug Linker compound incorporates an auristatin drug through covalent attachment of a Linker Unit of the Conjugate or Drug Linker compound to the secondary amine of an auristatin free drug having structure of D_E or D_F as follows:



wherein the dagger indicates the site of covalent attachment of the nitrogen atom that provides a carbamate functional group, wherein --OC(=O)-- of that functional group is Y^{Z} , on incorporation of the auristatin drug compound as -D into any one of the drug linker moieties of an antibody-drug conjugate or into any one of the Drug Linker compounds as described herein, so that for either type of compound subscript y is 2; and one R^{Z10} and R^{Z11} is hydrogen and the other is $\text{C}_1\text{--C}_8$ alkyl; R^{Z12} is hydrogen, $\text{C}_1\text{--C}_8$ alkyl, $\text{C}_3\text{--C}_8$ carbocyclyl, $\text{C}_6\text{--C}_{24}$ aryl, $\text{--X}^{\text{Z1}}\text{--C}_6\text{--C}_{24}$ aryl, $\text{--X}^{\text{Z1}}\text{--(C}_3\text{--C}_8\text{ carbocyclyl)}$, $\text{C}_3\text{--C}_8$ heterocyclyl or $\text{--X}^{\text{Z1}}\text{--(C}_3\text{--C}_8\text{ heterocyclyl)}$; R^{Z13} is hydrogen, $\text{C}_1\text{--C}_8$ alkyl, $\text{C}_3\text{--C}_8$ carbocyclyl, $\text{C}_6\text{--C}_{24}$ aryl, $\text{--X}^{\text{Z1}}\text{--C}_6\text{--C}_{24}$ aryl, $\text{--X}^{\text{Z1}}\text{--(C}_3\text{--C}_8\text{ carbocyclyl)}$, $\text{C}_3\text{--C}_8$ heterocyclyl and $\text{--X}^{\text{Z1}}\text{--(C}_3\text{--C}_8\text{ heterocyclyl)}$; R^{Z14} is hydrogen or methyl, or R^{Z13} and R^{Z14} taken together with the carbon to which they are attached comprise a spiro $\text{C}_3\text{--C}_8$ carbocyclo; R^{Z15} is hydrogen or $\text{C}_1\text{--C}_8$ alkyl; R^{Z16} is hydrogen, $\text{C}_1\text{--C}_8$ alkyl, $\text{C}_3\text{--C}_8$ carbocyclyl, $\text{C}_6\text{--C}_{24}$ aryl, $\text{--C}_6\text{--C}_{24}\text{--X}^{\text{Z1}}\text{--aryl}$, $\text{--X}^{\text{Z1}}\text{--(C}_3\text{--C}_8\text{ carbocyclyl)}$, $\text{C}_3\text{--C}_8$ heterocyclyl and $\text{--X}^{\text{Z1}}\text{--(C}_3\text{--C}_8\text{ heterocyclyl)}$; R^{Z17} independently are hydrogen, --OH , $\text{C}_1\text{--C}_8$ alkyl, $\text{C}_3\text{--C}_8$ carbocyclyl and $\text{O--(C}_1\text{--C}_8\text{ alkyl)}$; R^{Z18} is hydrogen or optionally

substituted C₁-C₈ alkyl; R^{Z19} is -C(R^{Z19A})₂-C(R^{Z19A})₂-C₆-C₂₄ aryl, -C(R^{Z19A})₂-C(R^{Z19A})₂-(C₃-C₈ heterocyclyl) or -C(R^{Z19A})₂-C(R^{Z19A})₂-(C₃-C₈ carbocyclyl), wherein C₆-C₂₄ aryl and C₃-C₈ heterocyclyl are optionally substituted; R^{Z19A} independently are hydrogen, optionally substituted C₁-C₈ alkyl, -OH or optionally substituted -O-C₁-C₈ alkyl; R^{Z20} is hydrogen or optionally substituted C₁-C₂₀ alkyl, optionally substituted C₆-C₂₄ aryl or optionally substituted C₃-C₈ heterocyclyl, or -(R^{Z47}O)_{mz}-R^{Z48}, or -(R^{Z47}O)_{mz}-CH(R^{Z49})₂; R^{Z21} is optionally substituted -C₁-C₈ alkylene-(C₆-C₂₄ aryl) or optionally substituted -C₁-C₈ alkylene-(C₅-C₂₄ heteroaryl), or C₁-C₈ hydroxylalkyl, or optionally substituted C₃-C₈ heterocyclyl; Z^Z is O, S, NH, or NR^{Z46}; R^{Z46} is optionally substituted C₁-C₈ alkyl; subscript mz is an integer ranging from 1-1000; R^{Z47} is C₂-C₈ alkyl; R^{Z48} is hydrogen or C₁-C₈ alkyl; R^{Z49} independently are -COOH, -(CH₂)_{nz}-N(R^{Z50})₂, -(CH₂)_{nz}-SO₃H, or -(CH₂)_{nz}-SO₃-C₁-C₈ alkyl; R^{Z50} independently are C₁-C₈ alkyl, or -(CH₂)_{nz}-COOH; subscript nz is an integer ranging from 0 to 6; and X^{Z1} is C₁-C₁₀ alkylene.

In some embodiments the auristatin drug compound has the structure of Formula **D_{E-1}**, Formula **D_{E-2}** or Formula **D_{F-1}**:




wherein Ar^Z in Formula **D_{E-1}** or Formula **D_{E-2}** is C₆-C₁₀ aryl or C₅-C₁₀ heteroaryl, and in Formula **D_{F-1}**, Z^Z is -O-, or -NH-; R^{Z20} is hydrogen or optionally substituted C₁-C₆ alkyl, optionally substituted C₆-C₁₀ aryl or optionally substituted C₅-C₁₀ heteroaryl; and R^{Z21} is optionally substituted C₁-C₆ alkyl, optionally substituted -C₁-C₆ alkylene-(C₆-C₁₀ aryl) or optionally substituted -C₁-C₆ alkylene-(C₅-C₁₀ heteroaryl).

In some embodiments of Formula **D_E**, **D_F**, **D_{E-1}**, **D_{E-2}** or **D_{F-1}**, one of R^{Z10} and R^{Z11} is hydrogen and the other is methyl.

In some embodiments of Formula **D_{E-1}** or **D_{E-2}**, Ar is phenyl or 2-pyridyl.


In some embodiments of Formula **D_{F-1}**, R^{Z21} is X^{Z1} -S- R^{Z21a} or X^{Z1} - Ar^Z , wherein X^{Z1} is C₁-C₆ alkylene, R^{Z21a} is C₁-C₄ alkyl and Ar^Z is phenyl or C₅-C₆ heteroaryl and/or $-Z^Z$ is -O- and R^{Z20} is C₁-C₄ alkyl or Z^Z is -NH- and R^{Z20} is phenyl or C₅-C₆ heteroaryl.

In some embodiments the auristatin drug compound has the structure of Formula **D_{F/E-3}**:



3



wherein one of R^{Z10} and R^{Z11} is hydrogen and the other is methyl; R^{Z13} is isopropyl or -CH₂-CH(CH₃)₂; and R^{Z19B} is -CH(CH₃)-CH(OH)-Ph, -CH(CO₂H)-CH(OH)-CH₃, -CH(CO₂H)-CH₂Ph, -CH(CH₂Ph)-2-thiazolyl, -CH(CH₂Ph)-2-pyridyl, -CH(CH₂-p-Cl-Ph), -CH(CO₂Me)-CH₂Ph, -CH(CO₂Me)-CH₂CH₂SCH₃, -CH(CH₂CH₂SCH₃)C(=O)NH-quinol-3-yl, -CH(CH₂Ph)C(=O)NH-

p-Cl-Ph, or R^{Z19B} has the structure of , wherein the wavy line indicates covalent attachment to the remainder of the auristatin compound.

In some embodiments the auristatin drug compound incorporated into -D is monomethylauristatin E (MMAE) or monomethylauristatin F (MMAF).

In some embodiments, the free drug that is conjugated within an antibody-drug conjugate or Drug Likar compound is an amine-containing tubulysin compound wherein the nitrogen atom

of the amine is the site of covalent attachment to the Linker Unit of the antibody-drug conjugate or Drug Linker compound and the amine-containing tubulysin compound has the structure of Formula **D_G** or **D_H**:




wherein the dagger represents the point of covalent attachment of the Drug Unit to the Linker Unit, in which the nitrogen atom so indicated becomes quaternized, in a Drug Linker compound or antibody-drug conjugate and the circle represents an 5-membered or 6-membered nitrogen heteroaryl wherein the indicated required substituents to that heteroaryl are in a 1,3- or *meta*-relationship to each other with optional substitution at the remaining positions; R^{Z2} is $X^{ZA}-R^{Z2A}$, wherein X^{ZA} is -O-, -S-, -N(R^{Z2B})-, -CH₂-, -(C=O)N(R^{Z2B})- or -O(C=O)N(R^{Z2B})- wherein R^{Z2B} is hydrogen or optionally substituted alkyl, R^{Z2A} is hydrogen, optionally substituted alkyl, optionally substituted aryl, or -C(=O) R^C , wherein R^C is hydrogen, optionally substituted alkyl, or optionally substituted aryl or R^{Z2} is an O-linked substituent; R^{Z3} is hydrogen or optionally substituted alkyl; R^{Z4} , R^{Z4A} , R^{Z4B} , R^{Z5} and R^{Z6} are optionally substituted alkyl, independently selected, one R^{Z7} is hydrogen or optionally substituted alkyl and the other R^{Z7} is optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and m^Z is 0 or 1. In other embodiments the quaternized drug is a tubulysin represented by structure **D_G** wherein one R^{Z7} is hydrogen or optionally substituted alkyl, the other R^{Z7} is an independently selected optionally substituted alkyl, and subscript m^Z is 0 or 1, wherein the other variable groups are as previously defined. In some embodiments, one R^{Z7} is hydrogen or optionally substituted lower alkyl, the other R^{Z7} is an independently selected optionally substituted C₁-C₆ alkyl, and subscript m^Z is 1, wherein the other variable groups are as previously defined.

In some embodiments, R^{Z2} is $X^{ZA}-R^{Z2A}$, wherein X^{ZA} is -O-, -S-, -N(R^{Z2B})-, -CH₂-, or -O(C=O)N(R^{Z2B})- wherein R^{Z2B} is hydrogen or optionally substituted alkyl, R^{Z2A} is hydrogen,

optionally substituted alkyl, optionally substituted aryl, or $-C(=O)R^{ZC}$, wherein R^{ZC} is hydrogen, optionally substituted alkyl, or optionally substituted aryl or R^{Z2} is an O-linked substituent.

In some embodiments, R^{Z2} is $X^{ZA}-R^{Z2A}$, wherein X^{ZA} is $-O-$, $-S-$, $-N(R^{Z2B})-$ or $-(C=O)N(R^{Z2B})-$ wherein R^{Z2A} and R^{Z2B} are independently hydrogen or optionally substituted alkyl, or R^{Z2} is an O-linked substituent.


In some embodiments $-N(R^{Z7})(R^{Z7})$ in **D_G** or **D_H** is replaced by $-N(R^{Z7})-CH(R^{Z10})(CH_2R^{Z11})$ to define tubulysin compounds of formula **D_H'** and **D_G'**:



wherein the dagger represents the point of covalent attachment to the Linker Unit, in which the nitrogen atom so indicated becomes quaternized, in a Drug Linker compound or antibody-drug conjugate; R^{Z10} is C_1 - C_6 alkyl substituted with $-CO_2H$, or ester thereof, and R^{Z7} is hydrogen or a C_1 - C_6 alkyl independently selected from R^{Z10} , or R^{Z7} and R^{Z10} together with the atoms to which they are attached define a 5 or 6-membered heterocycle; and R^{Z11} is aryl or 5- or 6-membered heteroaryl, optionally substituted with one or more, substituent(s) independently selected from the group consisting of halogen, lower alkyl, $-OH$ and $-O-C_1-C_6$ alkyl; and the remaining variable groups are as defined for **D_G** and **D_H**. In some embodiments, R^{Z11} is substituted with one or two substituents selected from the group consisting of halogen, lower alkyl, $-OH$ and $-O-C_1-C_6$ alkyl. In some embodiments, R^{Z11} is substituted with one substituent selected from the group consisting of halogen, lower alkyl, $-OH$ and $-O-C_1-C_6$ alkyl. In some embodiments, the halogen is F. In some embodiments, the $-O-C_1-C_6$ alkyl is $-OCH_3$. In some embodiments, the lower alkyl is $-CH_3$.


In still other embodiments one R^{Z7} in $-N(R^{Z7})(R^{Z7})$ in **D_G** or **D_H** is hydrogen or C_1 - C_6 alkyl, and the other R^{Z7} is an independently selected C_1 - C_6 alkyl optionally substituted by $-CO_2H$ or an ester thereof, or by an optionally substituted phenyl.

In some embodiments of structure **D_G** and **D_H**, one R^{Z7} is hydrogen and the other R^{Z7} is an optionally substituted arylalkyl having the structure of:




, wherein R^{Z7B} is hydrogen or an O-linked substituent, and R^{Z8A} is hydrogen or lower alkyl; and wherein the wavy line indicates the point of attachment to the remainder of **D_G** or **D_H**. In some embodiments, R^{Z7B} is hydrogen or -OH in the *para* position. In some embodiments, R^{Z8A} is methyl.

- 5 In some embodiments of structure **D_G** or **D_H**, one R^{Z7} is hydrogen, and the other R^{Z7} is an optionally substituted arylalkyl having the structure of



, wherein R^{Z7B} is -H or -OH; and wherein the wavy line indicates the point of attachment to the remainder of **D_G** or **D_H**.


- 10 In some embodiments of structure **D_G** and **D_H**, one R^{Z7} is hydrogen or lower alkyl, and the other R^{Z7} is optionally substituted arylalkyl having the structure of one of:



, wherein Z^Z is an optionally substituted alkylene or an optionally substituted alkenylene, R^{Z7B} is hydrogen or an O-linked substituent, R^{Z8A} is hydrogen or lower alkyl, and the subscript n_Z is 0, 1 or 2; and wherein the wavy line indicates the point of attachment to the remainder of **D_G** or **D_H**. In some embodiments, subscript n_Z is 0 or


- 15 1. In still other embodiments of structure **D_G** and **D_H** -N(R^{Z7})(R^{Z7}) is -NH(C₁-C₆ alkyl) wherein the C₁-C₆ alkyl is optionally substituted by -CO₂H or an ester thereof, or by an optionally substituted phenyl. In some embodiments -N(R^{Z7})(R^{Z7}) is selected from the group consisting of -NH(CH₃), -CH₂CH₂Ph, -CH₂-CO₂H, -CH₂CH₂CO₂H and -CH₂CH₂CH₂CO₂H. In some

embodiments, one R^{Z7} is hydrogen or methyl and the other R^{Z7} is an optionally substituted arylalkyl having the structure of:





$\text{HO}-\text{C}(=\text{O})-$, $-\text{C}(=\text{O})-$, and $-\text{C}(=\text{O})-$, wherein Z^{Z} is an optionally substituted alkylene or an optionally substituted alkenylene, R^{Z7B} is hydrogen or -OH in the *para* position, R^{Z8A} is hydrogen or methyl, and the subscript *nz* is 0, 1 or 2

In some embodiments of structure **D_G'** and **D_H'**, R^{Z7} and R^{Z10} together with the atoms to which they are attached define an optionally substituted 5 or 6-membered heterocycle wherein -N(R^{Z7})-



CH(R^{Z10})(CH₂R^{Z11}) has the structure of:  wherein the wavy line indicates the point of attachment to the remainder of **D_G'** or **D_H'**.

In some embodiments, the tubulysin compound is represented by the following formula wherein the indicated nitrogen ($\dagger$) is the site of quaternization when such compounds are incorporated into an ADC as a quaternized drug unit (D^+):




wherein the dagger represents the point of attachment of the Drug Unit to the Linker Unit in a Drug Linker compound or antibody-drug conjugate in which the nitrogen atom so indicated



becomes quaternized, and the circle represents an 5-membered or 6-membered nitrogen-heteroaryl wherein the indicated required substituents to that heteroaryl are in a 1,3- or *meta*-relationship to each other with optional substitution at the remaining positions; R^{Z2A} is hydrogen or optionally substituted alkyl or R^{Z2A} along with the oxygen atom to which it is attached defines an O-linked substituent; R^{Z3} is hydrogen or optionally substituted alkyl; R^{Z4} , R^{Z4A} , R^{Z4B} , R^{Z5} and R^{Z6} are optionally substituted alkyl, independently selected; R^{Z7A} is optionally substituted aryl or optionally substituted heteroaryl, R^{Z8A} is hydrogen or optionally substituted alkyl and subscript mz' is 0 or 1.

In some embodiments of structure **D_G**, **D_{G-1}**, **D_H**, or **D_{H-1}**, R^{Z4} is methyl or R^{Z4A} and R^{Z4B} are methyl. In other embodiments of structure **D_G'** or **D_H'** R^{Z4} is methyl or R^{Z4A} and R^{Z4B} are methyl. In other embodiments, R^{Z7A} is optionally substituted phenyl. In some embodiments R^{Z8A} is methyl in the (S)-configuration. In other embodiments, R^{Z2A} along with the oxygen atom to which it is attached defines an O-linked substituent other than -OH. In some embodiments, R^{Z2A} along with the oxygen atom to which it is attached defines an ester, ether, or an O-linked carbamate. In some embodiments the circle represents a 5-membered nitrogen-heteroarylene. Some embodiments, the circle represents a divalent oxazole or thiazole moiety. In some embodiments R^{Z4} is methyl or R^{Z4A} and R^{Z4B} are methyl. In some embodiments R^{Z7} is optionally substituted arylalkyl, wherein aryl is phenyl and R^{Z7A} is optionally substituted phenyl.

In other embodiments of **D_G**, **D_G'**, **D_{G-1}**, **D_H**, **D_H'** or **D_{H-1}** the circle represents a 5-membered nitrogen heteroarylene. In some embodiments, the 5-membered heteroarylene is represented by


the structure  wherein X^{ZB} is O, S, or N- R^{ZB} wherein R^{ZB} is hydrogen or lower alkyl. In some embodiments, the quaternized drug is a tubulysin represented by structure **D_G**, **D_G'** or **D_{G-1}**, wherein m is 1. In some embodiments, the tubulysins are represented by structure **D_G**, wherein m is 1 and the circle represents an optionally substituted divalent thiazole moiety.



In some embodiments, the tubulysin compound is represented by the following formula wherein the indicated nitrogen atom ($\dagger$) is the site of quaternization when such compounds are incorporated into an ADC as a quaternized drug unit (D^+):



wherein R^{Z2A} along with the oxygen atom to which it is attached defines an O-linked substituent,
 5 R^{Z3} is lower alkyl or $-\text{CH}_2\text{OC}(=\text{O})R^{Z3A}$ wherein R^{Z3A} is optionally substituted lower alkyl, and
 R^{Z7B} is hydrogen or an O-linked substituent. In some embodiments, R^{Z2A} along with the oxygen
 atom to which it is attached defines an ester, ether or O-linked carbamate. In some embodiments,
 R^{Z7B} is an O-linked substituent in the *para* position. In some embodiments, R^{Z3} is methyl or R^{Z3A}
 10 is methyl, ethyl, propyl, iso-propyl, iso-butyl or $-\text{CH}_2\text{C}(\text{CH}_3)_2$. In some embodiments R^{Z2A} is
 methyl, ethyl, propyl (i.e., $-\text{OR}^{Z2A}$ is an ether) or is $-\text{C}(=\text{O})R^{Z2B}$ (i.e., $-\text{OR}^{Z2A}$ is an ester) wherein
 R^{Z2B} is lower alkyl. In some embodiments, R^{Z2B} is methyl (i.e., $-\text{OR}^{Z2A}$ is acetate).




In some embodiments, the tubulysin compound that is incorporated into an antibody-drug
 conjugate or Drug Linker compound has the structure of one of the following formulae:





wherein R^{Z7B} is hydrogen or -OH, R^{Z3} is lower alkyl, and R^{Z2B} and R^{Z2C} are independently hydrogen or lower alkyl. In some embodiments, R^{Z3} is methyl or ethyl. In some embodiments of any one of structures **D_G**, **D_{G-1}**, **D_{G-2}**, **D_{G-3}**, **D_{G-4}**, **D_{G-5}**, **D_H**, **D_{H-1}** and **D_{H-2}**, R^{Z3} is methyl or is -CH₂OC(=O) R^{Z3A} , wherein R^{Z3A} is optionally substituted alkyl. In some embodiments of any one of structures **D_G'** and **D_H'**, R^{Z3} is methyl or is -CH₂OC(=O) R^{Z3A} , wherein R^{Z3A} is optionally substituted alkyl. In some embodiments of any one of those structures R^{Z3} is -C(R^{Z3A})(R^{Z3A})C(=O)-X^{ZC}, wherein X^{ZC} is -OR^{Z3B} or -N(R^{Z3C})(R^{Z3C}), wherein each R^{Z3A} , R^{Z3B} and R^{Z3C} independently is hydrogen, optionally substituted alkyl or optionally substituted cycloalkyl. In some embodiments, R^3 is -C(R^{Z3A})(R^{Z3A})C(=O)-N(R^{Z3C})(R^{Z3C}), with each R^{Z3A} hydrogen, one R^{Z3C} hydrogen and the other R^{Z3C} n-butyl or isopropyl. In some embodiments of any one of structures **D_G**, **D_G'**, **D_{G-1}**, **D_{G-2}**, **D_{G-3}**, **D_{G-4}**, **D_{G-5}**, **D_H**, **D_H'**, **D_{H-1}** and **D_{H-2}**, R^{Z3} is ethyl or propyl.




In some embodiments of any one of structures **D_{G-1}**, **D_{G-2}**, **D_{G-3}**, **D_{G-4}**, **D_{G-5}**, **D_{G-6}**, **D_{H-1}** and

D_{H-2}, the thiazole core heterocycle  is replaced with  or .

In some embodiments of any one of structures **D_G**, **D_{G-1}**, **D_{G-2}**, **D_{G-3}**, **D_{G-4}**, **D_{G-5}**, **D_H**, **D_{H-1}**, **D_{H-2}**, **D_{H-3}** and **D_{H-4}**, R^{Z3} is methyl or is -CH₂OC(=O) R^{Z3A} , wherein R^{Z3A} is optionally substituted alkyl. In some embodiments of any one of those structures R^{Z3} is -C(R^{Z3A})(R^{Z3A})C(=O)-X^{ZC}, wherein X^{ZC} is -OR^{3B} or -N(R^{3C})(R^{3C}), wherein each R^{3A} , R^{3B} and R^{3C} independently is hydrogen,

optionally substituted alkyl or optionally substituted cycloalkyl. In some embodiments, R^{Z3} is $-C(R^{Z3A})(R^{Z3A})C(=O)-N(R^{Z3C})(R^{Z3C})$, with each R^{Z3A} hydrogen, one R^{Z3C} hydrogen and the other R^{Z3C} is optionally substituted alkyl or optionally substituted cycloalkyl. In some embodiments, R^{Z3} is $-C(R^{Z3A})(R^{Z3A})C(=O)-N(R^{Z3C})(R^{Z3C})$, with each R^{Z3A} hydrogen, one R^{Z3C} hydrogen and the other R^{Z3C} is n-butyl or isopropyl.

In some embodiments of any one of structures **D_{G-3}**, **D_{G-4}**, **D_{G-5}**, **D_{H-3}** and **D_{H-4}**, the thiazole

core heterocycle  is replaced with  or .

In some embodiments, the tubulysin has structure **D_{G-3}** or **D_{G-4}** wherein m is 1, R^{Z3} is optionally substituted methyl, ethyl or propyl. In some embodiments, R^{Z3} is unsubstituted methyl, ethyl or propyl.


In some embodiments, the tubulysin compound has structure **D_{G-3}**, wherein subscript mz' is 1, R^{Z3} is methyl, ethyl or propyl, $-OC(O)R^{Z2B}$ is $-O-C(O)H$, $O-C(O)-C_1-C_6$ alkyl, or $-OC_2-C_6$ alkenyl, optionally substituted. In some embodiments, $-OC(O)R^{Z2B}$ is $-OC(O)CH_3$, $-OC(O)CH_2CH_3$, $-OC(O)CH(CH_3)_2$, $-OC(O)C(CH_3)_3$, or $-OC(O)CH=CH_2$.

In some embodiments, the tubulysin compound has structure **D_{G-4}**, wherein subscript mz' is 1, R^{Z3} is methyl, ethyl or propyl and $-OCH_2R^{Z2B}$ is $-OCH_3$, $-OCH_2CH_3$, $-OCH_2CH_2CH_3$ or $-OCH_2OCH_3$.

In some embodiments, the tubulysin compound has structure **D_{G-3}**, wherein subscript mz' is 1, R^{Z3} is methyl, ethyl or propyl, $-OC(O)R^{Z2B}$ is $-O-C(O)H$, $O-C(O)-C_1-C_6$ alkyl, or $-OC_2-C_6$ alkenyl, optionally substituted. In some embodiments, $-OC(O)R^{Z2B}$ is $-OC(O)CH_3$, $-OC(O)CH_2CH_3$, $-OC(O)CH(CH_3)_2$, $-OC(O)C(CH_3)_3$, or $-OC(O)CH=CH_2$.


In some embodiments, the tubulysin compound has structure **D_{G-4}**, wherein subscript mz' is 1, R^{Z3} is methyl, ethyl or propyl and $-OCH_2R^{Z2B}$ is $-OCH_3$, $-OCH_2CH_3$, $-OCH_2CH_2CH_3$ or $-OCH_2OCH_3$.

In some embodiments, the tubulysin has the structure of



wherein R^{Z2B} is $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2\text{C}(\text{CH}_3)_3$ and the indicated nitrogen atom ($\dagger$) is the site of quaternization when such compounds are incorporated into an ADC or Drug Linker compound as a quaternized drug unit (D^+).

In some embodiments, the tubulysin has the structure of



wherein R^{Z2B} is hydrogen, methyl or $-\text{OCH}_3$ (i.e., $-\text{OCH}_2\text{R}^{Z2B}$ is a methyl ethyl, methoxymethyl ether substituent).

In some embodiments, the tubulysin incorporated as D^+ in an ADC is a naturally occurring tubulysin including Tubulysin A, Tubulysin B, Tubulysin C, Tubulysin D, Tubulysin E, Tubulysin F, Tubulysin G, Tubulysin H, Tubulysin I, Tubulysin U, Tubulysin V, Tubulysin W, Tubulysin X or Tubulysin Z, whose structures are given by the following structure and variable group definitions wherein the indicated nitrogen atom ($\dagger$) is the site of quaternization when such

compounds are incorporated into an ADC or Drug Linker compound as a quaternized drug unit (D^+):











TABLE 1. Some Naturally Occurring Tubulysins

Tubulysin	R ^{Z7B}	R ^{Z2A}	R ^{Z3}
A	OH	C(=O)CH ₃	CH ₂ OC(=O)i-Bu
B	OH	C(=O)CH ₃	CH ₂ OC(=O)n-Pr
C	OH	C(=O)CH ₃	CH ₂ OC(=O)Et
D	H	C(=O)CH ₃	CH ₂ OC(=O)i-Bu
E	H	C(=O)CH ₃	CH ₂ OC(=O)n-Pr
F	H	C(=O)CH ₃	CH ₂ OC(=O)Et
G	OH	C(=O)CH ₃	CH ₂ OC(=O)CH=CH ₂
H	H	C(=O)CH ₃	CH ₂ OC(=O)Me
I	OH	C(=O)CH ₃	CH ₂ OC(=O)Me
U	H	C(=O)CH ₃	H
V	H	OH	H
Z	OH	OH	H

5

In some embodiments of structure **D_{G-6}** the tubulysin compound incorporated into an ADC or Drug Linker compound as a quaternized Drug Unit is Tubulysin M, wherein R^{Z3} is -CH₃, R^{Z2} is C(=O)CH₃ and R^{Z7B} is hydrogen.

10 In some embodiments, D incorporates the structure of a DNA damaging agent. In some embodiments, D incorporates the structure of a DNA replication inhibitor. In some embodiments, D incorporates the structure of acamptothecin. In some embodiments, that camptothecin compound has a formula selected from the group consisting of:



wherein R^{ZB} is selected from the group consisting of H, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ cycloalkyl, (C₃-C₈ cycloalkyl)-C₁-C₄ alkyl, phenyl, and phenyl-C₁-C₄ alkyl;


R^{ZC} is selected from the group consisting of C₁-C₆ alkyl and C₃-C₆ cycloalkyl; and

each R^{ZF} and $R^{ZF'}$ is independently selected from the group consisting of -H, C₁-C₈ alkyl, C₁-C₈ hydroxyalkyl, C₁-C₈ aminoalkyl, (C₁-C₄ alkylamino)-C₁-C₈ alkyl-, *N,N*-(C₁-C₄ hydroxyalkyl)(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, *N,N*-di(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, *N*-(C₁-C₄ hydroxyalkyl)-C₁-C₈ aminoalkyl, C₁-C₈ alkyl-C(O)-, C₁-C₈ hydroxyalkyl-C(O)-, C₁-C₈ aminoalkyl-C(O)-, C₃-C₁₀ cycloalkyl, (C₃-C₁₀ cycloalkyl)-C₁-C₄ alkyl-, C₃-C₁₀ heterocycloalkyl, (C₃-C₁₀ heterocycloalkyl)-C₁-C₄ alkyl-, phenyl, phenyl-C₁-C₄ alkyl-, diphenyl-C₁-C₄ alkyl-, heteroaryl, and heteroaryl-C₁-C₄ alkyl-, or

R^{ZF} and $R^{ZF'}$ are combined with the nitrogen atom to which each is attached to form a 5-, 6- or 7-membered ring having 0 to 3 substituents selected from the group consisting of halogen, C₁-C₄ alkyl, -OH, -OC₁-C₄ alkyl, -NH₂, -NH-C₁-C₄ alkyl, -N(C₁-C₄ alkyl)₂; and


wherein the cycloalkyl, heterocycloalkyl, phenyl and heteroaryl portions of R^{ZB} , R^{ZC} , R^{ZF} and $R^{ZF'}$ are substituted with from 0 to 3 substituents selected from the group consisting of halogen, C₁-C₄ alkyl, -OH, -OC₁-C₄ alkyl, -NH₂, -NHC₁-C₄ alkyl, and -N(C₁-C₄ alkyl)₂.

In some embodiments, the camptothecin compound, whose structure is incorporated as a Drug Unit in an ADC or Drug Linker compound, has the formula CPT1, the structure of which is:




wherein the dagger represents the point of attachment of the Drug Unit to the Linker Unit in a Drug Linker compound or antibody-drug conjugate.

In some embodiments, the camptothecin compound, whose structure is incorporated as a Drug Unit in an ADC or Drug Linker compound, has the formula CPT2, the structure of which is:




wherein the dagger represents the point of attachment of the Drug Unit to the Linker Unit in a Drug Linker compound or antibody-drug conjugate.

In some embodiments, the camptothecin compound, whose structure is incorporated as a Drug Unit in an ADC or Drug Linker compound, has the formula CPT3, the structure of which is:




wherein the dagger represents the point of attachment of the Drug Unit to the Linker Unit in a Drug Linker compound or antibody-drug conjugate.

In some embodiments, the camptothecin compound, whose structure is incorporated as a Drug Unit in an ADC or Drug Linker compound, has the formula CPT4, the structure of which is:




wherein the dagger represents the point of covalent attachment of the Drug Unit to the Linker Unit when the formula CPT4 compound is in the form of a Drug Unit in a Drug Linker compound or antibody-drug conjugate. In some embodiments, D incorporates the structure of exatecan.

In some embodiments, the camptothecin compound, whose structure is incorporated as a Drug Unit in an ADC or Drug Linker compound, has the formula CPT5, the structure of which is:




wherein the dagger represents the point of attachment to the Linker Unit when the formula CPT5 compound is in the form of a Drug Unit in a Drug Linker compound or antibody-drug conjugate.

In some embodiments, the camptothecin compound, whose structure is incorporated as a Drug Unit in an ADC or Drug Linker compound, has the formula CPT6, the structure of which is:




wherein the dagger represents the point of attachment to the Linker Unit when the formula CPT6 compound is in the form of a Drug Unit in a Drug Linker compound or antibody-drug conjugate.

In some embodiments, CPT6 has the structure of:




10 wherein the dagger represents the point of attachment to the Linker Unit when the formula CPT6 compound is in the form of a Drug Unit in a Drug Linker compound or antibody-drug conjugate.

In some embodiments, the camptothecin compound, whose structure is incorporated as a Drug Unit in an ADC or Drug Linker compound, has the formula CPT7 the structure of which is:



wherein the dagger represents the point of attachment to the Linker Unit in a Drug Linker compound or antibody-drug conjugate when the formula CPT7 compound is in the form of a Drug Unit.

- 5 In some embodiments, the camptothecin compound, whose structure is incorporated as a Drug Unit in an ADC or Drug Linker compound, has the formula



wherein one of R^{Z11} is n-butyl and one of R^{Z12} - R^{Z14} is $-NH_2$ and the other are hydrogen, or R^{Z12} is $-NH_2$ and R^{Z13} and R^{Z14} together are $-OCHO-$.

- 10 In some embodiments, R^{ZB} is selected from the group consisting of C_3 - C_8 cycloalkyl, (C_3 - C_8 cycloalkyl)- C_1 - C_4 alkyl, phenyl, and phenyl- C_1 - C_4 alkyl, and wherein the cycloalkyl and phenyl portions of R^{ZB} are substituted with from 0 to 3 substituents selected from halogen, C_1 - C_4 alkyl, OH, $-O$ - C_1 - C_4 alkyl, NH_2 , $-NH$ - C_1 - C_4 alkyl and $-N(C_1$ - C_4 alkyl) $_2$. In some embodiments, R^{ZB} is selected from the group consisting of H, C_1 - C_8 alkyl, and C_1 - C_8 haloalkyl. In some embodiments,
- 15 R^{ZB} is H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, 1-ethylpropyl, or hexyl. In some embodiments, R^{ZB} is chloromethyl or bromomethyl. In some embodiments, R^{ZB} is phenyl or halo-substituted phenyl. In some embodiments, R^{ZB} is phenyl or fluorophenyl.

- In some embodiments, R^{ZC} is C_1 - C_6 alkyl. In some embodiments, R^{ZC} is methyl. In some
- 20 embodiments, R^{ZC} is C_3 - C_6 cycloalkyl.


In some embodiments, R^{ZF} and $R^{ZF'}$ are both H. In some embodiments, at least one of R^{ZF} and $R^{ZF'}$ is selected from the group consisting of C₁-C₈ alkyl, C₁-C₈ hydroxyalkyl, C₁-C₈ aminoalkyl, (C₁-C₄ alkylamino)-C₁-C₈ alkyl-, *N,N*-(C₁-C₄ hydroxyalkyl)(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, *N,N*-di(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, *N*-(C₁-C₄ hydroxyalkyl)-C₁-C₈ aminoalkyl, C₁-C₈ alkyl-C(O)-, C₁-C₈ hydroxyalkyl-C(O)-, C₁-C₈ aminoalkyl-C(O)-, C₃-C₁₀ cycloalkyl, (C₃-C₁₀ cycloalkyl)-C₁-C₄ alkyl-, C₃-C₁₀ heterocycloalkyl, (C₃-C₁₀ heterocycloalkyl)-C₁-C₄ alkyl-, phenyl, phenyl-C₁-C₄ alkyl-, diphenyl-C₁-C₄ alkyl-, heteroaryl and heteroaryl-C₁-C₄ alkyl-. In some embodiments, one of R^{ZF} and $R^{ZF'}$ is H and the other is selected from the group consisting of C₁-C₈ alkyl, C₁-C₈ hydroxyalkyl, C₁-C₈ aminoalkyl, (C₁-C₄ alkylamino)-C₁-C₈ alkyl-, *N,N*-(C₁-C₄ hydroxyalkyl)(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, *N,N*-di(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, *N*-(C₁-C₄ hydroxyalkyl)-C₁-C₈ aminoalkyl, C₁-C₈ alkyl-C(O)-, C₁-C₈ hydroxyalkyl-C(O)-, C₁-C₈ aminoalkyl-C(O)-, C₃-C₁₀ cycloalkyl, (C₃-C₁₀ cycloalkyl)-C₁-C₄ alkyl-, C₃-C₁₀ heterocycloalkyl, (C₃-C₁₀ heterocycloalkyl)-C₁-C₄ alkyl-, phenyl, phenyl-C₁-C₄ alkyl-, diphenyl-C₁-C₄ alkyl-, heteroaryl and heteroaryl-C₁-C₄ alkyl-. In some embodiments, one of R^{ZF} and $R^{ZF'}$ is selected from the group consisting of C₁-C₈ alkyl, C₁-C₈ hydroxyalkyl, C₁-C₈ aminoalkyl, (C₁-C₄ alkylamino)-C₁-C₈ alkyl-, *N,N*-(C₁-C₄ hydroxyalkyl)(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, *N,N*-di(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, *N*-(C₁-C₄ hydroxyalkyl)-C₁-C₈ aminoalkyl, C₁-C₈ alkyl-C(O)-, C₁-C₈ hydroxyalkyl-C(O)-, C₁-C₈ aminoalkyl-C(O)-, C₃-C₁₀ cycloalkyl, (C₃-C₁₀ cycloalkyl)-C₁-C₄ alkyl-, C₃-C₁₀ heterocycloalkyl, (C₃-C₁₀ heterocycloalkyl)-C₁-C₄ alkyl-, phenyl, phenyl-C₁-C₄ alkyl-, diphenyl-C₁-C₄ alkyl-, heteroaryl and heteroaryl-C₁-C₄ alkyl-, and the other is selected from the group consisting of H, C₁-C₈ alkyl, C₁-C₈ hydroxyalkyl, C₁-C₈ aminoalkyl, (C₁-C₄ alkylamino)-C₁-C₈ alkyl-, *N,N*-(C₁-C₄ hydroxyalkyl)(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, *N,N*-di(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, *N*-(C₁-C₄ hydroxyalkyl)-C₁-C₈ aminoalkyl, C₁-C₈ alkyl-C(O)-, C₁-C₈ hydroxyalkyl-C(O)-, C₁-C₈ aminoalkyl-C(O)-, C₃-C₁₀ cycloalkyl, (C₃-C₁₀ cycloalkyl)-C₁-C₄ alkyl-, C₃-C₁₀ heterocycloalkyl, (C₃-C₁₀ heterocycloalkyl)-C₁-C₄ alkyl-, phenyl, phenyl-C₁-C₄ alkyl-, diphenyl-C₁-C₄ alkyl-, heteroaryl and heteroaryl-C₁-C₄ alkyl-. In some embodiments, R^{ZF} and $R^{ZF'}$ are both independently selected from the group consisting of C₁-C₈ alkyl, C₁-C₈ hydroxyalkyl, C₁-C₈ aminoalkyl, (C₁-C₄ alkylamino)-C₁-C₈ alkyl-, *N,N*-(C₁-C₄ hydroxyalkyl)(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, *N,N*-di(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, *N*-(C₁-C₄ hydroxyalkyl)-C₁-C₈ aminoalkyl, C₁-C₈ alkyl-C(O)-, C₁-C₈ hydroxyalkyl-C(O)-, C₁-C₈ aminoalkyl-C(O)-, C₃-C₁₀ cycloalkyl, (C₃-C₁₀ cycloalkyl)-C₁-C₄ alkyl-, C₃-C₁₀ heterocycloalkyl, (C₃-C₁₀ heterocycloalkyl)-C₁-C₄ alkyl-, phenyl, phenyl-C₁-C₄ alkyl-, diphenyl-C₁-C₄ alkyl-, heteroaryl and heteroaryl-C₁-C₄ alkyl-.

C₁₀ cycloalkyl)-C₁-C₄ alkyl-, C₃-C₁₀ heterocycloalkyl, (C₃-C₁₀ heterocycloalkyl)-C₁-C₄ alkyl-, phenyl, phenyl-C₁-C₄ alkyl-, diphenyl-C₁-C₄ alkyl-, heteroaryl and heteroaryl-C₁-C₄ alkyl-.


In some embodiments, the cycloalkyl, heterocycloalkyl, phenyl and heteroaryl moieties of R^{ZF} or R^{ZF'} are substituted with from 0 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, -OH, -OC₁-C₄ alkyl, -NH₂, -NHC₁-C₄ alkyl and -N(C₁-C₄ alkyl)₂.

In some embodiments, R^{ZF} and R^{ZF'} are combined with the nitrogen atom to which each is attached to form a 5-, 6- or 7-membered ring having 0 to 3 substituents selected from the group consisting of halogen, C₁-C₄ alkyl, -OH, -OC₁-C₄ alkyl, -NH₂, -NHC₁-C₄ alkyl and -N(C₁-C₄ alkyl)₂.


In some embodiments, D incorporates the structure of AMDCPT:




In some embodiments, D incorporates the structure of exatecan:



In some embodiments, D incorporates the structure of irinotecan:



In some embodiments, a camptothecin Drug Unit of an antibody-drug conjugate or Drug Linker compound incorporates a camptothecin drug through covalent attachment of a Linker Unit of the Conjugate or Drug Linker compound to an amine or hydroxyl of a camptothecin free drug having structure of **D_{1a}** or **D_{1b}** as follows:



or a salt thereof, wherein the dagger indicates the site of covalent attachment of D to the drug linker moiety,

R^{Zb1} is selected from the group consisting of H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkenyl, (C₆-C₁₂ aryl)-C₁-C₆ alkenyl- optionally substituted with -OR^{Za}, -OR^{Za}, -NHR^{Za}, and -SR^{Za}, or is combined with R^{Zb2} or R^{Zb5} and the intervening atoms to form a 5- or 6-membered carbocyclo or heterocyclo;

R^{Zb2} is selected from the group consisting of H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, -OR^{Za}, -NHR^{Za}, and -SR^{Za}, or is combined with R^{Zb1} or R^{Zb3} and the intervening atoms to form a 5- or 6-membered carbocyclo or heterocyclo;

R^{Zb3} is selected from the group consisting of H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, -OR^{Za}, -NHR^{Za}, and -SR^{Za}, or is combined with R^{Zb2} or R^{Zb4} and the intervening atoms to form a 5- or 6-membered carbocyclo or heterocyclo;

R^{Zb4} is selected from the group consisting of H or halogen, or is combined with R^{Zb3} and the intervening atoms to form a 5- or 6-membered carbocyclo or heterocyclo;

each R^{Zb5} and $R^{Zb5'}$ is independently selected from the group consisting of H, C₁-C₈ alkyl, C₁-C₈ hydroxyalkyl, C₁-C₈ aminoalkyl, (C₁-C₄ alkylamino)-C₁-C₈ alkyl-, *N,N*-(C₁-C₄ hydroxyalkyl)(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, *N,N*-di(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, *N*-(C₁-C₄ hydroxyalkyl)-C₁-C₈ aminoalkyl-, C₁-C₈ alkyl-C(O)-, C₁-C₈ hydroxyalkyl-C(O)-, C₁-C₈ aminoalkyl-C(O)-, C₃-C₁₀ cycloalkyl, (C₃-C₁₀ cycloalkyl)-C₁-C₄ alkyl-, C₃-C₁₀ heterocycloalkyl, (C₃-C₁₀ heterocycloalkyl)-C₁-C₄ alkyl-, phenyl, phenyl-C₁-C₄ alkyl-, diphenyl-C₁-C₄ alkyl-, heteroaryl, and heteroaryl-C₁-C₄ alkyl-, C₁-C₆ alkoxy-C(O)-C₁-C₈ aminoalkyl-, C₁-C₆ alkoxy-C(O)-*N*-(C₁-C₄ alkyl)amino-C₁-C₈ alkyl-, C₁-C₆ alkoxy-C(O)-(C₃-C₁₀ heterocycloalkyl)-, C₁-C₆ alkoxy-C(O)-(C₃-C₁₀ heterocycloalkyl)-C₁-C₈ alkyl-, C₁-C₄ alkyl-SO₂-C₁-C₈ alkyl-, NH₂-SO₂-C₁-C₈ alkyl-, (C₃-C₁₀ heterocycloalkyl)-C₁-C₄ hydroxyalkyl-, C₁-C₆ alkoxy-C(O)-(C₃-C₁₀ heterocycloalkyl)-C₁-C₈ alkyl-, phenyl-C(O)-, phenyl-SO₂-, and C₁-C₈ hydroxyalkyl-C₃-C₁₀ heterocycloalkyl-, or

R^{Zb5} and $R^{Zb5'}$ are combined with the nitrogen atom to which they are attached to form a 5-, 6- or 7-membered ring having 0 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, -OH, -OC₁-C₄ alkyl, -NH₂, -NH-C₁-C₄ alkyl, -N(C₁-C₄ alkyl)₂, C₁-C₆ alkoxy-C(O)-NH-, C₁-C₆ alkoxy-C(O)-C₁-C₈ aminoalkyl-, and C₁-C₈ aminoalkyl; or

$R^{Zb5'}$ is H and R^{Zb5} is combined with R^{Zb1} and the intervening atoms to form a 5- or 6-membered carbocyclo or heterocyclo;

wherein the cycloalkyl, carbocyclo, heterocycloalkyl, heterocyclo, phenyl and heteroaryl portions of R^{Zb1} , R^{Zb2} , R^{Zb3} , R^{Zb4} , R^{Zb5} and $R^{Zb5'}$ are substituted with from 0 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, -OH, -OC₁-C₄ alkyl, -NH₂, -NHC₁-C₄ alkyl, and -N(C₁-C₄ alkyl)₂; and

each R^{Za} is independently selected from the group consisting of H, C₁-C₆ alkyl, and C₁-C₆ haloalkyl.

In some embodiments of Formula **D_{1a}** or Formula **D_{1b}**, R^{Zb1} , R^{Zb2} , R^{Zb3} , and R^{Zb4} are each hydrogen.

In some embodiments of Formula **D_{1a}** or Formula **D_{1b}**, R^{Zb1} , R^{Zb2} , and R^{Zb4} are hydrogen, and R^{Zb3} is halogen. In some embodiments, R^{b3} is fluoro.

In some embodiments of Formula **D_{1a}** or Formula **D_{1b}**, R^{Zb2} , R^{Zb3} , and R^{Zb4} are hydrogen, and R^{Z3} is halogen. In some embodiments, R^{Zb1} is fluoro.

In some embodiments of Formula **D_{1a}** or Formula **D_{1b}**, R^{Zb2} and R^{Zb4} are hydrogen, and R^{Zb1} and R^{Zb3} are both halogen. In some embodiments, R^{Zb1} and R^{Zb3} are both fluoro.


5 In some embodiments of Formula **D_{1a}** or Formula **D_{1b}**, R^{Zb1} , R^{Zb3} and R^{Zb4} are hydrogen, and R^{Zb2} is C₁-C₆ alkyl, C₁-C₆ haloalkyl, halogen, -OR^{Za} or -SR^{Za}. In some embodiments, R^{Zb2} is C₁-C₆ alkyl or halogen. In some embodiments, R^{Zb2} is C₁-C₆ alkyl. In some embodiments, R^{Zb2} is methyl. In some embodiments, R^{Zb2} is C₁-C₆ alkoxy. In some embodiments, R^{Zb2} is methoxy. In some
10 embodiments, R^{Zb2} is halogen. In some embodiments, R^{Zb2} is fluoro. In some embodiments, R^{Zb2} is chloro. In some embodiments, R^{Zb2} is bromo. In some embodiments, R^{Zb2} is C₁-C₆ haloalkyl. In some embodiments, R^{Zb2} is trifluoromethyl. In some embodiments, R^{Zb2} is C₁-C₆ haloalkylthio. In some embodiments, R^{Zb2} is trifluoromethylthio. In some embodiments, R^{Zb2} is hydroxyl.

In some embodiments of Formula **D_{1a}** or Formula **D_{1b}**, R^{Zb1} and R^{Zb4} are hydrogen, R^{Zb2} is C₁-C₆ alkyl, C₁-C₆ haloalkyl, halogen, -OR^{Za} or -SR^{Za}, and R^{Zb3} is C₁-C₆ alkyl or halogen. In some
15 embodiments, R^{Zb2} is C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen or hydroxy, and R^{Zb3} is C₁-C₆ alkyl or halogen. In some embodiments, R^{Zb2} is C₁-C₆ alkyl. In some embodiments, R^{Zb2} is methyl. In some embodiments, R^{Zb2} is C₁-C₆ alkoxy. In some embodiments, R^{Zb2} is halogen. In some
20 embodiments, R^{Zb2} is fluoro. In some embodiments, R^{Zb2} is methoxy. In some embodiments, R^{Zb2} is hydroxyl. In some embodiments, R^{Zb3} is C₁-C₆ alkyl. In some embodiments, R^{Zb3} is methyl. In some
25 embodiments, R^{Zb3} is halogen. In some embodiments, R^{Zb3} is fluoro. In some embodiments, R^{Zb2} is C₁-C₆ alkyl and R^{Zb3} is halogen. In some embodiments, R^{Zb2} is methyl and R^{Zb3} is fluoro. In some embodiments, R^{Zb2} is C₁-C₆ alkoxy and R^{Zb3} is halogen. In some embodiments, R^{Zb2} is methoxy and R^{Zb3} is fluoro. In some embodiments, R^{Zb2} and R^{Zb3} are halogen. In some
embodiments, R^{Zb2} and R^{Zb3} are both fluoro. In some embodiments, R^{Zb2} is halogen and R^{Zb3} is C₁-C₆ alkyl. In some embodiments, R^{Zb2} is fluoro and R^{Zb3} is methyl. In some embodiments, R^{Zb2} is hydroxyl and R^{Zb3} is halogen. In some embodiments, R^{Zb2} is hydroxyl and R^{Zb3} is fluoro.


In some embodiments of Formula **D_{1a}** or Formula **D_{1b}**, R^{Zb2} is C₁-C₆ alkyl, C₁-C₆ haloalkyl, halogen, -OR^{Za} or -SR^{Za}, both R^{Zb1} and R^{Zb3} are independently selected from the group consisting of C₁-C₆ alkyl, halogen, C₁-C₆ alkenyl, (C₆-C₁₂ aryl)-C₁-C₆ alkenyl- optionally substituted with -
30 OR^{Za}, or -OR^{Za}, and R^{Zb4} is hydrogen. In some embodiments, R^{Zb1} is C₁-C₆ alkyl. In some
embodiments, R^{Zb1} is methyl. In some embodiments, R^{Zb1} is halogen. In some embodiments, R^{Zb1}

is fluoro. In some embodiments, R^{Zb1} is chloro. In some embodiments, R^{Zb1} is bromo. In some
embodiments, R^{Zb1} is (C₆-C₁₂ aryl)-C₁-C₆ alkenyl-, optionally substituted with -OR^{Za}. In some
embodiments, R^{Zb1} is 4-methoxystyryl. In some embodiments, R^{Zb1} is C₁-C₆ alkenyl. In some
embodiments, R^{Zb1} is vinyl. In some embodiments, R^{Zb1} is 1-methylvinyl. In some embodiments,
5 R^{Zb1} is 1-methylvinyl. In some embodiments, R^{Zb2} is C₁-C₆ alkyl. In some embodiments, R^{Zb2} is
methyl. In some embodiments, R^{Zb2} is C₁-C₆ alkoxy. In some embodiments, R^{Zb2} is methoxy. In
some embodiments, R^{Zb2} is hydroxyl. In some embodiments, R^{Zb3} is C₁-C₆ alkyl. In some
embodiments, R^{Zb3} is methyl. In some embodiments, R^{Zb3} is ethyl. In some embodiments, R^{Zb3} is
C₁-C₆ alkoxy. In some embodiments, R^{Zb3} is methoxy. In some embodiments, R^{Zb3} is halogen. In
10 some embodiments, R^{Zb3} is fluoro. In some embodiments, R^{Zb3} is chloro. In some embodiments,
 R^{Zb3} is bromo. In some embodiments, R^{Zb2} is C₁-C₆ alkyl and R^{Zb1} and R^{Zb3} are halogen. In some
embodiments, R^{Zb2} is methyl and R^{Zb1} and R^{Zb3} are both fluoro. In some embodiments, R^{Zb2} is
methyl, R^{Zb1} is fluoro and R^{Zb3} is bromo. In some embodiments, R^{Zb2} is methyl, R^{Zb1} is bromo and
 R^{Zb3} is fluoro. In some embodiments, R^{Zb2} is methyl, R^{Zb1} is chloro and R^{Zb3} is fluoro. In some
15 embodiments, R^{Zb2} is methyl, R^{Zb1} is fluoro and R^{Zb3} is chloro. In some embodiments, R^{Zb2} is C₁-
C₆ alkoxy and R^{Zb1} and R^{Zb3} is halogen. In some embodiments, R^{Zb2} is methoxy and R^{Zb1} and R^{b3}
are both fluoro. In some embodiments, R^{Zb2} is methoxy, R^{Zb1} is bromo and R^{Zb3} is fluoro. In some
embodiments, R^{Zb2} is methoxy, R^{Zb1} is fluoro and R^{Zb3} is bromo. In some embodiments, R^{Zb2} is
hydroxyl and R^{Zb1} and R^{Zb3} are halogen. In some embodiments, R^{Zb2} is hydroxyl and R^{Zb1} and R^{b3}
20 are both fluoro. In some embodiments, R^{Zb1} is halogen and R^{Zb2} and R^{Zb3} are both C₁-C₆ alkyl. In
some embodiments, R^{Zb1} is fluoro and R^{Zb2} and R^{Zb3} are both methyl. In some embodiments, R^{Zb1}
is fluoro, R^{Zb2} is methyl and R^{Zb3} is ethyl. In some embodiments, R^{Zb1} and R^{Zb2} are both C₁-C₆
alkyl and R^{Zb3} is halogen. In some embodiments, R^{Zb1} and R^{Zb2} are both methyl and R^{Zb3} is fluoro.

In some embodiments of Formula **D_{1a}** or Formula **D_{1b}**, R^{Zb1} is combined with R^{Zb2} and the
25 intervening atoms to form a 5- or 6-membered carbocyclo or heterocyclo ring. In some
embodiments, the drug has the structure of Formula **D_{1a/b}-I**, Formula **D_{1a/b}-II**, or Formula **D_{1a/b}-
III** as follows:




In some embodiments of Formula **D_{1a}** or Formula **D_{1b}**, R^{Zb2} is combined with R^{Zb3} and the intervening atoms to form a 5- or 6-membered carbocyclo or heterocyclo ring; wherein one or more hydrogens are optionally replaced with deuterium. In some embodiments, the drug has the structure of Formula **D_{1a/b}-IV**, **D_{1a/b}-V**, **D_{1a/b}-VI**, **D_{1a/b}-VII**, **D_{1a/b}-VIII** or **D_{1a/b}-IX** as follows:




In some embodiments of Formula **D₁**, R^{Zb5} and $R^{Zb5'}$ are both H. In some embodiments, R^{Zb5} is C₁-C₆ alkyl (e.g., methyl, ethyl) and $R^{Zb5'}$ is H.


In some embodiments of Formula **D_{1a}** or Formula **D_{1b}**, R^{Zb1} is combined with R^{Zb5} and the intervening atoms to form a 5- or 6-membered carbocyclo or heterocyclo ring. In some embodiments, the drug has the structure of Formula **D_{1a/b}-X** as follows:




In some embodiments, D incorporates the structure of a DNA minor groove binder. In some embodiments, D incorporates the structure of a pyrrolobenzodiazepine (PBD) compound with the following structure:



In some embodiments, D is a PBD Drug Unit that incorporates a Drug PBD dimer that is a DNA minor groove binder and has the general structure of Formula X:



or a salt thereof, wherein: the dotted lines represent a tautomeric double bond; $R^{Z2'}$ is of formula XI:



wherein the wavy line indicates the site of covalent attachment to the remainder of the Formula X structure; Ar^Z is an optionally substituted C_{5-7} arylene; X^{Za} is from a reactive or activateable group for conjugation to a Linker Unit, wherein X^{Za} is selected from the group comprising: -O-, -S-, -C(O)O-, -C(O)-, -NHC(O)-, and -N(R^{ZN})-, wherein R^{ZN} is H or C_1 - C_4 alkyl, and $(C_2H_4O)_{mz}CH_3$, where subscript mz is 1, 2 or 3; and either:



Q^{Z1} is a single bond; and Q^{Z2} is a single bond or $-Z^Z-(CH_2)_{nz}-$, wherein Z^Z is selected from the group consisting of a single bond, O, S, and NH; and subscript nz is 1, 2 or 3, or (ii) Q^{Z1} is $-CH=CH-$, and Q^{Z2} is a single bond; and

$R^{Z2'}$ is a optionally substituted C_1 - C_4 alkyl or a C_5 - 10 aryl group, optionally substituted by one or more substituents selected from the group consisting of halo, nitro, cyano, C_1 - C_6 ether, C_1 - C_7 alkyl, C_3 - C_7 heterocyclyl and bis-oxy- C_1 - C_3 alkylene, in particular by one such substituent, wherein the dotted lines indicate a single bond to $R^{Z2'}$, or $R^{Z2'}$ an optionally substituted C_1 - C_4 alkenylene, wherein the dotted lines indicate a double bond to $R^{Z2'}$; $R^{Z6''}$ and $R^{Z9''}$ are independently selected from the group consisting of H, R^Z , OH, OR^Z , SH, SR^Z , NH_2 , NHR^Z , $NR^Z R^{Z'}$, nitro, Me_3Sn and halo; $R^{Z7''}$ is selected from the group consisting of H, R^Z , OH, OR^Z , SH, SR^Z , NH_2 , NHR^Z , $NR^Z R^{Z'}$, nitro, Me_3Sn and halo; and R^Z and $R^{Z'}$ are independently selected from the group consisting of optionally substituted C_1 - C_{12} alkyl, optionally substituted C_3 - C_{20} heterocyclyl and optionally substituted C_5 - C_{20} aryl; either:


$R^{Z10''}$ is H, and $R^{Z11''}$ is OH or OR^{ZA} , wherein R^{ZA} is C_1 - C_4 alkyl, (b) $R^{Z10''}$ and $R^{Z11''}$ form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound, or (c) $R^{Z10''}$ is H and $R^{Z11''}$ is $SO_z M^Z$, wherein subscript z is 2 or 3 and M^Z is a monovalent pharmaceutically acceptable cation, or (d) $R^{Z10'}$, $R^{Z11'}$ and $R^{Z10''}$ are each H and $R^{Z11''}$ is $SO_z M^Z$, or $R^{Z10'}$ and $R^{Z11'}$ are each H and $R^{Z10''}$ and $R^{Z11''}$ form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound, or $R^{Z10''}$, $R^{Z11''}$ and $R^{Z10'}$ are each H and $R^{Z11'}$ is $SO_z M^Z$, or $R^{Z10''}$ and $R^{Z11''}$ are each H and $R^{Z10'}$ and $R^{Z11'}$ form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; wherein subscript z is 2 or 3 and M^Z is a monovalent pharmaceutically acceptable cation; and

$R^{Z''}$ is a C_{3-12} alkylene group, the carbon chain of which is optionally interrupted by one or more heteroatoms, in particular by one of O, S or NR^{ZN2} (where R^{ZN2} is H or C_1 - C_4 alkyl), and/or by aromatic rings, in particular by one of benzene or pyridine; Y^Z and $Y^{Z'}$ are selected from the group consisting of O, S, and NH; $R^{Z6'}$, $R^{Z7'}$, $R^{Z9'}$ are selected from the same groups as $R^{Z6''}$, $R^{Z7''}$ and $R^{Z9''}$, respectively, and $R^{Z10'}$ and $R^{Z11'}$ are the same as $R^{Z10''}$ and $R^{Z11''}$, respectively, wherein if $R^{Z11''}$ and $R^{Z11'}$ are $SO_z M^Z$, each M^Z is either a monovalent pharmaceutically acceptable cation or together represent a divalent pharmaceutically acceptable cation.

In some embodiments, a PBD Drug Unit that incorporates a PBD dimer that is a DNA minor groove binder has the general structure of Formula **XI** or **XII**:



5 or a salt thereof, wherein: the dotted lines indicate a tautomeric double bond; Q is of formula **XIV**:



wherein the wavy lines indicate the sites of covalent attachment to $Y^{Z'}$ and Y^Z in either orientation; Ar is a C_{5-7} arylene group substituted by X^{Za} and is otherwise optionally substituted, wherein X^{Za} is from an activateable group for conjugation to a Linker Unit, wherein X^{Za} is selected from the group comprising: -O-, -S-, -C(O)O-, -C(O)-, -NHC(O)-, and -N(R^{ZN})-, wherein R^{ZN} is H or C_1 - C_4 alkyl, and $(C_2H_4O)_mCH_3$, where subscript m is 1, 2 or 3; and either:

Q^{Z1} is a single bond; and Q^{Z2} is a single bond or $-(CH_2)_{nz}-$, wherein subscript nz is 1, 2 or 3, or (ii) Q^{Z1} is $-CH=CH-$, and Q^{Z2} is a single bond or $-CH=CH-$; and

$R^{Z2'}$ is a optionally substituted C_1 - C_4 alkyl or a C_{5-10} aryl group, optionally substituted by one or more substituents selected from the group consisting of halo, nitro, cyano, C_1 - C_6 ether, C_1 - C_7 alkyl, C_3 - C_7 heterocyclyl and bis-oxy- C_1 - C_3 alkylene, in particular by one such substituent, wherein the dotted lines indicate a single bond to $R^{Z2'}$, or $R^{Z2'}$ an optionally substituted C_1 - C_4 alkenylene wherein the dotted lines indicate a double bond to $R^{Z2'}$; and

$R^{Z2''}$ is an optionally substituted C_1 - C_4 alkyl or a C_{5-10} aryl group, optionally substituted by one or more substituents selected from the group consisting of halo, nitro, cyano, C_1 - C_6 ether, C_1 - C_7 alkyl, C_3 - C_7 heterocyclyl and bis-oxy- C_1 - C_3 alkylene, in particular by one such substituent; $R^{Z6''}$

and $R^{Z9''}$ are independently selected from the group consisting of H, R^Z , OH, OR^Z , SH, SR^Z , NH_2 , NHR^Z , NR^ZR^Z , nitro, Me_3Sn and halo; $R^{Z7''}$ is selected from the group consisting of H, R^Z , OH, OR, SH, SR^Z , NH_2 , NHR^Z , NR^ZR^Z , nitro, Me_3Sn and halo; and R^Z and R^Z are independently selected from the group consisting of optionally substituted C_1 - C_{12} alkyl, optionally substituted C_3 - C_{20} heterocyclyl and optionally substituted C_5 - C_{20} aryl; and either:

$R^{Z10''}$ is H, and $R^{Z11''}$ is OH or OR^{ZA} , wherein R^{ZA} is C_1 - C_4 alkyl, or (b) $R^{Z10''}$ and $R^{Z11''}$ form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound, or (c) $R^{Z10''}$ is H and $R^{Z11''}$ is SO_zM^Z , wherein subscript z is 2 or 3 and M^Z is a monovalent pharmaceutically acceptable cation, or (d) $R^{Z10'}$, $R^{Z11'}$ and $R^{Z10''}$ are each H and $R^{Z11''}$ is SO_zM^Z , or $R^{Z10'}$ and $R^{Z11'}$ are each H and $R^{Z10''}$ and $R^{Z11''}$ form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound, or $R^{Z10''}$, $R^{Z11''}$ and $R^{Z10'}$ are each H and $R^{Z11'}$ is SO_zM^Z , or $R^{Z10''}$ and $R^{Z11''}$ are each H and $R^{Z10'}$ and $R^{Z11'}$ form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; wherein subscript z is 2 or 3 and M^Z is a monovalent pharmaceutically acceptable cation; and

Y^Z and $Y^{Z'}$ are selected from the group consisting of O, S, and NH; $R^{Z''}$ represents one or more optional substituents; and $R^{Z6'}$, $R^{Z7'}$, $R^{Z9'}$ are selected from the same groups as $R^{Z6''}$, $R^{Z7''}$ and $R^{Z9''}$, respectively, and $R^{Z10'}$ and $R^{Z11'}$ are the same as $R^{Z10''}$ and $R^{Z11''}$, respectively, wherein if $R^{Z11''}$ and $R^{Z11'}$ are SO_zM^Z , each M^Z is either a monovalent pharmaceutically acceptable cation or together represent a divalent pharmaceutically acceptable cation.

In some embodiments, the PBD dimer has the general structure of Formula **X**, Formula **XII** or Formula **XIII** in which one, $R^{Z7''}$ is selected from the group consisting of H, OH and OR^Z , wherein R^Z is as previously defined for each of the formula, or is a C_{1-4} alkyloxy group, in particular $R^{Z7''}$ is $-OCH_3$. In some embodiments, Y^Z and $Y^{Z'}$ are O, $R^{Z9''}$ is H, or $R^{Z6''}$ is selected from the group consisting of H and halo.

In some embodiments, the PBD dimer has the general structure of Formula **X** in which Ar^Z is phenylene; X^{Za} is selected from the group consisting of $-O-$, $-S-$ and $-NH-$; and Q^{Z1} is a single bond, and in some embodiments of Formula **XII** Ar^Z is phenylene, X^Z is selected from the group consisting of $-O-$, $-S-$, and $-NH-$, $Q^{Z1}-CH_2-$ and Q^{Z2} is $-CH_2-$.


In some embodiments, the PBD dimer has the general structure of Formula **X** in which X^{Za} is NH. In some embodiments, the PBD Drug Units are of Formula **X** in which Q^{Z1} is a single bond and Q^{Z2} is a single bond.


In some embodiments, the PBD dimer has the general structure of Formula **X**, Formula **XII** or Formula **XIII** in which $R^{Z2'}$ is an optionally substituted C₅₋₇ aryl group so that the dotted lines indicate a single bond to $R^{Z2'}$ and the substituents when present are independently selected from the group consisting of halo, nitro, cyano, C₁₋₇ alkoxy, C₅₋₂₀ aryloxy, C₃₋₂₀ heterocycloxy, C₁₋₇ alkyl, C₃₋₇ heterocyclyl and bis-oxy-C₁₋₃ alkylene wherein the C₁₋₇ alkoxy group is optionally substituted by an amino group, and if the C₃₋₇ heterocyclyl group is a C₆ nitrogen containing heterocyclyl group, it is optionally substituted by a C₁₋₄ alkyl group.

In some embodiments, the PBD dimer has the general structure of Formula **X**, Formula **XI** or Formula **XII** in which Ar^Z is an optionally substituted phenyl that has one to three such substituents when substituted.

In some embodiments, the PBD dimer has the general structure of Formula **X**, Formula **XI** or Formula **XII** in which $R^{Z10''}$ and $R^{Z11''}$ form a nitrogen-carbon double bond and/or $R^{Z6'}$, $R^{Z7'}$, $R^{Z9'}$, and Y^Z are the same as $R^{Z6''}$, $R^{Z7''}$, $R^{Z9''}$, and Y^Z respectively.


In some embodiments, the PBD Drug Unit has the structure of:





or a salt thereof, wherein the dagger represents the point of attachment of the Drug Unit to the Linker Unit in a Drug Linker compound or antibody-drug conjugate.

5 In some embodiments, the PBD Drug Unit has the structure of:



or a salt thereof, wherein the dagger represents the point of attachment of the Drug Unit to the Linker Unit in a Drug Linker compound or antibody-drug conjugate.

In some embodiments, the Drug Unit incorporates the structure of an anthracyclin compound. Without being bound by theory, the cytotoxicity of those compounds to some extent may also be due to topoisomerase inhibition. In some of those embodiments the anthracyclin compound has a structure disclosed in Minotti, G., et al., "Anthracyclins: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity" *Pharmacol Rev.* (2004) 56(2): 185-229. In some embodiments, the anthracyclin compound is doxorubicin, idarubicin, daunorubicin, doxorubicin propyloxazoline (DPO), morpholino-doxorubicin, or cyanomorpholino-doxorubicin.

In some embodiments, the Drug Unit (D) is from a cytostatic agent. In some embodiments, D is from a compound having cellular cytostatic activity ranging from 1 to 100 nM. In some

embodiments, the Drug Unit (D) is from a cytotoxic agent. In some embodiments, D is from a cytotoxic agent having an IC_{50} value for cellular cytotoxic activity ranging from 1 to 100 nM. There are several methods for determining whether an ADC exerts a cytostatic or cytotoxic effect on a cell line. In one example for determining whether an ADC exerts a cytostatic or cytotoxic effect on a cell line, a thymidine incorporation assay is used. For example, cells at a density of 5,000 cells/well of a 96-well plate is cultured for a 72-hour period and exposed to 0.5 μ Ci of ^{3} H-thymidine during the final 8 hours of the 72-hour period, and the incorporation of ^{3} H-thymidine into cells of the culture is measured in the presence and absence of ADC. The ADC has a cytostatic or cytotoxic effect on the cell line if the cells of the culture have reduced ^{3} H-thymidine incorporation compared to cells of the same cell line cultured under the same conditions but not contacted with the ADC.

In another example, for determining whether an ADC exerts a cytostatic or cytotoxic effect on a cell line, cell viability is measured by determining in a cell the uptake of a dye such as neutral red, trypan blue, or ALAMARTM blue (see, e.g., Page *et al.*, 1993, *Intl. J. of Oncology* 3:473-476). In such an assay, the cells are incubated in media containing the dye, the cells are washed, and the remaining dye, reflecting cellular uptake of the dye, is measured spectrophotometrically. The protein-binding dye sulforhodamine B (SRB) is useful for measuring cytotoxicity (Skehan *et al.*, 1990, *J. Nat'l Cancer Inst.* 82:1107-12). Preferred ADCs include those with an IC_{50} value (defined as the mAB concentration that gives 50% cell kill) of less than 1000 ng/mL, for example, less than 500 ng/mL, less than 100 ng/mL, or less than 50 or even less than 10 ng/mL on the cell line.

In some embodiments, D is from a cytotoxic or cytostatic agent having a cellular potency that would not be expected to provide a sufficiently active ADC *in vitro* in which the DAR is 8.


In some embodiments, D is from a hydrophilic cytotoxic or cytostatic agent (i.e., D has a $cLogP \leq 1$). In some embodiments, D is from a hydrophobic cytotoxic or cytostatic agent (i.e., D has a $cLogP > 1$). In some embodiments, D is from a cytotoxic or cytostatic agent having a $cLogP$ of about -3 to about 3, for example, about -3, about -2.5, about -2, about -1.5, about -1, about -0.5, about 0, about 0.5, about 1, about 1.5, about 2, about 2.5, about 3, or any value in between. In some embodiments, D is from a cytotoxic or cytostatic agent having a $cLogP$ of about -3 to about 1, for example, about -3, about -2.5, about -2, about -1.5, about -1, about -0.5, about 0, about 0.5, about 1, or any value in between. In some embodiments, D is from a cytotoxic or cytostatic agent

having a cLogP of about -1 to about 1, for example, about -1, about -0.75, about -0.5, about -0.25, about 0, about 0.25, about 0.5, about 0.75, about 1, or any value in between. In some embodiments, D is from a cytotoxic or cytostatic agent having a cLogP of about 0 to about 1, for example, about 0, about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, or any value in between. In some embodiments, D is from a cytotoxic or cytostatic agent having a cLogP of about 1 to about 6, for example, about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, or any value in between. In some embodiments, D is from a cytotoxic or cytostatic agent has a cLogP of about 3 to about 6, for example, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, or any value in between.

In some embodiments, D is from a cytotoxic or cytostatic agent having a polar surface area of about 80 Å² to about 150 Å², for example, about 80 Å², about 90 Å², about 100 Å², about 110 Å², about 120 Å², about 130 Å², about 140 Å², about 150 Å², or any value in between. In some embodiments, D is from a cytotoxic or cytostatic agent having a polar surface area of about 80 Å² to about 120 Å², for example, about 80 Å², about 90 Å², about 100 Å², about 110 Å², about 120 Å², or any value in between. In some embodiments, D is from a cytotoxic or cytostatic agent having has a polar surface area of about 90 Å² to about 130 Å², for example, about 90 Å², about 100 Å², about 110 Å², about 120 Å², about 130 Å², or any value in between. In some embodiments, D is from a cytotoxic or cytostatic agent having has a polar surface area of about 110 Å² to about 150 Å², for example, about 110 Å², about 120 Å², about 130 Å², about 140 Å², about 150 Å², or any value in between. In some embodiments, D is from a cytotoxic or cytostatic agent having a polar surface area of about 130 Å² to about 150 Å², for example, about 130 Å², about 140 Å², about 150 Å², or any value in between.

In some embodiments, D is from a DNA replication inhibitors such as gemcitabine, or a tubulin disrupting agent such as MMAE, or MMAF. In some embodiments, D is from gemcitabine. In some embodiments, D is from MMAE. In some embodiments, D is form MMAF. In some embodiments, D is from an inhibitor or ATP production such as a NAMPT inhibitor.

In some embodiments, D is from a NAMPT inhibitor having the following formula:



wherein D is covalently attached to L² at the aa or bb nitrogen atom.

5 Drug-Linker Compounds

In some embodiments, D has an atom that forms a bond with L¹ (when M and L² are both absent), with M (when L² is absent) or with L². In some embodiments, the atom from D forming the bond with L¹, M, or L² is a nitrogen atom. In some embodiments, the atom from D forming the bond with L¹, M, or L² is a nitrogen atom that is quaternized upon forming the bond. In some
10 embodiments, the atom from D forming the bond with L¹, M, or L² is a sulfur atom from a thiol group. In some embodiments, the atom from D forming the bond with L¹, M, or L² is an oxygen atom from a hydroxyl group. In some embodiments, the hydroxyl group is present in the free drug. In some embodiments, the hydroxyl group is produced by reduction of a carbonyl group present in the free drug. In some embodiments, the atom from D forming the bond with L¹, M, or L² is a
15 carbon atom attached to a hydroxyl group that, prior to forming the bond, was a carbonyl group in the free drug. In some embodiments, D forms a bond with L¹, M, or L² via a carboxylic acid group.

In some embodiments, D comprises a functional group that is negatively charged at physiological pH, for example, a carboxylic acid or a phosphate. In some embodiments, D comprises a functional group that is positively charged at physiological pH, for example, an amine.
20 In some embodiments, when D comprises a negatively charged functional group at physiological pH, L¹ (when M and L² are both absent), M (when L² is absent) or L² (when present) comprise a functional group that is positively charged at physiological pH. In some embodiments, when D comprises a positively charged functional group at physiological pH, L¹ (when M and L² are both absent), M (when L² is absent) or L² (when present) comprise a functional group that is negatively
25 charged at physiological pH. In some embodiments, D is uncharged at physiological pH. In some embodiments, D has zero net charge at physiological pH. In some embodiments, when D is uncharged or has zero net charge at physiological pH, L¹ (when M and L² are both absent), M

(when L^2 is absent) or L^2 (when present) are uncharged or have zero net charge at physiological pH.


In some embodiments, each L^2 -D is uncharged or has a net zero charge at physiological pH. In some embodiments, each L^2 -D has no charged species (i.e., is uncharged) at physiological pH. In some embodiments, each L^2 -D is zwitterionic at physiological pH. In some embodiments, each L^2 -D comprises a carboxylate and an ammonium-containing moiety. In some embodiments, the ammonium-containing moiety is a quaternary ammonium-containing moiety. In some embodiments, the quaternary ammonium-containing moiety is pyridinium. In some embodiments, L^2 is anionic; and D is cationic. In some embodiments, L^2 comprises a carboxylate-containing moiety; and D comprises an ammonium-containing moiety.

In some embodiments, each L^1 -(M)_x-(D)_y (when L^2 is absent) has no charged species at physiological pH. In some embodiments, each L^1 -(M)_x-(D)_y (when L^2 is absent) is zwitterionic at physiological pH. In some embodiments, each L^1 -(M)_x-(D)_y (when L^2 is absent) comprises a carboxylate and an ammonium-containing moiety. In some embodiments, the ammonium-containing moiety is a quaternary ammonium-containing moiety. In some embodiments, the quaternary ammonium moiety is pyridinium. In some embodiments, L^1 -(M)_x is anionic; and D is cationic. In some embodiments, L^1 -(M)_x comprises a carboxylate-containing moiety; and D comprises an ammonium-containing moiety.

In some embodiments, each L^1 -D (when M and L^2 are absent) has no charged species at physiological pH. In some embodiments, each L^1 -D (when M and L^2 are absent) is zwitterionic at physiological pH. In some embodiments, each L^1 -D (when M and L^2 are absent) comprises a carboxylate and an ammonium-containing moiety. In some embodiments, the ammonium moiety is a quaternary ammonium moiety. In some embodiments, the quaternary ammonium-containing moiety is pyridinium. In some embodiments, L^1 is anionic; and D is cationic. In some embodiments, L^1 comprises a carboxylate-containing moiety; and D comprises an ammonium-containing moiety.


General procedures for linking a drug to linkers are known in the art. See, for example, U.S. Patent Nos. 8,163,888, 7,659,241, 7,498,298, U.S. Publication No. US20110256157 and International Application Nos. WO2011023883, and WO2005112919, each of which is incorporated by reference herein, particularly in regards to the aforementioned general procedures.


In some embodiments, D has a charge of +1 at physiological pH; and L^2 is selected from the group consisting of:



wherein dd is the point of covalent attachment to D; and R^{g1} is halogen, -CN, or -NO₂.


5 In some embodiments, D is uncharged at physiological pH; and L^2 is selected from the group consisting of:






wherein dd is the point of covalent attachment to D; and R^{g1} is halogen, -CN, or -NO₂.


In some embodiments, L^2 is selected from the group consisting of:



- 5 wherein R^{g1} is halogen, -CN, or -NO₂; D* is a cation that is part of the D moiety; dd represents the point of covalent attachment to the rest of D; and D (inclusive of D*) has a charge of +1 at physiological pH.


In some embodiments, D* is pyridinium. For example, D* can be



In some other embodiments, D* is , wherein each R^{d1} is independently C₁₋₆

10 alkyl.

In some embodiments, L^2 is selected from the group consisting of:



wherein R^{g1} is halogen, -CN, or -NO₂; D* is a cation that is part of the D moiety; dd represents point of covalent attachment to the rest of D; and D (inclusive of D*) is zwitterionic at physiological pH.

- 5 In some embodiments of the ADCs described herein, the ratio of D to Ab is 8:1 to 64:1. In some embodiments, the ratio of D to Ab is 8:1 to 16:1. In some embodiments, the ratio of D to Ab is 8:1 to 32:1. In some embodiments, the ratio of D to Ab is 16:1 to 64:1. In some embodiments, the ratio of D to Ab is 16:1 to 32:1. In some embodiments, the ratio of D to Ab is 32:1 to 64:1. In some embodiments, the ratio of D to Ab is 8:1. In some embodiments, the ratio of D to Ab is 16:1.
- 10 In some embodiments, the ratio of D to Ab is 32:1. In some embodiments, the ratio of D to Ab is 64:1.

- In some embodiments of the ADCs described herein, the ratio of D to Ab is 8:1; subscript y is 4; and subscript p is 2. In some embodiments, the ratio of D to Ab is 8:1; subscript y is 2; and subscript p is 4. In some embodiments, the ratio of D to Ab is 16:1; subscript y is 8; and subscript p is 4. In some embodiments, the ratio of D to Ab is 16:1; subscript y is 4; and subscript p is 4. In some embodiments, the ratio of D to Ab is 16:1; subscript y is 2; and subscript p is 8.
- 15

Polyethyleneglycol (PEG) Units

Polydisperse PEGs, monodisperse PEGs and discrete PEGs can be used to make the ADCs and intermediates thereof described herein. Polydisperse PEGs are a heterogeneous mixture of sizes and molecular weights whereas monodisperse PEGs are typically purified from heterogeneous mixtures and therefore provide a single chain length and molecular weight. Discrete PEGs are synthesized in step-wise fashion and not via a polymerization process. Discrete PEGs provide a single molecule with defined and specified chain length. The number of -CH₂CH₂O- subunits of a PEG Unit ranges, for example, from 2 to 72, from 8 to 24 or from 12 to 24, referred to as PEG2 to PEG72, PEG8 to PEG24 and PEG12 to PEG24, respectively.

The PEGs provided herein, which are also referred to as PEG Units, comprise one or multiple polyethylene glycol chains. The polyethylene glycol chains are linked together, for example, in a linear, branched, or star shaped configuration. Typically, at least one of the polyethylene glycol chains of a PEG Unit is derivatized at one end for covalent attachment to an appropriate site on a component of the ADC (e.g., L). Exemplary attachments to ADCs are by means of non-conditionally cleavable linkages or via conditionally cleavable linkages. Exemplary attachments are via amide linkage, ether linkages, ester linkages, hydrazone linkages, oxime linkages, disulfide linkages, peptide linkages, or triazole linkages.

Generally, at least one of the polyethylene glycol chains that make up the PEG Unit is functionalized to provide covalent attachment to the ADC. Functionalization of the polyethylene glycol-containing compound that is the precursor to the PEG Unit includes, for example, via an amine, thiol, NHS ester, maleimide, alkyne, azide, carbonyl, or other functional group. In some embodiments, the PEG Unit further comprises non-PEG material (i.e., material not comprised of -CH₂CH₂O-) that provides coupling to the ADC or in constructing the polyethylene glycol-containing compound or PEG facilitates coupling of two or more polyethylene glycol chains.

In some embodiments, attachment to the ADC is by means of a non-conditionally cleavable linkage. In some embodiments, attachment to the ADC is not via an ester linkage, hydrazone linkage, oxime linkage, or disulfide linkage. In some embodiments, attachment to the ADC is not via a hydrazone linkage. If a high DAR ADC having uncharged or net zero charged drug-linker moieties, as described herein, still exhibits one or more unsatisfactory biophysical property(ies), addition of a PEG Unit, may improve these one or more property(ies). For example,

a branched PEG Unit as described herein and by WO 2015/057699 (the disclosure of which is incorporated by reference in its entirety).

A conditionally cleavable linkage refers to a linkage that is not substantially sensitive to cleavage while circulating in plasma but is sensitive to cleavage in an intracellular or intratumoral environment. A non-conditionally cleavable linkage is one that is not substantially sensitive to cleavage in any biologically relevant environment in a subject that is administered the ADC. Chemical hydrolysis of a hydrazone, reduction of a disulfide bond, and enzymatic cleavage of a peptide bond or glycosidic bond of a Glucuronide Unit as described herein, and by WO 2007/011968 (the disclosure of which is incorporated by reference in its entirety) are examples of conditionally cleavable linkages.

In some embodiments, the PEG Unit is directly attached to the ADC at L¹, M, and/or L². In some embodiments, the other terminus (or termini) of the PEG Unit is free and untethered (i.e., not covalently attached) and in some embodiments, takes the form of a methoxy, carboxylic acid, alcohol, or other suitable functional group. The methoxy, carboxylic acid, alcohol, or other suitable functional group acts as a cap for the terminal polyethylene glycol subunit of the PEG Unit. By untethered, it is meant that the PEG Unit will not be covalently attached at that untethered site to a Drug Unit, to an antibody, or to a linking component to a Drug Unit and/or an antibody. Such an arrangement permits a PEG Unit of sufficient length to assume a parallel orientation with respect to the drug in conjugated form, i.e., as a Drug Unit (D). Without being bound by theory, that orientation is believed to mask the hydrophobicity of the conjugated drug in those instances in which the free drug has insufficient hydrophilicity, thus facilitating the higher loading provided by multiplexers within drug linker moieties that are uncharged or have net zero charge, as described herein. In some embodiments, each polyethylene glycol chain in a PEG Unit may be independently chosen, e.g., be the same or different chemical moieties (e.g., polyethylene glycol chains of different molecular weight or number of -CH₂CH₂O- subunits). A PEG Unit having multiple polyethylene glycol chains is attached to the ADC at a single attachment site. The skilled artisan will understand that the PEG Unit in addition to comprising repeating polyethylene glycol subunits may also contain non-PEG material (e.g., to facilitate coupling of multiple polyethylene glycol chains to each other or to facilitate coupling to the ADC). Non-PEG material refers to the atoms in the PEG Unit that are not part of the repeating -CH₂CH₂O- subunits. In some embodiments, the PEG Unit comprises two monomeric polyethylene glycol chains attached to

each other via non-PEG elements. In other embodiments provided herein, the PEG Unit comprises two linear polyethylene glycol chains attached to a central core that is attached to the ADC (i.e., the PEG Unit itself is branched).

There are a number of PEG attachment methods available to those skilled in the art: for example, Goodson, et al. (1990) *Bio/Technology* **8**:343 (PEGylation of interleukin-2 at its glycosylation site after site-directed mutagenesis); EP 0 401 384 (coupling PEG to G-CSF); Malik, et al., (1992) *Exp. Hematol.* **20**:1028-1035 (PEGylation of GM-CSF using tresyl chloride); ACT Pub. No. WO 90/12874 (PEGylation of erythropoietin containing a recombinantly introduced cysteine residue using a cysteine-specific mPEG derivative); U.S. Pat. No. 5,757,078 (PEGylation of EPO peptides); U.S. Pat. No. 5,672,662 (Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications); U.S. Pat. No. 6,077,939 (PEGylation of an N-terminal α -carbon of a peptide); Veronese et al., (1985) *Appl. Biochem. Biochnol* **11**:141-142 (PEGylation of an N-terminal α -carbon of a peptide with PEG-nitrophenylcarbonate ("PEG-NPC") or PEG-trichlorophenylcarbonate); and Veronese (2001) *Biomaterials* **22**:405-417 (Review article on peptide and protein PEGylation).

In some embodiments, a PEG Unit may be covalently bound to an amino acid residue via reactive groups of a polyethylene glycol-containing compound and the amino acid residue. Reactive groups of the amino acid residue include those that are reactive to an activated PEG molecule (e.g., a free amino or carboxyl group). For example, N-terminal amino acid residues and lysine (K) residues have a free amino group; and C-terminal amino acid residues have a free carboxyl group. Thiol groups (e.g., as found on cysteine residues) are also useful as a reactive group for forming a covalent attachment to a PEG. In addition, enzyme-assisted methods for introducing activated groups (e.g., hydrazide, aldehyde, and aromatic-amino groups) specifically at the C-terminus of a polypeptide have been described (see Schwarz, et al. (1990) *Methods Enzymol.* **184**:160; Rose, et al. (1991) *Bioconjugate Chem.* **2**:154; and Gaertner, et al. (1994) *J. Biol. Chem.* **269**:7224).

In some embodiments, a polyethylene glycol-containing compound forms a covalent attachment to an amino group using methoxylated PEG ("mPEG") having different reactive moieties. Non-limiting examples of such reactive moieties include succinimidyl succinate (SS), succinimidyl carbonate (SC), mPEG-imidate, para-nitrophenylcarbonate (NPC), succinimidyl

propionate (SPA), and cyanuric chloride. Non-limiting examples of such mPEGs include mPEG-succinimidyl succinate (mPEG-SS), mPEG₂-succinimidyl succinate (mPEG₂-SS); mPEG-succinimidyl carbonate (mPEG-SC), mPEG₂-succinimidyl carbonate (mPEG₂-SC); mPEG-imidate, mPEG-para-nitrophenylcarbonate (mPEG-NPC), mPEG-imidate; mPEG₂-para-nitrophenylcarbonate (mPEG₂-NPC); mPEG-succinimidyl propionate (mPEG-SPA); mPEG₂-succinimidyl propionate (mPEG₂-SPA); mPEG-N-hydroxy-succinimide (mPEG-NHS); mPEG₂-N-hydroxy-succinimide (mPEG₂-NHS); mPEG-cyanuric chloride; mPEG₂-cyanuric chloride; mPEG₂-Lysinol-NPC, and mPEG₂-Lys-NHS.


In some embodiments, the presence of the PEG Unit in an ADC is capable of having two potential impacts upon the pharmacokinetics of the resulting ADC. One impact is a decrease in clearance (and consequent increase in exposure) that arises from the reduction in non-specific interactions induced by the exposed hydrophobic elements of the Drug Unit (such as a Drug Unit comprising a hydrophobic free drug). The second impact is a decrease in volume and rate of distribution that sometimes arises from the increase in the molecular weight of the ADC. Increasing the number of polyethylene glycol subunits also increases the hydrodynamic radius of a conjugate, typically resulting in decreased diffusivity. In turn, decreased diffusivity typically diminishes the ability of the ADC to penetrate into a tumor (Schmidt and Wittrup, *Mol Cancer Ther* 2009; 8:2861-2871). Because of these two competing pharmacokinetic effects, it can be desirable to use a PEG Unit that is sufficiently large to decrease the ADC clearance thus increasing plasma exposure, but not so large as to greatly diminish its diffusivity to an extent that it interferes with the ability of the ADC to reach the intended target cell population. *See, e.g.*, Examples 1, 18, and 21 of U.S. Publ. No. 2016/0310612, which is incorporated by reference herein, for methodology for selecting an optimal size of a PEG Unit for a particular hydrophobic drug-linker moiety.

In some embodiments, the PEG Unit comprises one or more linear polyethylene glycol chains each having at least 2 subunits, at least 3 subunits, at least 4 subunits, at least 5 subunits, at least 6 subunits, at least 7 subunits, at least 8 subunits, at least 9 subunits, at least 10 subunits, at least 11 subunits, at least 12 subunits, at least 13 subunits, at least 14 subunits, at least 15 subunits, at least 16 subunits, at least 17 subunits, at least 18 subunits, at least 19 subunits, at least 20 subunits, at least 21 subunits, at least 22 subunits, at least 23 subunits, or at least 24 subunits. In some embodiments, the PEG comprises a combined total of at least 8 subunits, at least 10 subunits,

or at least 12 subunits. In some such embodiments, the PEG comprises no more than a combined total of about 72 subunits. In some such embodiments, the PEG comprises no more than a combined total of about 36 subunits. In some embodiments, the PEG comprises about 8 to about 24 subunits (referred to as PEG8 to PEG24).

5 In some embodiments, the PEG Unit comprises a combined total of from 2 to 72, 2 to 60, 2 to 48, 2 to 36 or 2 to 24 subunits, from 3 to 72, 3 to 60, 3 to 48, 3 to 36 or 3 to 24 subunits, from 4 to 72, 8 to 60, 4 to 48, 4 to 36 or 4 to 24 subunits, from 5 to 72, 5 to 60, 5 to 48, 5 to 36 or 5 to 24 subunits, from 6 to 72, 6 to 60, 6 to 48, 6 to 36 or 6 to 24 subunits, from 7 to 72, 7 to 60, 7 to 48, 7 to 36 or 7 to 24 subunits, from 8 to 72, 8 to 60, 8 to 48, 8 to 36 or 8 to 24 subunits, from 9 to 72, 9 to 60, 9 to 48, 9 to 36 or 9 to 24 subunits, from 10 to 72, 10 to 60, 10 to 48, 10 to 36 or 10 to 24 subunits, from 11 to 72, 11 to 60, 11 to 48, 11 to 36 or 11 to 24 subunits, from 12 to 72, 12 to 60, 12 to 48, 12 to 36 or 12 to 24 subunits, from 13 to 72, 13 to 60, 13 to 48, 13 to 36 or 13 to 24 subunits, from 14 to 72, 14 to 60, 14 to 48, 14 to 36 or 14 to 24 subunits, from 15 to 72, 15 to 60, 15 to 48, 15 to 36 or 15 to 24 subunits, from 16 to 72, 16 to 60, 16 to 48, 16 to 36 or 16 to 24 subunits, from 17 to 72, 17 to 60, 17 to 48, 17 to 36 or 17 to 24 subunits, from 18 to 72, 18 to 60, 18 to 48, 18 to 36 or 18 to 24 subunits, from 19 to 72, 19 to 60, 19 to 48, 19 to 36 or 19 to 24 subunits, from 20 to 72, 20 to 60, 20 to 48, 20 to 36 or 20 to 24 subunits, from 21 to 72, 21 to 60, 21 to 48, 21 to 36 or 21 to 24 subunits, from 22 to 72, 22 to 60, 22 to 48, 22 to 36 or 22 to 24 subunits, from 23 to 72, 23 to 60, 23 to 48, 23 to 36 or 23 to 24 subunits, or from 24 to 72, 24 to 60, 24 to 48, 24 to 36 or 24 subunits. In some embodiments, the PEG Unit comprises a combined total of from 2 to 24 subunits, 2 to 16 subunits, 2 to 12 subunits, 2 to 8 subunits, or 2 to 6 subunits.

Illustrative linear PEGs that can be used in any of the embodiments provided herein are as follows:



wherein the wavy line indicates the site of attachment to the ADC; each subscript b is independently selected from the group consisting of 2 to 12; and each subscript c is independently selected from the group consisting of 1 to 72, 8 to 72, 10 to 72, 12 to 72, 6 to 24, or 8 to 24. In some embodiments, each subscript b is 2 to 6. In some embodiments, each subscript c is about 2, about 4, about 8, about 12, or about 24.

As described herein, the PEG Unit can be selected such that it improves clearance of the resultant ADC but does not significantly impact the ability of the ADC to penetrate into a tumor. In embodiments in which the Drug Unit and the collective linker/multiplexer conjugate of the ADC has a SlogP value comparable to that of a maleimido-derived glucuronide MMAE Drug Unit, the PEG Unit has from about 8 subunits to about 24 subunits. In embodiments, the PEG Unit has about 12 subunits. In embodiments in which the Drug Unit and the collective linker/multiplexer

conjugate of the ADC has a SlogP value greater than that of a maleimido-derived glucuronide MMAE Drug Unit, a PEG Unit with more subunits is sometimes required.

In some embodiments, the PEG Unit is from about 300 daltons to about 5 kilodaltons; from about 300 daltons to about 4 kilodaltons; from about 300 daltons to about 3 kilodaltons; from about 300 daltons to about 2 kilodaltons; from about 300 daltons to about 1 kilodalton; or any value in between. In some embodiments, the PEG has at least 8, 10 or 12 subunits. In some embodiments, the PEG Unit is PEG2 to PEG72, for example, PEG2, PEG4, PEG8, PEG10, PEG12, PEG16, PEG20, PEG24, PEG28, PEG32, PEG36, PEG48, or PEG72.

In some embodiments, apart from the PEGylation of the ADC, there are no other PEG subunits present in the ADC (i.e., no PEG subunits are present as part of any of the other components of the conjugates and linkers provided herein). In some embodiments, apart from the PEG, there are no more than 8, no more than 7, no more than 6, no more than 5, no more than 4, no more than 3, no more than 2 or no more than 1 other polyethylene glycol (-CH₂CH₂O-) subunits present in the ADC (i.e., no more than 8, 7, 6, 5, 4, 3, 2, or 1 other polyethylene glycol subunits in other components of the ADCs provided herein).

It will be appreciated that when referring to polyethylene glycol subunits of a PEG Unit, and depending on context, the number of subunits can represent an average number, e.g., when referring to a population of ADCs and/or using polydisperse PEGs.

Antibodies

The term “antibody” as used herein covers intact monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), including intact antibodies and antigen binding antibody fragments, and reduced forms thereof in which one or more of the interchain disulfide bonds are disrupted, that exhibit the desired biological activity and provided that the antigen binding antibody fragments have the requisite number of attachment sites for the desired number of attached groups, such as a linker (L), as described herein. In some aspects, the linkers are attached to an antibody via a succinimide or hydrolyzed succinimide to the sulfur atoms of cysteine residues of reduced interchain disulfide bonds and/or cysteine residues introduced by genetic engineering. The native form of an antibody is a tetramer and consists of two identical pairs of immunoglobulin chains, each pair having one light chain and one heavy chain. In each pair, the light and heavy chain variable domains (VL and

VH) are together primarily responsible for binding to an antigen. The light chain and heavy chain variable domains consist of a framework region interrupted by three hypervariable regions, also called “complementarity determining regions” or “CDRs.” The light chain and heavy chains also contain constant regions that may be recognized by and interact with the immune system. (see, 5 *e.g.*, Janeway *et al.*, 2001, *Immuno. Biology*, 5th Ed., Garland Publishing, New York). An antibody includes any isotype (*e.g.*, IgG, IgE, IgM, IgD, and IgA) or subclass (*e.g.*, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) thereof. The antibody is derivable from any suitable species. In some aspects, the antibody is of human or murine origin, and in some aspects the antibody is a human, humanized or chimeric antibody. Antibodies can be fucosylated to varying extents or afucosylated.

10 An “intact antibody” is one which comprises an antigen-binding variable region as well as light chain constant domains (C_L) and heavy chain constant domains, C_H1, C_H2, C_H3 and C_H4, as appropriate for the antibody class. The constant domains are either native sequence constant domains (*e.g.*, human native sequence constant domains) or amino acid sequence variants thereof.

15 An “antibody fragment” comprises a portion of an intact antibody, comprising the antigen-binding or variable region thereof. Antibody fragments of the present disclosure include at least one cysteine residue (natural or engineered) and/or at least one lysine residue (natural or engineered) that provides a site for attachment of a linker and/or linker-drug compound. In some embodiments, an antibody fragment includes Fab, Fab', or F(ab')₂.

20 As used herein the term “engineered cysteine residue” or “eCys residue” refers to a cysteine amino acid or a derivative thereof that is incorporated into an antibody. In those aspects one or more eCys residues can be incorporated into an antibody, and typically, the eCys residues are incorporated into either the heavy chain or the light chain of an antibody. Generally, incorporation of an eCys residue into an antibody is performed by mutagenizing a nucleic acid sequence of a parent antibody to encode for one or more amino acid residues with a cysteine or a 25 derivative thereof. Suitable mutations include replacement of a desired residue in the light or heavy chain of an antibody with a cysteine or a derivative thereof, incorporation of an additional cysteine or a derivative thereof at a desired location in the light or heavy chain of an antibody, as well as adding an additional cysteine or a derivative thereof to the N- and/or C-terminus of a desired heavy or light chain of an amino acid. Further information can be found in U.S. Pat. No. 30 9,000,130, the contents of which are incorporated herein in its entirety. Derivatives of cysteine (Cys) include but are not limited to beta-2-Cys, beta-3-Cys, homocysteine, and N-methyl cysteine.

In some embodiments, the antibodies of the present disclosure include those having one or more engineered cysteine (eCys) residues. In some embodiments, one or more eCys residues are derivatives of cysteine, for example, beta-2-Cys, beta-3-Cys, homocysteine, or N-methyl-Cys.

In some embodiments, the antibodies of the present disclosure include those having one or more engineered lysine (eLys) residues. In some embodiments, one or more native lysine and/or eLys residues are activated prior to conjugation with a drug-linker intermediate (to form an ADC, as described herein). In some embodiments, the activation comprises contacting the antibody with a compound comprising a succinimydyl ester and a functional group selected from the group consisting of: maleimido, pyridyldisulfide, and iodoacetamido.

An “antigen” is an entity to which an antibody specifically binds.

The terms “specific binding” and “specifically binds” mean that the antibody or antibody fragment thereof will bind, in a selective manner, with its corresponding target antigen and not with a multitude of other antigens. Typically, the antibody or antibody fragment binds with an affinity of at least about 1×10^{-7} M, for example, 10^{-8} M to 10^{-9} M, 10^{-10} M, 10^{-11} M, or 10^{-12} M and binds to the predetermined antigen with an affinity that is at least two-fold greater than its affinity for binding to a non-specific antigen (*e.g.*, BSA, casein) other than the predetermined antigen or a closely-related antigen.

The term “amino acid” as used herein, refers to natural and non-natural, and proteogenic amino acids. Exemplary amino acids include, but are not limited to alanine, arginine, aspartic acid, asparagine, histidine, glycine, glutamic acid, glutamine, phenylalanine, lysine, leucine, serine, tyrosine, threonine, isoleucine, proline, tryptophan, valine, cysteine, methionine, ornithine, β -alanine, citrulline, serine methyl ether, aspartate methyl ester, glutamate methyl ester, homoserine methyl ether, and N,N-dimethyl lysine.

In some embodiments, an antibody is a polyclonal antibody. In some embodiments, an antibody is a monoclonal antibody. In some embodiments, an antibody is chimeric. In some embodiments, an antibody is humanized. In some embodiments, an antibody is an antigen binding fragment.

The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single

antigenic site. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any particular method.

Useful polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of immunized animals. Useful monoclonal antibodies are homogeneous populations of antibodies to a particular antigenic determinant (*e.g.*, a cancer or immune cell antigen, a protein, a peptide, a carbohydrate, a chemical, nucleic acid, or fragments thereof). A monoclonal antibody (mAb) to an antigen-of-interest can be prepared by using any technique known in the art which provides for the production of antibody molecules by continuous cell lines in culture.

Useful monoclonal antibodies include, but are not limited to, human monoclonal antibodies, humanized monoclonal antibodies, or chimeric human-mouse (or other species) monoclonal antibodies. The antibodies include full-length antibodies and antigen binding fragments thereof. Human monoclonal antibodies may be made by any of numerous techniques known in the art. *See, e.g.*, Teng *et al.*, 1983, *Proc. Natl. Acad. Sci. USA.* 80:7308-7312; Kozbor *et al.*, 1983, *Immunology Today* 4:72-79; and Olsson *et al.*, 1982, *Meth. Enzymol.* 92:3-16.

In some embodiments, an antibody includes a functionally active fragment, derivative or analog of an antibody that binds specifically to target cells (*e.g.*, cancer cell antigens) or other antibodies bound to cancer cells or matrix. In this regard, “functionally active” means that the fragment, derivative or analog is able to bind specifically to target cells. To determine which CDR sequences bind the antigen, synthetic peptides containing the CDR sequences are typically used in binding assays with the antigen by any binding assay method known in the art (*e.g.*, the Biacore assay). *See, e.g.*, Kabat *et al.*, 1991, *Sequences of Proteins of Immunological Interest*, 5th Ed., NIH, Bethesda, Md; and Kabat, *et al.*, 1980, *J. Immunology* 125(3):961-969.

Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which are typically obtained using standard recombinant DNA techniques, are useful antibodies. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as for example, those having a variable region derived from a murine monoclonal and a constant region derived from a human immunoglobulin. *See, e.g.*, U.S. Patent No. 4,816,567; and U.S. Patent No. 4,816,397, which are each incorporated herein by reference in their entireties. Humanized antibodies are antibody molecules from non-human species having one or more CDRs from the non-human

species and a framework region from a human immunoglobulin molecule. *See, e.g.*, U.S. Patent No. 5,585,089, which is incorporated herein by reference in its entirety. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in International Publ. No. WO 87/02671; European Publ. No. 0 184 187; European Publ. No. 0171496; European Publ. No. 0173494; International Publ. No. WO 86/01533; U.S. Patent No. 4,816,567; European Publ. No. 012023; Berter *et al.*, 1988, *Science* 240:1041-1043; Liu *et al.*, 1987, *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu *et al.*, 1987, *J. Immunol.* 139:3521-3526; Sun *et al.*, 1987, *Proc. Natl. Acad. Sci. USA* 84:214-218; Nishimura *et al.*, 1987, *Cancer. Res.* 47:999-1005; Wood *et al.*, 1985, *Nature* 314:446-449; and Shaw *et al.*, 1988, *J. Natl. Cancer Inst.* 80:1553-1559; Morrison, 1985, *Science* 229:1202-1207; Oi *et al.*, 1986, *BioTechniques* 4:214; U.S. Patent No. 5,225,539; Jones *et al.*, 1986, *Nature* 321:522-525; Verhoeyan *et al.*, 1988, *Science* 239:1534; and Beidler *et al.*, 1988, *J. Immunol.* 141:4053-4060; each of which is incorporated herein by reference in its entirety.

In some embodiments, an antibody is a completely human antibody. In some embodiments, an antibody is produced using transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light chain genes, but which are capable of expressing human heavy and light chain genes.

In some embodiments, the antibodies are those that are intact or fully-reduced antibodies. The term 'fully-reduced' is meant to refer to antibodies in which all four inter-chain disulfide linkages have been reduced to provide eight thiols that are capable of attachment to a linker (L¹).

Attachment to the antibody can be via thioether linkages from native and/or engineered cysteine residues, or from an amino acid residue engineered to participate in a cycloaddition reaction (such as a click reaction) with the corresponding linker intermediate, as described herein. In some embodiments, the antibodies are those that are intact or fully-reduced antibodies, or are antibodies bearing engineered cysteine groups that are modified with a functional group that are capable of participating in, for example, click chemistry or other cycloaddition reactions for attachment of other components of the ADC as described herein (e.g., Diels-Alder reactions or other [3+2] or [4+2] cycloadditions). *See, e.g.*, Agard, et al., *J. Am. Chem. Soc.* Vol. 126, pp. 15046-15047 (2004); Laughlin, et al., *Science*, Vol. 320, pp. 664-667 (2008); Beatty, et al., *ChemBioChem*, Vol. 11, pp. 2092-2095 (2010); and Van Geel, et al., *Bioconjug. Chem.* Vol. 26, pp.2233-2242 (2015).

Antibodies that bind specifically to a cancer or immune cell antigen are available commercially or produced by any method known to one of skill in the art such as, *e.g.*, chemical synthesis or recombinant expression techniques. The nucleotide sequences encoding antibodies that bind specifically to a cancer or immune cell antigen are obtainable, *e.g.*, from the GenBank database or similar database, literature publications, or by routine cloning and sequencing.

In some embodiments, the antibody can be used for the treatment of a cancer (*e.g.*, an antibody approved by the FDA and/or EMA). Antibodies that bind specifically to a cancer or immune cell antigen are available commercially or produced by any method known to one of skill in the art such as, *e.g.*, recombinant expression techniques. The nucleotide sequences encoding antibodies that bind specifically to a cancer or immune cell antigen are obtainable, *e.g.*, from the GenBank database or similar database, literature publications, or by routine cloning and sequencing.

In some embodiments, an antibody can bind specifically to a receptor or a receptor complex expressed on lymphocytes. The receptor or receptor complex can comprise an immunoglobulin gene superfamily member, a TNF receptor superfamily member, an integrin, a cytokine receptor, a chemokine receptor, a major histocompatibility protein, a lectin, or a complement control protein or other immune cell expressed surface receptor.

In some embodiments, an antibody can bind specifically to a cancer cell antigen. In some embodiments, an antibody can bind specifically to an immune cell antigen. It will be understood that the antibody component in an ADC is an antibody in residue form such that “Ab” in the ADC structures described herein incorporates the structure of the antibody.

Non-limiting examples of antibodies that can be used for treatment of cancer and antibodies that bind specifically to tumor associated antigens are disclosed in Franke, A. E., Sievers, E. L., and Scheinberg, D. A., “Cell surface receptor-targeted therapy of acute myeloid leukemia: a review” *Cancer Biother Radiopharm.* 2000,15, 459-76; Murray, J. L., “Monoclonal antibody treatment of solid tumors: a coming of age” *Semin Oncol.* 2000, 27, 64-70; Breitling, F., and Dubel, S., *Recombinant Antibodies*, John Wiley, and Sons, New York, 1998, each of which is hereby incorporated by reference in its entirety.

In some embodiments, the antibodies for the treatment of an autoimmune disorder are used in accordance with the compositions and methods described herein. Antibodies immunospecific for an antigen of a cell that is responsible for producing autoimmune antibodies

are obtainable if not commercially or otherwise available by any method known to one of skill in the art such as, *e.g.*, chemical synthesis or recombinant expression techniques.

In some embodiments, the antibodies are to a receptor or a receptor complex expressed on an activated lymphocyte. The receptor or receptor complex can comprise an immunoglobulin gene superfamily member, a TNF receptor superfamily member, an integrin, a cytokine receptor, a chemokine receptor, a major histocompatibility protein, a lectin, or a complement control protein.

Examples of antibodies available for the treatment of cancer to and internalizing antibodies that bind to tumor associated antigens are disclosed in Franke, A. E., Sievers, E. L., and Scheinberg, D. A., "Cell surface receptor-targeted therapy of acute myeloid leukemia: a review" *Cancer Biother Radiopharm.* 2000,15, 459-76; Murray, J. L., "Monoclonal antibody treatment of solid tumors: a coming of age" *Semin Oncol.* 2000, 27, 64-70; Breitling, F., and Dubel, S., *Recombinant Antibodies*, John Wiley, and Sons, New York, 1998, each of which is hereby incorporated by reference in its entirety.

Exemplary antigens are provided below. Exemplary antibodies that bind the indicated antigen are shown in parentheses.

In some embodiments, the antigen is a tumor-associated antigen. In some embodiments, the tumor-associated antigen is a transmembrane protein. For example, the following antigens are transmembrane proteins: ANT XR1, BAFF-R, CA9 (exemplary antibodies include girentuximab), CD147 (exemplary antibodies include gavilimomab and metuzumab), CD19, CD20 (exemplary antibodies include divozilimab and ibritumomab tiuxetan), CD274 also known as PD-L1 (exemplary antibodies include adebrelimab, atezolizumab, garivulimab, durvalumab, and avelumab), CD30 (exemplary antibodies include iratumumab and brentuximab), CD33 (exemplary antibodies include lintuzumab), CD352, CD45 (exemplary antibodies include apamistamab), CD47 (exemplary antibodies include letaplimab and magrolimab), CLPTM1L, DPP4, EGFR, ERVMER34-1, FASL, FSHR, FZD5, FZD8, GUCY2C (exemplary antibodies include indusatumab), IFNAR1 (exemplary antibodies include faralimomab), IFNAR2, LMP2, MLANA, SIT1, TLR2/4/1 (exemplary antibodies include tomaralimab), TM4SF5, TMEM132A, TMEM40, UPK1B, VEGF, and VEGFR2 (exemplary antibodies include gentuximab).

In some embodiments, the tumor-associated antigen is a transmembrane transport protein. For example, the following antigens are transmembrane transport proteins: ASCT2 (exemplary antibodies include idactamab), MFSD13A, Mincle, NOX1, SLC10A2, SLC12A2, SLC17A2,

SLC38A1, SLC39A5, SLC39A6 also known as LIV1 (exemplary antibodies include ladiratuzumab), SLC44A4, SLC6A15, SLC6A6, SLC7A11, and SLC7A5.

In some embodiments, the tumor-associated antigen is a transmembrane or membrane-associated glycoprotein. For example, the following antigens are transmembrane or membrane-associated glycoproteins: CA-125, CA19-9, CAMPATH-1 (exemplary antibodies include
5 alemtuzumab), carcinoembryonic antigen (exemplary antibodies include arcitumomab, cergutuzumab, amunaleukin, and labetuzumab), CD112, CD155, CD24, CD247, CD37 (exemplary antibodies include lilotomab), CD38 (exemplary antibodies include felzartamab), CD3D, CD3E (exemplary antibodies include foralumab and teplizumab), CD3G, CD96, CDCP1,
10 CDH17, CDH3, CDH6, CEACAM1, CEACAM6, CLDN1, CLDN16, CLDN18.1 (exemplary antibodies include zolbetuximab), CLDN18.2 (exemplary antibodies include zolbetuximab), CLDN19, CLDN2, CLEC12A (exemplary antibodies include tepoditamab), DPEP1, DPEP3, DSG2, endosialin (exemplary antibodies include ontuxizumab), ENPP1, EPCAM (exemplary antibodies include adecatumumab), FN, FN1, Gp100, GPA33, gpNMB (exemplary antibodies
15 include glembatumumab), ICAM1, L1CAM, LAMP1, MELTF also known as CD228, NCAM1, Nectin-4 (exemplary antibodies include enfortumab), PDPN, PMSA, PROM1, PSCA, PSMA, Siglecs 1-16, SIRPa, SIRPg, TACSTD2, TAG-72, Tenascin, Tissue Factor also known as TF (exemplary antibodies include tisotumab), and ULBP1/2/3/4/5/6.

In some embodiments, the tumor-associated antigen is a transmembrane or membrane-associated receptor kinase. For example, the following antigens are transmembrane or membrane-associated receptor kinases: ALK, Axl (exemplary antibodies include tilvestamab), BMPR2,
20 DCLK1, DDR1, EPHA receptors, EPHA2, ERBB2 also known as HER2 (exemplary antibodies include trastuzumab, bevacizumab, pertuzumab, and margetuximab), ERBB3, FLT3, PDGFR-B (exemplary antibodies include rinucumab), PTK7 (exemplary antibodies include cofetuzumab),
25 RET, ROR1 (exemplary antibodies include cirmtuzumab), ROR2, ROS1, and Tie3.

In some embodiments, the tumor-associated antigen is a membrane-associated or membrane-localized protein. For example, the following antigens are membrane-associated or membrane-localized proteins: ALPP, ALPPL2, ANXA1, FOLR1 (exemplary antibodies include farletuzumab), IL13Ra2, IL1RAP (exemplary antibodies include nidanilimab), NT5E, OX40, Ras
30 mutant, RGS5, RhoC, SLAMF7 (exemplary antibodies include elotuzumab), and VSIR.

In some embodiments, the tumor-associated antigen is a transmembrane G-protein coupled receptor (GPCR). For example, the following antigens are GPCRs: CALCR, CD97, GPR87, and KISS1R.

In some embodiments, the tumor-associated antigen is cell-surface-associated or a cell-surface receptor. For example, the following antigens are cell-surface-associated and/or cell-surface receptors: B7-DC, BCMA, CD137, CD 244, CD3 (exemplary antibodies include orelizumab and visilizumab), CD48, CD5 (exemplary antibodies include zolimomab aritox), CD70 (exemplary antibodies include cusatuzumab and vorsetuzumab), CD74 (exemplary antibodies include milatuzumab), CD79A, CD-262 (exemplary antibodies include tigatuzumab), DR4 (exemplary antibodies include mapatumumab), FAS, FGFR1, FGFR2 (exemplary antibodies include aprutumab), FGFR3 (exemplary antibodies include vofatamab), FGFR4, GTR (exemplary antibodies include ragifilimab), Gpc3 (exemplary antibodies include ragifilimab), HAVCR2, HLA-E, HLA-F, HLA-G, LAG-3 (exemplary antibodies include encelimab), LY6G6D, LY9, MICA, MICB, MSLN, MUC1, MUC5AC, NY-ESO-1, OY-TES1, PVRIG, Sialyl-Thomsen-Nouveau Antigen, Sperm protein 17, TNFRSF12, and uPAR.

In some embodiments, the tumor-associated antigen is a chemokine receptor or cytokine receptor. For example, the following antigens are chemokine receptors or cytokine receptors: CD115 (exemplary antibodies include axatilimab, cabiralizumab, and emactuzumab), CD123, CXCR 4 (exemplary antibodies include ulocuplumab), IL-21R, and IL-5R (exemplary antibodies include benralizumab).

In some embodiments, the tumor-associated antigen is a co-stimulatory, surface-expressed protein. For example, the following antigens are co-stimulatory, surface-expressed proteins: B7-H3 (exemplary antibodies include enoblituzumab and omburtamab), B7-H4, B7-H6, and B7-H7.

In some embodiments, the tumor-associated antigen is a transcription factor or a DNA-binding protein. For example, the following antigens are transcription factors: ETV6-AML, MYCN, PAX3, PAX5, and WT1. The following protein is a DNA-binding protein: BORIS.

In some embodiments, the tumor-associated antigen is an integral membrane protein. For example, the following antigens are integral membrane proteins: SLITRK6 (exemplary antibodies include sirtratumab), UPK2, and UPK3B.

In some embodiments, the tumor-associated antigen is an integrin. For example, the following antigens are integrin antigens: alpha v beta 6, ITGAV (exemplary antibodies include abituzumab), ITGB6, and ITGB8.

5 In some embodiments, the tumor-associated antigen is a glycolipid. For example, the following are glycolipid antigens: FucGM1, GD2 (exemplary antibodies include dinutuximab), GD3 (exemplary antibodies include mitumomab), GloboH, GM2, and GM3 (exemplary antibodies include racotumomab).

10 In some embodiments, the tumor-associated antigen is a cell-surface hormone receptor. For example, the following antigens are cell-surface hormone receptors: AMHR2 and androgen receptor.

In some embodiments, the tumor-associated antigen is a transmembrane or membrane-associated protease. For example, the following antigens are transmembrane or membrane-associated proteases: ADAM12, ADAM9, TMPRSS11D, and metalloproteinase.

15 In some embodiments, the tumor-associated antigen is aberrantly expressed in individuals with cancer. For example, the following antigens may be aberrantly expressed in individuals with cancer: AFP, AGR2, AKAP-4, ARTN, BCR-ABL, C5 complement, CCNB1, CSPG4, CYP1B1, De2-7 EGFR, EGF, Fas-related antigen 1, FBP, G250, GAGE, HAS3, HPV E6 E7, hTERT, IDO1, LCK, Legumain, LYPD1, MAD-CT-1, MAD-CT-2, MAGEA3, MAGEA4, MAGEC2, MerTk, ML-IAP, NA17, NY-BR-1, p53, p53 mutant, PAP, PLAVI, polysialic acid, PR1, PSA, Sarcoma
20 translocation breakpoints, SART3, sLe, SSX2, Survivin, Tn, TRAIL, TRAIL1, TRP-2, and XAGE1.

In some embodiments, the antigen is an immune-cell-associated antigen. In some embodiments, the immune-cell-associated antigen is a transmembrane protein. For example, the following antigens are transmembrane proteins: BAFF-R, CD163, CD19, CD20 (exemplary
25 antibodies include rituximab, ocrelizumab, divozilimab; ibritumomab tiuxetan), CD25 (exemplary antibodies include basiliximab), CD274 also known as PD-L1 (exemplary antibodies include adebrelimab, atezolizumab, garivulimab, durvalumab, and avelumab), CD30 (exemplary antibodies include iratumumab and brentuximab), CD33 (exemplary antibodies include lintuzumab), CD352, CD45 (exemplary antibodies include apamistamab), CD47 (exemplary
30 antibodies include letaplimab and magrolimab), CTLA4 (exemplary antibodies include ipilimumab), FASL, IFNAR1 (exemplary antibodies include faralimomab), IFNAR2, LAYN,

LILRB2, LILRB4, PD-1 (exemplary antibodies include ipilimumab, nivolumab, pembrolizumab, balstilimab, budigalimab, geptanolimab, toripalimab, and pidilizumab), SIT1, and TLR2/4/1 (exemplary antibodies include tomaralimab).

In some embodiments, the immune-cell-associated antigen is a transmembrane transport protein. For example, Mincle is a transmembrane transport protein.

In some embodiments, the immune-cell-associated antigen is a transmembrane or membrane-associated glycoprotein. For example, the following antigens are transmembrane or membrane-associated glycoproteins: CD112, CD155, CD24, CD247, CD28, CD30L, CD37 (exemplary antibodies include lilotomab), CD38 (exemplary antibodies include felzartamab), CD3D, CD3E (exemplary antibodies include foralumab and teplizumab), CD3G, CD44, CLEC12A (exemplary antibodies include tepoditamab), DCIR, DCSIGN, Dectin 1, Dectin 2, ICAM1, LAMP1, Siglecs 1-16, SIRPa, SIRPg, and ULBP1/2/3/4/5/6.

In some embodiments, the immune-cell-associated antigen is a transmembrane or membrane-associated receptor kinase. For example, the following antigens are transmembrane or membrane-associated receptor kinases: Axl (exemplary antibodies include tilvestamab) and FLT3.

In some embodiments, the immune-cell-associated antigen is a membrane-associated or membrane-localized protein. For example, the following antigens are membrane-associated or membrane-localized proteins: CD83, IL1RAP (exemplary antibodies include nidanilimab), OX40, SLAMF7 (exemplary antibodies include elotuzumab), and VSIR.

In some embodiments, the immune-cell-associated antigen is a transmembrane G-protein coupled receptor (GPCR). For example, the following antigens are GPCRs: CCR4 (exemplary antibodies include mogamulizumab-kpkc), CCR8, and CD97.

In some embodiments, the immune-cell-associated antigen is cell-surface-associated or a cell-surface receptor. For example, the following antigens are cell-surface-associated and/or cell-surface receptors: B7-DC, BCMA, CD137, CD2 (exemplary antibodies include siplizumab), CD244, CD27 (exemplary antibodies include varlilumab), CD278 (exemplary antibodies include feladilimab and vopratelimab), CD3 (exemplary antibodies include oteelixizumab and visilizumab), CD40 (exemplary antibodies include dacetuzumab and lucatumumab), CD48, CD5 (exemplary antibodies include zolimomab aritox), CD70 (exemplary antibodies include cusatuzumab and vorsetuzumab), CD74 (exemplary antibodies include milatuzumab), CD79A, CD-262 (exemplary antibodies include tigatuzumab), DR4 (exemplary antibodies include mapatumumab), GTR

(exemplary antibodies include ragifilimab), HAVCR2, HLA-DR, HLA-E, HLA-F, HLA-G, LAG-3 (exemplary antibodies include encelimumab), MICA, MICB, MRC1, PVRIG, Sialyl-Thomsen-Nouveau Antigen, TIGIT (exemplary antibodies include etigilimab), Trem2, and uPAR.

In some embodiments, the immune-cell-associated antigen is a chemokine receptor or cytokine receptor. For example, the following antigens are chemokine receptors or cytokine receptors: CD115 (exemplary antibodies include axatilimab, cabiralizumab, and emactuzumab), CD123, CXCR4 (exemplary antibodies include ulocuplumab), IL-21R, and IL-5R (exemplary antibodies include benralizumab).

In some embodiments, the immune-cell-associated antigen is a co-stimulatory, surface-expressed protein. For example, the following antigens are co-stimulatory, surface-expressed proteins: B7-H 3 (exemplary antibodies include enoblituzumab and omburtamab), B7-H4, B7-H6, and B7-H7.

In some embodiments, the immune-cell-associated antigen is a peripheral membrane protein. For example, the following antigens are peripheral membrane proteins: B7-1 (exemplary antibodies include galiximab) and B7-2.

In some embodiments, the immune-cell-associated antigen is aberrantly expressed in individuals with cancer. For example, the following antigens may be aberrantly expressed in individuals with cancer: C5 complement, IDO1, LCK, MerTk, and Tyrol.

In some embodiments, the antigen is a stromal-cell-associated antigen. In some embodiments, the stromal-cell-associated antigen is a transmembrane or membrane-associated protein. For example, the following antigens are transmembrane or membrane-associated proteins: FAP (exemplary antibodies include sibrotuzumab), IFNAR1 (exemplary antibodies include faralimomab), and IFNAR2.

In some embodiments, the antigen is CD30. In some embodiments, the antibody is an antibody or antigen-binding fragment that binds to CD30, such as described in International Patent Publication No. WO 02/43661. In some embodiments, the anti-CD30 antibody is cAC10, which is described in International Patent Publication No. WO 02/43661. cAC10 is also known as brentuximab. In some embodiments, the anti-CD30 antibody comprises the CDRs of cAC10. In some embodiments, the CDRs are as defined by the Kabat numbering scheme. In some embodiments, the CDRs are as defined by the Chothia numbering scheme. In some embodiments, the CDRs are as defined by the IMGT numbering scheme. In some embodiments, the CDRs are

as defined by the AbM numbering scheme. In some embodiments, the anti-CD30 antibody comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 5, and 6, respectively. In some embodiments, the anti-CD30 antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 95%, at least 96%, at least 97%, at last 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising an amino acid sequence that is at least 95% at least 96%, at least 97%, at last 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the anti-CD30 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 10 and a light chain comprising the amino acid sequence of SEQ ID NO: 11.

In some embodiments, the antigen is CD70. In some embodiments, the antibody is an antibody or antigen-binding fragment that binds to CD70, such as described in International Patent Publication No. WO 2006/113909. In some embodiments, the antibody is a h1F6 anti-CD70 antibody, which is described in International Patent Publication No. WO 2006/113909. h1F6 is also known as vorsetuzumab. In some embodiments, the anti-CD70 antibody comprises a heavy chain variable region comprising the three CDRs of SEQ ID NO:12 and a light chain variable region comprising the three CDRs of SEQ ID NO:13. In some embodiments, the CDRs are as defined by the Kabat numbering scheme. In some embodiments, the CDRs are as defined by the Chothia numbering scheme. In some embodiments, the CDRs are as defined by the IMGT numbering scheme. In some embodiments, the CDRs are as defined by the AbM numbering scheme. In some embodiments, the anti-CD70 antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 95%, at least 96%, at least 97%, at last 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and a light chain variable region comprising an amino acid sequence that is at least 95% at least 96%, at least 97%, at last 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 13. In some embodiments, the anti-CD30 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 14 and a light chain comprising the amino acid sequence of SEQ ID NO: 15.

In some embodiments, the antigen is interleukin-1 receptor accessory protein (IL1RAP). IL1RAP is a co-receptor of the IL1 receptor (IL1R1) and is required for interleukin-1 (IL1) signaling. IL1 has been implicated in the resistance to certain chemotherapy regimens. IL1RAP is

overexpressed in various solid tumors, both on cancer cells and in the tumor microenvironment, but has low expression on normal cells. IL1RAP is also overexpressed in hematopoietic stem and progenitor cells, making it a candidate to target for chronic myeloid leukemia (CML). IL1RAP has also been shown to be overexpressed in acute myeloid leukemia (AML). Antibody binding to IL1RAP could block signal transduction from IL-1 and IL-33 into cells and allow NK-cells to recognize tumor cells and subsequent killing by antibody dependent cellular cytotoxicity (ADCC).

In some embodiments, the antigen is ASCT2. ASCT2 is also known as SLC1A5. ASCT2 is a ubiquitously expressed, broad-specificity, sodium-dependent neutral amino acid exchanger. ASCT2 is involved in glutamine transport. ASCT2 is overexpressed in different cancers and is closely related to poor prognosis. Downregulating ASCT2 has been shown to suppress intracellular glutamine levels and downstream glutamine metabolism, including glutathione production. Due to its high expression in many cancers, ASCT2 is a potential therapeutic target. These effects attenuated growth and proliferation, increased apoptosis and autophagy, and increased oxidative stress and mTORC1 pathway suppression in head and neck squamous cell carcinoma (HNSCC). Additionally, silencing ASCT2 improved the response to cetuximab in HNSCC.

In some embodiments, an antibody-drug conjugate provided herein binds to TROP2. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 16, 17, 18, 19, 20, and 21, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 22 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 23. In some embodiments, the antibody of the antibody drug conjugate is sacituzumab. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 24, 25, 26, 27, 28, and 29, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 30 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 31. In some embodiments, the antibody of the antibody drug conjugate is datopotamab.

In some embodiments, an antibody-drug conjugate provided herein binds to MICA. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs:

32, 33, 34, 35, 36, and 37, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 38 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 39. In some embodiments, the antibody of the antibody drug conjugate is h1D5v11 hIgG1K. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 40, 41, 42, 43, 44, and 45, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 46 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 47. In some embodiments, the antibody of the antibody drug conjugate is MICA.36 hIgG1K G236A. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 48, 49, 50, 51, 52, and 53, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 54 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 55. In some embodiments, the antibody of the antibody drug conjugate is h3F9 H1L3 hIgG1K. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 56, 57, 58, 59, 60, and 61, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 62 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 63. In some embodiments, the antibody of the antibody drug conjugate is CM33322 Ab28 hIgG1K.

In some embodiments, an antibody-drug conjugate provided herein binds to CD24. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 64, 65, 66, 67, 68, and 69, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 70 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 71. In some embodiments, the antibody of the antibody drug conjugate is SWA11.

In some embodiments, an antibody-drug conjugate provided herein binds to ITGav. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 72, 73, 74, 75, 76, and 77, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 78 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 79. In some embodiments, the antibody of the antibody drug conjugate is intetumumab. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 80, 81, 82, 83, 84, and 85, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 86 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 87. In some embodiments, the antibody of the antibody drug conjugate is abituzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to gpA33. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 88, 89, 90, 91, 92, and 93, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 94 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 95.

In some embodiments, an antibody-drug conjugate provided herein binds to IL1Rap. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 96, 97, 98, 99, 100, and 101, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 102 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 103. In some embodiments, the antibody of the antibody drug conjugate is nidanilimab.

In some embodiments, an antibody-drug conjugate provided herein binds to EpCAM. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 104, 105, 106, 107, 108, and 109, respectively. In some embodiments, the antibody of the antibody

drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 110 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 111. In some embodiments, the antibody of the antibody drug conjugate is adecatumumab. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 112, 113, 114, 115, 116, and 117, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 118 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 119. In some embodiments, the antibody of the antibody drug conjugate is Ep157305. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 120, 121, 122, 123, 124, and 125, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 126 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 127. In some embodiments, the antibody of the antibody drug conjugate is Ep3-171. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 128, 129, 130, 131, 132, and 133, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 134 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 135. In some embodiments, the antibody of the antibody drug conjugate is Ep3622w94. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 136, 137, 138, 139, 140, and 141, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 142 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 143. In some embodiments, the antibody of the antibody drug conjugate is EpING1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 144, 145, 146, 147, 148, and 149, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ

ID NO: 150 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 151. In some embodiments, the antibody of the antibody drug conjugate is EpAb2-6.

In some embodiments, an antibody-drug conjugate provided herein binds to CD352. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 152, 153, 154, 155, 156, and 157, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 158 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 159. In some embodiments, the antibody of the antibody drug conjugate is h20F3.

In some embodiments, an antibody-drug conjugate provided herein binds to CS1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 160, 161, 162, 163, 164, and 165, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 166 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 167. In some embodiments, the antibody of the antibody drug conjugate is elotuzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to CD38. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 168, 169, 170, 171, 172, and 173, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 174 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 175. In some embodiments, the antibody of the antibody drug conjugate is daratumumab.

In some embodiments, an antibody-drug conjugate provided herein binds to CD25. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 176, 177, 178, 179, 180, and 181, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 182 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 183. In some embodiments, the antibody of the antibody drug conjugate is daclizumab.

In some embodiments, an antibody-drug conjugate provided herein binds to ADAM9. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 184, 185, 186, 187, 188, and 189, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 190 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 191. In some embodiments, the antibody of the antibody drug conjugate is chMAbA9-A. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 192, 193, 194, 195, 196, and 197, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 198 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 199. In some embodiments, the antibody of the antibody drug conjugate is hMAbA9-A.

In some embodiments, an antibody-drug conjugate provided herein binds to CD59. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 200, 201, 202, 203, 204, and 205, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 206 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 207.

In some embodiments, an antibody-drug conjugate provided herein binds to CD25. In some embodiments, the antibody of the antibody drug conjugate is Clone123.

In some embodiments, an antibody-drug conjugate provided herein binds to CD229. In some embodiments, the antibody of the antibody drug conjugate is h8A10.

In some embodiments, an antibody-drug conjugate provided herein binds to CD19. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 208, 209, 210, 211, 212, and 213, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 214 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:

215. In some embodiments, the antibody of the antibody drug conjugate is denintuzumab, which is also known as hBU12. See WO2009052431.

In some embodiments, an antibody-drug conjugate provided herein binds to CD70. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 216, 217, 218, 219, 220, and 221, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 222 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 223. In some embodiments, the antibody of the antibody drug conjugate is vorsetuzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to B7H4. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 224, 225, 226, 227, 228, and 229, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 230 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 231. In some embodiments, the antibody of the antibody drug conjugate is mirzotamab.

In some embodiments, an antibody-drug conjugate provided herein binds to CD138. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 232, 233, 234, 235, 236, and 237, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 238 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 239. In some embodiments, the antibody of the antibody drug conjugate is indatuxumab.

In some embodiments, an antibody-drug conjugate provided herein binds to CD166. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 240, 241, 242, 243, 244, and 245, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 246 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 247. In some embodiments, the antibody of the antibody drug conjugate is praluzatamab.

In some embodiments, an antibody-drug conjugate provided herein binds to CD51. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 248, 249, 250, 251, 252, and 253, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 254 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 255. In some embodiments, the antibody of the antibody drug conjugate is intetumumab.

In some embodiments, an antibody-drug conjugate provided herein binds to CD56. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 256, 257, 258, 259, 260, and 261, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 262 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 263. In some embodiments, the antibody of the antibody drug conjugate is lorvotuzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to CD74. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 264, 265, 266, 267, 268, and 269, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 270 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 271. In some embodiments, the antibody of the antibody drug conjugate is milatuzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to CEACAM5. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 272, 273, 274, 275, 276, and 277, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 278 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 279. In some embodiments, the antibody of the antibody drug conjugate is labetuzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to CanAg. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs:

280, 281, 282, 283, 284, and 285, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 286 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 287. In some embodiments, the antibody of the antibody drug conjugate is cantuzumab.

5 In some embodiments, an antibody-drug conjugate provided herein binds to DLL-3. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 288, 289, 290, 291, 292, and 293, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of
10 SEQ ID NO: 294 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 295. In some embodiments, the antibody of the antibody drug conjugate is rovalpituzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to DPEP-3. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs:
15 296, 297, 298, 299, 300, and 301, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 302 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 303. In some embodiments, the antibody of the antibody drug conjugate is tamrintamab.

In some embodiments, an antibody-drug conjugate provided herein binds to EGFR. In
20 some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 304, 305, 306, 307, 308, and 309, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 310 and a light chain variable region comprising the amino acid sequence of SEQ ID
25 NO: 311. In some embodiments, the antibody of the antibody drug conjugate is laprituximab. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 312, 313, 314, 315, 316, and 317, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of
30 SEQ ID NO: 318 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 319. In some embodiments, the antibody of the antibody drug conjugate is losatuxizumab. In

some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 320, 321, 322, 323, 324, and 325, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 326 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 327. In some embodiments, the antibody of the antibody drug conjugate is serclutamab. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 328, 329, 330, 331, 332, and 333, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 334 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 335. In some embodiments, the antibody of the antibody drug conjugate is cetuximab.

In some embodiments, an antibody-drug conjugate provided herein binds to FRa. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 336, 337, 338, 339, 340, and 341, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 342 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 343. In some embodiments, the antibody of the antibody drug conjugate is mirvetuximab. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 344, 345, 346, 347, 348, and 349, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 350 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 351. In some embodiments, the antibody of the antibody drug conjugate is farletuzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to MUC-1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 352, 353, 354, 355, 356, and 357, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of

SEQ ID NO: 358 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 359. In some embodiments, the antibody of the antibody drug conjugate is gatipotuzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to mesothelin. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 360, 361, 362, 363, 364, and 365, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 366 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 367. In some embodiments, the antibody of the antibody drug conjugate is anetumab.

In some embodiments, an antibody-drug conjugate provided herein binds to ROR-1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 368, 369, 370, 371, 372, and 373, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 374 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 375. In some embodiments, the antibody of the antibody drug conjugate is zilovertamab.

In some embodiments, an antibody-drug conjugate provided herein binds to ASCT2.

In some embodiments, an antibody-drug conjugate provided herein binds to B7H4. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 376, 377, 378, 379, 380, and 381, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 382 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 383. In some embodiments, the antibody of the antibody drug conjugate is 20502. See WO2019040780.

In some embodiments, an antibody-drug conjugate provided herein binds to B7-H3. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 384, 385, 386, 387, 388, and 389, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 390 and a light chain variable region comprising the amino acid sequence of SEQ ID

NO: 391. In some embodiments, the antibody of the antibody drug conjugate is chAb-A (BRCA84D). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 392, 393, 394, 395, 396, and 397, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 398 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 399. In some embodiments, the antibody of the antibody drug conjugate is hAb-B. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 400, 401, 402, 403, 404, and 405, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 406 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 407. In some embodiments, the antibody of the antibody drug conjugate is hAb-C. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 408, 409, 410, 411, 412, and 413, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 414 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 415. In some embodiments, the antibody of the antibody drug conjugate is hAb-D. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 416, 417, 418, 419, 420, and 421, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 422 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 423. In some embodiments, the antibody of the antibody drug conjugate is chM30. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 424, 425, 426, 427, 428, and 429, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 430 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 431. In some embodiments, the antibody of

the antibody drug conjugate is hM30-H1-L4. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 432, 433, 434, 435, 436, and 437, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 438 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 439. In some embodiments, the antibody of the antibody drug conjugate is AbV_huAb18-v4. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 440, 441, 442, 443, 444, and 445, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 446 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 447. In some embodiments, the antibody of the antibody drug conjugate is AbV_huAb3-v6. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 448, 449, 450, 451, 452, and 453, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 454 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 455. In some embodiments, the antibody of the antibody drug conjugate is AbV_huAb3-v2.6. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 456, 457, 458, 459, 460, and 461, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 462 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 463. In some embodiments, the antibody of the antibody drug conjugate is AbV_huAb13-v1-CR. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 464, 465, 466, 467, 468, and 469, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 470 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 471. In some embodiments, the antibody of the antibody drug conjugate is 8H9-

6m. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 472 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 473. In some embodiments, the antibody of the antibody drug conjugate is m8517. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 474, 475, 476, 477, 478, and 479, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 480 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 481. In some embodiments, the antibody of the antibody drug conjugate is TPP-5706. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 482 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 483. In some embodiments, the antibody of the antibody drug conjugate is TPP-6642. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 484 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 485. In some embodiments, the antibody of the antibody drug conjugate is TPP-6850.

In some embodiments, an antibody-drug conjugate provided herein binds to CDCP1. In some embodiments, the antibody of the antibody drug conjugate is 10D7.

In some embodiments, an antibody-drug conjugate provided herein binds to HER3. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 486 and a light chain comprising the amino acid sequence of SEQ ID NO: 487. In some embodiments, the antibody of the antibody drug conjugate is patritumab. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 488 and a light chain comprising the amino acid sequence of SEQ ID NO: 489. In some embodiments, the antibody of the antibody drug conjugate is seribantumab. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 490 and a light chain comprising the amino acid sequence of SEQ ID NO: 491. In some embodiments, the antibody of the antibody drug conjugate is elgemtumab. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain the amino acid sequence of SEQ ID NO:

492 and a light chain comprising the amino acid sequence of SEQ ID NO: 493. In some embodiments, the antibody of the antibody drug conjugate is lumretuzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to RON. In some embodiments, the antibody of the antibody drug conjugate is Zt/g4.

5 In some embodiments, an antibody-drug conjugate provided herein binds to claudin-2.

In some embodiments, an antibody-drug conjugate provided herein binds to HLA-G.

In some embodiments, an antibody-drug conjugate provided herein binds to PTK7. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 494, 495, 496, 497, 498, and 499, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 500 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 501. In some embodiments, the antibody of the antibody drug conjugate is PTK7 mab 1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 502, 503, 504, 505, 506, and 507, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 508 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 509. In some embodiments, the antibody of the antibody drug conjugate is PTK7 mab 2. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 510, 511, 512, 513, 514, and 515, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 516 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 517. In some embodiments, the antibody of the antibody drug conjugate is PTK7 mab 3.

In some embodiments, an antibody-drug conjugate provided herein binds to LIV1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 518, 519, 520, 521, 522, and 523, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 524 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:

525. In some embodiments, the antibody of the antibody drug conjugate is ladiratuzumab, which is also known as hLIV22 and hglg. See WO2012078668.

In some embodiments, an antibody-drug conjugate provided herein binds to avb6. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 526, 527, 528, 529, 530, and 531, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 532 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 533. In some embodiments, the antibody of the antibody drug conjugate is h2A2. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 534, 535, 536, 537, 538, and 539, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 540 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 541. In some embodiments, the antibody of the antibody drug conjugate is h15H3.

In some embodiments, an antibody-drug conjugate provided herein binds to CD48. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 542, 543, 544, 545, 546, and 547, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 548 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 549. In some embodiments, the antibody of the antibody drug conjugate is hMEM102. See WO2016149535.

In some embodiments, an antibody-drug conjugate provided herein binds to PD-L1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 550, 551, 552, 553, 554, and 555, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 556 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 557. In some embodiments, the antibody of the antibody drug conjugate is SG-559-01 LALA mAb.

In some embodiments, an antibody-drug conjugate provided herein binds to IGF-1R. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 558, 559, 560, 561, 562, and 563, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 564 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 565. In some embodiments, the antibody of the antibody drug conjugate is cixutumumab.

In some embodiments, an antibody-drug conjugate provided herein binds to claudin-18.2. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 566, 567, 568, 569, 570, and 571, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 572 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 573. In some embodiments, the antibody of the antibody drug conjugate is zolbetuximab (175D10). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 574, 575, 576, 577, 578, and 579, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 580 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 581. In some embodiments, the antibody of the antibody drug conjugate is 163E12.

In some embodiments, an antibody-drug conjugate provided herein binds to Nectin-4. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 582, 583, 584, 585, 586, and 587, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 588 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 589. In some embodiments, the antibody of the antibody drug conjugate is enfortumab. See WO 2012047724.

In some embodiments, an antibody-drug conjugate provided herein binds to SLTRK6. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2,

CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 590, 591, 592, 593, 594, and 595, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 596 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 597. In some embodiments, the antibody of the antibody drug conjugate is sirtratumab.

In some embodiments, an antibody-drug conjugate provided herein binds to CD228. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 598, 599, 600, 601, 602, and 603, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 604 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 605. In some embodiments, the antibody of the antibody drug conjugate is hL49. See WO 2020/163225.

In some embodiments, an antibody-drug conjugate provided herein binds to CD142 (tissue factor; TF). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 606, 607, 608, 609, 610, and 611, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 612 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 613. In some embodiments, the antibody of the antibody drug conjugate is tisotumab. See WO 2010/066803.

In some embodiments, an antibody-drug conjugate provided herein binds to STn. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 614, 615, 616, 617, 618, and 619, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 620 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 621. In some embodiments, the antibody of the antibody drug conjugate is h2G12.

In some embodiments, an antibody-drug conjugate provided herein binds to CD20. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 622,

623, 624, 625, 626, and 627, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 628 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 629. In some embodiments, the antibody of the antibody drug conjugate is rituximab.

5 In some embodiments, an antibody-drug conjugate provided herein binds to HER2. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 630, 631, 632, 633, 634, and 635, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of
10 SEQ ID NO: 636 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 637. In some embodiments, the antibody of the antibody drug conjugate is trastuzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to FLT3.

In some embodiments, an antibody-drug conjugate provided herein binds to CD46.

In some embodiments, an antibody-drug conjugate provided herein binds to GloboH.

15 In some embodiments, an antibody-drug conjugate provided herein binds to AG7.

In some embodiments, an antibody-drug conjugate provided herein binds to mesothelin.

In some embodiments, an antibody-drug conjugate provided herein binds to FCRH5.

In some embodiments, an antibody-drug conjugate provided herein binds to ETBR.

In some embodiments, an antibody-drug conjugate provided herein binds to Tim-1.

20 In some embodiments, an antibody-drug conjugate provided herein binds to SLC44A4.

In some embodiments, an antibody-drug conjugate provided herein binds to ENPP3.

In some embodiments, an antibody-drug conjugate provided herein binds to CD37.

In some embodiments, an antibody-drug conjugate provided herein binds to CA9.

In some embodiments, an antibody-drug conjugate provided herein binds to Notch3.

25 In some embodiments, an antibody-drug conjugate provided herein binds to EphA2.

In some embodiments, an antibody-drug conjugate provided herein binds to TRFC.

In some embodiments, an antibody-drug conjugate provided herein binds to PSMA.

In some embodiments, an antibody-drug conjugate provided herein binds to LRRC15.

In some embodiments, an antibody-drug conjugate provided herein binds to 5T4.

30 In some embodiments, an antibody-drug conjugate provided herein binds to CD79b. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2,

CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 638, 639, 640, 641, 642, and 643, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 644 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 645. In some embodiments, the antibody of the antibody drug conjugate is polatuzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to NaPi2B. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 646, 647, 648, 649, 650, and 651, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 652 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 653. In some embodiments, the antibody of the antibody drug conjugate is lifastuzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to Muc16. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 654, 655, 656, 657, 658, and 659, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 660 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 661. In some embodiments, the antibody of the antibody drug conjugate is sofituzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to STEAP1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 662, 663, 664, 665, 666, and 667, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 668 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 669. In some embodiments, the antibody of the antibody drug conjugate is vandortuzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to BCMA. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 670, 671, 672, 673, 674, and 675, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of

SEQ ID NO: 676 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 677. In some embodiments, the antibody of the antibody drug conjugate is belantamab.

In some embodiments, an antibody-drug conjugate provided herein binds to c-Met. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 678, 679, 680, 681, 682, and 683, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 684 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 685. In some embodiments, the antibody of the antibody drug conjugate is telisotuzumab.

In some embodiments, an antibody-drug conjugate provided herein binds to EGFR. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 686, 687, 688, 689, 690, and 691, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 692 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 693. In some embodiments, the antibody of the antibody drug conjugate is depatuxizumab.

In some embodiments, an antibody-drug conjugate provided herein binds to SLAMF7. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 694, 695, 696, 697, 698, and 699, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 700 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 701. In some embodiments, the antibody of the antibody drug conjugate is azintuxizumab.

In some embodiments, an antibody-drug conjugate provided herein binds to SLITRK6. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 702, 703, 704, 705, 706, and 707, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 708 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 709. In some embodiments, the antibody of the antibody drug conjugate is sirtratumab.

In some embodiments, an antibody-drug conjugate provided herein binds to C4.4a. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 710, 711, 712, 713, 714, and 715, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 716 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 717. In some embodiments, the antibody of the antibody drug conjugate is lupatumab.

In some embodiments, an antibody-drug conjugate provided herein binds to GCC. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 718, 719, 720, 721, 722, and 723, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 724 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 725. In some embodiments, the antibody of the antibody drug conjugate is indusatumab.

In some embodiments, an antibody-drug conjugate provided herein binds to Axl. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 726, 727, 728, 729, 730, and 731, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 732 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 733. In some embodiments, the antibody of the antibody drug conjugate is enapotamab.

In some embodiments, an antibody-drug conjugate provided herein binds to gpNMB. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 734, 735, 736, 737, 738, and 739, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 740 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 741. In some embodiments, the antibody of the antibody drug conjugate is glembatumumab.

In some embodiments, an antibody-drug conjugate provided herein binds to Prolactin receptor. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of

SEQ ID NOs: 742, 743, 744, 745, 746, and 747, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 748 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 749. In some embodiments, the antibody of the antibody drug conjugate is rolinsatamab.

In some embodiments, an antibody-drug conjugate provided herein binds to FGFR2. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 750, 751, 752, 753, 754, and 755, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 756 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 757. In some embodiments, the antibody of the antibody drug conjugate is aprutumab.

In some embodiments, an antibody-drug conjugate provided herein binds to CDCP1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 758, 759, 760, 761, 762, and 763, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 764 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 765. In some embodiments, the antibody of the antibody drug conjugate is Humanized CUB4 #135 HC4-H. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 766, 767, 768, 769, 770, and 771, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 772 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 773. In some embodiments, the antibody of the antibody drug conjugate is CUB4. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 774, 775, 776, 777, 778, 779, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 780 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 781. In some embodiments, the antibody of the antibody drug

conjugate is CP13E10-WT. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 782, 783, 784, 785, 786, and 787, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 788 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 789. In some embodiments, the antibody of the antibody drug conjugate is CP13E10-54HCv13-89LCv1.

In some embodiments, an antibody-drug conjugate provided herein binds to ASCT2. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 790 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 791. In some embodiments, the antibody of the antibody drug conjugate is KM8094a. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 792 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 793. In some embodiments, the antibody of the antibody drug conjugate is KM8094b. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 794, 795, 796, 797, 798, and 799, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 800 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 801. In some embodiments, the antibody of the antibody drug conjugate is KM4018.

In some embodiments, an antibody-drug conjugate provided herein binds to CD123. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 802, 803, 804, 805, 806, and 807, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 808 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 809. In some embodiments, the antibody of the antibody drug conjugate is h7G3. See WO 2016201065.

In some embodiments, an antibody-drug conjugate provided herein binds to GPC3. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-

H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 810, 811, 812, 813, 814, and 815, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 816 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 817. In some embodiments, the antibody of the antibody drug conjugate is hGPC3-1. See WO 2019161174.

In some embodiments, an antibody-drug conjugate provided herein binds to B6A. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 818, 819, 820, 821, 822, and 823, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 824 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 825. In some embodiments, the antibody of the antibody drug conjugate is h2A2. See PCT/US20/63390. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 826, 827, 828, 829, 830, and 831, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 832 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 833. In some embodiments, the antibody of the antibody drug conjugate is h15H3. See WO 2013/123152.

In some embodiments, an antibody-drug conjugate provided herein binds to PD-L1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 834, 835, 836, 837, 838, and 839, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 840 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 841. In some embodiments, the antibody of the antibody drug conjugate is SG-559-01. See PCT/US2020/054037.

In some embodiments, an antibody-drug conjugate provided herein binds to TIGIT. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs:

842, 843, 844, 845, 846, and 847, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 848 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 849. In some embodiments, the antibody of the antibody drug conjugate is Clone 13 (also known as ADI-23674 or mAb13). See WO 2020041541.

In some embodiments, an antibody-drug conjugate provided herein binds to STN. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 850, 851, 852, 853, 854, and 855, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 856 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 857. In some embodiments, the antibody of the antibody drug conjugate is 2G12-2B2. See WO 2017083582.

In some embodiments, an antibody-drug conjugate provided herein binds to CD33. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 858, 859, 860, 861, 862, and 863, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 864 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 865. In some embodiments, the antibody of the antibody drug conjugate is h2H12. See WO2013173496.

In some embodiments, an antibody-drug conjugate provided herein binds to NTBA (also known as CD352). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 866, 867, 868, 869, 870, and 871, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 872 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 873. In some embodiments, the antibody of the antibody drug conjugate is h20F3 HDLD. See WO 2017004330.

In some embodiments, an antibody-drug conjugate provided herein binds to BCMA. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2,

CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 874, 875, 876, 877, 878, and 879, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 880 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 881. In some embodiments, the antibody of the antibody drug conjugate is SEA-BCMA (also known as hSG16.17). See WO 2017/143069.

In some embodiments, an antibody-drug conjugate provided herein binds to Tissue Factor (also known as TF). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 882, 883, 884, 885, 886, and 887, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 888 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 889. In some embodiments, the antibody of the antibody drug conjugate is tisotumab. See WO 2010/066803 and US 9,150,658.

Table of Sequences

SEQ ID NO	Description	Sequence
1	cAC10 CDR-H1	DYYIT
2	cAC10 CDR-H2	WIYPGSGNTKYNEKFKG
3	cAC10 CDR-H3	YGNYWFAY
4	cAC10 CDR-L1	KASQSVDFDGDSYMN
5	cAC10 CDR-L2	AASNLES
6	cAC10 CDR-L3	QQSNEDPWT
7	cAC10 VH	QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKP GQGLEWIGWIYPGSGNTKY NEKFKGKATLTVDTSSTAFMQLSSLTSEDNAVYFCANYG NYWFAYWGQGTQVTVSA
8	cAC10 VL	DIVLTQSPASLAIVSLGQRATISCKASQSVDFDGDSYMNWY QQKPGQPPKVLIIAASNLES

		GIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWT FGGGTKLEIK
9	cAC10 HC	QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKP GQGLEWIGWIYPGSGNTKY NEKFKGKATLTVDTSSTAFMQLSSLTSEDNAVYFCANYG NYWFAYWGQGTQVTVSAAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPK SCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK
10	cAC10 HC v2	QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKP GQGLEWIGWIYPGSGNTKY NEKFKGKATLTVDTSSTAFMQLSSLTSEDNAVYFCANYG NYWFAYWGQGTQVTVSAAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPK SCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDE

		LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPG
11	cAC10 LC	DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWY QQKPGQPPKVLIYAASNLES GIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWT FGGGTKLEIKR TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWK VDNALQSGNSQESVTEQDS KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC
12	h1F6 VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVR QAPGQGLKWMGWINTYTGEPTY ADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDY GDYGM DYWGQGTTVTVSS
13	h1F6 VL	DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWY QQKPGQPPKLLIYLASNLES GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWT FGQGTKVEIK
14	h1F6 HC	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVR QAPGQGLKWMGWINTYTGEPTY ADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDY GDYGM DYWGQGTTVTVSSAS TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGL YSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC DKHTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNST

		YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK
15	h1F6 LC	DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWY QQKPGQPPKLLIYLASNLES GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWT FGQGTKVEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
16	TROP2 CDR-H1	NYGMN
17	TROP2 CDR-H2	WINTYTGEPTYTDDFKG
18	TROP2 CDR-H3	GGFGSSYWYFDV
19	TROP2 CDR-L1	KASQDVSIABA
20	TROP2 CDR-L2	SASYRYT
21	TROP2 CDR-L3	QQHYITPLT
22	TROP2 VH	QVQLQQSGSELKKPGASVKVSCASGYTFTNYGMNWVKQ APGQGLKWMGWINTYTGEPT YTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCARGG FGSSYWYFDVWGQGSLVTVSS
23	TROP2 VL	DIQLTQSPSSLSASVGDVRSITCKASQDVSIABAWYQQKPG KAPKLLIYSASYRYTGVP DRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAG TKVEIK
24	TROP2 CDR-H1	TAGMQ
25	TROP2 CDR-H2	WINTHSGVPKYAEDFKG
26	TROP2 CDR-H3	SGFGSSYWYFDV

27	TROP2 CDR-L1	KASQDVSTAVA
28	TROP2 CDR-L2	SASYRYT
29	TROP2 CDR-L3	QQHYITPLT
30	TROP2 VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTTAGMQWVR QAPGQGLEWMGWINTHSGVPKYAEDFKGRVTISADTSTST AYLQLSSLKSEDTAVYYCARSFGSSYWFVDVWGQGTLV TVSS
31	TROP2 VL	DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKP GKAPKLLIYSASYRYTGVPSTRFSGSGSGTDFTLTISLQPEDF AVYYCQQHYITPLTFGQGGTKLEIK
32	MICA CDR-H1	SQNIY
33	MICA CDR-H2	YIEPYNVPMYNPKFKG
34	MICA CDR-H3	SGSSNFDY
35	MICA CDR-L1	SASSISSHYLH
36	MICA CDR-L2	RTSNLAS
37	MICA CDR-L3	QQGSSLPLT
38	MICA VH	EIQLVQSGAEVKKPGASVKVSCKASGYAFTSQNIYWVRQA PGQGLEWIGYIEPYNVPMYNPKFKGRATLTVDKSTSTAY LELSSLRSEDTAVYYCARSFGSSNFDYWQGQGTLVTVSS
39	MICA VL	DIQLTQSPSSLSASVGDRVTITCSASSISSHYLHWYQQKPG KSPKLLIYRTSNLASGVPSRFSGSGSGTDYTLTISLQPEDFA TYYCQQGSSLPLTFGQGGTKVEIK
40	MICA CDR-H1	NYAMH
41	MICA CDR-H2	LIWYDGSNKFYGDsvkg
42	MICA CDR-H3	EGSGHY
43	MICA CDR-L1	RASQGISSALA
44	MICA CDR-L2	DASSLES
45	MICA CDR-L3	QQFNSYPIT

46	MICA VH	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMHWVRQ APGEGLEWVALIWYDGSNKFYGDSVKGRFTISRDN SKNTL YLQMNSLSAEDTAVYYCAREGSGHYWGQGTLVTVSS
47	MICA VL	AIQLTQSPSSLSASVGDRVITITCRASQGISSALAWYQQKPG KVPKSLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFA TYYCQQFNSYPITFGQGTRLEIK
48	MICA CDR-H1	NYAMS
49	MICA CDR-H2	YISPGGDYIYYADSVKG
50	MICA CDR-H3	DRRHYSYAMDY
51	MICA CDR-L1	RSSKSLHLSNLNTYLY
52	MICA CDR-L2	RMSNLAS
53	MICA CDR-L3	MQHLEYPFT
54	MICA VH	QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWIRQA PGKGLEWVSYISPGGDYIYYADSVKGRFTISRDN AKNSLYL QMNSLRAEDTAVYYCTTDRRHYSYAMDYWGQGTLVTV SS
55	MICA VL	DIVMTQSPLSLPVTPGEPASISCRSSKSLHLSNLNTYLYWFL QKPGQSPQILIYRMSNLASGVPDRFSGSGSGTAFTLKISRVE AEDVGVYYCMQHLEYPFTFGPGTKLEIK
56	MICA CDR-H1	TYAFH
57	MICA CDR-H2	GIVPIFGTLKYAQKFQD
58	MICA CDR-H3	AIQLEGRPFDH
59	MICA CDR-L1	RASQGITSYLA
60	MICA CDR-L2	AASALQS
61	MICA CDR-L3	QQVNRGAIT
62	MICA VH	QVQLVQSGAEVKKPGSSVRVSCRASGGSSTTYAFHWVRQ APGQGLEWMGGIVPIFGTLKYAQKFQDRVTLTADKSTGTA YMELNSLRLLDDTAVYYCARAIQLEGRPFDPHWGQGTQVTV SA

63	MICA VL	DIQLTQSPSFLSASVGDRVTITCRASQGITSYLA WYQQKPG KAPKLLIYAASALQSGVPSRFSGRGSGTEFTLTISSLPEDF ATYYCQQVNRGAAITFGHGTRLDIK
64	CD24 CDR-H1	TYAFH
65	CD24 CDR-H2	GIVPIFGTLKYAQKFQD
66	CD24 CDR-H3	AIQLEGRPFDH
67	CD24 CDR-L1	RASQGITSYLA
68	CD24 CDR-L2	AASALQS
69	CD24 CDR-L3	QQVNRGAAIT
70	CD24 VH	QVQLVQSGAEVKKPGSSVRVSCRASGGSSTTYAFHWVRQ APGQGLEWMGGIVPIFGTLKYAQKFQDRVTLTADKSTGTA YMELNSLRLLDDTAVYYCARAIQLEGRPFDHWGQGTQVTV SA
71	CD24 VL	DIQLTQSPSFLSASVGDRVTITCRASQGITSYLA WYQQKPG KAPKLLIYAASALQSGVPS RFSGRGSGTEFTLTISSLPEDFATYYCQQVNRGAAITFGHG TRLDIK
72	ITGav CDR-H1	RYTMH
73	ITGav CDR-H2	VISFDGSNKYYVDSVKG
74	ITGav CDR-H3	EARGSYAFDI
75	ITGav CDR-L1	RASQSVSSYLA
76	ITGav CDR-L2	DASNRAT
77	ITGav CDR-L3	QQRSNWPPFT
78	ITGav VH	QVQLVESGGGVVQPGRSRRLSCAASGFTFSRYTMHWVRQ APGKGLEWVAVISFDGSNKYYVDSVKGRFTISRDNSENTL YLQVNILRAEDTAVYYCAREARGSYAFDIWGQGTMTVTVSS

79	ITGav VL	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPG QAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFA VYYCQQRSNWPPFTFGPGTKVDIK
80	ITGav CDR-H1	SFWMH
81	ITGav CDR-H2	YINPRSGYTEYNEIFRD
82	ITGav CDR-H3	FLGRGAMDY
83	ITGav CDR-L1	RASQDISNYLA
84	ITGav CDR-L2	YTSKIHS
85	ITGav CDR-L3	QQGNTFPYT
86	ITGav VH	QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHVVRQ APGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAY MELSSLRSEDNAVYYCASFLGRGAMDYWGQGTTVTVSS
87	ITGav VL	DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPG KAPKLLIYYTSKIHSGVPSRFSGSGSGTDYFTTISLQPEDIA TYYCQQGNTFPYTFGGGKVEIK
88	gpA33 CDR-H1	TSSYYWG
89	gpA33 CDR-H2	TIYYNGSTYYSPSLKS
90	gpA33 CDR-H3	QGYDIKINIDV
91	gpA33 CDR-L1	RASQSVSSYLA
92	gpA33 CDR-L2	VASNRAT
93	gpA33 CDR-L3	QQRSNWPLT
94	gpA33 VH	QLQLQESGPGLVKPSETLSLTCTVSGGSISTSSYYWGWIRQP PGKGLEWIGTIYYNGSTYYSPSLKSRVSISVDTSKNQFSLKL SSVTAADTSVYYCARQGYDIKINIDVWGQGTTVTVSS
95	gpA33 VL	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPG QAPRLLIYVASNRATGIPARFSGSGSGTDFTLTISSLEPEDFA VYYCQQRSNWPLTFGGGKVEIK
96	IL1Rap CDR-H1	SSWMN
97	IL1Rap CDR-H2	RIYPGDGNTHYAQKFQG
98	IL1Rap CDR-H3	GYLDPMDY

99	IL1Rap CDR-L1	QASQGINNYLN
100	IL1Rap CDR-L2	YTSGLHA
101	IL1Rap CDR-L3	QQYSILPWT
102	IL1Rap VH	QVQLVQSGAEVKKPGSSVKVSCASGYAFTSSWMNWVRQ APGQGLEWMGRIYPGDGNTHYAQKFQGRVTLTADKSTST AYMELSSLRSED TAVYYCGEGYLDPM DYWGQGT LVT VSS
103	IL1Rap VL	DIQMTQSPSSLSASVGDRVTITCQASQGINNYLNWYQQKPG KAPKLLIHYTSLHAGVPSRFSGSGSGTDYTLTISSLEPEDV ATYYCQQYSILPWTFGGG TKVEIK
104	EpCAM CDR-H1	SYGMH
105	EpCAM CDR-H2	VISYDGSNKYYADSVKG
106	EpCAM CDR-H3	DMG
107	EpCAM CDR-L1	RTSQSISSYLN
108	EpCAM CDR-L2	WASTRES
109	EpCAM CDR-L3	QQSYDIPYT
110	EpCAM VH	EVQLLES GGGV VQPGRSLRLSCAASGFT FSSYGMHWVRQA PGKGLEWVAVISYDGSNKYYADSVKGRFTISRDN SKNTLY LQMNSLRAEDTAVYYCAKDMGWGSGWRPYYYYGMDVW GQGTTVT VSS
111	EpCAM VL	ELQMTQSPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPG QPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQPEDS ATYYCQQSYDIPYTFGQGT KLEIK
112	EpCAM CDR-H1	NYWMS
113	EpCAM CDR-H2	NIKQDGSEKFYADSVKG
114	EpCAM CDR-H3	VGPSWEQDY
115	EpCAM CDR-L1	TGSSSNIGSYYG VH
116	EpCAM CDR-L2	SDTNRPS
117	EpCAM CDR-L3	QSYDKGFGHRV
118	EpCAM VH	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMSWVRQ APGKGLEWVANIKQDGSEKFYADSVKGRFTISRDN AKNSL

		YLQMNSLRAEDTAVYYCARVGPSWEQDYWGQGTLVTVS A
119	EpCAM VL	QSVLTQPPSVSGAPGQRTISCTGSSSNIGSYYGVHWYQQL PGTAPKLLIYSDTNRPSGVPDRFSGSKSGTSASLAITGLQAE DEADYYCQSYD
120	EpCAM CDR-H1	SYAIS
121	EpCAM CDR-H2	GIPIFGTANYAQKFQG
122	EpCAM CDR-H3	GLLWNY
123	EpCAM CDR-L1	RASQSVSSNLA
124	EpCAM CDR-L2	GASTTAS
125	EpCAM CDR-L3	QQYNNWPPAYT
126	EpCAM VH	QVQLVQSGAEVKKPGSSVKVSCASGGTFSSYAISWVRQA PGQGLEWMGGIPIFGTANYAQKFQGRVTITADESTSTAYM ELSSLRSED TAVYYCARGLLWNYWGQGTLVTVSS
127	EpCAM VL	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPG QAPRLIY GASTTASGIPARFSASGSGTDFLTISLQSEDF A VYYCQQYNNWPPAYTFGQGTKLEIK
128	EpCAM CDR-H1	NYGMN
129	EpCAM CDR-H2	WINTYTGEPTYGEDFKG
130	EpCAM CDR-H3	FGNYVDY
131	EpCAM CDR-L1	RSSKNLLHSNGITYLY
132	EpCAM CDR-L2	QMSNLAS
133	EpCAM CDR-L3	AQNLEIPRT
134	EpCAM VH	QVQLVQSGPEVKKPGASVKVSCASGYTFTNYGMNWVRQ APGQGLEWMGWINTYTGEPTYGEDFKGRFAFSLDTSASTA YMELSSLRSED TAVYFCARFGNYVDYWGQGSLVTVSS
135	EpCAM VL	DIVMTQSPLSLPVTPGEPASISCRSSKNLLHSNGITYLYWYL QKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLKISRVE AEDVGVYYCAQNLEIPRTFGQGTKVEIK
136	EpCAM CDR-H1	KYGMN

137	EpCAM CDR-H2	WINTYTEPTYGDDFKG
138	EpCAM CDR-H3	FGSAVDY
139	EpCAM CDR-L1	RSSKSLHLSNGITYLY
140	EpCAM CDR-L2	QMSNRAS
141	EpCAM CDR-L3	AQNLELPRT
142	EpCAM VH	QIQLVQSGPEVKKPGESVKISCKASGYTFTKYGMNWVKQA PGQGLKWMGWINTYTEPTYGDDFKGRFTFTLDTSTSTAY LEISLRS EDTATYFCARFGSAVDYWGQGTLVTVSS
143	EpCAM VL	DIVMTQSALSNPVTLGESGSISCRSSKSLHLSNGITYLYWYL QKPGQSPQLLIYQMSNRASGVPDRFSSSGSGTDFTLKISRVE AEDVGVYYCAQNLELPRTFGQGTKLEMKR
144	EpCAM CDR-H1	DYSMH
145	EpCAM CDR-H2	WINTETGEPTYADDFKG
146	EpCAM CDR-H3	TAVY
147	EpCAM CDR-L1	RASQEISVSLS
148	EpCAM CDR-L2	ATSTLDS
149	EpCAM CDR-L3	LQYASYPWT
150	EpCAM VH	QVKLQESGPELKKPGETVKISCKASGYTFTDYSMHWVKQA PGKGLKWMGWINTETGEPTYADDFKGRFAFSLETSASTAY LQINN LKNEDTATYFCARTAVYWGQGTTVTVSS
151	EpCAM VL	DIQMTQSPSSLSASLGERVSLTCRASQEISVSLSWLQQEPDG TIKRLIYATSTLDSGVPKRFSGRSGSDYSLTISSLESEDFVD YYCLQYASYPWTFGGGTKLEIKR
152	CD352 CDR-H1	NYGMN
153	CD352 CDR-H2	WINTYSGEPRYADDFKG
154	CD352 CDR-H3	DYGRWYFDV
155	CD352 CDR-L1	RASSSVSHMH
156	CD352 CDR-L2	ATSNLAS
157	CD352 CDR-L3	QQWSSTPRT

158	CD352 VH	QIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMNWVRQ APGQDLKWMGWINTYSGEPRYADDFKGRFVFLDKSVNT AYLQISSLKAEDTAVYYCARDYGRWYFDVWGQGTTVTVS S
159	CD352 VL	QIVLSQSPATLSLSPGERATMSCRASSSVSHMHQYQQKPG QAPRPWIYATSNLASGVPARFSGSGSGTDYTLTISSLEPEDF AVYYCQQWSSTPRTFGGGTKVEIKR
160	CS1 CDR-H1	RYWMS
161	CS1 CDR-H2	EINPDSSTINYAPSLKD
162	CS1 CDR-H3	PDGNYWYFDV
163	CS1 CDR-L1	KASQDVGIAVA
164	CS1 CDR-L2	WASTRHT
165	CS1 CDR-L3	QQYSSYPYT
166	CS1 VH	EVQLVESGGGLVQPGGSLRLSCAASGFDTSRYWMSWVRQ APGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNANKNSLYL QMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS
167	CS1 VL	DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKP GKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISLQPED VATYYCQQYSSYPYTFGQGGTKVEIKR
168	CD38 CDR-H1	SFAMS
169	CD38 CDR-H2	AISGSGGGTTYADSVKG
170	CD38 CDR-H3	DKILWFGPEVFDY
171	CD38 CDR-L1	RASQSVSSYLA
172	CD38 CDR-L2	DASNRAT
173	CD38 CDR-L3	QQRSNWPPT
174	CD38 VH	EVQLLES GGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQA PGKGLEWVSAISGSGGGTTYADSVKGRFTISRDNANKNTLYL QMNSLRAEDTAVYFCAKDKILWFGPEVFDYWGGQTLVTV SS

175	CD38 VL	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPG QAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSELPEDFA VYYCQQRSNWPPTFGQGTKVEIKR
176	CD25 CDR-H1	SYRMH
177	CD25 CDR-H2	YINPSTGYTEYNQKFKD
178	CD25 CDR-H3	GGGVFDY
179	CD25 CDR-L1	SASSSISYMH
180	CD25 CDR-L2	TTSNLAS
181	CD25 CDR-L3	HQRSTYPLT
182	CD25 VH	QVQLVQSGAEVKKPGSSVKVSCASGYTFTSYRMHWVRQ APGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAY MELSSLRSEDNAVYYCARGGGVFDYWGQGTLVTVSS
183	CD25 VL	DIQMTQSPSTLSASVGDRVTITCSASSSISYMHYQQKPGK APKLLIYTTSNLASGVPARFSGSGSGTEFTLTISLQPDDEFAT YYCHQRSTYPLTFGQGTKVEVK
184	ADAM9 CDR-H1	SYWM
185	ADAM9 CDR-H2	EIIPINGHTNYNEKFKS
186	ADAM9 CDR-H3	GGYYYYGSRDYFDY
187	ADAM9 CDR-L1	KASQSVDYDGDSYMN
188	ADAM9 CDR-L2	AASDLES
189	ADAM9 CDR-L3	QQSHEDPFT
190	ADAM9 VH	QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVK QRPQGQGLEWIGEIIIPINGHTNYNEKFKSKATLTLDKSSSTAY MQLSSLASEDSAVYYCARGGGYYYYGSRDYFDYWGQGTTL TVSS
191	ADAM9 VL	DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWY QQIPGQPPKLLIYAASDLESGIPARFSGSGSGTDFTLNHPVE EEDAATYYCQQSHEDPFTFGGGTKLEIK
192	ADAM9 CDR-H1	SYWM

193	ADAM9 CDR-H2	EIIPIFGHTNYNEKFKS
194	ADAM9 CDR-H3	GGYYYYPRQGFLDY
195	ADAM9 CDR-L1	KASQSVDYDSGDSYMN
196	ADAM9 CDR-L2	AASDLES
197	ADAM9 CDR-L3	QQSHEDPFT
198	ADAM9 VH	EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYWMHWVRQ APGKGLEWVGEIPIFGHTNYNEKFKSRFTISLDNSKNTLYL QMGSRAEDTAVYYCARGGGYYYYPRQGFLDYWGQGTTV TVSS
199	ADAM9 VL	DIVMTQSPDSLAVSLGERATISCKASQSVDYSGDSYMNWY QQKPGQPPKLLIYAASDLESGIPARFSGSGSGTDFTLTISSE PEDFATYYCQQSHEDPFTFGQGTKLEIK
200	CD59 CDR-H1	YGMN
201	CD59 CDR-H2	YISSSSSTIYADSVKG
202	CD59 CDR-H3	GPGMDV
203	CD59 CDR-L1	KSSQSVLYSSNNKNYLA
204	CD59 CDR-L2	WASTRES
205	CD59 CDR-L3	QQYYSTPQLT
206	CD59 VH	QVQLQQSGGGVVQPGRSLGLSCAASFTFSSYGMNWVRQA PGKGLEWVSYISSSSSTIYADSVKGRFTISRDNKNTLYLQM NSLRAEDTAVYYCARGPGMDVWGQGTTVTVS
207	CD59 VL	DIVLTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAW YQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTPAISS LQAEDVAVYYCQQYYSTPQLTFGGGTKVDIK
208	CD19 CDR-H1	TSGMGVG
209	CD19 CDR-H2	HIWWDDDKRYNPALKS
210	CD19 CDR-H3	MELWSYYFDY
211	CD19 CDR-L1	SASSSVSYMH
212	CD19 CDR-L2	DTSKLAS

213	CD19 CDR-L3	FQGSVYPFT
214	CD19 VH	QVQLQESGPGLVKPSQTLSTCTVSGGSISTSGMGVGVWIRQ HPGKGLEWIGHIWWDDDKRYNPALKSRVTISVDTSKNQFS LKLSSVTAADTAVYYCARMELWSYFYFDYWGQGTLTVSS
215	CD19 VL	EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQ APRLLIYDTSKLGIPARFSGSGSGTDFTLTISSLEPEDVAV YYCFQGSVYPFTFGQGTKLEIKR
216	CD70 CDR-H1	NYGMN
217	CD70 CDR-H2	WINTYTGEPTYADAFKG
218	CD70 CDR-H3	DYGDYGM DY
219	CD70 CDR-L1	RASKSVSTSGYSFMH
220	CD70 CDR-L2	LASNLES
221	CD70 CDR-L3	QHSREVPWT
222	CD70 VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVR QAPGQGLKWMGWINTYTGEPTYADAFKGRVTMTRDTSIS TAYMELSRRLRSDDTAVYYCARDYGDYGM DYWGQGTTVT VSS
223	CD70 VL	DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWY QQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSL QAEDVAVYYCQHSREVPWTFGQGTKVEIK
224	B7H4 CDR-H1	SGYSWH
225	B7H4 CDR-H2	YIHSSGSTNYPNPSLKS
226	B7H4 CDR-H3	YDDYFEY
227	B7H4 CDR-L1	KASQNVGFNVA
228	B7H4 CDR-L2	SASYRYS
229	B7H4 CDR-L3	QQYNWYPFT
230	B7H4 VH	EVQLQESGPGLVKPSETLSLTCAVTGYSITSGYSWHWIRQF PGNGLEWMGYIHSSGSTNYPNPSLKSRLISRDTSKNQFFLKL SSVTAADTAVYYCAGYDDYFEYWGQGTTVTVSS

231	B7H4 VL	DIQMTQSPSSLSASVGDRVTITCKASQNVGFNVAWYQQKP GKSPKALIYSASYRYSRVSRFSGSGSGTDFTLTISLQPEDF AEYFCQQYNWYPFTFGQGTKLEIK
232	CD138 CDR-H1	NYWIE
233	CD138 CDR-H2	EILPGTGRTIYNEKFKG
234	CD138 CDR-H3	RDYYGNFYAMDY
235	CD138 CDR-L1	SASQGINNYLN
236	CD138 CDR-L2	YTSTLQS
237	CD138 CDR-L3	QQYSKLPRT
238	CD138 VH	QVQLQQSGSELMMPGASVKISCKATGYTFSNYWIEWVKQ RPGHGLEWIGEILPGTGRTIY NEKFKGKATFTADISSNTVQMQLSSLTSEDSAVYYCARRD YYGNFYAMDYWGQGTSTVTVSS
239	CD138 VL	DIQMTQSTSSLSASLGDRVTISCSASQGINNYLNWYQQKPD GTVELLIYYTSTLQSGVP SRFSGSGSGTDYSLTISNLEPEDIGTYYCQQYSKLPRTFGGG TKLEIK
240	CD166 CDR-H1	TYGMGVG
241	CD166 CDR-H2	NIWWSSEDKHYSPSLKS
242	CD166 CDR-H3	IDYGNDYAFTY
243	CD166 CDR-L1	RSSKSLLHSNGITYLY
244	CD166 CDR-L2	QMSNLAS
245	CD166 CDR-L3	AQNLELPYT
246	CD166 VH	QITLKESGPTLVKPTQTLTLCTFSGFSLSTYGMGVGWIRQP PGKALEWLANIWWSEDKHYSPSLKSRLTITKDTSKNQVVL TITNVDPVDTATYYCVQIDYGNDYAFTYWGQGTSLTVTVSS
247	CD166 VL	DIVMTQSPLSLPVTGPGEPAISCRSSKSLLHSNGITYLYWYL QKPGQSPQLLIYQMSNLASGVDPDRFSGSGSGTDFTLKISRVE AEDVGVYYCAQNLELPYTFGQGTKLEIK
248	CD51 CDR-H1	RYTMH

249	CD51 CDR-H2	VISFDGSNKYYVDSVKG
250	CD51 CDR-H3	EARGSYAFDI
251	CD51 CDR-L1	RASQSVSSYLA
252	CD51 CDR-L2	DASNRAT
253	CD51 CDR-L3	QQRSNWPPFT
254	CD51 VH	QVQLVESGGGVVQPGRSRRLSCAASGFTFSRYTMHWVRQ APGKGLEWVAVISFDGSNKYYVDSVKGRFTISRDNSENTL YLQVNILRAEDTAVYYCAREARGSYAFDIWGQGTMVTVSS
255	CD51 VL	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPG QAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFA VYYCQQRSNWPPFTFGPGTKVDIK
256	CD56 CDR-H1	SFGMH
257	CD56 CDR-H2	YISSGSFTIYYADSVKG
258	CD56 CDR-H3	MRKGYAMDY
259	CD56 CDR-L1	RSSQIIIHSDGNTYLE
260	CD56 CDR-L2	KVSNRFS
261	CD56 CDR-L3	FQGSHVPHT
262	CD56 VH	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQA PGKGLEWVAYISSGSFTIYYADSVKGRFTISRDN SKNTLYL QMNSLRAEDTAVYYCARMRKGYAMDYWGQGT LVTVSS
263	CD56 VL	DVVMTQSPLSLPVTLGQPASISCRSSQIIIHSDGNTYLEWFQ QRPGQSPRRLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVE AEDVGVYYCFQGSHVPHTFGQGTKVEIK
264	CD74 CDR-H1	NYGVN
265	CD74 CDR-H2	WINPNTGEPTFDDDFKG
266	CD74 CDR-H3	SRGKNEAWFAY
267	CD74 CDR-L1	RSSQSLVHRNGNTYLH
268	CD74 CDR-L2	TVSNRFS
269	CD74 CDR-L3	SQSSHVPPT

270	CD74 VH	QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGVNWIQK APGQGLQWMGWINPNTGEPTFDDDFKGRFAFSLDTSVSTA YLQISSLKADDTAVYFCRSRGKNEAWFAYWGQGTLVTVS S
271	CD74 VL	DIQLTQSPLSLPVTLGQPASISCRSSQSLVHRNGNTYLHWFQ QRPGQSPRLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRVE AEDVGVYFCSQSSHVPPTFGAGTRLEIK
272	CEACAM5 CDR- H1	TYWMS
273	CEACAM5 CDR- H2	EIHPDSSSTINYAPSLKD
274	CEACAM5 CDR- H3	LYFGFPWFAY
275	CEACAM5 CDR- L1	KASQDVGTSVA
276	CEACAM5 CDR- L2	WTSTRHT
277	CEACAM5 CDR- L3	QQYSLYRS
278	CEACAM5 VH	EVQLVESGGGVVQPGRSLRLSCSASGFDFTTYWMSWVRQ APGKGLEWIGEIHDPDSSSTINYAPSLKDRFTISRDNKNTLFL QMDSLRLPEDTGVYFCASLYFGFPWFAYWGQGTPVTVSS
279	CEACAM5 VL	DIQLTQSPSSLSASVGDRVTITCKASQDVGTSVAWYQQKPG KAPKLLIYWTSTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIA TYYCQQYSLYRSFGQGGTKVEIK
280	CanAg CDR-H1	YYGMN
281	CanAg CDR-H2	WIDTTTGEPTYAQKFQG
282	CanAg CDR-H3	RGPYNWYFDV
283	CanAg CDR-L1	RSSKSLLHSNGNTYLY
284	CanAg CDR-L2	RMSNLVS

285	CanAg CDR-L3	LQHLEYPFT
286	CanAg VH	QVQLVQSGAEVKKPGETVKISCKASDYFTFTYYGMNWVKQ APGQGLKWMGWIDTTTGEPTYAQKFQGRIAFSLETSASTA YLQIKSLKSEDTATYFCARRGPYNWYFDVWGQGTTVTVSS
287	CanAg VL	DIVMTQSPLSVPVTPGEPVSISCRSSKSLHNSNGNTYLYWFL QRPQGSPQLLIYRMSNLVSGVPDRFSGSGSGTAFTLRISRVE AEDVGVIYYCLQHLEYPFTFGPGTKLELK
288	DLL-3 CDR-H1	NYGMN
289	DLL-3 CDR-H2	WINTYTGEPTYADDFKG
290	DLL-3 CDR-H3	IGDSSPSDY
291	DLL-3 CDR-L1	KASQSVSNDVV
292	DLL-3 CDR-L2	YASNRYT
293	DLL-3 CDR-L3	QQDYTSPWT
294	DLL-3 VH	QVQLVQSGAEVKKPGASVKVSCKASGYFTFTNYGMNWVR QAPGQGLEWMGWINTYTGEPTY ADDFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARIG DSSPSDYWGQGTLVTVSS
295	DLL-3 VL	EIVMTQSPATLSVSPGERATLSCKASQSVSNDVVWYQQKP GQAPRLLIYYASNRYTGIPA RFSGSGSGTEFTLTISLQSEDFAVYYCQQDYTSPWTFGQG TKLEIK
296	DPEP-3 CDR-H1	SYWIE
297	DPEP-3 CDR-H2	EILPGSGNTYYNERFKD
298	DPEP-3 CDR-H3	RAAAYYSNPEWFAY
299	DPEP-3 CDR-L1	TASSSVNSFY LH
300	DPEP-3 CDR-L2	STSNLAS
301	DPEP-3 CDR-L3	HQYHRSPYT
302	DPEP-3 VH	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYWIEWVRQ APGQGLEWMGEILPGSGNTYYNERFKDRVTITADESTSTA

		YMELSSLRSEDТАVYYCARRAAAYYSNPEWFAYWGQGTЛ VTVSS
303	DPEP-3 VL	EIVLTQSPATLSLSPGERATLSCTASSSVNSFYЛHWYQQKPG LAPRLLIYSTSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFA VYYCHQYHRSPYTFGQGГKLEIK
304	EGFR CDR-H1	SYWMQ
305	EGFR CDR-H2	TIYPGDGDTTYTQKFQG
306	EGFR CDR-H3	YDAPGYAMDY
307	EGFR CDR-L1	RASQDINNYLA
308	EGFR CDR-L2	YTSTLHP
309	EGFR CDR-L3	LQYDNLLYT
310	EGFR VH	QVQLVQSGAEVAKPGASVKLSCKASGYTFTSYWMQWVK QRPQGQGLECIGTIYPGDGDTTYTQKFQGKATLTADKSSSTA YMQЛSSLRSEDSAVYYCARYDAPGYAMDYWGQGTЛVTV SS
311	EGFR VL	DIQMTQSPSSLSASVGDRVTITCRASQDINNYLAWYQHKPG KGPKLLIHYTSTLHPGIPSRFSGSGSGRDYSFSISSLEPEDIA TYYCLQYDNLLYTFGQGГKLEIK
312	EGFR CDR-H1	RDFAWN
313	EGFR CDR-H2	YISYNGNTRYQPSLKS
314	EGFR CDR-H3	ASRGFPY
315	EGFR CDR-L1	HSSQDINSNIG
316	EGFR CDR-L2	HGTNLDD
317	EGFR CDR-L3	VQYAQFPWT
318	EGFR VH	EVQLQESGPGLVKPSQTLSTCTVSGYSISRDFAWNWIRQP PGKGLEWMGYISYNGNTRYQPSLKSRTISRDTSKNQFFLK LNSVTAADTATYYCVTASRGFPYWGQGTЛVTVSS
319	EGFR VL	DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPG KSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDF ATYYCVQYAQFPWTFGGGГKLEIK

320	EGFR CDR-H1	RDFAWN
321	EGFR CDR-H2	YISYNGNTRYQPSLKS
322	EGFR CDR-H3	ASRGFPY
323	EGFR CDR-L1	HSSQDINSNIG
324	EGFR CDR-L2	HGTNLDD
325	EGFR CDR-L3	VQYAQFPWT
326	EGFR VH	EVQLQESGPGLVKPSQTLSTCTVSGYSISRDFAWNWIRQP PGKGLEWMGYISYNGNTRYQPSLKSRLTISRDTSKNQFFLK LNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS
327	EGFR VL	DIQMTQSPSSMSVSVGDRVITICHSSQDINSNIGWLQKPG KSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDF ATYYCVQYAQFPWTFGGGTKLEIK
328	EGFR CDR-H1	NYGVH
329	EGFR CDR-H2	VIWSGGNTDYNTPTFS
330	EGFR CDR-H3	ALTYDYEFAY
331	EGFR CDR-L1	RASQSIGTNIH
332	EGFR CDR-L2	YASESIS
333	EGFR CDR-L3	QQNNNWPTT
334	EGFR VH	QVQLKQSGPGLVQPSQSLSTCTVSGFSLTNYGVHWVRQSP GKGLEWLGVWSGGNTDYNTPTFSRLSINKDNSKSKQVFFK MNSLQSNDAIYYCARALTYDYEFAYWGQGTLVTVSA
335	EGFR VL	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNG SPRLLIK YASESISGIPSRFSGSGSGTDFTLSINSVESEDIADY YCQQNNNWPTTFGAGTKLELK
336	FRa CDR-H1	GYFMN
337	FRa CDR-H2	RIHPYDGDTFYNQKFQG
338	FRa CDR-H3	YDGSRAMDY
339	FRa CDR-L1	KASQSVSFAGTSLMH
340	FRa CDR-L2	RASNLEA
341	FRa CDR-L3	QQSREYPYT

342	FRa VH	QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQ SPGQSLEWIGRIHPYDGDIFY NQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYD GSRAMDYWGQGTTVTVSS
343	FRa VL	DIVLTQSPLSLAVSLGQPAISCKASQSVSFAGTSLMHWYH QKPGQQPRLLIYRASNLEAGVPDRFSGSGSKTDFTLTISPVE AEDAATYYCQQSREYPYTFGGGGTKLEIK
344	FRa CDR-H1	GYGLS
345	FRa CDR-H2	MISSGGSYTTYADSVKG
346	FRa CDR-H3	HGDDPAWFAY
347	FRa CDR-L1	SVSSSISSNNLH
348	FRa CDR-L2	GTSNLAS
349	FRa CDR-L3	QQWSSYPMYT
350	FRa VH	EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQA PGKGLEWVAMISSGGSYTTY ADSVKGRFAISRDNANKNTLFLQMDSLRLPEDTGVYFCARHG DDPAWFAYWGQGPVTVSS
351	FRa VL	DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPG KAPKPWIYGTSNLASGVPSRFSGSGSGTDYFTISLQPEDI ATYYCQQWSSYPMYTFGQGTKVEIK
352	MUC-1 CDR-H1	NYWMN
353	MUC-1 CDR-H2	EIRLKSNNYTTHYAESVKG
354	MUC-1 CDR-H3	HYYFDY
355	MUC-1 CDR-L1	RSSKSLHSNGITYFF
356	MUC-1 CDR-L2	QMSNLAS
357	MUC-1 CDR-L3	AQNLELPPT
358	MUC-1 VH	EVQLVESGGGLVQPGGSMRLSCVASGFPSNYWMNWVRQ APKGGLEWVGEIRLKSNNYTTHYAESVKGRFTISRDDSKNS LYLQMNSLKTEDTAVYYCTRHYYFDYWGQGLTVTVSS

359	MUC-1 VL	DIVMTQSPLSNPVTGPGEPAISCRSSKSLHNSNGITYFFWYL QKPGQSPQLLIYQMSNLA SGVPDRFSGSGSGTDFTLRISRVE AEDVGVVYYCAQNLELPPTFGQGTKVEIK
360	Mesothelin CDR-H1	SYWIG
361	Mesothelin CDR-H2	IIDPGDSRTRYSPSFQG
362	Mesothelin CDR-H3	GQLYGGTYMDG
363	Mesothelin CDR-L1	TGTSSDIGGYNSVS
364	Mesothelin CDR-L2	GVNNRPS
365	Mesothelin CDR-L3	SSYDIESATPV
366	Mesothelin VH	QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQA PGKGLEWMGIIDPGDSRTRYSPSFQGGVTISADKSISTAYLQ WSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS
367	Mesothelin VL	DIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHP GKAPKLMYGVNNRPSGV SNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVF GGGTKLTVL
368	ROR-1 CDR-H1	AYNIH
369	ROR-1 CDR-H2	SFDPYDGGSSYNQKFKD
370	ROR-1 CDR-H3	GWYYFDY
371	ROR-1 CDR-L1	RASKSISKYLA
372	ROR-1 CDR-L2	SGSTLQS
373	ROR-1 CDR-L3	QQHDESPYT
374	ROR-1 VH	QVQLQESGPGLVKPSQTLSTCTVSGYAFTAYNIHWVRQA PGQGLEWMGSFDPYDGGSSYNQKFKDRLTISKDTSKNQVV LTMTNMDPVDATATYYCARGWYYFDYWGHGTLVTVSS
375	ROR-1 VL	DIVMTQTPLSLPVTGPGEPAISCRASKSISKYLAWYQQKPGQ APRLLIYSGSTLQSGIPRFSGSGYGTDFTLTINNIESEDAAY YFCQQHDESPYTFGEGTKVEIK
376	B7H4 CDR-H1	GSIKSGSYWYG
377	B7H4 CDR-H2	NIYYSGSTYYNPSLRS

378	B7H4 CDR-H3	AREGSYPNQFDP
379	B7H4 CDR-L1	RASQSVSSNLA
380	B7H4 CDR-L2	GASTRAT
381	B7H4 CDR-L3	QQYHSFPFT
382	B7H4 VH	QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYWGWIRQ PPGKGLEWIGNIYYSGSTY YNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREG SYPNQFDPWGQGTLTVSS
383	B7H4 VL	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWEYQQKPG QAPRLLIYGASTRATGIPA RFGSGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGT KVEIK
384	B7-H3 CDR-H1	SFGMH
385	B7-H3 CDR-H2	YISSDSSAIYY
386	B7-H3 CDR-H3	GRENIYYGSRLD
387	B7-H3 CDR-L1	KASQNVD
388	B7-H3 CDR-L2	SASYRYSGVPD
389	B7-H3 CDR-L3	QQYNNYPFTFGS
390	B7-H3 VH	DVQLVESGGGLVQPGGSRKLSAASGFTFSSFGMHWVRQ APEKGLEWVAYISSDSSAIYY ADTVKGRFTISRDNPKNTLFLQMTSLRSEDAMYYCGRGR ENIYYGSRLDYWGQGTTTLTVSS
391	B7-H3 VL	DIAMTQSQKFMSTSVGDRVSVTCKASQNVDTNVAWEYQQK PGQSPKALIYSASYRYSGVPD RFTGSGSGTDFTLTINNVSQSEDLAEYFCQQYNNYPFTFGSG TKLEIK
392	B7-H3 CDR-H1	SYWMQWVRQA
393	B7-H3 CDR-H2	TIYPGDGDTRY
394	B7-H3 CDR-H3	RGIPRLWYFDVM
395	B7-H3 CDR-L1	ITCRASQDIS

396	B7-H3 CDR-L2	YTSRLHSGVPS
397	B7-H3 CDR-L3	QQGNTLPPFTGG
398	B7-H3 VH	DVQLVESGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQ APEKGLEWVAYISSDSSAIYY ADTVKGRFTISRDNPKNTLFLQMTSLRSEDAMYYCGRGR ENIYYGSRLDYWGQGTTTLTVSS
399	B7-H3 VL	DIAMTQSQKFMSTSVGDRVSVTCKASQNVDTNVAWYQQK PGQSPKALIYSASYRYSVGP RFTGSGSGTDFTLTINNVSQSEDLAEYFCQQYNNYPFTFGSG TKLEIK
400	B7-H3 CDR-H1	SYGMSWVRQA
401	B7-H3 CDR-H2	INSGGSNTYY
402	B7-H3 CDR-H3	HDGGAMDYW
403	B7-H3 CDR-L1	ITCRASESIYSYLA
404	B7-H3 CDR-L2	NTKTLPE
405	B7-H3 CDR-L3	HHYGTTPWTFG
406	B7-H3 VH	EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWVRQA PGKGLEWVATINSGGSNTYY PDSLKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCARHD GGAMDYWGQGTTTVTVSS
407	B7-H3 VL	DIQMTQSPSSLSASVGDRVTITCRASESIYSYLAWYQQKPG KAPKLLVYNTKTLPEGVPSRFSGSGSGTDFTLTISLQPEDF ATYYCQHHYGTTPWTFGQGTTRLEIK
408	B7-H3 CDR-H1	SFGMHWVRQA
409	B7-H3 CDR-H2	ISSGSGTIYYADTVKGRFTI
410	B7-H3 CDR-H3	HGYRYEGFDYWG
411	B7-H3 CDR-L1	ITCKASQNVDTNVA
412	B7-H3 CDR-L2	SASYRYSVPS
413	B7-H3 CDR-L3	QQYNNYPFTFGQ

414	B7-H3 VH	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQA PGKGLEWVAYISSGSGTIY YADTVKGRFTISRDNANKNSLYLQMNSLRAEDTAVYYCAR HGYRYEGFDYWGGQTITVTVSS
415	B7-H3 VL	DIQMTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKP GKAPKALIYSASYRYSQVPSRFSGSGSGTDFTLTISLQPED FAEYFCQQYNNYPFTFGQGTKLEIK
416	B7-H3 CDR-H1	NYVMH
417	B7-H3 CDR-H2	YINPYNDDVKYNEKFKG
418	B7-H3 CDR-H3	WGYYGSPLYFFDY
419	B7-H3 CDR-L1	RASSRLIYMH
420	B7-H3 CDR-L2	ATSNLAS
421	B7-H3 CDR-L3	QQWNSNPPT
422	B7-H3 VH	EVQLQQSGPELVKPGASVKMSCASGYTFTNYVMHWVKQ KPGQGLEWIGYINPYNDDVKYNEKFKGKATQTSKSSSTA YMESSLTSEDSAVYYCARWGYYGSPLYFFDYWGQGTTL TVSS
423	B7-H3 VL	QIVLSQSPTILSASPGEKVTMTCRASSRLIYMHYQQKPGS SPKPWIYATSNLASGVPAR FSGSGSGTSYSLTISRVEAEDAATYYCQQWNSNPPTFGTGT KLELK
424	B7-H3 CDR-H1	NYVMH
425	B7-H3 CDR-H2	YINPYNDDVKYNEKFKG
426	B7-H3 CDR-H3	WGYYGSPLYFFDY
427	B7-H3 CDR-L1	RASSRLIYMH
428	B7-H3 CDR-L2	ATSNLAS
429	B7-H3 CDR-L3	QQWNSNPPT
430	B7-H3 VH	QVQLVQSGAEVKKPGSSVKVSCASGYTFTNYVMHWVRQ APGQGLEWMGYINPYNDDVKYNE

		KFKGRVTITADESTSTAYMELSSLRSEDNAVYYCARWGY GSPLYFYFDYWGGTLTVSS
431	B7-H3 VL	EIVLTQSPATLSLSPGERATLSCRASSRLIYMHYQQKPGQ APRPLIYATSNLASGIPARFSGSGSGTDFTLTISSEPEDFAV YYCQQWNSNPPTFGQGTKVEIK
432	B7-H3 CDR-H1	GYSFTSYTIH
433	B7-H3 CDR-H2	YINPNSRNTDYAQKFQG
434	B7-H3 CDR-H3	YSGSTPYWYFDV
435	B7-H3 CDR-L1	RASSSVSYMN
436	B7-H3 CDR-L2	ATSNLAS
437	B7-H3 CDR-L3	QQWSSNPLT
438	B7-H3 VH	EVQLVQSGAEVKKPGSSVKVSCKASGYSFTSYTIHWVRQA PGQGLEWMGYINPNSRNTDYAQKFQGRVTLTADKSTSTA YMELSSLRSEDNAVYYCARYSGSTPYWYFDVWGQGTTVT VSS
439	B7-H3 VL	DIQMTQSPSSLSASVGDRVTITCKASQNVGFNVAWYQQK GKSPKALIYSASYRYSYGVPSRFSGSGSGTDFTLTISLQPEDF AEYFCQQYNWYPPTFGQGTKLEIK
440	B7-H3 CDR-H1	GYTFSSYWMH
441	B7-H3 CDR-H2	LIHPDSGSTNYNEMFKN
442	B7-H3 CDR-H3	GGRLYFD
443	B7-H3 CDR-L1	RSSQSLVHSNGDTYLR
444	B7-H3 CDR-L2	KVSNRFS
445	B7-H3 CDR-L3	SQSTHVPYT
446	B7-H3 VH	EVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYWMHWVRQ APGQGLEWIGLIHPDSGSTNYNEMFKNRATLTVDRSTSTAY VELSSLRSEDNAVYFCAGGGRLYFDYWGGQTTVTVSS
447	B7-H3 VL	DVVMQTQSPSLPVTPGEPASISCRSSQSLVHSNGDTYLRWY LQKPGQSPQLLIYKVSNRFSYGVPSRFSGSGSGTDFTLKISRV EAEDVGVYYCSQSTHVPYTFGGGKVEIK

448	B7-H3 CDR-H1	GYTFSSYWMH
449	B7-H3 CDR-H2	LIHPESGSTNYNEMFKN
450	B7-H3 CDR-H3	GGRLYFDY
451	B7-H3 CDR-L1	RSSQSLVHSNQDTYLR
452	B7-H3 CDR-L2	KVSNRFS
453	B7-H3 CDR-L3	SQSTHVPYT
454	B7-H3 VH	EVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYWMHWVRQ APGQGLEWIGLIHPESGSTNY NEMFKNRATLTVDRSTSTAYMELSSLRSEDVAVYYCAGGG RLYFDYWGQGTTVTVSS
455	B7-H3 VL	DIVMTQSPLSLPVTPGEPASISCRSSQSLVHSNQDTYLRWYL QKPGQSPQLLIYKVSNR SGVPDRFSGSGSGTDFTLKKISRVEAEDVGVYYCSQSTHVP YTFGGGTKVEIK
456	B7-H3 CDR-H1	TGYSITSGYSWH
457	B7-H3 CDR-H2	YIHSSGSTNYNPSLKS
458	B7-H3 CDR-H3	YDDYFEY
459	B7-H3 CDR-L1	KASQNVGFNVAV
460	B7-H3 CDR-L2	SASYRYS
461	B7-H3 CDR-L3	QQYNWYPFT
462	B7-H3 VH	EVQLQESGPGLVKPSSETLSLTCAVTGYSITSGYSWHWIRQF PGNGLEWMGYIHSSGSTNY NPSLKSRLISIRDTSKNQFFLKLSSVTAADTAVYYCAGYDD YFEYWGQGTTVTVSS
463	B7-H3 VL	DIQMTQSPSSLSASVGDRVTITCKASQNVGGFNVAVWYQQK PGKSPKALIYSASYRYS PSRFSGSGSGTDFTLTISLQPEDFAEYFCQQYNWYPFTFGQ GTKLEIK
464	B7-H3 CDR-H1	NYDIN
465	B7-H3 CDR-H2	WIGWIFPGDDSTQYNEKFKG

466	B7-H3 CDR-H3	QTTGTWFAY
467	B7-H3 CDR-L1	RASQSIDYLY
468	B7-H3 CDR-L2	YASQIS
469	B7-H3 CDR-L3	CQNGHSFPL
470	B7-H3 VH	QVQLVQSGAEVVKPGASVKLSCKTSGYTFTNYDINWVRQ RPGQGLEWIGWIFPGDDSTQY NEKFKGKATLTDTSTSTAYMELSSLRSEDNAVYFCARQTT GTWFAYWGQGTLLTVSS
471	B7-H3 VL	EIVMTQSPATLSVSPGERVTLSCLASQSIDYLYWYQQKSH ESPRLLIKYASQSIGIPA RFSGSGSGSEFTLTINSVEPEDVGVYYCQNGHSFPLTFGQGT KLELK
472	B7-H3 VH	QVQLQQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQA PGQGLEWMGGIIPILGIAN YAQKFQGRVTITADESTSTAYMELSSLRSEDNAVYYCARG GSGSYHMDVWGKGTTTVTVSS
473	B7-H3 VL	EIVLTQSPATLSLSPGERATLSCLASQSVSSYLAWYQQKPG QAPRLLIYDASNRATGIP ARFSGSGSGTDFTLTISSELPEDFAVYYCQQRSNWPPRITFG QGTRLEIK
474	B7-H3 CDR-H1	IYNVH
475	B7-H3 CDR-H2	TIFPGNGDTSYNQKFKD
476	B7-H3 CDR-H3	WDDGNVGFAH
477	B7-H3 CDR-L1	RASENINNYLT
478	B7-H3 CDR-L2	HAKTLAE
479	B7-H3 CDR-L3	QHHYGTPPT
480	B7-H3 VH	QVQLQQPGAELVKPGASVKMSCKASGYFTIYNVHWIKQT PGQGLEWMGTIFPGNGDTSY NQKFKDKATLTDDKSSKTAYMQLNSLTSEDSAVYYCARW DDGNVGFAHWGQGTLLTVSA

481	B7-H3 VL	DIQMTQSPASLSASVGETVTITCRASENINNYLTWFQQKQG KSPQLLVYHAKTLAEGVPS RFSGSGSGTQFSLKINSLQPEDFGSYQCQHHYGTPTFGGG TKLEIK
482	B7-H3 VH	EVQLVQSGAEVKKPGASVKVSCKASGYTFTIYNVHWVRQ APGQGLEWMGTIFPGNGDTS YNQKFKDKVTMTTDTSTSTAYMELSSLRSEDNAVYYCAR WDDGNVGFAHWGQGTLVTVSS
483	B7-H3 VL	DIQMTQSPSSLSASVGDRVITITCRASENINNYLTWFQQKQG KSPQLLIYHAKTLAEGVP SRFSGSGSGTDFTLTISLQPEDFATYYCQHHYGTPTFGGG TKVEIK
484	B7-H3 VH	EVQLVQSGAEVKKPGASVKVSCKASGYTFTIYNVHWIRQA PGQGLEWMGTIFPGNGDTSY NQKFKDRATLTDDKSTKTAYMELRSLRSDDTAVYYCARW DDGNVGFAHWGQGTLVTVSS
485	B7-H3 VL	DIQMTQSPSSLSASVGDRVITITCRASENINNYLTWFQQKPG KAPKLLVYHAKTLAEGVPS RFSGSGSGTQFTLTISLQPEDFATYYCQHHYGTPTFGQGT KLEIK
486	HER3 H	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQP PGKGLEWIGEINHSGSTNYN PSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWT WYFDLWGRGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVELTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG

		QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK
487	HER3 L	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAW YQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISS LQAEDVAVYYCQQYYSTPRTFGQGTKVEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSSTYLSSTLTLSKADYEKHKVYACEVT HQGLSSPVTKSFNRGEC
488	HER3 H	EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQ APGKGLEWVSSISSSGGWTLY ADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCTRGL KMATIFDYWGQGT LTVSSA STKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSNFGTQTYTCNV DHKPSNTKVDK TVERK CCVECPPCPAPPVAGPSVFL FPPKPKDTLMISRTPEVTCVVDVSHEDPEVQFNWYVDGV EVHNAKTKPREEQFNSTFRV VSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQ PREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPMLDSG SFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK
489	HER3 L	QSALTQPASVSGSPGQSITISCTGTSSDVGSYNV VSWYQQH PGKAPKLIIEVSQRPSGVSNRFSGSKSGNTASLTISGLQTE DEADYYCCSYAGSSIFVIFGGGTKVTVLGQPKAAPSVTLFP PSSEELQANKATLVCLVSDFYPGA VTVAWKADGSPVKVG VETTKPSKQSN NKYAASSYLSLTPEQWKSHRSYSCRVTHE GSTVEKTVAPAEC S

490	HER3 H	EVQLLESGGGLVQPGGSLRLSCAASGFTSSYAMSWVRQA PGKGLEWVSAINSQGKSTYYADSVKGRFTISRDN SKNTLYL QMNSLRAEDTAVYYCARWGDEGFDIWGQGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN HKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFP PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK
491	HER3 L	DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPG KAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFA TYYCQQYSSFPSTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSSTLSSTLTLSKADYEKHKVYACEVTHQGLSSPVT KSFNRGEC
492	HER3 H	QVQLVQSGAEVKKPGASVKVSCKASGYTFRSSYISWVRQA PGQGLEWMGWYIAGTGSPSYNQKLQGRVTMTTDTSTSTA YMELRSLRSDDTAVYYCARHRDYYSNSLTYWGQGTLVTV SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPG

493	HER3 L	DIVMTQSPDSLAVSLGERATINCKSSQSVLNSGNQKNYLT WYQQKPGQPPLLIYWASTRESGVPDRFSGSGSGTDFTLTI SSLQAEDVAVYYCQSDYSYPYTFGQGTKLEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDYSLSSLTTLTKADYEKHKVYACEV THQGLSSPVTKSFNRGEC
494	PTK7 CDR-H1	TSNMGVG
495	PTK7 CDR-H2	HIWWDDDDKYSPSLKS
496	PTK7 CDR-H3	SNYGYAWFAY
497	PTK7 CDR-L1	KASQDIYPYLN
498	PTK7 CDR-L2	RTNRLLD
499	PTK7 CDR-L3	LQYDEFPLT
500	PTK7 VH	QITLKESGPTLVKPTQTLTLCTFSGFSLSTSNMGVGWIRQP PGKALEWLAHIWWDDDDKYSPSLKSRLTITKDTSKNQVVL TMTNMDPVDTATYYCVRSNYGYAWFAYWGQGTLLTVSS
501	PTK7 VL	DIQMTQSPSSLSASVGDRVTITCKASQDIYPYLNWFQQKPG KAPKTLIYRTNRLLDGVPS RFSGSGSGTDFTFTISSLPEDIATYYCLQYDEFPLTFGAGT KLEIK
502	PTK7 CDR-H1	DYAVH
503	PTK7 CDR-H2	VISTYNDYTYNNQDFKG
504	PTK7 CDR-H3	GNSYFYALDY
505	PTK7 CDR-L1	RASESVDSYGKSFMH
506	PTK7 CDR-L2	RASNLES
507	PTK7 CDR-L3	QQSNEDPWT
508	PTK7 VH	QVQLVQSGPEVKKPGASVKVSCKASGYTFTDYAVHWVRQ APGKRLEWIGVISTYNDYTY NNQDFKGRVTMTRDTSASTAYMELSRLESDTAVYYCAR GNSYFYALDYWGQGTSTVTVSS

509	PTK7 VL	EIVLTQSPATLSLSPGERATLSCRASESVDSYGKSFMHWYQ QKPGQAPRLLIYRASNLES GIPARFSGSGSGTDFTLTISSELPEDFAVYYCQQSNEDPWTF GGGTKLEIK
510	PTK7 CDR-H1	RYWMS
511	PTK7 CDR-H2	DLNPDSSAINYVDSVKG
512	PTK7 CDR-H3	ITTLVPYTMDF
513	PTK7 CDR-L1	ITNTDIDDDMN
514	PTK7 CDR-L2	EGNGLRP
515	PTK7 CDR-L3	LQSDNLPLT
516	PTK7 VH	EVQLVESGGGLVQPGGSLRLSCAASGFDLSRYWMSWVRQ APGKGLEWIGDLNPDSSAINY VDSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCTLITT LVPYTMDFWGQGTSTVTVSS
517	PTK7 VL	ETTLTQSPAFMSATPGDKVNISCITNTDIDDDMNWYQQKP GEAAILLISEGNGLRPGIPPRFSGSGYGTDFLTINNIESEDA AYYFCLQSDNLPLTFGSGTKLEIK
518	LIV1 CDR-H1	DYYMH
519	LIV1 CDR-H2	WIDPENGDEYGPKEFQG
520	LIV1 CDR-H3	HNAHYGTWFAY
521	LIV1 CDR-L1	RSSQSLLHSSGNTYLE
522	LIV1 CDR-L2	KISTRFS
523	LIV1 CDR-L3	FQGSHVPYT
524	LIV1 VH	QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQ APGQGLEWMGWIDPENGDEY GPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCAVHN AHYGTWFAYWGQGTSTVTVSS
525	LIV1 VL	DVVMVTQSPSLPVTLGQPASISCRSSQSLLHSSGNTYLEWY QQRPGQSPRPLIYKISTRFSGVPDRFSGSGSGTDFTLKISRVE AEDVGVYYCFQGSHVPYTFGGGTKVEIK

526	avb6 CDR-H1	DYNVN
527	avb6 CDR-H2	VINPKYGTTRYNQKFKG
528	avb6 CDR-H3	GLNAWDY
529	avb6 CDR-L1	GASENIYGALN
530	avb6 CDR-L2	GATNLED
531	avb6 CDR-L3	QNVLTTPYT
532	avb6 VH	QFQLVQSGAEVKKPGASVKVSCASGYSTFDYNVNWVRQ APGQGLEWIGVINPKYGTTRY NQKFKGRATLTVDKSTSTAYMELSSLRSEDNAVYYCTRGL NAWDYWGQGTLVTVSS
533	avb6 VL	DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWDYQQKPG KAPKLLIYGATNLEDGVPS RFSGSGSGRDYFTISSLPEDIATYYCQNVLTTPYTFGQGT KLEIK
534	avb6 CDR-H1	GYFMN
535	avb6 CDR-H2	LINPYNGDSFYNQKFKG
536	avb6 CDR-H3	GLRRDFDY
537	avb6 CDR-L1	KSSQSLLSDGKTYLN
538	avb6 CDR-L2	LVSELD
539	avb6 CDR-L3	WQGTHFPRT
540	avb6 VH	QVQLVQSGAEVKKPGASVKVSCASGYSTFGYFMNWVRQ APGQGLEWMGLINPYNGDSFY NQKFKGRVTMTRQTSTSTVYMELSSLRSEDNAVYYCVRGL RRDFDYWGQGTLVTVSS
541	avb6 VL	DVVMQTQSPSLPVTLGQPASISCKSSQSLLSDGKTYLNWL FQRPGQSPRRLIYLVSELD SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFP RTFGGGTKLEIK
542	CD48 CDR-H1	DFGMN
543	CD48 CDR-H2	WINTFTGEPSYGNVFKG

544	CD48 CDR-H3	RHGNGNVFDS
545	CD48 CDR-L1	RASQSIGSNH
546	CD48 CDR-L2	YTSEIS
547	CD48 CDR-L3	QQSNSWPLT
548	CD48 VH	QVQLVQSGSELKKPGASVKVSCASGYTFTDFGMNWVRQ APGQGLEWMGWINTFTGEPSTYGNVFKGRFVFSLDTSVSTA YLQISSLKAEDTAVYYCARRHGNGNVFDSWGQGTLVTVSS
549	CD48 VL	EIVLTQSPDFQSVTPKEKVTITCRASQSIGSNHWHYQQKPDQ SPKLLIKYTSEISGVPSRFSGSGSGTDFTLTINSLEAEDAAT YYCQQSNSWPLTFGGGTKVEIKR
550	PD-L1 CDR-H1	TAAIS
551	PD-L1 CDR-H2	GIPIFGKAHYAQKFQG
552	PD-L1 CDR-H3	KFHFVSGSPFGMDV
553	PD-L1 CDR-L1	RASQSVSSYLA
554	PD-L1 CDR-L2	DASNRAT
555	PD-L1 CDR-L3	QQRSNWPT
556	PD-L1 VH	QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTAISWVRQA PGQGLEWMGGIPIFGKAHYAQKFQGRVTITADESTSTAYM ELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTV SS
557	PD-L1 VL	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPG QAPRLLIYDASNRATGIPA RFSGSGSGTDFTLTISSELPEDFAVYYCQQRSNWPTFGQGT KVEIK
558	IGF-1R CDR-H1	SYAIS
559	IGF-1R CDR-H2	GIPIFGTANYAQKFQG
560	IGF-1R CDR-H3	APLRFLEWSTQDHYYYYYMDV
561	IGF-1R CDR-L1	QGDSLRSYYAT
562	IGF-1R CDR-L2	GENKRPS
563	IGF-1R CDR-L3	KSRDGSGQHLV

564	IGF-1R VH	EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQA PGQGLEWMGGIPIFGTANY AQKFQGRVTITADKSTSTAYMELSSLRSEDVAVYYCARAP LRFLEWSTQDHYYYYYMDVWGKGTTVTVSS
565	IGF-1R VL	SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPG QAPILVIYGENKRPSGIPDR FSGSSSGNTASLTITGAQAEDEADYYCKSRDGSQHLVFGG GTKLTVL
566	Claudin-18.2 CDR-H1	SYWIN
567	Claudin-18.2 CDR-H2	NIYPSDSYTNYNQKFKD
568	Claudin-18.2 CDR-H3	SWRGNSFDY
569	Claudin-18.2 CDR-L1	KSSQSLNLSGNQKNYLT
570	Claudin-18.2 CDR-L2	WASTRES
571	Claudin-18.2 CDR-L3	QNDYSYPFT
572	Claudin-18.2 VH	QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQ RPGQGLEWIGNIYPSDSYTN YNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRS WRGNSFDYWGQGTTTLTVSS
573	Claudin-18.2 VL	DIVMTQSPSSLTVTAGEKVTMSCKSSQSLNLSGNQKNYLT WYQQKPGQPPLLIYWASTR ESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYP FTFGSGTKLEIK
574	Claudin-18.2 CDR-H1	NYGMN

575	Claudin-18.2 CDR-H2	WINTNTGEPTYAEEFKG
576	Claudin-18.2 CDR-H3	LGFGNAMDY
577	Claudin-18.2 CDR-L1	KSSQSLNLSGNQKNYLT
578	Claudin-18.2 CDR-L2	WASTRES
579	Claudin-18.2 CDR-L3	QNDYSYPLT
580	Claudin-18.2 VH	QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQA PGKGLKWMGWINTNTGEPTY AEEFKGRFAFSLETSASTAYLQINNLSKEDTATYFCARLGF GNAMDYWGQGTSTVTVSS
581	Claudin-18.2 VL	DIVMTQSPSSLTVTAGEKVTMSCKSSQSLNLSGNQKNYLT WYQQKPGQPPLLIYWASTR ESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYP LTFGAGTKLELK
582	Nectin-4 CDR-H1	SYNMN
583	Nectin-4 CDR-H2	YISSSSSTIYYADSVKG
584	Nectin-4 CDR-H3	AYYYGMDV
585	Nectin-4 CDR-L1	RASQGISGWL
586	Nectin-4 CDR-L2	AASTLQS
587	Nectin-4 CDR-L3	QQANSFPPT
588	Nectin-4 VH	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNMNWVRQA PGKGLEWVSYISSSSSTIYY ADSVKGRFTISRDNALNSLSLQMNSLRDEDTAVYYCARAY YYGMDVWGQGTSTVTVSS
589	Nectin-4 VL	DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKP GKAPKFLIYAASSTLQSGVPS

		RFSGSGSGTDFTLTISLQPEDFATYYCQQANSFPPTFGGGT KVEIK
590	SLTRK6 CDR-H1	SYGMH
591	SLTRK6 CDR-H2	VIWYDGSNQYYADSVKG
592	SLTRK6 CDR-H3	GLTSGRYGMDV
593	SLTRK6 CDR-L1	RSSQSLLL SHGFNYLD
594	SLTRK6 CDR-L2	LGSSRAS
595	SLTRK6 CDR-L3	MQPLQIPWT
596	SLTRK6 VH	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQ APGKGLEWVA VIWYDGSNQYY ADSVKGRFTISRDN SKNTLFLQMHS LRAEDTAVYYCARGL TSGRYGMDVWGQGTTVTVSS
597	SLTRK6 VL	DIVMTQSPLSLPVT PGEPASISCRSSQSLLL SHGFNYLDWYL QKPGQSPQLLIYLGSSRASGVPDRFSGSGSGTDFTLKISRVE AEDVGLYYCMQPLQIPWTFGQGTKVEIK
598	CD228 CDR-H1	SGYWN
599	CD228 CDR-H2	YISDSGITYYNPSLKS
600	CD228 CDR-H3	RTLATYYAMDY
601	CD228 CDR-L1	RASQSLVHSDGNTYLH
602	CD228 CDR-L2	RVS NRFS
603	CD228 CDR-L3	SQSTHVPPT
604	CD228 VH	QVQLQESGPGLVKPSETLSLTCTVSGDSITSGYWNWIRQPP GKGLEYIGYISDSGITYYN PSLKS RVTISRDT SKNQYSLKLSSVTAADTAVYYCARRTLA TYYAMDYWGQGTLVTVSS
605	CD228 VL	DFVMTQSPLSLPVT LGQPASISCRASQSLVHSDGNTYLHWY QQRPGQSPRLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRV EAEDVG VYYCSQSTHVPPTFGQGTKLEIKR
606	CD142 (TF) CDR- H1	NYAMS

607	CD142 (TF) CDR-H2	SISGSGDYTTYTDSVKG
608	CD142 (TF) CDR-H3	SPWGYLDS
609	CD142 (TF) CDR-L1	RASQGISSRLA
610	CD142 (TF) CDR-L2	AASSLQS
611	CD142 (TF) CDR-L3	QQYNSYPYT
612	CD142 (TF) VH	EVQLLES GGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQA PGKGLEWVSSISGSGDYTY YTDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARS PWGYLDSWGQGTLVTVSS
613	CD142 (TF) VL	DIQMTQSPPSLSASAGDRVITITCRASQGISSRLAWYQQKPE KAPKSLIYAASSLQSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGT KLEIK
614	STn CDR-H1	DHAIH
615	STn CDR-H2	YFSPGNDDIKYNEKFRG
616	STn CDR-H3	SLSTPY
617	STn CDR-L1	KSSQSLLNRGNHKNYLT
618	STn CDR-L2	WASTRES
619	STn CDR-L3	QNDYTYPYT
620	STn VH	EVQLVQSGAEVKKPGASVKVSCASGYTFTDHAIHWVRQ APGQGLEWMGYFSPGNDDIKY NEKFRGRVTMTADKSSSTAYMELRSLRSDDTAVYFCKRSL STPYWGQGTLVTVSS
621	STn VL	DIVMTQSPDSLAVSLGERATINCKSSQSLLNRGNHKNYLT WYQQKPGQPPLLIYWAST

		RESGVDPDRFSGSGSGTDFLTISLQAEDVAVYYCQNDYTY PYTFGQGKVEIK
622	CD20 CDR-H1	SYNMH
623	CD20 CDR-H2	AIYPGNGDTSYNQKFKG
624	CD20 CDR-H3	STYYGGDWYFNV
625	CD20 CDR-L1	RASSSVSYIH
626	CD20 CDR-L2	ATSNLAS
627	CD20 CDR-L3	QQWTSNPPT
628	CD20 VH	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVK QTPGRGLEWIGAIYPGNGDTSY NQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARST YYGGDWYFNVWGAGTTVTSA
629	CD20 VL	QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSS PKPWIYATSNLASGVPVR FSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGT KLEIK
630	HER2 CDR-H1	DTYIH
631	HER2 CDR-H2	RIYPTNGYTRYADSVKG
632	HER2 CDR-H3	WGGDGFYAMDY
633	HER2 CDR-L1	RASQDVNTAVA
634	HER2 CDR-L2	SASFLYS
635	HER2 CDR-L3	QQHYTTPPT
636	HER2 VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQA PGKGLEWVARIYPTNGYTRY ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRW GGDGFYAMDYWGQGTLVTVSS
637	HER2 VL	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQK GKAPKLLIYSASFLYSGVPS

		RFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGT KVEIK
638	CD79b CDR-H1	SYWIE
639	CD79b CDR-H2	EILPGGGDTNYNEIFKG
640	CD79b CDR-H3	RVPIRLDY
641	CD79b CDR-L1	KASQSVDYEGDSFLN
642	CD79b CDR-L2	AASNLES
643	CD79b CDR-L3	QQSNEDPLT
644	CD79b VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQA PGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYL QMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS
645	CD79b VL	DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWWYQ QKPGKAPKLLIYAASNLES GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTF GQGTKVEIK
646	NaPi2B CDR-H1	DFAMS
647	NaPi2B CDR-H2	TIGRVAFTYYPDMSMKG
648	NaPi2B CDR-H3	HRGFDVGHFDF
649	NaPi2B CDR-L1	RSSETLVHSSGNTYLE
650	NaPi2B CDR-L2	RVSNRFS
651	NaPi2B CDR-L3	FQGSFNPLT
652	NaPi2B VH	EVQLVESGGGLVQPGGSLRLSCAASGFSFSDFAMSWVRQA PGKGLEWVATIGRVAFTYY PDMSMKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCARHR GFDVGHFDFWGQGTLVTVSS
653	NaPi2B VL	DIQMTQSPSSLSASVGDRVTITCRSSETLVHSSGNTYLEWY QQKPGKAPKLLIYRVSNRF SGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSFNPLTF GQGTKVEIK
654	Muc16 CDR-H1	NDYAWN

655	Muc16 CDR-H2	YISYSGYTTYNPSLKS
656	Muc16 CDR-H3	WTSGLDY
657	Muc16 CDR-L1	KASDLIHNWLA
658	Muc16 CDR-L2	GATSLET
659	Muc16 CDR-L3	QQYWTPFT
660	Muc16 VH	EVQLVESGGGLVQPGGSLRLSCAASGYSITNDYAWNWR QAPGKGLEWVGYISYSGYTTY NPSLKSRTISRDTSKNTLYLQMNSLRAEDTAVYYCARWT SGLDYWGQGTLVTVSS
661	Muc16 VL	DIQMTQSPSSLSASVGDRVTITCKASDLIHNWLAWYQQKP GKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISLQPEDF ATYYCQQYWTPFTFGQGKVEIK
662	STEAP1 CDR-H1	SDYAWN
663	STEAP1 CDR-H2	YISNSGSTSYNPSLKS
664	STEAP1 CDR-H3	ERNYDYDDYYYAMDY
665	STEAP1 CDR-L1	KSSQSLLYRSNQKNYLA
666	STEAP1 CDR-L2	WASTRES
667	STEAP1 CDR-L3	QQYYNYPRT
668	STEAP1 VH	EVQLVESGGGLVQPGGSLRLSCAVSGYSITSDYAWNWRQ APGKGLEWVGYISNSGSTSYNPSLKSRTISRDTSKNTLYLQ MNSLRAEDTAVYYCARERNYDYDDYYYAMDYWGQGTL VTVSS
669	STEAP1 VL	DIQMTQSPSSLSASVGDRVTITCKSSQSLLYRSNQKNYLAW YQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTIS LQPEDFATYYCQQYYNYPRTFGQGKVEIK
670	BCMA CDR-H1	NYWMH
671	BCMA CDR-H2	ATYRGHSPTYYNQKFKG
672	BCMA CDR-H3	GAIYDGYDVLN
673	BCMA CDR-L1	SASQDISNYLN
674	BCMA CDR-L2	YTSNLHS

675	BCMA CDR-L3	QQYRKLPWT
676	BCMA VH	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVR QAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTS TAYMELSSLRSEDTAVYYCARGAIYDGYDVLNWDGQGT LVTSS
677	BCMA VL	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPG KAPKLLIYYTSNLSHGVPSRFSGSGSGTDFTLTISLQPEDFA TYYCQQYRKLPWTFGQGTKLEIK
678	c-Met CDR-H1	AYTMH
679	c-Met CDR-H2	WIKPNNGLANYAQKFQG
680	c-Met CDR-H3	SEITTEFDY
681	c-Met CDR-L1	KSSESVDSYANSFLH
682	c-Met CDR-L2	RASTRES
683	c-Met CDR-L3	QQSKEDPLT
684	c-Met VH	QVQLVQSGAEVKKPGASVKVSCKASGYIFTAYTMHWVRQ APGQGLEWMGWIKPNNGLAN YAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARS EITTEFDYWGQGTLLVTSS
685	c-Met VL	DIVMTQSPDSLAVSLGERATINCKSSESVDSYANSFLHWYQ QKPGQPPKLLIYRASTRE SGVPDRFSGSGSGTDFTLTISLQAEDVAVYYCQQSKEDPL TFGGGTKVEIK
686	EGFR CDR-H1	SDFAWN
687	EGFR CDR-H2	YISYSGNTRYQPSLKS
688	EGFR CDR-H3	AGRGPY
689	EGFR CDR-L1	HSSQDINSNIG
690	EGFR CDR-L2	HGTNLDD
691	EGFR CDR-L3	VQYAFQFWT
692	EGFR VH	QVQLQESGPGLVKPSQTLSTCTVSGYISISDFAWNWRQP PGKGLEWMGYISYSGNTRY

		QPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTAGR GFPYWGQGTLVTVSS
693	EGFR VL	DIQMTQSPSSMSVSVGDRVITITCHSSQDINSNIGWLQQKPG KSFKGLIYHGTNLDDGVPS RFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGG TKLEIK
694	SLAMF7 CDR-H1	DYYMA
695	SLAMF7 CDR-H2	SINYDGSSTYYVDSVKG
696	SLAMF7 CDR-H3	DRGYFFDY
697	SLAMF7 CDR-L1	RSSQSLVHSNGNTYLH
698	SLAMF7 CDR-L2	KVSNRFS
699	SLAMF7 CDR-L3	SQSTHVPPFT
700	SLAMF7 VH	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMAWVRQ APGKGLEWVASINYDGSSTY YVDSVKGRFTISRDNANKNSLYLQMNSLRAEDTAVYYCAR DRGYFFDYWGQGTTVTVSS
701	SLAMF7 VL	DVVMQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWY LQKPGQSPQLLIYKVS NRF SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPPF TFGGGTKVEIK
702	SLITRK6 CDR-H1	SYGMH
703	SLITRK6 CDR-H2	VIWYDGSNQYYADSVKG
704	SLITRK6 CDR-H3	GLTSGRYGMDV
705	SLITRK6 CDR-L1	RSSQSLLLSHGFNYLD
706	SLITRK6 CDR-L2	LGSSRAS
707	SLITRK6 CDR-L3	MQPLQIPWT
708	SLITRK6 VH	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQ APGKGLEWVAVIWYDGSNQYY ADSVKGRFTISRDNANKNTLFLQMNSLRAEDTAVYYCARGL TSGRYGMDVWGQGTTVTVSS

709	SLITRK6 VL	DIVMTQSPLSLPVTGPGEPAISCRSSQSLLLSHGFNYLDWYL QKPGQSPQLLIYLGSSRA SGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQPLQIPW TFGQGTKVEIK
710	C4.4a CDR-H1	NAWMS
711	C4.4a CDR-H2	YISSSGSTIYYADSVKG
712	C4.4a CDR-H3	EGLWAFDY
713	C4.4a CDR-L1	TGSSSNIGAGYVVH
714	C4.4a CDR-L2	DNNKRPS
715	C4.4a CDR-L3	AAWDDRLNGPV
716	C4.4a VH	EVQLLES GGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQ APGKGLEWVSYISSSGSTIYY ADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAREG LWAFDYWGQGTLVTVSS
717	C4.4a VL	ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYVVHWYQQ PGTAPKLLIYDNNKRPSGV PDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDRLNGP VFGGGTKLTVL
718	GCC CDR-H1	GYYS
719	GCC CDR-H2	EINHRGNTNDNPSLKS
720	GCC CDR-H3	ERGYTYGNFDH
721	GCC CDR-L1	RASQSVSRNLA
722	GCC CDR-L2	GASTRAT
723	GCC CDR-L3	QQYKTWPRT
724	GCC VH	QVQLQQWGAGLLKPSETLSLTCAVFGGSFSGYYWSWIRQP PGKGLEWIGEINHRGNTNDN PSLKSRTVISVDTSKNQFALKLSSVTAADTAVYYCARERGY TYGNFDHWGQGTLVTVSS
725	GCC VL	EIVMTQSPATLSVSPGERATLSCRASQSVSRNLAWYQQKPG QAPRLLIYGASTRATGIP

		ARFSGSGSGTEFTLTIGSLQSEDFAVYYCQQYKTPRTFGQ GTNVEIK
726	Axl CDR-H1	SYAMN
727	Axl CDR-H2	TTSGSGASTYYADSVKG
728	Axl CDR-H3	IWIAFDI
729	Axl CDR-L1	RASQSVSSSYLA
730	Axl CDR-L2	GASSRAT
731	Axl CDR-L3	QQYGSSPYT
732	Axl VH	EVQLLES GGLVQPGSLRLSCAASGFTFSSYAMNWRQA PGKGLEWVSTTSGSGASTYY ADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKIW IAFDIWGQGTMVTVSS
733	Axl VL	EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKP GQAPRLLIYGASSRATGIP DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQ GTKLEIK
734	gpNMB CDR-H1	SFNYYWS
735	gpNMB CDR-H2	YIYYSGSTYSNP SLKS
736	gpNMB CDR-H3	GYNWNYFDY
737	gpNMB CDR-L1	RASQSV DNNLV
738	gpNMB CDR-L2	GASTRAT
739	gpNMB CDR-L3	QQYNNWPPWT
740	gpNMB VH	QVQLQESG PGLVKPSQTLSTCTVSGGSIS SFNYYWSWIRH HPGKGLEWIGYIYYSGSTY SNPSLKS RVTISVDTSKNQFSLTLSSVTAADTAVYYCARGY NWN YFDYWGQGT LVT VSS
741	gpNMB VL	EIVMTQSPATLSVSPGERATLSCRASQSV DNNLVWYQQKP GQAPRLLIYGASTRATGIPA RFSGSGSGTEFTLTIS SLQSEDFAVYYCQQYNNWPPWTFGQ GTKVEIK

742	Prolactin receptor CDR-H1	TYWMH
743	Prolactin receptor CDR-H2	EIDPSDSYSNYNQKFKD
744	Prolactin receptor CDR-H3	NGGLGPAWFSY
745	Prolactin receptor CDR-L1	KASQYVGTAVA
746	Prolactin receptor CDR-L2	SASNRYT
747	Prolactin receptor CDR-L3	QQYSSYPWT
748	Prolactin receptor VH	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQ APGQGLEWIGEIDPSDSYSNY NQKFKDRATLTVDKSTSTAYMELSSLRSEDVAVYYCARNG GLGPAWFSYWGQGTLVTVSS
749	Prolactin receptor VL	DIQMTQSPSSVSASVGDRVITITCKASQYVGTAVAWYQQKP GKSPKLLIYSASNRYTGVP RFSDSGSGTDFTLTISLQPEDFATYFCQQYSSYPWTFGGGT KVEIK
750	FGFR2 CDR-H1	SYAMS
751	FGFR2 CDR-H2	AISGSGTSTYYADSVKG
752	FGFR2 CDR-H3	VRYNWNHGDWFD
753	FGFR2 CDR-L1	SGSSSNIGNNYVS
754	FGFR2 CDR-L2	ENYNRPA
755	FGFR2 CDR-L3	SSWDDSLNYWV
756	FGFR2 VH	EVQLLESGLLVQPGGSLRLSCAASGFTFSSYAMSWVRQA PGKGLEWVSAISGSGTSTYYADSVKGRFTISRDN SKNTLYL QMNSLR AEDTAVYYCARVRYNWNHGDWFD PWGQGT LVTVSS

757	FGFR2 VL	QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVSWYQQLP GTAPKLLIYENYNRPAGVP DRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSLNYWVF GGGTKLTVL
758	CDCP1 CDR-H1	SYGMS
759	CDCP1 CDR-H2	TISSGGSYKYYVDSVKG
760	CDCP1 CDR-H3	HPDYDGVWFAY
761	CDCP1 CDR-L1	SVSSSVFYVH
762	CDCP1 CDR-L2	DTSKLAS
763	CDCP1 CDR-L3	QQWNSNPPT
764	CDCP1 VH	EVQLVESGGGLVQPGGSLRLSCAASGFTFNSYGMSWVRQA PGKGLEWVATISSGGSYKYY VDSVKGRFTISRDNANKSLYLQMNSLRAEDTAVYYCARHP DYDGVWFAYWGQGTLLTVSS
765	CDCP1 VL	DIQMTQSPSSLSASVGDRVTITCSVSSSVFYVHWYQQKPGK APKLLIYDTSKLASSGVPS RFSGSGSGTDFTFTISSLQPEDIATYYCQQWNSNPPTFGGGT KVEIK
766	CDCP1 CDR-H1	SYGMS
767	CDCP1 CDR-H2	TISSGGSYTYYPDSVKG
768	CDCP1 CDR-H3	HPDYDGVWFAY
769	CDCP1 CDR-L1	SVSSSVFYVH
770	CDCP1 CDR-L2	DTSKLAS
771	CDCP1 CDR-L3	QQWNSNPPT
772	CDCP1 VH	EVQLVESGGDLVKPGGSLKLSCAASGFTFNSYGMSWVRQT PDKRLEWVATISSGGSYTTY PDSVKGRFTISRDNANKNTLYLQMSSLKSEDTAMYYCARHP DYDGVWFAYWGQGTLLTVSA
773	CDCP1 VL	QIVLTQSPAIMASPGKVTMTCSVSSSVFYVHWYQQKSGTS PKRWIYDTSKLASGVPARF

		SGSGSGTSYSLTISSMEAEDAATYYCQQWNSNPPTFGGGTK LEIK
774	CDCP1 CDR-H1	SYMH
775	CDCP1 CDR-H2	IINPSGGSTSYAQKFQG
776	CDCP1 CDR-H3	DGVLRYFDWLLDY
777	CDCP1 CDR-L1	RASQSVGSYLA
778	CDCP1 CDR-L2	DASNRAT
779	CDCP1 CDR-L3	QQRANVFT
780	CDCP1 VH	EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHVVRQ APGQGLEWMGIINPSGGSTSY AQKFQGRVTMTRDTSTSTVYMELSSLRSEDYAVYYCARDG VLRFDWLLDYMDVWGKG TTVTVSS
781	CDCP1 VL	EIVLTQSPATLSLSPGERATLSCRASQSVGSYLAWYQQRPG QAPRLLIYDASNRATGIPA RFSGSGSGTDFTLTISLEPEDFAVYYCQQRANVFTFGQGT KVEIK
782	CDCP1 CDR-H1	SYMH
783	CDCP1 CDR-H2	IINPSGGSTSYAQKFQG
784	CDCP1 CDR-H3	DAELRHFDHLLDYHYMDV
785	CDCP1 CDR-L1	RASQSVGSYLA
786	CDCP1 CDR-L2	DASNRAT
787	CDCP1 CDR-L3	QQRANVFT
788	CDCP1 VH	EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHVVRQ APGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTV YMELSSLRSEDYAVYYCARDAELRHFDHLLDYHYMDVW GQGT
789	CDCP1 VL	EIVMTQSPATLSLSPGERATLSCRASQSVGSYLAWYQKPG QAPRLLIYDASNRATGIPA

		RFSGSGSGTDFTLTISSLQPEDFAVYYCQQRAQEFTFGQGT KVEIK
790	ASCT2 VH	QVQLVQSGSELKKPGAPVKVSCKASGYTFSTFGMSWVRQ APGQGLKWMGWIHTYAGVPIYGDDFKGRFVFSLDTSVSTA YLQISSLKAEDTAVYFCARRSDNYRYFFDYWGQGTTVTVS S
791	ASCT2 VL	DIQMTQSPSSLSASLGDRVITITCRASQDIRNYLNWYQQKPG KAPKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDF ATYFCQQGHTLPPTFGQGTKLEIK
792	ASCT2 VH	QIQLVQSGPELKKPGAPVKISCKASGYTFTTFGMSWVKQAP GQGLKWMGWIHTYAGVPIYGDDFKGRFVFSLDTSVSTAYL QISSVKAEDTATYFCARRSDNYRYFFDYWGQGTTTLTVSS
793	ASCT2 VL	DIQMTQSPSSLSASLGDRVITITCRASQDIRNYLNWYQQKPG KAPKLLIYYTSRLHSGVPS RFSGSGSGTDYTLTISSLQPEDFATYFCQQGHTLPPTFGQGT KLEIK
794	ASCT2 CDR-H1	NYYMA
795	ASCT2 CDR-H2	SITKGGGNTYYRDSVKG
796	ASCT2 CDR-H3	QVTIAAVSTSYFDS
797	ASCT2 CDR-L1	KTNQKVDYYGNSYVY
798	ASCT2 CDR-L2	LASNLAS
799	ASCT2 CDR-L3	QQSRNLPYT
800	ASCT2 VH	EVQLVESGGGLVQSGRSIRLSCAASGFSFSNYMAWVRQA PSKGLEWVASITKGGGNTYYRDSVKGRFTFSRDNAKSTLY LQMDSLRS EDTATYYCARQVTIAAVSTSYFDSWGQGVMV TVSS
801	ASCT2 VL	DIVLTQSPALAVSLGQRATISCKTNQKVDYYGNSYVYWYQ QKPGQQPKLLIYLASNLAGIPARFSGRSGTDFTLTIDPVE ADDTATYYCQQSRNLPYTFGAGTKLELK
802	CD123 CDR-H1	DYYMK

803	CD123 CDR-H2	diipsngatfynqkfkkg
804	CD123 CDR-H3	shllraswfay
805	CD123 CDR-L1	kssqslInsgnqnknylt
806	CD123 CDR-L2	wastres
807	CD123 CDR-L3	qndyspyt
808	CD123 VH	qvqlvqsgaevkkpgasvkmckasgytftdyymkwvkqapggglewigdiipsnga tfynqkfkkgkatltvdrisstaymhlrlrsddtavyyctrshllraswfaywgqgtlvtvss
809	CD123 VL	dfvmtqspdslavslgeratinckssqslInsgnqnknyltwylqkpgqppklliywastres gvpdrfsgsgsgtdftltisslqaedvavyycqndyspytfgqgtkleik
810	GPC3 CDR-H1	DYEMH
811	GPC3 CDR-H2	WIGGIDPETGGTAYNQKFKG
812	GPC3 CDR-H3	YYSFAY
813	GPC3 CDR-L1	RSSQSIVHSNGNTYLQ
814	GPC3 CDR-L2	KVSNRFS
815	GPC3 CDR-L3	FQVSHVPYT
816	GPC3 VH	EVQLVQSGAEVKKPGATVKISCKVSGYTFTDYEMHWWVQQ APGKGLEWMGGIDPETGGTAYNQKFKGRVTLTADKSTDT AYMELSSLRSEDNAVYYCGRYYSFAYWGQGTSLTVSS
817	GPC3 VL	DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNANTYLQWF QQRPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVA EAEDVGVYYCFQVSHVPYTFGQGTLEIK
818	B6A CDR-H1	DYNVN
819	B6A CDR-H2	VINPKYGTTRYNQKFKG
820	B6A CDR-H3	GLNAWDY
821	B6A CDR-L1	GASENIYGALN
822	B6A CDR-L2	GATNLED
823	B6A CDR-L3	QNVLTTPYT
824	B6A VH	QFQLVQSGAEVKKPGASVKVSCKASGYSTFDYNNWVRQ APGQGLEWIGVINPKYGTTRYNQKFKGRATLTVDKSTSTA YMELSSLRSEDNAVYYCTRGLNAWDYWGQGTSLTVSS

825	B6A VL	DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWDYQQKPG KAPKLLIYGATNLEDGVPSRFSGSGSGRDYFTISSLPEDI ATYYCQNVLTTPYTFGQGTKLEIK
826	B6A CDR-H1	GYFMN
827	B6A CDR-H2	linpyngdsfynqkfkq
828	B6A CDR-H3	glrrdfdy
829	B6A CDR-L1	kssqslldsdgktyln
830	B6A CDR-L2	lvselds
831	B6A CDR-L3	wqgthfprt
832	B6A VH	QVQLVQSGAEVKKPGASVKVSCKASGYSFSGYFMNWVRQ APGQGLEWMGLINPYNGDSFYNQKFKGRVTMTRQTSTST VYMELSSLRSEDTAVYYCVRGLRRDFDYWGQGTLLTVSS
833	B6A VL	DVVMQTSPSLPVTLGQPASISCKSSQSLDSDGKTYLNWL FQRPGQSPRRLIYLVSELD SGVPDRFSGSGSGTDFTLKISR V EAEDVGVYYCWQGTHFPRTFGGGGTKLEIK
834	PD-L1 CDR-H1	TAAIS
835	PD-L1 CDR-H2	GIPIFGKAHYAQKFQG
836	PD-L1 CDR-H3	KFHFVSGSPFGMDV
837	PD-L1 CDR-L1	RASQSVSSYLA
838	PD-L1 CDR-L2	DASNRAT
839	PD-L1 CDR-L3	QQRSNWPT
840	PD-L1 VH	QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTAAISWVRQA PGQGLEWMGGIPIFGKAHYAQKFQGRVTITADESTSTAYM ELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTITVTV SS
841	PD-L1 VL	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWDYQQKPG QAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISLSEPEDFA VYYCQQRSNWPTFGQGTKVEIK
842	TIGIT CDR-H1	GTFSSYAIS
843	TIGIT CDR-H2	SIPIFGTANYAQKFQG

844	TIGIT CDR-H3	ARGPSEVGAILGYVWFDP
845	TIGIT CDR-L1	RSSQSLHLSNGYNYLD
846	TIGIT CDR-L2	LGSNRAS
847	TIGIT CDR-L3	MQARRIPIT
848	TIGIT VH	QVQLVQSGAEVKKPGSSVKVSCASGGTFSSYAISWVRQA PGQGLEWMGSIPIFGTANYAQKFQGRVTITADESTSTAYM ELSSLRSEDTAVYYCARGPSEVGAILGYVWFDPWGQGTLV TVSS
849	TIGIT VL	DIVMTQSPSLPVTGPGEPAISCRSSQSLHLSNGYNYLDWYL QKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVE AEDVGVYYCMQARRIPITFGGGTKVEIK
850	STN CDR-H1	GYTFTDHAIHWV
851	STN CDR-H2	FSPGNDDIKY
852	STN CDR-H3	KRSLSTPY
853	STN CDR-L1	QSLNLRGNHKNY
854	STN CDR-L2	WASTRES
855	STN CDR-L3	QNDYTPYT
856	STN VH	EVQLVQSGAEVKKPGASVKVSCASGYTFTDHAIHWVRQ APGQGLEWMGYFSPGNDDIKYNEKFRGRVTMTADKSSST AYMELRSLRSDDTAVYFCKRSLSTPYWGQGTLVTVSS
857	STN VL	DIVMTQSPDSLAVSLGERATINCKSSQSLNLRGNHKNYLT WYQQKPGQPPLLIYWASTRESGVPDRFSGSGSGTDFTLTI SSLQAEDVAVYYCQNDYTPYTFTGQGTKVEIK
858	CD33 CDR-H1	NYDIN
859	CD33 CDR-H2	WIYPGDGSTKYNEKFA
860	CD33 CDR-H3	GYEDAMDY
861	CD33 CDR-L1	KASQDINSYLS
862	CD33 CDR-L2	RANRLVD
863	CD33 CDR-L3	LQYDEFPLT

864	CD33 VH	QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYDINWVRQA PGQGLEWIGW IYPGDGSTKY NEKFKAKATL TADTSTSTAY MELRSLRSDD TAVYYCASGY EDAMDYWGQG TTVTVSS
865	CD33 VL	DIQMTQSPS SLSASVGDRVT INCKASQDINSYLSWFQQKPGKAPKTL IYRANRLVDGVPS RFSGSGSGQDYTLT ISSLPEDFATYYCLQYDEFPLTFGGGTKVE
866	NTBA CDR-H1	NYGMN
867	NTBA CDR-H2	WINTYSGEPRYADDFKG
868	NTBA CDR-H3	DYGRWYFDV
869	NTBA CDR-L1	RASSSVSHMH
870	NTBA CDR-L2	ATSNLAS
871	NTBA CDR-L3	QQWSSTPRT
872	NTBA VH	QIQLVQSGSELKKPGASVKV SCKASGYTFTNYGMNWVRQ APGQDLKWMGWINTYSGEPRYADDFKGRFVFSLDKSVNT AYLQISSLKAEDTAVYYCARDYGRWYFDVWGQGTTVTVS S
873	NTBA VL	QIVLSQSPATLSLSPGERATMSCRASSSVSHMHYQQKPG QAPRPWIYATSNLASGVPARFSGSGSGTDYTLTISSLEPEDF AVYYCQQWSSTPRTFGGGGTKVEIK
874	BCMA CDR-H1	DYYIH
875	BCMA CDR-H2	YINPNSGYTNYAQKFQG
876	BCMA CDR-H3	YMWERTVGFFDF
877	BCMA CDR-L1	LASEDISDDLA
878	BCMA CDR-L2	TTSSLQS
879	BCMA CDR-L3	QQTYKFPPT
880	BCMA VH	QVQLVQSGAEVKKPGASVKLSCKASGYTFTDYYIHWVRQ APGQGLEWIGYINPNSGYTNYAQKFQGRATMTADKSINTA

		YVELSRLRSDDTAVYFCTRYMWERTGFFDFWGQGTMT VSS
881	BCMA VL	DIQMTQSPSSVSASVGDRVTITCLASEDISDDLAWYQQKPG KAPKVLVYTTSSLQSGVPSRFSGSGSGTDFTLTISLQPEDF ATYFCQQTYKFPPTFGGGTKVEIK
882	TF CDR-H1	GFTFSNYA
883	TF CDR-H2	ISGSGDYT
884	TF CDR-H3	ARSPWGYYLDS
885	TF CDR-L1	QGISSR
886	TF CDR-L2	AAS
887	TF CDR-L3	QQYNSYPYT
888	TF VH	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQA PGKGLEWVSSISGSGDYTTYTDSVKGRFTISRDN SKNTLYL QMNSLRAEDTAVYYCARSPWGYYLDSWGQGT LVT VSS
889	TF VL	DIQMTQSPPSLSASAGDRVTITCRASQGISSRLAWYQQKPE KAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISLQPEDFA TYYCQQYNSYPYTFGQG TKLEIK

Methods of Use

In some embodiments, the ADCs described herein (e.g., Formula (I), or a pharmaceutically acceptable salt thereof) are used to deliver a drug to a target cell. Without being bound by theory, in some embodiments, an ADC associates with an antigen on the surface of a target cell, and the ADC is then taken up inside a target-cell through receptor-mediated endocytosis. Once inside the cell, the Drug Unit is released as free drug and will induce its biological effect (such as a cytotoxic or cytostatic effect, as defined herein). In some embodiments, the Drug Unit is cleaved from the ADC outside the target cell, and the free drug subsequently penetrates the cell.

Some embodiments provide a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Formula (I), or a pharmaceutically acceptable salt thereof.

Some embodiments provide a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Formula (I), or a pharmaceutically acceptable salt thereof, before, during, or after administration of another anticancer agent to the subject (e.g., an immunotherapy such as nivolumab or pembrolizumab).

5 Some embodiments provide a method for reversing or preventing acquired resistance to an anticancer agent, comprising administering a therapeutically effective amount of Formula (I), or a pharmaceutically acceptable salt thereof, to a subject at risk for developing or having acquired resistance to an anticancer agent. In some embodiments, the subject is administered a dose of the anticancer agent (e.g., at substantially the same time as a dose of Formula (I), or a pharmaceutically
10 acceptable salt thereof is administered to the subject).

Some embodiments provide a method of delaying and/or preventing development of cancer resistant to an anticancer agent in a subject, comprising administering to the subject a therapeutically effective amount of Formula (I), or a pharmaceutically acceptable salt thereof, before, during, or after administration of a therapeutically effective amount of the anticancer agent.

15 In some embodiments, the ADCs described herein are useful for inhibiting the multiplication of a tumor cell or cancer cell, causing apoptosis in a tumor or cancer cell, and/or for treating cancer in a subject in need thereof. The ADCs can be used accordingly in a variety of settings for the treatment of cancers. The ADCs can be used to deliver a drug (e.g., cytotoxic or cytostatic drug) to a tumor cell or cancer cell. Without being bound by theory, in some
20 embodiments, the antibody of an ADC binds to or associates with a cancer-cell or a tumor-cell-associated antigen, and the ADC can be taken up (internalized) inside a tumor cell or cancer cell through receptor-mediated endocytosis or other internalization mechanism. The antigen can be attached to a tumor cell or cancer cell or can be an extracellular matrix protein associated with the tumor cell or cancer cell. Once inside the cell, via a cleavable mechanism, the drug is released
25 within the cell. In some embodiments, the Drug Unit is cleaved from the ADC outside the tumor cell or cancer cell, and the free drug subsequently penetrates the cell.

In some embodiments, the antibody binds to the tumor cell or cancer cell. In some embodiments, the antibody binds to a tumor cell or cancer cell antigen which is on the surface of the tumor cell or cancer cell. In some embodiments, the antibody binds to a tumor cell or cancer
30 cell antigen which is an extracellular matrix protein associated with the tumor cell or cancer cell.

The specificity of the antibody of the ADC described herein for a particular tumor cell or cancer cell can be important for determining those tumors or cancers that are most effectively treated. For example, ADCs that target a cancer cell antigen present on hematopoietic cancer cells in some embodiments treat hematologic malignancies. In some embodiments, ADCs that target a cancer cell antigen present on abnormal cells of solid tumors treat such solid tumors. In some
5 embodiments, an ADC are directed against abnormal cells of hematopoietic cancers such as, for example, lymphomas (Hodgkin Lymphoma and Non-Hodgkin Lymphomas) and leukemias and solid tumors.

Cancers, including, but not limited to, a tumor, metastasis, or other disease or disorder
10 characterized by abnormal cells that are characterized by uncontrolled cell growth in some embodiments are treated or inhibited by administration of an ADC.

In some embodiments, the subject has previously undergone treatment for the cancer. In some embodiments, the prior treatment is surgery, radiation therapy, administration of one or more anticancer agents, or a combination of any of the foregoing.

In some embodiments, the cancer is selected from the group of: adenocarcinoma, adrenal
15 gland cortical carcinoma, adrenal gland neuroblastoma, anus squamous cell carcinoma, appendix adenocarcinoma, bladder urothelial carcinoma, bile duct adenocarcinoma, bladder carcinoma, bladder urothelial carcinoma, bone chordoma, bone marrow leukemia lymphocytic chronic, bone marrow leukemia non-lymphocytic acute myelocytic, bone marrow lymph proliferative disease,
20 bone marrow multiple myeloma, bone sarcoma, brain astrocytoma, brain glioblastoma, brain medulloblastoma, brain meningioma, brain oligodendroglioma, breast adenoid cystic carcinoma, breast carcinoma, breast ductal carcinoma in situ, breast invasive ductal carcinoma, breast invasive lobular carcinoma, breast metaplastic carcinoma, cervix neuroendocrine carcinoma, cervix squamous cell carcinoma, colon adenocarcinoma, colon carcinoid tumor, duodenum
25 adenocarcinoma, endometrioid tumor, esophagus adenocarcinoma, esophagus and stomach carcinoma, eye intraocular melanoma, eye intraocular squamous cell carcinoma, eye lacrimal duct carcinoma, fallopian tube serous carcinoma, gallbladder adenocarcinoma, gallbladder glomus tumor, gastroesophageal junction adenocarcinoma, head and neck adenoid cystic carcinoma, head and neck carcinoma, head and neck neuroblastoma, head and neck squamous cell carcinoma,
30 kidney chromophore carcinoma, kidney medullary carcinoma, kidney renal cell carcinoma, kidney renal papillary carcinoma, kidney sarcomatoid carcinoma, kidney urothelial carcinoma, kidney

carcinoma, leukemia lymphocytic, leukemia lymphocytic chronic, liver cholangiocarcinoma, liver hepatocellular carcinoma, liver carcinoma, lung adenocarcinoma, lung adenosquamous carcinoma, lung atypical carcinoid, lung carcinosarcoma, lung large cell neuroendocrine carcinoma, lung non-small cell lung carcinoma, lung sarcoma, lung sarcomatoid carcinoma, lung small cell carcinoma, lung small cell undifferentiated carcinoma, lung squamous cell carcinoma, upper aerodigestive tract squamous cell carcinoma, upper aerodigestive tract carcinoma, lymph node lymphoma diffuse large B cell, lymph node lymphoma follicular lymphoma, lymph node lymphoma mediastinal B-cell, lymph node lymphoma plasmablastic lung adenocarcinoma, lymphoma follicular lymphoma, lymphoma, non-Hodgkins, nasopharynx and paranasal sinuses undifferentiated carcinoma, ovary carcinoma, ovary carcinosarcoma, ovary clear cell carcinoma, ovary epithelial carcinoma, ovary granulosa cell tumor, ovary serous carcinoma, pancreas carcinoma, pancreas ductal adenocarcinoma, pancreas neuroendocrine carcinoma, peritoneum mesothelioma, peritoneum serous carcinoma, placenta choriocarcinoma, pleura mesothelioma, prostate acinar adenocarcinoma, prostate carcinoma, rectum adenocarcinoma, rectum squamous cell carcinoma, skin adnexal carcinoma, skin basal cell carcinoma, skin melanoma, skin Merkel cell carcinoma, skin squamous cell carcinoma, small intestine adenocarcinoma, small intestine gastrointestinal stromal tumors (GISTs), large intestine/colon carcinoma, large intestine adenocarcinoma, soft tissue angiosarcoma, soft tissue Ewing sarcoma, soft tissue hemangioendothelioma, soft tissue inflammatory myofibroblastic tumor, soft tissue leiomyosarcoma, soft tissue liposarcoma, soft tissue neuroblastoma, soft tissue paraganglioma, soft tissue perivascular epithelioid cell tumor, soft tissue sarcoma, soft tissue synovial sarcoma, stomach adenocarcinoma, stomach adenocarcinoma diffuse-type, stomach adenocarcinoma intestinal type, stomach adenocarcinoma intestinal type, stomach leiomyosarcoma, thymus carcinoma, thymus thymoma lymphocytic, thyroid papillary carcinoma, unknown primary adenocarcinoma, unknown primary carcinoma, unknown primary malignant neoplasm, lymphoid neoplasm, unknown primary melanoma, unknown primary sarcomatoid carcinoma, unknown primary squamous cell carcinoma, unknown undifferentiated neuroendocrine carcinoma, unknown primary undifferentiated small cell carcinoma, uterus carcinosarcoma, uterus endometrial adenocarcinoma, uterus endometrial adenocarcinoma endometrioid, uterus endometrial adenocarcinoma papillary serous, and uterus leiomyosarcoma.

In some embodiments, the subject is concurrently administered one or more additional anticancer agents with Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the subject is concurrently receiving radiation therapy with Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the subject is administered one or more additional anticancer agents after administration of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the subject receives radiation therapy after administration of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the subject has discontinued the prior therapy, for example, due to unacceptable or unbearable side effects, or wherein the prior therapy was too toxic.

Some embodiments provide a method of treating an autoimmune disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Formula (I), or a pharmaceutically acceptable salt thereof.

Some embodiments provide a method of treating an autoimmune disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Formula (I), or a pharmaceutically acceptable salt thereof, to the subject before, during, or after administration of an additional therapeutic agent (e.g., methotrexate, adalimumab, or rituxumab).

Some embodiments provide a method of ameliorating one or more symptoms of an autoimmune disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Formula (I), or a pharmaceutically acceptable salt thereof.

Some embodiments provide a method of ameliorating one or more symptoms of an autoimmune disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Formula (I), a pharmaceutically acceptable salt thereof, before, during, or after administration of an additional therapeutic agent to the subject (e.g., methotrexate, adalimumab, or rituxumab).

Some embodiments provide a method of reducing the occurrence of flare-ups of an autoimmune disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Formula (I), or a pharmaceutically acceptable salt thereof.

Some embodiments provide a method of reducing the occurrence of flare-ups an autoimmune disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Formula (I), or a pharmaceutically acceptable salt thereof, to

the subject before, during, or after administration of an additional therapeutic agent (e.g., methotrexate, adalimumab, or rituxumab).

A “flare-up” refers to a sudden onset of symptoms, or sudden increase in severity of symptoms, of a disorder. For example, a flare-up in mild joint pain typically addressed with NSAIDs could result in debilitating joint pain preventing normal locomotion even with NSAIDs.

In some embodiments, the antibody of the ADC binds to an autoimmune antigen. In some embodiments, the antigen is on the surface of a cell involved in an autoimmune disorder. In some embodiments, the antibody binds to an autoimmune antigen which is on the surface of a cell. In some embodiments, the antibody binds to activated lymphocytes that are associated with the autoimmune disorder state. In some embodiments, the ADC kills or inhibits the multiplication of cells that produce an autoimmune antibody associated with a particular autoimmune disorder.

In some embodiments, the subject is concurrently administered one or more additional therapeutic agents with Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, one or more additional therapeutic agents are compounds known to treat and/or ameliorate the symptoms of an autoimmune disorder (e.g., compounds that are approved by the FDA or EMA for the treatment of an autoimmune disorder).

In some embodiments, the autoimmune disorders include, but are not limited to, Th2 lymphocyte related disorders (e.g., atopic dermatitis, atopic asthma, rhinoconjunctivitis, allergic rhinitis, Omenn’s syndrome, systemic sclerosis, and graft versus host disease); Th1 lymphocyte-related disorders (e.g., rheumatoid arthritis, multiple sclerosis, psoriasis, Sjorgren’s syndrome, Hashimoto’s thyroiditis, Grave’s disease, primary biliary cirrhosis, Wegener’s granulomatosis, and tuberculosis); and activated B lymphocyte-related disorders (e.g., systemic lupus erythematosus, Goodpasture’s syndrome, rheumatoid arthritis, and type I diabetes).

In some embodiments, the one or more symptoms of an autoimmune disorder include, but are not limited to joint pain, joint swelling, skin rash, itching, fever, fatigue, anemia, diarrhea, dry eyes, dry mouth, hair loss, and muscle aches.

Compositions and Methods of Administration

The present disclosure provides pharmaceutical compositions comprising the ADCs described herein and a pharmaceutically acceptable carrier. The preferred route of administration is parenteral. Parenteral administration includes subcutaneous injections, intravenous,

intramuscular, intrasternal injection or infusion techniques. In some embodiments, the compositions are administered parenterally. In one of those embodiments, the conjugates are administered intravenously. Administration is typically through any convenient route, for example by infusion or bolus injection.

5 Pharmaceutical compositions of an ADC are formulated so as to allow it to be bioavailable upon administration of the composition to a subject. In some embodiments, the compositions will be in the form of one or more injectable dosage units.

 Materials used in preparing the pharmaceutical compositions can be non-toxic in the amounts used. It will be evident to those of ordinary skill in the art that the optimal dosage of the
10 active ingredient(s) in the pharmaceutical composition will depend on a variety of factors. Relevant factors include, without limitation, the type of animal (*e.g.*, human), the particular form of the compound, the manner of administration, and the composition employed.

 In some embodiments, the ADC composition is a solid, for example, as a lyophilized powder, suitable for reconstitution into a liquid formulation prior to administration. In some
15 embodiments, the ADC composition is a liquid composition, such as a solution or a suspension. A liquid composition or suspension is useful for delivery by injection and a lyophilized solid is suitable for reconstitution as a liquid or suspension using a diluent suitable for injection. In a composition administered by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent is typically included.

20 In some embodiments, the liquid compositions, whether they are solutions, suspensions or other like form, can also include one or more of the following: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which can serve as the solvent or suspending medium, polyethylene glycols, glycerin, cyclodextrin, propylene glycol or other
25 solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as amino acids, acetates, citrates or phosphates; detergents, such as nonionic surfactants, polyols; and agents for the adjustment of tonicity such as sodium chloride or dextrose. A parenteral composition is typically enclosed in ampoule, a disposable syringe or a multiple-dose vial made
30 of glass, plastic or other material. Physiological saline is an exemplary adjuvant. An injectable composition is preferably a liquid composition that is sterile.

The amount of the ADC that is effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, which is usually determined by standard clinical techniques. In addition, *in vitro* and/or *in vivo* assays are sometimes employed to help identify optimal dosage ranges. The precise dose to be employed in the compositions will also depend on the route of parenteral administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each subject's circumstances.

In some embodiments, the compositions comprise an effective amount of an ADC such that a suitable dosage will be obtained. Typically, this amount is at least about 0.01% of the ADC by weight of the composition.

In some embodiments, the compositions dosage of an ADC administered to a subject is from about 0.01 mg/kg to about 100 mg/kg, from about 1 to about 100 mg of a per kg or from about 0.1 to about 25 mg/kg of the subject's body weight. In some embodiments, the dosage administered to a subject is about 0.01 mg/kg to about 15 mg/kg of the subject's body weight. In some embodiments, the dosage administered to a subject is about 0.1 mg/kg to about 15 mg/kg of the subject's body weight. In some embodiments, the dosage administered to a subject is about 0.1 mg/kg to about 20 mg/kg of the subject's body weight. In some embodiments, the dosage administered is about 0.1 mg/kg to about 5 mg/kg or about 0.1 mg/kg to about 10 mg/kg of the subject's body weight. In some embodiments, the dosage administered is about 1 mg/kg to about 15 mg/kg of the subject's body weight. In some embodiments, the dosage administered is about 1 mg/kg to about 10 mg/kg of the subject's body weight. In some embodiments, the dosage administered is about 0.1 to about 4 mg/kg, about 0.1 to about 3.2 mg/kg, or about 0.1 to about 2.7 mg/kg of the subject's body weight over a treatment cycle.

The term "carrier" refers to a diluent, adjuvant or excipient, with which a compound is administered. Such pharmaceutical carriers are liquids. Water is an exemplary carrier when the compounds are administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions are also useful as liquid carriers for injectable solutions. Suitable pharmaceutical carriers also include glycerol, propylene, glycol, or ethanol. The present compositions, if desired, will in some embodiments also contain minor amounts of wetting or emulsifying agents, and/or pH buffering agents.

In some embodiments, the ADCs are formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to animals, particularly human beings. Typically, the carriers or vehicles for intravenous administration are sterile isotonic aqueous buffer solutions. In some embodiments, the composition further comprises a local anesthetic, such as lignocaine, to ease pain at the site of the injection. In some embodiments, the ADC and the remainder of the formulation are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where an ADC is to be administered by infusion, it is sometimes dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the conjugate is administered by injection, an ampoule of sterile water for injection or saline is typically provided so that the ingredients are mixed prior to administration.

The pharmaceutical compositions are generally formulated as sterile, substantially isotonic and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration.

EXAMPLES

General Information

All commercially available anhydrous solvents were used without further purification. Silica gel chromatography was performed on a Biotage Isolera One flash purification system (Charlotte, NC). UPLC-MS was performed on a Waters Xevo G2 ToF mass spectrometer interfaced to a Waters Acquity H-Class Ultra Performance LC equipped with an Acquity UPLC BEH C18 2.1 x 50 mm, 1.7 μ m reverse phase column. The acidic mobile phase (0.1% formic acid) consisted of a gradient of 3% acetonitrile/97% water to 100% acetonitrile (flow rate = 0.7 mL/min). Preparative HPLC was carried out on a Waters 2545 solvent delivery system configured with a Waters 2998 PDA detector. Products were purified over a C12 Phenomenex Synergi reverse phase column (10.0-50 mm diameter x 250 mm length, 4 μ m, 80 Å) eluting with 0.1% trifluoroacetic acid in water (solvent A) and 0.1% trifluoroacetic acid in acetonitrile (solvent B). The purification methods generally consisted of linear gradients of solvent A to solvent B, ramping from 5% aqueous solvent B to 95% solvent B; flow rate was varied depending on column diameter. NMR

spectral data were collected on a Varian Mercury 400 MHz spectrometer. Coupling constants (J) are reported in hertz.

Product purification: Products were purified by flash column chromatography utilizing a Biotage Isolera One flash purification system (Charlotte, NC). Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) was performed on a Waters single quad detector mass spectrometer interfaced to a Waters Acquity UPLC system. Preparative-High Performance Liquid Chromatography (HPLC) was carried out on a Waters 2454 Binary Gradient Module solvent delivery system configured with a Waters 2998 PDA detector. Products were purified with the appropriate diameter of column of a Phenomenex Max-RP 4 μm Synergi 80 Å 250 mm reverse phase column eluting with 0.05% trifluoroacetic acid in water and 0.05% trifluoroacetic acid in acetonitrile unless otherwise specified. All commercially available anhydrous solvents were used without further purification. Starting materials, reagents and solvents were purchased from commercial suppliers (Sigma Aldrich and/or Fischer Scientific).

Analytical LCMS methods

Method A: Chromatography was performed on a Waters Acquity H Class UPLC equipped with a C18 column (Phenomenex Luna, 2.1 x 50 mm, 1.6 μm). Solvent A comprised 0.05% formic acid in water. Solvent B comprised 0.05% formic acid in acetonitrile. The flow rate was 0.7 ml/min, and elution was carried out with the following gradient: 0 to 1.21 min, 3% to 60% solvent B; 1.21 to 1.43 min, 60% to 95% solvent B; 1.43 to 1.79 min, 95% to 3% solvent B. Mass detection was performed on a Waters Xevo G2 TOF by electrospray ionization in positive ion mode.

Method B: Chromatography was performed on a Waters Acquity H Class UPLC equipped with a C8 column (Phenomenex Kinetex, 2.1 x 50 mm, 1.7 μm). Solvent A comprised 0.05% formic acid in water. Solvent B comprised 0.05% formic acid in acetonitrile. The flow rate was 0.7 ml/min, and elution was carried out with the following gradient: 0 to 1.21 min, 3% to 60% solvent B; 1.21 to 1.43 min, 60% to 95% solvent B; 1.43 to 1.79 min, 95% to 3% solvent B. Mass detection was performed on a Waters Xevo G2 TOF by electrospray ionization in positive ion mode.

Method C: Chromatography was performed on a Waters Acquity H Class UPLC equipped with a C18 column (Phenomenex Luna, 2.1 x 50 mm, 1.6 μm). Solvent A comprised 0.05% formic acid in water. Solvent B comprised 0.05% formic acid in acetonitrile. The flow rate was 0.6

ml/min, and elution was carried out with the following gradient: 0 to 1.10 min, 3% to 60% solvent B; 1.10 to 1.50 min, 60% to 97% solvent B; 1.50 min to 2.50 min, 97% solvent B; 2.50 min to 2.60 min; 97% to 3% solvent B. Mass detection was performed on a Waters Xevo G2 TOF by electrospray ionization in positive ion mode.

5 *Method D:* Chromatography was performed on a Waters Acquity H Class UPLC equipped with a C18 column (Phenomenex Luna, 2.1 x 50 mm, 1.6 μ m). Solvent A comprised 0.05% formic acid in water. Solvent B comprised 0.05% formic acid in acetonitrile. The flow rate was 0.7 ml/min, and elution was carried out with the following gradient: 0 to 1.21 min, 3% to 60% solvent B; 1.21 to 1.43 min, 60% to 97% solvent B; 1.43 min to 4.00 min, 97% to 3% solvent B. Mass
10 detection was performed on a Waters Xevo G2 TOF by electrospray ionization in positive ion mode.

Method E: Chromatography was performed on a Waters Acquity UPLC equipped with a C18 column (Phenomenex Luna, 2.1 x 50 mm, 1.6 μ m). Solvent A comprised 0.1% formic acid in water. Solvent B comprised 0.1% formic acid in acetonitrile. The flow rate was 0.5 ml/min, and
15 elution was carried out with the following gradient: 0 to 1.70 min, 3% to 60% solvent B; 1.70 to 1.2.00 min, 60% to 95% solvent B; 2.00 min to 2.50 min, 97% to 3% solvent B. Mass detection was performed on a Waters Acquity SQ by electrospray ionization in positive ion mode.

CORTECS C18 General Method:

20 Column - Waters CORTECS C18 1.6 μ m, 2.1 x 50 mm, reversed-phase column

Solvent A - 0.1% aqueous formic acid

Solvent B - acetonitrile with 0.1% formic acid

Time (min)	Flow (mL/min)	A%	B%	Gradient
Initial	0.6	97	3	
1.70	0.6	40	60	Linear
2.00	0.6	5	95	Linear
2.50	0.6	5	95	Linear
2.80	0.6	97	3	Linear
3.00	0.6	97	3	Linear

CORTECS C18 Hydrophobic Method:Column - Waters CORTECS C18 1.6 μ m, 2.1 x 50 mm, reversed-phase column

Solvent A - 0.1% aqueous formic acid

Solvent B - acetonitrile with 0.1% formic acid

Time (min)	Flow (mL/min)	A%	B%	Gradient
Initial	0.6	97	3	
1.50	0.6	5	95	Linear
2.40	0.6	5	95	Linear
2.50	0.6	97	3	Linear
2.80	0.6	97	3	Linear

5



CORTECS C18 Hydrophilic Method:Column - Waters CORTECS C18 1.6 μ m, 2.1 x 50 mm, reversed-phase column

Solvent A - 0.1% aqueous formic acid

Solvent B - acetonitrile with 0.1% formic acid

Time (min)	Flow (mL/min)	A%	B%	Gradient
Initial	0.6	97	3	
1.70	0.6	67	33	Linear
2.00	0.6	5	95	Linear
2.50	0.6	97	3	Linear
2.80	0.6	97	3	Linear

10


Example 2: Synthesis of MC 1 (Glucuronide-Gemcitabine conjugate)**5 Step 1:**

To 10 mL anhydrous pyridine was dissolved 782.6 mg Gemcitabine (2.973 mmol). To this solution, 1.89 mL trimethylsilyl chloride (TMSCl) (14.9 mmol) was added over 5 minutes while continually and vigorously stirred for 15 minutes. To the reaction, 961.5 mg fluorenylmethyloxycarbonyl chloride (Fmoc-Cl) (3.717mmol) was added where the reaction turned from yellow to colorless over 30 minutes, and a white precipitate persisted over the course of the reaction. To hydrolyze the trimethylsilyl (TMS) groups and excess chlorofomate, 2.0 mL H₂O was added, and the reaction was stirred for 2 hours. The reaction mixture was diluted with 100 mL EtOAc, and washed 3 times with 100 mL 1M hydrochloric acid (HCl), dried magnesium sulfate (MgSO₄). At this time, the reaction is filtered and concentrated *in vacuo*. Crude product is purified by flash chromatography 100G KP-Sil 50-100% EtOAc in Hex. R_f (product) = 0.15 in 1:2 Hex:EtOAc.

Fractions containing the desired product were concentrated *in vacuo* to produce the product as a white solid (1.169 g, 2.407 mmol, 80.9 %). R_t = 1.71 min, CORTECS C18 General Method

UPLC (as described above in connection with Example 1). MS (m/z) $[M + H]^+$ calc. for $C_{24}H_{22}F_2N_3O_6$ 486.45, found 486.12.


Step 2:



A solution was created of 185 mg Linker (**L-1**) (0.206 mmol) dissolved in 2 mL dichloromethane (DCM). To this solution, 185 mg paraformaldehyde (6.18 mmol) was added followed by 1.0 mL TMSCl. The reaction was stirred for 10 minutes at which point complete conversion was observed by diluting 2 μ L aliquot into 98 μ L of MeOH and observing the MeOH adduct by UPLC-MS. The reaction was filtered with a syringe filter, rinsed with 1 mL DCM, and 2 mL toluene was added to azeotrope final mixture upon concentration. The eluent was concentrated *in vacuo* to afford an activated linker as a colorless solid.


The Fmoc-Gemcitabine (**Step 1**), was azeotroped with toluene and dried under high vacuum prior to use. After which 100 mg Fmoc-Gemcitabine (0.206 mmol) was suspended in 2 mL anhydrous DCM and 71.8 μ L DIPEA (0.412 mmol) was added. The activated linker was dissolved in 2 mL anhydrous DCM and added dropwise to the stirring reaction at a rate of 10 mL/hour. The reaction was stirred for 45 minutes at which point complete conversion was observed. The reaction was quenched with 0.1 mL MeOH, filtered, and the eluent was concentrated *in vacuo* to afford a colorless solid which was used in the next step without purification (182 mg, 0.130 mmol, crude, 63 %). $R_t = 1.56$ min CORTECS C18 Hydrophobic Method UPLC. MS (m/z) $[M + H]^+$ calc. for $C_{67}H_{69}F_2N_6O_{23}S$ 1395.41, found 1395.40.

Step 3:



A solution of 2 mL THF:MeOH 1:1 into which was dissolved 182 mg of step 2 product (0.130 mmol). The reaction was cooled with an ice/water bath. After which 31.2 mg LiOH (1.30 mmol) was added and the reaction was stirred for 30 minutes. Conversion to the acetate deprotected product was observed by UPLC-MS (as described in Example 1) and 1 mL H₂O was added to the reaction mixture and the reaction was stirred for 60 minutes. Complete conversion observed by UPLC-MS (as described in Example 1). The reaction was quenched with 30 μ L AcOH, concentrated *in vacuo* and purified by preparative HPLC using a 21.2 x 250 mm Max-RP column eluted with a gradient of 5-35-95% MeCN in H₂O 0.05% TFA. Fractions containing the desired compound were concentrated *in vacuo* to afford the desired compound as a colorless solid (65.1 mg, 0.0803 mmol, 62%). Rt = 0.82 min CORTECS C18 Hydrophilic Method UPLC. MS (m/z) [M + H]⁺ calc. for C₃₀H₄₁F₂N₆O₁₆S 811.23, found 811.04.


Step 4: Gemcitabine and Linker and N-Succinimidyl 3-Maleimidopropionate:



A solution of 0.5 mL anhydrous DMF into which 65.1 mg of the product of step 3 (0.0803 mmol) was dissolved. To the reaction was added 26.5 μ L DIPEA (0.160 mmol) was added followed by 23.5 mg N-Succinimidyl 3-Maleimidopropionate (0.0883 mmol, purchased from TCI America product number S0427). The reaction was stirred for 15 minutes. Complete conversion

was observed after UPLC-MS. The reaction was quenched with 0.020 mL AcOH and purified by preparative HPLC eluting with 5-35-95% MeCN in H₂O 0.05% TFA on a 21.2 x 250 mm Max-RP. Fractions containing the desired product were lyophilized to afford desired compound as a colorless powder (41.2 mg, 0.0428 mmol, 53.3%). Rt = 1.29 min CORTECS C18 Hydrophilic Method UPLC. MS (m/z) [M + H]⁺ calc. for C₃₇H₄₆F₂N₇O₁₉S 962.25, found 962.06.

Example 3: Synthesis of Protected Duplexing Agent (S)-N,N'-(((2-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido)butane-1,4-diyl)bis(sulfanediyl))bis(methylene)) diacetamide (MC2 diacetamide)




A vial was charged with 200 mg (S)-2-aminobutane-1,4-dithiol hydrochloride (1.15 mmol) and 308 mg N-(hydroxymethyl)acetamide (3.45 mmol) and suspended in 0.6 mL water. The suspension was cooled in an ice water bath and 0.2 mL hydrochloric acid (11.7 M, 2.34 mmol) was added dropwise. The reaction was slowly warmed to room temperature. After stirring overnight, the reaction was concentrated at 45°C to afford the intermediate (S)-N,N'-(((2-aminobutane-1,4-diyl)bis(sulfanediyl))bis(methylene))diacetamide hydrochloride as a clear semi-solid that was used without further purification. Analytical UPLC-MS: tr = 0.57 min, m/z (ES⁺) calculated 280.1 (M+H)⁺, found 280.0.


Combined in a vial: 232 mg of the intermediate (S)-N,N'-(((2-aminobutane-1,4-diyl)bis(sulfanediyl))bis(methylene))diacetamide hydrochloride (0.73 mmol), and 391 mg 2,5-dioxopyrrolidin-1-yl 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoate (1.47 mmol) dissolved in 2.5 mL DMF, and 0.51 mL DIPEA (2.94 mmol) was added dropwise. After stirring for 2 hours at room temperature, the reaction was quenched with 0.25 mL acetic acid, diluted with methanol, purified by preparative HPLC (as described above in connection with Example 1), and lyophilized to dryness to provide (S)-N,N'-(((2-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-

yl)propanamido)butane-1,4-diyl)bis(sulfanediyl))bis(methylene))diacetamide (42 mg, 13.3%. Analytical UPLC: t_r = 0.89 min, m/z (ES⁺) calculated 431.1 (M+H)⁺, found 431.1; calculated 453.1 (M+Na)⁺, found 453.0.


5 Example 4: Synthesis of MC9



MC9




Step 1: (2R,3R,4S,5S)-2-(acetoxymethyl)-6-bromotetrahydro-2H-pyran-3,4,5-triyl triacetate (Compound 5): (2R,3S,4S,5R,6R)-6-(acetoxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate (2.55g, 6.53 mmol) was dissolved in 11.5 mL CH₂Cl₂ and cooled to 0°C in ice bath. A solution of 33% HBr in 4.3 mL acetic acid was added dropwise, stirred at 0°C for 30 min, and allowed to slowly warm to room temperature overnight. Reaction was determined complete by TLC (conditions: 30% EtOAc/hexanes, stained with KMnO₄). The crude reaction mixture was diluted with CH₂Cl₂ and washed once each with water, sat. NaHCO₃ solution, water, and brine, then dried over Na₂SO₄, filtered, and concentrated *in vacuo* to provide **compound 5** (2.68 g, 6.52 mmol, 100%). ¹H NMR (CDCl₃, 400 MHz): δ 2.01 (s, 3H), 2.08 (s, 3H), 2.10 (s, 3H), 2.18 (s, 3H), 4.13 (dd, J = 12.5 Hz, 2.2 Hz, 1H), 4.18-4.26 (m, 1H), 4.33 (dd, J = 12.5 Hz, 4.8 Hz, 1H), 5.33-5.41 (m, 1H), 5.44 (dd, J = 3.5 Hz, 1.6 Hz, 1H), 5.70 (dd, J = 10.3 Hz, 3.3 Hz, 1H), 6.33 (dd, J = 1.7 Hz, 0.8 Hz, 1H).




Step 2: (2R,3R,4S,5S,6R)-2-(acetoxymethyl)-6-(4-formyl-2-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (Compound 6): **Compound 5** (3.227 g, 7.85 mmol) was dissolved in 10 mL acetonitrile and silver oxide (7.82 g, 33.74 mmol) added. Dissolved 4-formyl-2-nitrophenol (1.312 g, 7.85 mmol) in 55 mL acetonitrile was added portion-wise to the reaction mixture. Reaction was determined complete after 2 hours by TLC (conditions: 5% MeOH/DCM, stained with KMnO₄), the solution filtered through celite with ethyl acetate, and the filtrate concentrated *in vacuo* to provide **compound 6** (3.643 g, 7.32 mmol, 93%). LCMS Method A: tr = 1.31 min; m/z = 520.2 [M+Na]⁺.

10




Step 3: (2R,3R,4S,5S,6R)-2-(acetoxymethyl)-6-(4-(hydroxymethyl)-2-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (Compound 7): **compound 6** (3.245 g, 6.52 mmol) suspended in 60 mL 1:1:1 THF:MeOH:AcOH and cooled to 0°C in ice bath. Sodium borohydride (740 mg, 19.56 mmol) added in portions over 2 hours. Upon completion, the reaction mixture was diluted with methanol, filtered through celite, and concentrated *in vacuo*. The crude residue was partitioned between DCM and sat. NaHCO₃ solution, the aqueous layer extracted twice with DCM, and the combined organic layers washed once with brine, dried over Na₂SO₄, filtered, and concentrated *in vacuo* to provide compound 7 (3.09 g, 6.19 mmol, 95%). LCMS Method A: tr = 1.14 min; m/z = 522.2 [M+Na]⁺.

20




Step 4: (2R,3R,4S,5S,6R)-2-(acetoxymethyl)-6-(2-amino-4-(hydroxymethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (compound 8): **compound 7** (1.376 g, 2.76 mmol) was taken up in 40 mL methanol and cooled to 0°C in ice bath. Zinc dust (1.80 g, 27.55 mmol) and ammonium chloride (1.474 g, 27.55 mmol) were added sequentially. The reaction was stirred on ice for 15 min. Then the ice bath was removed, and stirring was continued at room temperature for 2 hours. The reaction was filtered through celite with methanol, and the filtrate was concentrated *in vacuo*. Crude residue was re-suspended in ethyl acetate and washed twice with saturated NaHCO₃ solution and once with brine. Combined aqueous layers were extracted three times with ethyl acetate, the combined organic layers dried over sodium sulfate and concentrated *in vacuo*. The crude product was purified by silica gel chromatography using a gradient from 10 to 100% ethyl acetate in dichloromethane to provide 410 mg compound 8 (0.87 mmol, 32%). LCMS Method B: tr = 0.85 min; m/z = 470.2 [M+H]⁺.



Step 5: (2R,3S,4S,5R,6R)-2-(2-(3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanamido)-4-(hydroxymethyl)phenoxy)-6-(acetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (Compound 9): To a solution of 151 mg compound 8 (0.32 mmol) in 5 mL dichloromethane was added 110 mg 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino) propanoic acid (0.35 mmol) with addition of 0.2 mL DMF to aid solubility, and 87.5 mg EEDQ (0.35 mmol), and the reaction stirred at room temperature overnight. The reaction mixture was concentrated *in*


vacuo, and the crude product purified by silica gel chromatography using a gradient from 0 to 3% methanol in dichloromethane to provide **compound 9** (214 mg, 0.28 mmol, 87%). LCMS Method A: *tr* = 1.43 min; *m/z* = 763.3 [M+H]⁺.



5

Step 6: (2*R*,3*S*,4*S*,5*R*,6*R*)-2-(2-(3-(((9*H*-fluoren-9-yl)methoxy)carbonyl)amino)propanamido)-4-(((4-nitrobenzoyl)oxy)methyl)phenoxy)-6-(acetoxymethyl)tetrahydro-2*H*-pyran-3,4,5-triyl triacetate (**compound 10**): To a solution of **compound 9** (258 mg, 0.34 mmol) in 3 mL DMF was added 88.6 μ L DIEA (0.51 mmol) and bis(4-nitrophenyl) carbonate (206 mg, 0.68 mmol), and the reaction mixture stirred at room temperature overnight. The reaction mixture was partitioned between water and ethyl acetate, and the organic layer washed three times with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The crude product was purified by silica gel chromatography using a gradient from 10 to 70% ethyl acetate in hexanes to give 208 mg **compound 10** (0.22 mmol, 65%). LCMS Method A: *tr* = 1.61 min; *m/z* = 928.4 [M+H]⁺.


15




Step 7: (2*R*,3*S*,4*S*,5*R*,6*R*)-2-(2-(3-(((9*H*-fluoren-9-yl)methoxy)carbonyl)amino)propanamido)-4-(((3-(4-(4-((*E*)-3-(pyridin-3-yl)acrylamido)butyl)piperidine-1-carbonyl)phenyl)carbamoyl)oxy)methyl)phenoxy)-6-(acetoxymethyl)tetrahydro-2*H*-pyran-3,4,5-triyl triacetate (**Compound 11**): (*E*)-*N*-(4-(1-(3-aminobenzoyl)piperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide (581 mg, 0.916 mmol) and 934 mg **compound 10** (1.01 mmol) were dissolved in

20

106 mL DMF and 2.1 mL pyridine. 12.5 mg HOAt (0.092 mmol) was added as a solution in DMF, and the reaction stirred at room temperature overnight. The reaction was poured into EtOAc, and the organic layer washed 2x water, dried over MgSO₄ and concentrated *in vacuo*. The crude product was purified by silica gel chromatography using a gradient from 0 to 10% methanol in dichloromethane to provide 850 mg **compound 11** (0.711 mmol, 78%). LCMS Method C: tr = 1.84 min; m/z = 1195.8 [M+H]⁺.




10 Step 8: 3-(3-aminopropanamido)-4-(((2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl) tetrahydro-2H-pyran-2-yl)oxy)benzyl (3-(4-(4-((E)-3-(pyridin-3-yl)acrylamido)butyl) piperidine-1-carbonyl) phenyl)carbamate (Compound 12): 383 mg compound 11 (0.293 mmol) was dissolved in 6 mL THF and 6 mL MeOH and cooled on ice. A solution of 5.9 mL LiOH (0.5M, 2.93 mmol) was slowly added. After 30 minutes, the reaction was removed from ice and allowed to warm to room temperature. After 4 hours, the reaction was quenched with 167.5 µL acetic acid (2.93 mmol) and concentrated *in vacuo*. Crude residue taken up in DMSO, filtered, and purified by preparative HPLC to give 230 mg **compound 12** (0.223 mmol, 76%) as the TFA salt. LCMS Method D: tr = 0.79 min; m/z = 805.4 [M+H]⁺.




20 Step 9: 3-(3-((S)-3-((tert-butoxycarbonyl)amino)-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido)propanamido)-4-(((2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzyl (3-(4-(4-((E)-3-(pyridin-3-yl)acrylamido)butyl)piperidine-1-carbonyl)phenyl)carbamate (Compound 13): **compound 12** (334 mg, 0.324 mmol) was dissolved in 3.5 mL DMF and 0.17 mL DIPEA (0.971 mmol) followed


by addition of 148 mg 2,5-dioxopyrrolidin-1-yl (2S)-3-[(tert-butoxycarbonyl)amino]-2-(2,5-dioxopyrrol-1-yl)propanoate (0.388 mmol). After 3 hours, the reaction was diluted with DMSO and purified by preparative HPLC to give compound 13 (299 mg, 0.253 mmol, 78%) as the TFA salt. LCMS Method C: $t_r = 1.32$ min; $m/z = 1071.7$ $[M+H]^+$.




Step 10: 3-(3-((S)-3-amino-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido)propanamido)-4-(((2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzyl (3-(4-(4-((E)-3-(pyridin-3-yl)acrylamido)butyl)piperidine-1-carbonyl)phenyl)carbamate (Compound 14 -- MC9): **compound 13** (299 mg, 0.253 mmol) was treated with 20% TFA in 15 mL DCM for 2 hours. The solvent was removed *in vacuo*, and the residue dissolved in 50/50 CH₃CN/H₂O and purified by preparative HPLC to provide compound 14 (201 mg, 0.168 mmol, 66%) as the TFA salt. LCMS Method C: $t_r = 1.10$ min; $m/z = 971.6$ $[M+H]^+$.

Example 5: Synthesis of MC10






Step 1: (2R,3S,4S,5R,6R)-2-(2-(3-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanamido)-4-(bromomethyl)phenoxy)-6-(acetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (Compound 10): the benzyl alcohol analog of **compound 10** (200 mg, 0.262 mmol) and 103 mg PPh₃ (0.393 mmol) were dissolved in 8 mL DCM at 0°C. N-bromosuccinimide (70 mg, 0.393 mmol) was added in two portions at the same temperature. Ice bath was then removed and allowed the reaction to slowly warm up to room temperature. After 4 hours the solvent was removed and the crude reaction mixture was purified by flash column chromatography to provide **compound 10** (154mg, 0.187 mmol, 71.0%). LCMS Method E: *t_r* = 2.31 min; *m/z* = 825.04 [M+1]⁺.




Step 2: 1-(3-(3-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanamido)-4-(((2R,3S,4S,5R,6R)-3,4,5-triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzyl)-3-(((E)-3-((4-(1-(3-((tert-butoxycarbonyl)amino)benzoyl)piperidin-4-yl)butyl)amino)-3-oxoprop-1-en-1-yl)pyridin-1-ium) (Compound 11): **compound 10** (109.3 mg, 0.132 mmol) and tert-butyl (E)-3-(4-(4-(3-(pyridin-3-yl)acrylamido)butyl)piperidine-1-carbonyl)phenyl)carbamate (51.6 mg, 0.102 mmol) was dissolved in anhydrous 800 μL DMF and heated up to 55 °C for 2 hours. The reaction was cooled to room temperature, diluted with DMSO and water, purified by preparative

HPLC to provide 108.2 mg compound 11 (0.079 mmol, 77.8%). LCMS Method E: t_r = 2.00 min; m/z = 1251.40 $[M]^+$.




Step 3: 1-(3-(3-aminopropanamido)-4-(((2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzyl)-3-((E)-3-((4-(1-(3-((tert-butoxycarbonyl)amino)benzoyl)piperidin-4-yl)butyl)amino)-3-oxoprop-1-en-1-yl)pyridin-1-ium 2,2,2-trifluoroacetate (Compound 12): **compound 11** (508 mg, 0.037 mmol) was dissolved in 1.8 mL of a 1:1 mixture of MeOH and THF. The solution was cooled on ice prior to the addition of LiOH solution (1.86 mL, 0.2 M, 0.372 mmol). The reaction was stirred on ice for 30 mins, and then warmed to room temperature. After 3 hours, the reaction was acidified with 20 μ L acetic acid, then diluted with DMSO/water and purified by preparative HPLC to provide 20.6 mg of compound 12 (0.019 mmol, 50.8 %). LCMS Method E: t_r = 0.84 min; m/z = 861.39 $[M]^+$.



Step 4: 1-(3-(3-((S)-3-((tert-butoxycarbonyl)amino)-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido)propanamido)-4-(((2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzyl)-3-((E)-3-((4-(1-(3-((tert-butoxycarbonyl)amino)benzoyl)piperidin-4-yl)butyl)amino)-3-oxoprop-1-en-1-yl)pyridin-1-ium 2,2,2-trifluoroacetate (Compound 13): **compound 12** (10.2 mg, 0.011 mmol) was dissolved in anhydrous 300 μ L DMF followed by the addition of 9.3 μ L DIPEA. 6.12 mg 2,5-Dioxopyrrolidin-1-yl (S)-3-((tert-butoxycarbonyl)amino)-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoate (0.016 mmol) in anhydrous 100 μ L DMF was then added. The reaction mixture was stirred at room temperature for 30 min. After 30 min, reaction was acidified with HOAc (10 μ L), diluted with

DMSO/water and purified by prep-HPLC to provide **compound 13** (10.3 mg, 0.008 mmol, 77.5%). LCMS Method E: $t_r = 1.58$ min; $m/z = 1127.79$ $[M]^+$.



Step 5: 1-(3-(3-((S)-3-ammonio-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido)propanamido)-4-(((2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzyl)-3-((E)-3-((4-(1-(3-ammoniobenzoyl)piperidin-4-yl)butyl)amino)-3-oxoprop-1-en-1-yl)pyridin-1-ium 2,2,2-trifluoroacetate (Compound 14 MC10): 10.3 mg compound 13 (0.008mmol) was suspended in 240 μ L DCM and 60 μ L TFA was added. The reaction mixture turned homogenous after adding TFA. The reaction was stirred at room temperature for 4 hours. After 4 hours, solvent was removed under vacuum and the crude product was diluted with DMSO/water and purified by prep-HPLC to provide **compound 14 (MC10)** (5.4 mg, 0.004 mmol, 51.3%). LCMS Method E: $t_r = 1.45$ min; $m/z = 927.46$ $[M]^+$.


Example 6: Hydrophobic Interaction Chromatography (HIC) of hAC10ec Conjugates with MC1 or MC3

Hydrophobic interaction was measured with HIC (280 nm). Results of the HIC are shown in Figure 1. The retention time of unconjugated hAC10ec (first peak) was about 4 minutes. The retention time of hAC10ec-MC1(10) (second peak) was about 4.5 minutes. The retention time of hAC10ec-MC1(20) (third peak) was about 5.3 minutes. The retention time of hAC10ec-MC1(38.5) (fourth peak) was about 6.0 minutes. The retention time of hAC10ec-MC3(38.4) (fifth peak) was about 11.8 minutes.


Example 7: Conjugation with MC2 and N-Ethyl maleimide (NEM)

An exemplary embodiment of antibody conjugation with duplexer MC2 and N-Ethyl maleimide and corresponding spectroscopy data is shown in Figure 2.

Referring to Figure 2, an Antibody (cAC10) having a L0=23152 was conjugated with duplexer MC2 to form an antibody-duplexer conjugate (*see below*) (expected mass: 23476; observed mass: 23475).



The antibody-duplexer conjugate was then reduced with TCEP, followed by conjugation with *N*-ethylmaleimide (NEM) to form an antibody-duplexer-NEM conjugate (*see below*) (expected mass 23723; observed mass 23725).



Example 8: Experimental procedure for conjugation of IgG1-MC6(8) to produce 16-load ADCs of MC7/-MC8/-MC9/-MC10 (PEG on duplexer)

Step 1: 15 mg fully reduced antibody IgG1 in 1.16 mL PBS was conjugated with MC6 (13.3 mM solution in DMSO; 1.45 equiv of scaffold per reactive thiol) in PBS at room temperature for 2 hours. Reaction completion was confirmed by PLRP-MS analysis. The reaction mixture was purified by size-exclusion chromatography eluting with PBS. The resulting solution was concentrated to provide the antibody-scaffold conjugate at 11.8 mg/ml. The solution was adjusted to pH 8 using 1M potassium phosphate buffer at pH 8. The scaffold disulfides were reduced using TCEP (2 equiv per disulfide), incubating at 37 °C for 75 min. Complete reduction was verified by reaction of an analytical aliquot with excess N-acetyl maleimide followed by PLRP-MS analysis. The completed reaction was purified by size exclusion chromatography eluting with PBS + 2 mM EDTA. The eluent was concentrated to 15.6 mg/mL and stored at -20 °C until further use.

Step 2: 3mg fully reduced antibody-scaffold conjugate was conjugated with indicated drug linkers (10 mM solutions in DMSO; 1.25-1.45 equiv of drug linker per reactive thiol) in PBS at room temperature for 2 hours. Reaction completion was confirmed by PLRP-MS analysis. The reactions were purified by size-exclusion chromatography eluting with PBS. The eluents were diluted to 4 ml prior to concentration to ~1 ml. This dilution/concentration procedure was repeated once more prior to final concentration to ~300 µl. Concentration of the resulting ADCs was determined using the DC Protein Assay (Bio-Rad). The identity of the final conjugates was confirmed by PLRP-MS, and the presence of high-molecular weight species determined by analytical SEC.

Example 9: Experimental analytical data for antibody-drug conjugates

L_{exp} and H_{exp} are predicted masses of antibody light and heavy chains, respectively, excluding hydrolysis of the thiosuccinimide moiety after conjugation. L_{obs} and H_{obs} are observed masses of the predominant species as determined by PLRP-MS analysis; the number of additional waters (from thiosuccinimide hydrolysis prior to analysis) are indicated. %HMW indicates the percentage of high molecular weight species as determined by analytical size-exclusion chromatography.

	L _{exp}	L _{obs}	H _{exp}	H _{obs}	% HMW
IgG1		23151		50470	Not measured
IgG1-MC6(8)	24679	24698 (L _{exp} +1 H ₂ O)	55053	55110 (H _{exp} +3 H ₂ O)	Not measured
IgG1-MC6(8)- MC7(16)	26650	26670 (L _{exp} +1 H ₂ O)	60965	61043 (H _{exp} +4 H ₂ O)	3.4%
IgG1-MC6(8)- MC8(16)	26564	26600 (L _{exp} +1 H ₂ O)	60707	60798 (H _{exp} +5 H ₂ O)	2.4%
IgG1-MC6(8)- MC9(16)	26622	26660 (L _{exp} +2 H ₂ O)	60881	60995 (H _{exp} +6 H ₂ O)	7.6%
IgG1-MC6(8)- MC10(16)	26536	26572 (L _{exp} +2 H ₂ O)	60623	60750 (H _{exp} +7 H ₂ O)	1.8%
IgG1-MC2(8)	23452	23471 (L _{exp} +1 H ₂ O)	51373	51428 (H _{exp} +3 H ₂ O)	Not measured
IgG1-MC2(8)- MC8(16)	25337	25373 (L _{exp} +2 H ₂ O)	57027	57115 (H _{exp} +5 H ₂ O)	1.2%
cAC10		23724		50320	
cAC10-MC6(8)- MC7(16)	27223	27279 (L _{exp} + 3 H ₂ O)	60817	60985 (H _{exp} + 9 H ₂ O)	2.2%
cAC10-MC6(8)- MC8(16)	27137	27190 (L _{exp} + 3 H ₂ O)	60559	60715 (H _{exp} + 9 H ₂ O)	<5%
cAC10-MC6(8)- MC9(16)	27195	27251 (L _{exp} + 3 H ₂ O)	60733	60901 (H _{exp} + 9 H ₂ O)	9.6%
cAC10-MC6(8)- MC10(16)	27109	27163 (L _{exp} + 3 H ₂ O)	60475	60640 (H _{exp} + 9 H ₂ O)	<5%
Ab1ec		24210		50763	
Ab1ec-MC6-MC9 (20)	27681	27732 (L _{exp} + 3 H ₂ O)	64647	64648 (H _{exp} + 0 H ₂ O)	4.6%

Example 10: Analytical characterization of auristatin conjugates with cAC10 and conjugate intermediates thereof

Size exclusion chromatogram of 16-load auristatin ADCs with formula cAC10-MC2(8)-
5 MC4(16) is shown in Figure 3 (A) (retention time: about 6.6 minutes). Size exclusion chromatography data for 16-load auristatin ADCs with formula cAC10-MC2(8)-MC5(16) is shown in Figure 3(B) (retention time: about 6.6 minutes).

Chromatography and Mass Spectroscopy data on duplexer conjugates with MC4 (Ab-MC2(8)-MC4(16)).




Figure 4(A) shows the PLRP chromatogram of cAC10 conjugates with MC2 and MC4 (retention time of light chain: about 1.29 minutes; retention time of heavy chain: about 1.97 mins). The mass spectrometry data indicate conjugation of 2 equivalent of MC4 to each light chain and 6 equivalent of MC4 to each heavy chain. As such, the antibody in total was found to be conjugated with 16 equivalents of MC4.

Figure 4(B) shows the mass spectrum of antibody (cAC10) light chain conjugated to one unit of MC2 (expected: 25,737; observed 25,737).

Figure 4(C) shows the mass spectrum of antibody (cAC10) light chain conjugated to MC2(1)-MC4(2) (expected: 28,072; observed 28,072).

Figure 4(D) shows the mass spectrum of antibody (cAC10) heavy chain conjugated to MC2(3)-MC4(6) (expected: 63,364; observed: 63,364). Observation of multiple peaks is attributable to G0, G1 and G2 oligosaccharide forms of the heavy chain.

Chromatography and Mass Spectroscopy data on duplexer conjugates with MC5 (Ab-MC2(8)-MC5(16)).




Figure 5(A) shows the PLRP chromatogram of cAC10 conjugates with MC2 and MC5 (retention time of light chain: about 0.33 minutes; retention time of heavy chain: about 1.0 minutes. The mass spectrometry data indicate conjugation of 2 equivalent of MC4 to each light chain and 6 equivalent of MC5 to each heavy chain. As such, the antibody in total was found to be conjugated with 16 equivalents of MC5.

Figure 5(B) shows the mass spectrum of antibody (cAC10) light chain conjugated MC2(1)-MC5(2) (expected: 26,244; observed: 26,244).

Figure 5(C) shows the mass spectrum data of antibody (cAC10) heavy chain conjugated to MC2(3)-MC5(6) (expected: 57,880; observed: 57,879). Observation of multiple peaks is attributable to G0, G1 and G2 oligosaccharide forms of the heavy chain.

Example 11: Preparation of dendrimeric ADCs comprising one or more multiplexers

Figure 6 schematically depicts a method for the preparation of dendrimeric ADCs comprising one or more multiplexer moieties. An individual Ab can be reduced and conjugated with a duplexer MC2. In a reduced cysteine engineered monoclonal antibody (ECmAb) having 10 cysteine moieties, the thiol group of each cysteine can be conjugated to an MC2 unit. Each MC2 unit can then be conjugated further to two MC2 units. Conjugation of L²-D moieties to the terminal MC2 units therefore allow the formation of ADCs with DAR = 40. These ADCs have the general formula of Ab-MC2(10)-MC2(20)-(L²-D)₄₀.

Example 12: Characterization of hydrophilic dendrimeric ADCs

Figure 7 is the Hydrophobic Interaction Chromatography (HIC) chromatogram of hAC10 conjugates with a drug moiety (MC1 or MC3) having different DARs (DAR = 0, 10, 20, and 38.5). Hydrophobic interaction was measured with 280 nm HIC. The retention time of naked hAC10ec (first peak) was about 4 minutes. The retention time of hAC10ec-MC1(10) (second peak) was about 4.5 minutes. The retention time of hAC10ec-MC1(20) (third peak) was about 5.3 minutes. The retention time of hAC10ec-MC1(38.5) (fourth peak) was about 6.0 minutes. The retention time of hAC10ec-MC3(38.4) (fifth peak) was about 11.8 minutes. The retention time for commercial drug linker vcMMAE DAR(4) is about 7 minutes.

Example 13: Cytotoxicity of duplexer-based gemcitabine ADCs on L540cy cells

Figure 8 shows the *in vitro* cytotoxicity of cAC10ec-MC1 ADCs having different DAR values to Hodgkin's Lymphoma cell line L540cy. The IC₅₀ value for hAC10ec-MC1(38.5) was 313 ng/mL (circles), the IC₅₀ value for hAC10ec-MC1 (20) was 501 ng/mL (squares), and the IC₅₀ value for hAC10ec-MC1 (10) was >10k (triangles).

Example 14: Rat pharmacokinetic data for IgG1-MC6(8)-MC7(16)-MC8(16)-MC9(16)-MC10(16) and IgG1-MC2(8)-MC8(16)

Figure 9 shows the rat pharmacokinetic data of DAR16 conjugates of antibody IgG1 with an NAMPT inhibitor, having different charges at the L²-D units. Constructs with neutral or zwitterionic L²-D units showed extended half-lives compared to those with net negative or positive charge (which were rapidly cleared). Results can be seen by comparing ADCs with L²-D = MC9 (neutral, dashed line with squares) or MC8 (zwitterionic, solid line with circles) with those having L²-D = MC7 (negatively charged, solid line with triangles) and MC10 (positively charged, dashed line with diamonds).

Example 15: Xenograft efficacy data for cAC10-MC6(8)-(L²-D)(16)

Figure 10 shows the xenograft efficacy of cAC10 and IgG1 conjugates with an NAMPT inhibitor having the general formula of cAC10-MC6(8)-(L²-D)(16) on L540cy-161 cells, wherein L²-D is MC7, MC8, MC9, or MC10. Post-implant mean tumor volume absent treatment (i.e., 0mg/kg (* markers, solid line))) is compared with the mean tumor volume following treatment with cAC10-MC6(8)-MC8(16) 1mg/kg (open diamonds, short dash)), cAC10-MC6(8)-MC7(16) 1mg/kg (filled circles, dotted line), cAC10-MC6(8)-MC9(16) 1mg/kg (open circles, solid line), cAC10-MC6(8)-MC10(16) 1mg/kg (X markers, long dash), and IgG-MC6(8)-MC8(16) 1mg/kg (open triangle, short dash).

Example 16: Xenograft efficacy data for Ab3(ec)-MC6(10)-MC9(20) versus Ab3(ec)-MC7(10) (KG-1 xenograft model)

Figure 11 shows the xenograft efficacy of Ab3(ec)-MC6(10)-MC9(20) and Ab3(ec)-MC7(10) ADCs on KG-1 cells. 10- and 20-load ADCs are compared *in vivo* using both Ab- and drug normalized dosing (mean tumor data). Mean tumor volume with untreated KG-1 cells 0

mg/kg (open diamonds, solid line) is compared with the mean tumor volume following treatment with Ab3(ec)-MC7(10) 10mg/kg (open triangles, dotted line), Ab3(ec)-MC6(10)-MC9-(20) 10mg/kg (open squares, long-dash line), and Ab3(ec)-MC6(10)-MC9(20) 5mg/kg (open circles, short-dash line). Dosing schedule is q7dx2.

5

Example 17: Experimental data of NAD-Glo Assay of high load ADCs

Experimental data from Nad-Glo (Promega) Assays according to manufactures instructions.

TABLE 1A: *In vitro* data for cAC10 high load ADCs

ADC	Antigen	Assay	Cell lines; x50 (ng/ml)		
			L540cy	L428	Karpas-299
cAC10-MC6(8)-MC7(16)	CD30	NAD-Glo	8.4	74	44
cAC10-MC6(8)-MC8(16)	CD30	NAD-Glo	6.8	35	27
cAC10-MC6(8)-MC9(16)	CD30	NAD-Glo	2.7	24	10
cAC10-MC6(8)-MC10(16)	CD30	NAD-Glo	6.5	430	78

10

Example 18: Experimental data of CTG Assays of high load ADCs

Experimental data from CTG Assays (Promega) according to manufactures instructions.

Table 1B

ADC	Antigen	Assay	Cell lines; x50 (ng/ml)		
			L540cy	L428	Karpas-299
cAC10-MC6(8)-MC7(16)	CD30	CTG	100	>2000	1230
cAC10-MC6(8)-MC8(16)	CD30	CTG	55	>2000	>2000
cAC10-MC6(8)-MC9(16)	CD30	CTG	35	>2000	>2000
cAC10-MC6(8)-MC10(16)	CD30	CTG	170	>2000	>2000

15

Example 19: Experimental data of Nad-Glo Assays of high load ADCs against acute myeloid leukemia (AML) cell lines

TABLE 2: *In vitro* data for various ADCs against AML cell lines


ADC	Antigen	Assay	Cell lines; x50 (ng/ml)			
			HL-60	HNT-34	KG-1	MOLM-13
Ab1ec-MC6-MC9 (20)	Ag1	NAD-Glo	90	29	19	49
Ab2(ec)-MC6-MC9 (20)	Ag2	NAD-Glo	782	432	183	3
Ab3(ec)-MC6-MC9 (20)	Ag3	NAD-Glo	>2000	27	71	7





5 Example 20: Experimental data of Nad-Glo Assays of high load ADCs against multiple myeloma (MM) cell lines





TABLE 3: *In vitro* data for various ADCs against MM cell lines

ADC	Antigen	Assay	Cell lines; x50 (ng/ml)		
			MM.1R	MM.1S	U-266
Ab4-MC6(8)-MC9(16)	Ag4	NAD-Glo	4	3	20
Ab5-MC6(8)-MC9(16)	Ag5	NAD-Glo	25	28	180
Ab6-MC6(8)-MC9(16)	Ag6	NAD-Glo	2	3	62

The chemical entities recited in the foregoing examples have the following structures:

Compound	Structure
MC1	


MC2 diacetamide	
MC2	
MC3	
MC4	

MC5	
MC6	
MC7	
MC8	

[illegible]

WHAT IS CLAIMED IS:

1. An antibody-drug conjugate (ADC) compound of Formula (I):




wherein:

Ab is an antibody;


each S^* is a sulfur atom from a cysteine residue of the antibody, an ϵ -nitrogen atom from a lysine residue of the antibody, or a triazole moiety, and

each L^1 is a first linker optionally substituted with a PEG Unit ranging from PEG2 to PEG72;


wherein S^*-L^1 is selected from the group consisting of formulae A-K:




A




B




C




D




E




F




G




H



I



J



K

wherein:

each L^A is a C_{1-10} alkylene optionally substituted with 1-3 independently selected R^a , or a 2-24 membered heteroalkylene optionally substituted with 1-3 independently selected R^b ;

each Ring B is an 8-12 membered heterocyclyl optionally substituted with 1-3 independently selected R^c , and further optionally fused to 1-2 rings each independently selected from the group consisting of C_{6-10} aryl and 5-6 membered heteroaryl;

each R^a , R^b , and R^c is independently selected from the group consisting of: C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, halogen, $-OH$, $=O$, $-NR^dR^e$, $-C(O)NR^dR^e$, $-C(O)(C_{1-6} \text{ alkyl})$, $-(C_{1-6} \text{ alkylene})-NR^dR^e$, and $-C(O)O(C_{1-6} \text{ alkyl})$;

each R^d and R^e are independently hydrogen or C_{1-3} alkyl; or R^d and R^e together with the nitrogen atom to which both are attached form a 5-6 membered heterocyclyl;

L^2 is an optional second linker optionally substituted with a PEG Unit selected from PEG2 to PEG20;

each M is a multiplexer;

subscript x is 0, 1, 2, 3, or 4;

subscript y is 2^x ;

each D is a Drug Unit;

wherein L^1 and each $(M)_x-(D)_y$ when L^2 is absent, or each $(M)_x-(L^2-D)_y$ when L^2 is present, have a net zero charge at physiological pH;

subscript p is an integer ranging from 2 to 10; and


the ratio of D to Ab is 8:1 to 64:1.

2. The ADC compound of claim 1, wherein each S^* is a sulfur atom from a cysteine residue of the antibody.

3. The ADC compound of claim 1 or 2, wherein the cysteine residues are native cysteine residues.
4. The ADC compound of claim 1 or 2, wherein the cysteine residues are from reduced interchain disulfide bonds, or are from engineered cysteine residues, or a combination thereof.
5. The ADC compound of claim 1 or 2, wherein the cysteine residues are engineered cysteine residues.
6. The ADC compound of claim 1 or 2, wherein one or more S* is a sulfur atom from an engineered cysteine residue(s); and each remaining S* is a sulfur atom from a native cysteine residue.
7. The ADC compound of claim 1, wherein each S* is an ϵ -nitrogen atom from a lysine residue of the antibody.
8. The ADC compound of claim 1 or 7, wherein the lysine residues are native lysine residues.
9. The ADC compound of claim 1 or 7, wherein the lysine residues are engineered lysine residues.
10. The ADC compound of claim 1 or 7, wherein one or more S* is an ϵ -nitrogen atom from an engineered lysine residue(s) of the antibody; and each remaining S* is an ϵ -nitrogen atom from a native lysine residue of the antibody.
11. The ADC compound of claim 1, wherein each S* of formula D is a triazole moiety.


12. The ADC compound of any one of claims 1-11, wherein L^A is substituted with a PEG Unit ranging from PEG2 to PEG36.

13. The ADC compound of any one of claims 1-6, wherein S^*-L^1 is:




, wherein L^A is a C_{1-10} alkylene or a 2-10-membered heteroalkylene optionally substituted with 1 R^a or 1 R^b , respectively, and optionally substituted with a PEG Unit ranging from PEG8 to PEG24 or PEG12 to PEG32.

14. The ADC compound of any one of claims 1-6, wherein S^*-L^1 is:




, wherein L^A is a C_{2-10} alkylene or 2-10-membered heteroalkylene either of which is unsubstituted or substituted with 1 R^a , wherein R^a is $-NR^dR^e$.

15. The ADC compound of any one of claims 1-6, wherein S^*-L^1 is:



wherein L^A is a C_{2-10} alkylene or 2-10-membered heteroalkylene; each optionally substituted with 1 R^a or 1 R^b , respectively.

16. The ADC compound of claim 1 or 11, wherein S^*-L^1 is:





, wherein L^A is C_{1-10} alkylene or a 2-10 membered heteroalkylene; each optionally substituted with 1-2 R^a or 1-2 R^b , respectively, provided

that one R^b is =O and the carbon atom of the 2-10 membered heteroalkylene so substituted is covalently attached to the nitrogen atom of Ring B;

wherein Ring B is unsubstituted or substituted with 1-2 R^c , and is optionally fused to 1-2 rings each independently selected from the group consisting of C₆₋₁₀ aryl and 5-6 membered heteroaryl.

17. The ADC compound of any one of claims 1-16, wherein L^A is





; wherein L^{A1} is a bond or a C₁₋₄ alkylene optionally substituted with 1 R^a ; subscript $n1$ is 1-4; and subscript $n2$ is 0-4.



18. The ADC compound of any one of claims 1-17, wherein R^a and R^b are -(C₁₋₆ alkylene)-NR^dR^e.

19. The ADC compound of any one of claims 1-18, wherein R^d and R^e are each hydrogen or are each methyl.

20. The ADC compound of claim 19, wherein L^A is




; wherein subscript $n1$ is 1 or 2; and subscript $n2$ is 0, 1, or 2.

21. The ADC compound of any one of claims 1-20, wherein L^A is  or ; wherein L^{A2} is a C_{2-10} alkylene; subscript $n1$ is 1 or 2; subscript $n2$ is 0 or 1; and L^{A2} is further optionally substituted with a PEG Unit ranging from PEG12 to PEG32.

22. The ADC compound of any one of claims 1-21, wherein L^A is further optionally substituted with a PEG Unit ranging from PEG8 to PEG32.

23. The ADC compound of any one of claims 1-16 and 22, wherein L^A is




24. The ADC compound of any one of claims 1, 7, and 16-23, wherein Ring B is an unsubstituted, unfused 8-12 membered heterocyclyl ring.
25. The ADC compound of any one of claims 1, 7, and 16-23, wherein Ring B is an unsubstituted 8-12 membered heterocyclyl fused to a C_{6-10} aryl or 5-6 membered heteroaryl ring.
26. The ADC compound of any one of claims 1, 7, and 16-23, wherein Ring B is an unsubstituted 8-12 membered heterocyclyl fused to two C_{6-10} aryl rings or two 5-6 membered heteroaryl ring rings.
27. The ADC compound of any one of claims 1, 7, and 16-23, wherein Ring B is an unfused 8-12 membered heterocyclyl substituted with 1 R^c .


28. The ADC compound of any one of claims 1, 7, and 16-23, wherein Ring B is an 8-12 membered heterocyclyl substituted with 1 R^c , and fused to a C_{6-10} aryl or 5-6 membered heteroaryl ring.

29. The ADC compound of any one of claims 1, 7, and 16-23, wherein Ring B is an unsubstituted 8-12 membered heterocyclyl and fused to two C_{6-10} aryl rings or two 5-6 membered heteroaryl ring rings.

30. The ADC compound of any one of claims 1, 7, and 16-23, wherein Ring B is:




31. The ADC compound of any one of claim 1-6, wherein S^*-L^1 is selected from the group consisting of:




wherein subscript n1 is 1 or 2; and subscript n2 is 0, 1, or 2; and S* is a sulfur atom from a cysteine residue of the antibody.

32. The ADC compound of claim 31, wherein *S-L is selected from the group consisting of:




wherein S* is a sulfur atom from a cysteine residue of the antibody.

33. The ADC compound of any one of claims 1-6, wherein S*-L:




34. The ADC compound of any one of claims 1-6, wherein *S-L¹ is selected from the group consisting of:




wherein R^P is a PEG Unit ranging from PEG8-PEG24, wherein the PEG Unit comprises a -(C₁₋₃ alkylene)C(=O)- group, the carbonyl carbon atom of which provides covalent attachment of R^P to the nitrogen atom; and S* is a sulfur atom from a cysteine residue of the antibody.

35. The ADC compound of claim 34, wherein *S-L¹ is selected from the group consisting of:




36. The ADC compound of claim 1 or 7, wherein *S-L¹ is:



37. The ADC compound of any one of claims 1-36, wherein subscript x is 1.

38. The ADC compound of claim 1 or 37, wherein M is:



wherein the wavy line represents the covalent attachment of M to L¹;

each * represents the covalent attachment of M to -L²-D;

Y¹ is selected from the group consisting of: a bond, -S-, -O-, and -NH-;

Y² is selected from the group consisting of: CH and N;

L^B is absent or a C₁₋₆ alkylene that is optionally interrupted with a group selected from the group consisting of: -O-, -NH-, -N(C₁₋₃ alkyl)-, -C(=O)NH-, -NHC(=O)-, -C(=O)O-, and -O(C=O)-;


X¹ and X² are each independently -S-, -O-, or -NH-; and

subscripts m₁ and m₂ are each independently 1-4.

39. The ADC compound of any one of claims 1 or 37-38, wherein Y¹ is -NH-; L^B is present; Y² is CH; and X¹ and X² are each -S-.


40. The ADC compound of any one of claims 1 or 37-38, wherein Y¹ is a bond; L^B is absent; Y² is N; and X¹ and X² are each -S-.

41. The ADC compound of any one of claims 1 or 37-38, wherein M is selected from the group consisting of:



wherein the wavy line represents the covalent attachment of M to L¹; and
 wherein each * represents the covalent attachment of M to -(L²-D).

42. The ADC compound of any one of claims 1-36, wherein M is




43. The ADC compound of any one of claims 1-36, wherein subscript x is 2-4; and (M)_x is -M¹-(M²)_{x-1}, wherein M¹ and each M² are independently selected multiplexers.

44. The ADC compound of claim 43, wherein subscript x is 2; and (M)_x is -M¹-M².

45. The ADC compound of claim 43, wherein subscript x is 3; and (M)_x is -M¹-(M²)₂.

46. The ADC compound of any one of claims 3-45, wherein M¹ is:



wherein the wavy line represents the covalent attachment of M to L¹;

each * represents the covalent attachment of M¹ to M²;

Y¹ is selected from the group consisting of: a bond, -S-, -O-, and -NH-;

Y² is selected from the group consisting of: CH and N;

L^B is absent or a C₁₋₆ alkylene that is optionally interrupted with a group selected from the group consisting of: -O-, -NH-, -N(C₁₋₃ alkyl)-, -C(=O)NH-, -NHC(=O)-, -C(=O)O-, and -O(C=O)-;

X¹ and X² are each independently -S-, -O-, or -NH-; and


subscripts m₁ and m₂ are each independently 1-4.

47. The ADC compound of claim 46, wherein Y¹ is -NH-; L^B is present; Y² is CH; and X¹ and X² are each -S-.

48. The ADC compound of claim 46, wherein Y¹ is a bond; L^B is absent; Y² is N; and X¹ and X² are each -S-.

49. The ADC compound of claim 46, wherein Y¹ is a bond; L^B is absent; Y² is N; and X¹ and X² are each -NH.

50. The ADC compound of claim 46, wherein M¹ is selected from the group consisting of:




;


wherein the wavy line represents the covalent attachment of M to L¹; and

wherein each * represents the covalent attachment of M to -(L²-D).


51. The ADC compound of claim 46, wherein M¹ is



52. The ADC compound claim 46, wherein M¹ is



53. The ADC compound of any one of claims 43-52, wherein each M² is independently:



wherein the wavy line represents the covalent attachment of M² to M¹ or to another M²;

each * represents the covalent attachment of M^2 to L^2 -D or another M^2 ;

Y^1 is a bond, -S-, -O-, or -NH-;

Y^2 is CH or N;

Y^3 is an optional group that provides covalent attachment of M^1 to the L^C (when present) or to Y^1 (when L^C is absent) of M^2 ;


L^B is absent or a C_{1-6} alkylene that is optionally interrupted with a group selected from the group consisting of: -O-, -NH-, -N(C_{1-3} alkyl)-, -C(=O)NH-, -NHC(=O)-, -C(=O)O-, and -O(C=O)-;

X^1 and X^2 are each independently -S-, -O-, or -NH-;

L^C is a C_{1-10} alkylene optionally substituted with 1-3 substituents each independently selected from -(C_{1-6} alkylene)- NR^dR^e , NR^dR^e , and oxo; and
subscripts m1 and m2 are each independently 1-4.


54. The ADC compound of claim 53, wherein Y^3 is -C(=O)-.

55. The ADC compound of claim 53, wherein Y^3 is selected from the group consisting




wherein * represents the covalent attachment to L^C ; and the wavy line represents the covalent attachment to M^1 or another M^2 .

56. The ADC compound of claim 53, wherein Y^3 - L^C is selected from the group consisting of:




wherein * represents covalent attachment to Y^1 ; and the wavy line represents the covalent attachment to M^1 or another M^2 .




wherein each * represents the covalent attachment to L²-D or another M²; and the wavy bond presents the covalent attachment to M¹ or another M².

61. The ADC compound of any one of claims 43-52, wherein subscript x is 2; and (M)_x is:



wherein each * represents the covalent attachment to L²-D; the wavy line represents the covalent attachment to L¹; and each succinimide ring is in hydrolyzed form.

62. The ADC compound of any one of claims 1-36, wherein subscript x is 3; and (M)_x is:



wherein each * represents the covalent attachment to L²-D; and each succinimide ring is in hydrolyzed form.

63. The ADC compound of any one of claims 1-36, wherein subscript x is 0.
64. The ADC compound of any one of claims 1-63, wherein L² is substituted with a PEG Unit ranging from PEG2 to PEG36.
65. The ADC compound of any one of claims 1-63, wherein L² is not substituted with a PEG Unit.
66. The ADC compound of any one of claims 1-63, wherein L² has the formula $-(Q)_q-(A)_a-(W)_w-(Y)_y$, wherein:

A is a C₂₋₂₀ alkylene optionally substituted with 1-3 R^{a1}; or a 2 to 40 membered heteroalkylene optionally substituted with 1-3 R^{b1};

each R^{a1} is independently selected from the group consisting of: C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, halogen, $-OH$, $=O$, $-NR^{d1}R^{e1}$, $-(C_{1-6} \text{ alkylene})-NR^{d1}R^{e1}$, $-C(=O)NR^{d1}R^{e1}$, $-C(=O)(C_{1-6} \text{ alkyl})$, and $-C(=O)O(C_{1-6} \text{ alkyl})$;

each R^{b1} is independently selected from the group consisting of: C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, halogen, $-OH$, $-NR^{d1}R^{e1}$, $-(C_{1-6} \text{ alkylene})-NR^{d1}R^{e1}$, $-C(=O)NR^{d1}R^{e1}$, $-C(=O)(C_{1-6} \text{ alkyl})$, and $-C(=O)O(C_{1-6} \text{ alkyl})$;

each R^{d1} and R^{e1} are independently hydrogen or C_{1-3} alkyl;


Q is a succinimide or hydrolyzed succinimide;

subscript q is 0 or 1;

subscript a is 0 or 1;

subscript w is 0 or 1;

wherein when subscript w is 1 then W is from 1-12 amino acids or has the structure:



wherein Su is a Sugar moiety;

$-O^A-$ represents the oxygen atom of a glycosidic bond;

each R^g is independently hydrogen, halogen, $-CN$, or $-NO_2$;

W^1 is selected from the group consisting of: a bond, $-O-$, $-NH-$, $-N(C_{1-6} \text{ alkyl})-$, $-[N(C_{1-6} \text{ alkyl})_2]^+$, and $-OC(=O)-$;

the wavy line represents the covalent attachment to A, Q, or L^1 ; and

the * represents the covalent attachment to Y or D;


y is 0 or 1; and

Y is a self-immolative or non-self-immolative moiety; and y is 0 or 1.


67. The ADC compound of any one of claims 1-66, wherein each L^2 -D is uncharged.

68. The ADC compound of any one of claims 1-66, wherein each L^2 -D has a net zero charge.

69. The ADC compound of any one of claims 66-68, wherein Q-A is selected from the group consisting of:



wherein Q^1 is selected from the group consisting of:



, wherein the wavy line adjacent to

Q^1 represents covalent attachment to $(M)_x$;

subscript a_1 is 1-4;

subscript a_2 is 0-3;

subscript a_3 is 0 or 1;

L^D is a C_{1-6} alkylene;

A^3 is $-NH-(C_{1-10} \text{ alkylene})-C(=O)-$ or $-NH-(2-20 \text{ membered heteroalkylene})-C(=O)-$, wherein the C_{1-6} alkylene is optionally substituted with 1-3 independently selected R^a , and the 2-20 membered heteroalkylene is optionally substituted with 1-3 independently selected R^b ; and

wherein A^3 is further optionally substituted with a PEG Unit selected from PEG8 to PEG24.


70. The ADC compound of claim 69, wherein subscript a_3 is 1.


71. The ADC compound of any one of claims 68-70, wherein A^3 is $-\text{NH}-(\text{C}_{1-10} \text{ alkylene})-\text{C}(=\text{O})-$.

72. The ADC compound of any one of claims 68-70, wherein A^3 is $-\text{NH}-(\text{CH}_2\text{CH}_2)-\text{C}(=\text{O})-$.

73. The ADC compound of any one of claims 68-70, wherein A^3 is $-\text{NH}-(2-20 \text{ membered heteroalkylene})-\text{C}(=\text{O})-$, wherein the 2-20 membered heteroalkylene is optionally substituted with 1-3 independently selected R^b ; and

wherein A^3 is further optionally substituted with a PEG Unit selected from PEG8 to PEG24.



74. The ADC compound of claim 69, wherein A^3 is , wherein R^P is selected from PEG2 to PEG24.

75. The ADC compound of claim 74, wherein R^P is PEG12.

76. The ADC compound of claim 74, wherein the PEG Unit R^P comprises a $-(\text{C}_{1-6} \text{ alkylene})\text{C}(=\text{O})-$ group, the carbonyl carbon atom of which provides covalent attachment of R^P to the nitrogen atom.


77. The ADC compound of any one of claims 66-76, wherein W is from 2 to 12 amino acids independently selected from natural and unnatural amino acids.

78. The ADC compound of claim 77, wherein W is a dipeptide.

79. The ADC compound of any one of claims 66-78, wherein the bond between W, and D or Y, is enzymatically cleavable by a tumor-associated protease.

80. The ADC compound of claim 79, wherein the tumor-associate protease is a cathepsin.

81. The ADC compound of any one of claims 66-76, wherein W has the structure of:



wherein Su is a Sugar moiety;

$-O^A$ - represents the oxygen atom of a glycosidic bond;

each R^g is independently hydrogen, halogen, $-CN$, or $-NO_2$;

W^1 is selected from the group consisting of: a bond, $-O-$, $-C(=O)-$, $-S(O)_{0-2}-$, $-NH-$, $-N(C_{1-6} \text{ alkyl})-$, $-[N(C_{1-6} \text{ alkyl})_2]^+-$, $-OC(=O)-$, $-NHC(=O)-$, $-C(=O)O-$, and $-C(=O)NH-$;


the wavy line represents the covalent attachment to A, Q, or L^1 ; and

the * represents the covalent attachment to Y or D.

82. The ADC compound of any one of claims 66-75 and 81, wherein O^A -Su is charge neutral at physiological pH.


83. The ADC compound of any one of claims 66-75 and 81-82, wherein Su of O^A -Su is mannose.

84. The ADC compound of any one of claims 66-75 and 81, wherein O^A -Su is




85. The ADC compound of any one of claims 66-75 and 81, wherein Su of O^A-Su comprises a carboxylate moiety.

86. The ADC compound of any one of claims 66-75, 81, and 85, wherein Su of O^A-Su is glucuronic acid.




87. The ADC compound of claim 77, wherein O^A-Su is



88. The ADC compound of any one of claims 66-75 and 81, wherein W is

89. The ADC compound of any one of claims 66-75 and 81, wherein W is




90. The ADC compound of any one of claims 66-89, wherein W¹ is a bond.

91. The ADC compound of any one of claims 66-89, wherein W¹ is -O(C=O)-.

92. The ADC compound of any one of claims 66-91, wherein subscript y is 0.

93. The ADC compound of claims 66-91, wherein subscript y is 1; and Y is





, wherein the wavy line represents covalent attachment to W or A;


and

the * represents covalent attachment to D.

94. The ADC compound of any one of claims 66-68, wherein Q-A is



or




wherein R^p is PEG8 to PEG24,

95. The ADC compound of claim 94, wherein R^p is PEG12.

96. The ADC compound of claim 94 or 95, wherein the PEG Unit R^p comprises a -(C₁₋₆ alkylene)C(=O)- group, the carbonyl carbon atom of which provides covalent attachment of R^p to the nitrogen atom.

97. The ADC compound of any one of claims 66-76, 81, and 92-96, wherein W has the structure of:



wherein Su is a Sugar moiety;

-O^A- represents the oxygen atom of a glycosidic bond;

each R^g is independently hydrogen, halogen, -CN, or -NO₂;

W¹ is selected from the group consisting of: a bond, -O-, -C(=O)-, -S(O)₀₋₂-, -NH-, -N(C₁₋₆ alkyl)-, and -[N(C₁₋₆ alkyl)₂]⁺;

the wavy line represents the covalent attachment to A, Q, or L¹; and

the * represents the covalent attachment to Y or D.

98. The ADC compound of any one of claims 66, 81, and 96, wherein each R^g is hydrogen or one R^g is halogen, -CN, or -NO₂ and each remaining R^g is hydrogen.

99. The ADC compound of claim 97, wherein W¹ is -OC(=O)-; and O^A-Su is charged neutral.

100. The ADC compound of claim 97, wherein W¹ is a bond; D is conjugated to W through a nitrogen atom which forms an ammonium cation at physiological pH; and O^A-Su comprises a carboxylate.


101. The ADC compound of any one of claims 1-100 wherein D is a hydrophilic Drug Unit.

102. The ADC compound of any one of claims 1-101, wherein D is from a cytotoxic agent.

103. The ADC compound of any one of claims 1-100 wherein D is from gemcitabine, MMAE, or MMAF.

104. The ADC compound of any one of claims 1-100 wherein D is a from a NAMPT inhibitor.

105. The ADC compound of any one of claims 1-100 and 104, wherein D has the



following formula: , wherein D is covalently attached to L² at the aa or bb position.

106. The ADC compound of any one of claims 1-105, wherein each L²-D has zero net charge at physiological pH.

107. The ADC compound of any one of claims 1-106, wherein each L²-D has no charged species at physiological pH.

108. The ADC compound of any one of claims 1-105, wherein each L²-D is zwitterionic at physiological pH.

109. The ADC compound of claims 1-106 and 108, wherein each L²-D comprises a carboxylate and an ammonium.

110. The ADC compound of claim 109, wherein the ammonium is a quaternary ammonium.

111. The ADC compound of claim 110, wherein the quaternary ammonium is pyridinium.

112. The ADC compound of any one of claims 1-106, wherein L^2 is anionic; and D is cationic.

113. The ADC compound of any one of claims 1-106 and 108-109, wherein L^2 comprises a carboxylate; and D comprises an ammonium.

114. The ADC compound of any one of claims 1-113, wherein the ratio of D to Ab is 8:1.

115. The ADC compound of any one of claims 1-113, wherein the ratio of D to Ab is 16:1 to 64:1

116. The ADC compound of any one of claims 1-113, wherein the ratio of D to Ab is 16:1 to 32:1.

117. The ADC compound of any one of claims 1-113, wherein the ratio of D to Ab is 16:1.

118. The ADC of any one of claims 1-113, wherein the ratio of D to Ab is 8:1; subscript y of $(L^2-D)_y$ is 4; and subscript p is 2.

119. The ADC of any one of claims 1-113, wherein the ratio of D to Ab is 8:1; y of $(L^2-D)_y$ is 2; and subscript p is 4.

120. The ADC of any one of claims 1-113, wherein the ratio of D to Ab is 16:1; y of $(L^2-D)_y$ is 8; and subscript p is 2.

121. The ADC of any one of claims 1-113, wherein the ratio of D to Ab is 16:1; y of $(L^2-D)_y$ is 4; and subscript p is 4.

122. The ADC of any one of claims 1-113, wherein the ratio of D to Ab is 16:1; y of $(L^2-D)_y$ is 2; and subscript p is 8.

123. The ADC of any one of claims 1-122, wherein the total number of charges for each instance of $(M)_x-(L^2-D)_y$ is an even number at physiological pH.

124. The ADC of any one of claims 1-123, wherein the total number of charges for each instance of $(M)_x-(L^2-D)_y \geq 2(x + 2y)$ at physiological pH.

125. The ADC of any one of claims 1-124, wherein the total number of charges for each instance of $(M)_x-(L^2-D)_y$ is $2(x + 2y)$ at physiological pH.

126. A composition comprising the ADC of any one of claims 1-125, or a pharmaceutically acceptable salt thereof.

127. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the ADC of any one of claims 1-125, or a pharmaceutically acceptable salt thereof, or the composition of claim 126.

128. A method of treating an autoimmune disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the ADC of any one of claims 1-125, or a pharmaceutically acceptable salt thereof, or the composition of claim 126.





FIG. 1






FIG. 3A







FIG. 3B






FIG. 5B

Channel name: MaxEnt1 : Combined : Average Time 1.1166 minutes : 1: TOF MS (500-4000) ESI+




FIG. 5C




FIG. 6





FIG. 7



In vitro cytotoxic activity of variably loaded dendrimeric nucleoside payload cAC10 (anti-CD30) ADCs against Hodgkin lymphoma line L540cy.

FIG. 8

Rat pharmacokinetics for DAR16 ADCs





FIG. 9



Impact on efficacy of 16-load NAMPTi-ADCs with varying charge states on drug linkers.
(mean tumor data)




FIG. 10

Efficacy of 10- and 20-load ADCs *in vivo* using KG-1 xenograft model




FIG. 11